Registration No. 333-                    

As filed with the Securities and Exchange Commission on April 14, 2016

October 10, 2019

Registration No. 333-___



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549




FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933




VERIFYME, INC.

(Exact name of registrant as specified in its charter)

Nevada679423-3023677

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(IRSI.R.S. Employer Identification

Number)

VerifyMe, Inc.

12 West 21st Street, 8th Floor
New York,

75 S. Clinton Ave., Suite 510

Rochester, NY 10010

(212) 994-7002

14604

(585) 736-9400

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)


Paul Donfried

Patrick White

Chief Executive Officer

VerifyMe, Inc.

12 West 21st Street, 8th Floor
New York,

75 S. Clinton Ave., Suite 510

Rochester, NY 10010

(212) 994-7002

14604

(585) 736-9400

(Name, address, including zip code, and telephone number, including area code, of agent for service)


With a copy to:


Tonya Mitchem Grindon
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
211 Commerce Street
Suite 800
Nashville, Tennessee 37201
(615) 726-5600


copies to:

Alexander R. McClean, Esq.

Harter Secrest & Emery LLP

1600 Bausch & Lomb Place

Rochester, New York 14604

(585) 232-6500

Leslie Marlow, Esq.

Hank Gracin, Esq.

Patrick J. Egan, Esq.

Gracin & Marlow, LLP

The Chrysler Building

405 Lexington Avenue, 26th Floor

New York, NY 10074

(212) 907-6457

Approximate date of commencement of proposed sale to the public: From time to time after the effectiveness of this registration statement.


If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  x


If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o


If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company,” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer o
 
Accelerated filer  o
Non-accelerated filer ox
 
Smaller reporting company  x
(Do not check if a smaller reporting company)  Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   o

CALCULATION OF REGISTRATION FEE

 
Title of each class of
securities to be registered
 
Amount
to be
Registered(1)(2)
 
Proposed
Maximum
Offering Price
Per Security(3)
 
Proposed
Maximum
 Aggregate
Offering Price
 
Amount of
 Registration
Fee
Common Stock, par value $0.001 per share 6,175,000 
$0.58
 
$3,581,500
 
$361
         

Title of each class of

securities to be registered(1)

 

Proposed

Maximum

 Aggregate

Offering Price

 

Amount of

 Registration

Fee

Units consisting of shares of Common Stock, par value $0.001 per
share, and Warrants to purchase shares of Common Stock, par
value $0.001 per share(2)
9,200,000$1,194
Common Stock included as part of the Units  
Warrants to purchase shares of Common Stock included as part of
the Units(3)
  
Shares of Common Stock issuable upon exercise of the Warrants(4)(5)$$ 
Representative’s Warrants(5)  
Shares of Common Stock issuable upon exercise of Representative’s
Warrants(6)(7)
$   704,000$    92
Total$9,904,000$1,286

(1)In the event of a stock split, reverse stock split, stock dividend, or similar transaction involving our common stock, the number of shares registered shall automatically be adjustedincreased to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act.

(2)
Includes 3,087,500stock and/or warrants that may be issued upon exercise of a 45-day option granted to the underwriters to cover over-allotments, if any.

(3)In accordance with Rule 457(i) under the Securities Act, because the shares of the Registrant’s common stock underlying the warrants and Representative’s warrants are registered hereby, no separate registration fee is required with respect to the warrants registered hereby.

(4)There will be issued     warrants to purchase     shares of common stock issuable upon conversion of the registrant’s 0% Series C Convertible Preferred Stock, par value $0.001 per share, and 3,087,500for every     shares of common stock issuableoffered. The warrants are exercisable at a per share price of     % of the common stock public offering price.

(5)No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.

(6)Includes shares of common stock which may be issued upon the exercise of outstanding warrants.additional warrants which may be issued upon exercise of 45-day option granted to the underwriters to cover over-allotments, if any.

(3)(7)Estimated solely for purposesthe purpose of calculating the registration fee in accordance withpursuant to Rule 457(c)457(g) under the Securities Act. The warrants are exercisable at a per share exercise price equal to 110% of the public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, using the averageproposed maximum aggregate offering price of the high and low bids as reported on the OTCBB on April 11, 2016,Representative’s warrants is $704,000, which was $0.58 per share.is equal to 110% of $640,000 (8% of $8,000,000).

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.




 


The information in this prospectus is not complete and may be changed. The selling security holdersWe may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and the Company is not soliciting an offer to buy thethese securities in any statejurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION
Dated April 14, 2016
Shares

SUBJECT TO COMPLETION, DATED OCTOBER 10, 2019 

PRELIMINARY PROSPECTUS

$8,000,000 of Units

Each Unit Consisting of

One Share of Common Stock

and

One Warrant to Purchase One Share of Common Stock

This prospectus relatesis a firm commitment underwritten public offering of $8,000,000 of units (the “Units”) of VerifyMe, Inc., a Nevada corporation. Each Unit consists of one share of common stock, $0.001 par value per share, and one warrant to purchase one share of common stock at an exercise price of $     per share (     % of the saleprice of each Unit sold in this offering). Each warrant offered hereby is immediately exercisable on the date of issuance and will expire on      , 2024, the date that is five years from the date of issuance.

The Units have no stand-alone rights and will not be certificated or other disposition from time to time of 6,175,000issued as stand-alone securities. The shares of our common stock par value $0.001 per share, by certain of our security holders (the “selling security holders”).  The shares offered for resale by this prospectus include the following:

·3,087,500 shares of common stock issuable upon conversion of the 0% Series C Convertible Preferred Stock, par value $0.001 per share, sold in our February 2016 private offering that had closings on each of February 9, 2016 and February 29, 2016, which refer to collectively as our February 2016 offering; and
·3,087,500 shares of common stock issuable upon exercise of the warrants sold in our February 2016 offering, which may be exercised at a price of $0.40 per share.
We will not receive any of the proceeds from the sale of shares of common stock by the selling security holders.  However, we will receive the proceeds from the exercise of warrants by the selling security holders, if any, to the extent that the warrants comprising our Units are exercised on a cash basis; to the extent we receive such proceeds, theyimmediately separable and will be used for general corporate and working capital purposes.  See “USE OF PROCEEDS” beginning on page 18 of this prospectus.
The selling security holders may sell these securities from time to time at the prevailing market price or in negotiated transactions or in any other manner specified under “PLAN OF DISTRIBUTION”issued separately in this prospectus.  The selling security holders will bear all discounts, concessions, commissions and similar expenses, if any, attributable to the sale of shares of common stock.  We will bear all other costs, expenses and fees in connection with the registration of shares of common stock.  For more information, see “PLAN OF DISTRIBUTION” beginning on page 21 of this prospectus.
offering.

Our common stock is presently traded on the over-the-counter market and quoted on the OTCBBOTCQB market under the symbol “VRME.” Our principal offices are located at 12 West 21st Street, 8th Floor, New York, NY 10010, andWe expect to apply to list our telephone number is 212-994-7002.

This prospectus may only be used where it is legal to offer and sell the shares of common stock covered by this prospectus. Weand warrants on the Nasdaq Capital Market under the symbols “VRME” and “VRMEW”, respectively. No assurance can be given that our application will be approved. On October 9, 2019, the last reported sales price for our common stock as quoted on the OTCQB market was $0.11 per share. Trading prices of our common stock as reported on the OTCQB market may not be indicative of the prices of our common stock if our common stock were traded on the Nasdaq Capital Market.

Certain of our directors or entities affiliated with such persons have not taken any actionindicated an interest in purchasing up to register or obtain permission foran aggregate of approximately $     of our Units (or     Units based on the assumed public offering price of $     per Unit) in this offering oron the distribution ofsame terms as those offered to the public.

The share and per share information in this prospectus does not reflect a recommended reverse stock split of the outstanding common stock in any country other thana range of 1-for-25 to 1-for-120 to occur before the United States.

offering.

Investing in our common stock is highly speculative andsecurities involves a high degree of risk. You should purchase these securities only if you can afford a complete loss of your investment.  You should carefully consider the risks and uncertainties described under the headingSee “Risk Factors” beginning on page 512 of this prospectus. You should carefully consider these risk factors, as well as the information contained in this prospectus, before making a decision to purchase our common stock.you invest.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

Per UnitTotal
Offering price$$
Underwriting discount and commissions(1)$$
Proceeds to us before offering expenses(2)$$

(1)We have also agreed to issue warrants to purchase shares of our common stock to the Representative and to reimburse the underwriters for certain expenses and to issue to the representative of the underwriters warrants to purchase shares of common stock as additional compensation. See “Underwriting” for additional information regarding total underwriter compensation.

(2)The amount of offering proceeds to us presented in this table does not give effect to any exercise of the: (i) over-allotment option (if any) we have granted to the underwriters as described below and (ii) warrants being issued in this offering.

We have granted a 45-day option to the underwriters to purchase up to     additional shares of common stock at a price of $     per share and/or     additional warrants at a price of $     per warrant less, in each case, the underwriting discounts payable by us, in any combination solely to cover over-allotments, if any.

The underwriter expects to deliver the securities against payment to the investors in this offering on or about          , 2019.

Sole Book-Running Manager

Maxim Group LLC

The date of this prospectus is                              , 2016.


2019.

  

TABLE OF CONTENTS

5
17
18
191
  
PLAN OF DISTRIBUTIONPROSPECTUS SUMMARY213
  
12
USE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERSPROCEEDS23
  
24
  
25
DIVIDEND POLICY25
DILUTION26
OUR BUSINESS27
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION  AND
RESULTS OF OPERATIONS
2548
  
3156
  
MANAGEMENTEXECUTIVE AND DIRECTOR COMPENSATION4661
  
EXECUTIVECERTAIN RELATIONSHIPS AND DIRECTOR COMPENSATIONRELATED TRANSACTIONS5465
  
63
6467
  
DESCRIPTION OF CAPITAL STOCK66
69
  
6972
  
75
LEGAL MATTERS79
EXPERTS79
WHERE YOU CAN FIND MORE INFORMATION6979
  
F-1

 

This summary highlights

You should rely only on information set forth in greater detail elsewherecontained in this prospectus. It mayWe have not, contain all the information that may be important to you. Before making an investment decision, you should read this entire prospectus carefully, including the sections entitled “Risk Factors” beginning on page 5, the financial statements and the notesunderwriters have not, authorized anyone to the financial statements. All referencesprovide you with additional information or information different from that contained in this prospectus to “VerifyMe,” “the Company,” “we,” “us,” “our” and similar references mean VerifyMe, Inc., unless we state otherwise orprospectus. Neither the context otherwise requires.

Our Business
Overview
VerifyMe is a technology pioneer in the anti-counterfeiting industry. This broad market encompasses counterfeiting of physical and material goods and products, as well as counterfeiting of identity in digital transactions. We deliver security solutions for identification and authentication of people, products and packaging in a variety of applications in the security field for both digital and physical transactions. Our products can be used to manage and issue secure credentials, including national identifications, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications.
The challenges associated with digital access control and identity theft are problems that are highly relevant in the world today. Consumers, citizens, employees, governments and employers demand comprehensive solutions that are reliable but not intrusive. The current widespread use of passwords or PINs for authentication has been proven insecure and inadequate. Individuals increasingly expect anywhere-anytime experiences—whether they are making purchases, crossing borders, accessing services or logging into online accounts or corporate resources. They expect those experiences to ensure the protection of their privacy and to provide uncompromising confidentiality.
We believe that the digital technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from identity and authentication to the management of legacy passwords and PINs. We empower our customers to take advantage of the full capabilities of smart mobile devices and provide solutions that are both simple to use and deliver the highest level of security. These solutions can be applied to corporate networks, financial services, e-gov services, digital wallets, mobile payments, entertainment, subscription services, and social media.
Brand owners, government agencies, professional associations, and others all share in the challenge of responding to counterfeit goods and product protection issues. Counterfeit goods span across multiple industries including from currency, passports, ID cards, pharmaceuticals, apparel, accessories, music, software, food, beverages, tobacco, automobile and airplane parts, consumer goods, toys and electronics. Described by the U.S. Federal Bureau of Investigation as the crime of the twenty-first century, product counterfeiting accounts for an estimated 5% of global trade and wreaks dire global health, safety and economic consequences on individuals, corporations, government and society.
We believe that the physical technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from counterfeit identification to employee or customer monitoring. Potential applications of our technologies are available in different types of products and industries—e.g., gaming, apparel, tobacco, fragrances,  pharmaceuticals, event and transportation tickets, driver’s licenses, insurance cards, passports, computer software, and credit cards. We generate sales through licenses of our technology or through direct sales of our technology.
Our physical technologies involve the utilization of invisible and/or color shifting/changing inks, which are compatible with today’s printing machines. The inks may be used with certain printing systems such as offset, flexographic, silkscreen, gravure, and laser. Based upon our experience, we believe that the ink technologies may be incorporated into existing manufacturing processes. We believe that some of our patents may have non-security applications, and we are attempting to commercialize these opportunities.
Our digital technologies involve the utilization of multiple authentication mechanisms, some of which we own and some of which we license.  These mechanisms include biometric factors, knowledge factors, possession factors and location factors.   Biometric factors include facial recognition with liveness detection and fingerprint on supported devices.  Knowledge factors include a personal gesture swipe and a secret color. The secret color contains a unique safety feature which allows the user to select either their normal, safe color when they willingly participate in a transaction or they can select their duress color, if they are under form of coercion. Possession factor includes devices that the user has in their possession such as a smartphone, smartwatch, and other wearable computing devices.  The location factor geo-locates the user during a secure login.  We surround these authentication mechanisms with proprietary systems that improve the usability and the security of the solutions. Our solutions allow the assessment and quantification of risk using a sophisticated heuristic scoring mechanism. We have specialized systems that perform ‘liveness’ detection to insure the subject of authentication is in fact a live human being. We have systems that introduce learning capabilities into our solutions to improve the ease of use and flexibility.
Risks Related to Our Business
We are a development stage company, and our business and ability to execute our business strategy are subject to a number of risks of which you should be aware before you decide to invest in our common stock.  You should carefully consider all of the information set forth in this prospectus and, in particular, the risks described under the sectiondelivery of this prospectus entitled “Risk Factors,” beginning on page 5 prior to making an investment in our common stock.  These risks include, among others, the following:
·We have incurred significant operating losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability;

·Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern, and as a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2015 with respect to this uncertainty;

·We have not generated significant revenues to date and may never generate revenue or achieve profitability. The continuation of our business is dependent on our ability to raise additional capital. If we are unable to raise capital when needed, we may need to substantially curtail our operations;

·If we are unable to enter into or maintain distribution arrangements with packaging manufacturers, website and mobile application developers and/or other partners and develop relationships with such third parties, we will be unable to distribute our products effectively or generate significant revenue;

·
We may not be able to continue to maintain our VerifyMeTM application on all of the operating systems which we currently support;

·Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products, services and brand;

·Our business depends upon our ability to keep pace with the latest technological changes, and our failure to do so could make us less competitive in our industry;

·Potential product liability claims could affect our earnings and financial condition;

·Our future success depends on our ability to retain key executives; and

·We are subject to numerous regulatory, legal, operational, and other risks as a result of our operations which could adversely impact our business.
Corporate Information
We were incorporated in Nevada on November 10, 1999 under the name LaserLock Technologies, Inc.  We changed our name to VerifyMe, Inc., effective July 23, 2015.  Our principal offices are located at 12 West 21st Street, 8th Floor, New York, NY 10010, and our telephone number is 212-994-7002.  Our website address is http://www.verifyme.com/#intro.  Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on our website or any such information contained thereon in making your decision to purchase our common stock.
Reverse Stock Split
The Company completed a 1-for-85 reverse split of our common stock and preferred stock, effective July 23, 2015.  The reverse split combined every 85 shares of our outstanding common stock into one share of common stock. We also combined every 85 shares of our outstanding Series A Preferred Stock, or Series A Preferred Stock, into one share of Series A Preferred Stock, and we combined every 85 shares of our outstanding Series B Preferred Stock, or Series B Preferred Stock, into one share of Series B Preferred Stock. Further, we correspondingly adjusted the conversion shares with respect to our Series A Preferred Stock and Series B Preferred Stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share. All references to common stock, Series A Preferred Stock, Series B Preferred Stock, options to purchase common stock, share data, per share data and related information have been retroactively adjusted, where applicable, in this prospectus to reflect the reverse split of our common stock (and the corresponding adjustments of the conversion prices of our Series A Preferred Stock and Series B Preferred Stock, respectively) as if it had occurred at the beginning of the earliest period presented.
Summary of the Offering
The shares offered for resale by this prospectus include the following:
·3,087,500 shares of common stock issuable upon conversion of the 0% Series C Convertible Preferred Stock, par value $0.001 per share, which we refer to as our Series C Preferred Stock, sold in our February 2016 offering; and

·3,087,500 shares of common stock issuable upon exercise of the warrants sold in our February 2016 offering, which may be exercised at a price of $0.40 per share.

Use of Proceeds
The selling security holders will receive all of the proceeds fromnor the sale of any of our common stock offered in this prospectus that is issued upon conversion of our outstanding Series C Preferred Stock or a cashless exercise of outstanding warrants held by the selling seurity holders. We will not receive any of the proceeds from any sale of the shares of common stock by selling security holders.  However, we will receive the proceeds from the exercise of warrants by the selling security holders, if any, to the extentsecurities means that the warrants are exercised on a cash basis; to the extent we receive such proceeds, they will be used for general corporate and working capital purposes and/or the expansion of our business through internal growth or acquisitions.
Any investment in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below and all information contained in this prospectus before you decide whetheris correct after the date of this prospectus. This prospectus is not an offer to purchasesell or the solicitation of an offer to buy our common stock. Ifsecurities in any circumstances under which the offer or solicitation is unlawful or in any state or other jurisdiction where the offer is not permitted.

For investors outside the United States and Canada: Neither we nor any of the following risksunderwriters have taken any action that would permit this offering or uncertainties actually occurs, ourpossession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States and Canada. Persons outside the United States and Canada who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities covered hereby and the distribution of this prospectus outside of the United States and Canada. 

The information in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects would likely suffer, possibly materially. In addition,may have changed since those dates.

No person is authorized in connection with this prospectus to give any information or to make any representations about us, the trading price of our common stock could decline due tosecurities offered hereby or any of these risksmatter discussed in this prospectus, other than the information and representations contained in this prospectus. If any other information or uncertainties, and you may lose partrepresentation is given or all of your investment.

Risks relating to our financial position, business and operations
There is substantial doubt concerning our ability to continue as a going concern.
Our financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We expect to incur further losses in the operations of our business and have been dependent on funding our operations through the issuance and sale of equity and debt securities. These circumstances raise substantial doubt about our ability to continue as a going concern. As a result of this uncertainty and the substantial doubt about our ability to continue as a going concern as of December 31, 2015, Morison Cogen LLP, our independent registered public accounting firm, issued a report dated March 30, 2016, stating its opinion that our recurring losses from operations, negative cash flows from operating activities, and potential insufficiency of cashmade, such information or available sources of liquidity to support our current operating requirements raise substantial doubt as to our ability to continue as a going concern. Investors in our securities should review carefully the report of Morison Cogen LLP, which is included in our Annual Report on Form 10-K for the year ended December 31, 2015. Management’s plans include increasing revenue through the licensing of our intellectual property, development and sale of our technology and strategic partnerships. We also intend to continue to expand our planned operations through acquisitions and monetization of additional patents, other intellectual property or operating businesses. However, no assurance can be given at this time as to whether we will be able to achieve these objectives or whether we will have the sources of liquidity for follow through with these plans.
We have a 16 year operating history, a yet unproven business model, and have not produced significant revenues. This makes it difficult to evaluate our future prospects and increases the risk that we will not be successful.
We were formed in November 1999; however, we have a short operating history with our current business model, which involves the marketing, sale and distribution of anti-counterfeiting and multi-factor authentication solutions. Our operations since inception have produced limited revenues, and may not produce significant revenues in the near term, or at all, which may harm our ability to obtain additional financing and may require us to reduce or discontinue our operations. If we create significant revenues in the future, we expect to derive most of such revenues from the sale of anti-counterfeiting and multi-factor authentication solutions, which are nascent industries. You must consider our business and prospects in light of the risks and difficulties we will encounter as an early-stage operating company in a new and rapidly evolving industry. Werepresentation may not be able to successfully address these risks and difficulties, which could significantly harm our business, operating results, and financial condition.
To date,relied upon as having been authorized by us.

Neither we nor the underwriters have generated only losses, which are expected to continue for the foreseeable future.

For the years ended December 31, 2015 and 2014, we incurred a net loss of approximately $2.3 million, and $7.9 million respectively, and used cash in operations of approximately $1.5 million and $2.0 million, respectively, in connection with the development of our security pigments and software for mobile phones. As of December 31, 2015, we had unrestricted cash and cash equivalents of approximately $4,000 and an accumulated deficit of approximately $40.0 million. We expect our net losses and negative cash flow to continue for the foreseeable future as we expand ourdone anything that would permit this offering or possession or distribution network and continue to develop our mobile platform. We cannot assure you that our net losses and negative cash flow will not accelerate and surpass our expectations, nor can we assure you that we will ever generate any net income or positive cash flow. Furthermore, we might have insufficient liquidity to meet our obligations to our suppliers and creditors.  If these events occur, they will have a material adverse effect on our business and results of operations.
We are a development stage company with no significant source of income and our independent auditors have expressed doubt about our ability to continue our activities as a going concern and the continuation of our business is dependent on us raising additional capital.
We were incorporated in November 1999 and are still a development stage company. Our operations are subject to all of the risks inherent in development stage companies which do not have significant revenues or operating income. Our potential for success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with a new business, especially technology start-up companies. We cannot provide any assurance that our business objectives will be accomplished. All of our audited financial statements since inception have contained a statement by our auditors that raises substantial doubt about us being able to continue as a going concern unless we are able to raise additional capital. Our financial statements do not include any adjustment relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our operations cease.
The continuation of our business is dependent upon us raising additional financing. The issuance of additional equity securities by us could result in a substantial dilution to our current stockholders. Obtaining commercial loans, assuming those loans would be available, or if available on terms acceptable to us, will increase our liabilities and future cash commitments. If we should fail to continue as a going concern, you may lose the value of your investment in our securities.
Our expected future growth will place a significant strain on our management, systems and resources.
Our business was formed in November 1999. In order to execute our business strategy, we will need to continue to experience growth, which will place a significant strain on our systems, processes, resources, management and other infrastructure and support mechanisms. To manage the anticipated growth of our operations, we will be required to:
·Improve existing, and implement new, operational, financial and management information controls, reporting systems and procedures;
·Establish relationships with additional vendors and strategic partners and maintain existing relationships; and
·Hire, train, manage and retain additional personnel.
To the extent we are unable to assemble the personnel, controls, systems, procedures and relationships necessary to manage our future growth, if any, management resources may be diverted, and our opportunity for success may be limited.  This may have an adverse impact on business and results of operations.
We are subject to industrial risks that could adversely affect our results of operations.
The industry in which we compete is subject to the traditional risks faced by any industry of adverse changes in general economic conditions, the availability and expense of liability insurance and adverse changes in local markets. However, we will also be subject to industry specific risks such as counterfeiters learning how to circumvent new and existing technologies; evolving consumer preference and federal, state and local chemical processing controls; consumer product liability claims; and risks of product tampering.
We face significant competition in our industry, which could adversely affect our business, financial condition and results of operations.
In some of the areas in which we operate, such as document security and product authentication and serialization, we are aware of other companies and other similar technologies, including both covert and overt surface marking techniques, which require decoding elements or analytical methods to reveal the relevant information. These technologies are offered by other companies for the same anti-counterfeiting and anti-diversion purposes for which we market our technologies.
A significant number of companies of varying sizes, which may include divisions or subsidiaries of larger companies, are vying for the same market segment as we are. A number of these competitors may have substantially greater financial and other resources available to them. There can be no assurance that we can compete successfully with such other companies. Competitive pressures or other factors could cause us to lose market share if it develops at all, or result in significant price erosion, either of which would have a material adverse effect on our results of operations.
Any change to government regulation or administrative practices may have a negative impact on our ability to operate and potential profitability.
Our operations may be subject to varying degrees to federal, state or local laws and regulations. Our operations may also be subject to federal, state and local laws and regulations controlling the development of technologies related to privacy protection, to the protection of the environment from materials that we may use in our inks, and advanced algorithm formulations or encryption tactics that we may develop. Any of these regulations may have a material adverse effect upon our operations.
Rapid technological change could make our products obsolete.
We believe that the market for our products is rapidly changing with evolving industry standards. Our future success will depend in part upon our ability to introduce new products and features to meet changing customer requirements and emerging industry standards. There can be no assurance that we will successfully complete the development of future products or that our current or future products will achieve market acceptance. Any delay or failure of these products to achieve market acceptance would adversely affect our business. In addition, there can be no assurance that products or technologies developed by others will not render our products or technologies non-competitive or obsolete.
The value of our technology and any products derived from our technology could be substantially reduced as new or modified techniques for combating document and product counterfeiting and product diversion are developed and become widely accepted. We cannot guarantee that future technological developments will not result in the obsolescence of our technologies.
If we are unable to enter into or maintain distribution arrangements with packaging manufacturers, website and mobile application developers and/or other partners and develop relationships with such packaging manufacturers, website and mobile application developers and/or other partners, we will be unable to distribute our products effectively or generate significant revenue.
Our strategy for pursuing the security pigment and multi-factor authentication markets is dependent upon establishing commercial arrangements with major packaging manufacturers, website and mobile application developers and other partners. We need to develop and maintain strategic relationships with these entities in order for them to use our products and market them.  While we have entered into agreements with certain partners pursuant to which our service may be made available to their end-users, such agreements are not exclusive and generally do not obligate the partner to market or distribute our service. We are dependent upon the subsequent success of these partners in performing their responsibilities and sufficiently marketing our service. We cannot provide you any assurance that we will be able to negotiate, execute and maintain favorable agreements and relationships with any additional partners, that the partners with whom we have a contractual relationship will choose to promote our service or that such partners will be successful and/or will not pursue alternative technologies.
If we are unsuccessful in entering into and maintaining purchase and/or license agreements, our revenues will be negatively affected.
The success of our products and services is dependent upon our providing end-users with security solutions they desire. An important aspect of this strategyprospectus in any jurisdiction where action for that purpose is establishing relationships with parties that require security for their products and/or online services. Purchase and license agreements generally have a fixed term, may or may not include provisions for exclusivity and may require us to make significant minimum payments. While our business is not dependent on any particular purchase or license agreement, there is no assurance that we will enter into a sufficient number of purchase or license agreements or thatrequired, other than the ones that we enter into will be profitable and will not be terminated early.
We are dependent on customers and other partners to make timely payments to us.
We will receive our revenue from customers and other distribution partners who may delay payment to us, dispute amounts owed to us, or in some cases refuse to pay us at all.  Our failure to collect payments owed to us from our partners will have an adverse effect on our business and our results of operations.
We may not be able to continue to maintain our VerifyMeTM application on all of the operating systems which we currently support.
Our application is compatible with various computer programming languages and mobile operating systems. If we are unable to maintain our application on these computer programming languages and operating systems or on any other operating systems, users of these operating systems will not be able to use our application, which could adversely affect our business and results of operations.
Our business depends upon our ability to keep pace with the latest technological changes, and our failure to do so could make us less competitive in our industry.
The market for our products and services is characterized by rapid technological change, frequent new product innovations, changes in customer requirements and expectations and evolving industry standards. Products using new technologies or emerging industry standards could make our products and services less attractive. Furthermore, our competitors may have access to technology not available to us, which may enable them to produce products of greater interest to consumers or at a more competitive cost. Failure to respond in a timely and cost-effective way to these technological developments may result in serious harm to our business and operating results. As a result, our success will depend, in part, on our ability to develop and market product and service offerings that respond in a timely manner to the technological advances available to our customers, evolving industry standards and changing preferences.
Our inability to identify, hire and retain qualified personnel would adversely affect our business.
We will be dependent on our current management for the foreseeable future. The loss of the services of any member of these persons would have a material adverse effect on our operations and prospects. The expansion of our business will be largely contingent on our ability to attract and retain a highly qualified management team. There is no assurance that we will be able to find suitable management personnel or that we will have the financial resources to attract or retain such people, if found.  If one or more of our key officers join a competitor or form a competing company, we may experience interruptions in product development, delays in bringing products to market, difficulties in our relationships with customers and loss of additional personnel, which could significantly harm our business, financial condition, operating results and projected growth.
We depend on third-party contractors for a substantial portion of our operations and may not be able to control their work as effectively as if we performed these functions ourselves.
We outsource substantial portions of our operations to third-party service providers.  Our agreements with third-party service providers are on a project-by-project basis.  Typically, we may terminate the agreements with notice and are responsible for the supplier’s previously incurred costs.
Because we have relied on third parties, our internal capacity to perform these functions is limited to management oversight.  Outsourcing these functions involves the risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all.  Although we have not experienced any significant difficulties with our third-party contractors, it is possible that we could experience difficulties in the future. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.  There are a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives.  Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs.  We currently have a small number of employees, which limits the internal resources we have available to identify and monitor third-party service providers.  To the extent we are unable to identify, retain and successfully manage the performance of third-party service providers in the future, our business may be adversely affected.
We rely on the sales and marketing efforts of third parties.
We pursue a policy of licensing our technologies for incorporation into products made and distributed by third parties. Although we negotiate guaranteed minimum royalties in our licensing arrangements, our revenues are substantially dependent on the sale of products incorporating our technologies by third parties. The successful marketing of such products and, therefore, our revenues and operating income, depend substantially on the marketing efforts of such third parties, over which we have little, if any, control.
Our success will depend on, among other factors, implementing a successful marketing strategy.
While we believe that our products will meet unsatisfied market demand, our ability to generate sales will depend upon developing and implementing a successful marketing strategy. There can be no assurance that we will be able to successfully develop, promote and maintain an active market for our products.
Lack of diversification may negatively impact our operations and profitability.
Our operations, even if successful, will in all likelihood result in our engaging in a business which is concentrated in only one industry. Consequently, our activities will be limited to the anti-counterfeiting industry. Our inability to diversify our activities into a number of areas may subject us to economic fluctuations within a particular business or industry and, therefore, increase the risks associated with our operations.
Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.
We do not carry insurance for all categories of risk that our business may encounter.  We do not know, however, if we will be able to maintain insurance with adequate levels of coverage.  Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.
Major network failures could have an adverse effect on our business.
Major equipment failures, natural disasters, including severe weather, terrorist acts, acts of war, cyber-attacks or other breaches of network or information technology security that affect third-party networks, transport facilities, communications switches, routers, microwave links, cell sites or other third-party equipment on which we rely, could cause major network failures and/or unusually high network traffic demands that could have a material adverse effect on our operations or our ability to provide service to our customers. These events could disrupt our operations, require significant resources to resolve, result in a loss of customers or impair our ability to attract new customers, which in turn could have a material adverse effect on our business, results of operations and financial condition.
In addition, with the growth of wireless data services, enterprise data interfaces and Internet-based or Internet Protocol-enabled applications, wireless networks and devices are exposed to a greater degree to third-party data or applications over which we have less direct control. As a result, the network infrastructure and information systems on which we rely, as well as our customers’ wireless devices, may be subject to a wider array of potential security risks, including viruses and other types of computer-based attacks, which could cause lapses in our service or adversely affect the ability of our customers to access our service. Such lapses could have a material adverse effect on our business and our results of operations.
We are subject to numerous regulatory, legal, operational, and other risks as a result of our international operations which could adversely impact our businesses in many ways.
As a U.S. company, weUnited States. You are required to comply with the economic sanctionsinform yourself about, and embargo programs administered by Office of Foreign Assets Control and similar multi-national bodies and governmental agencies worldwide,to observe any restrictions relating to, this offering and the Foreign Corrupt Practices Act (“FCPA”). A violation of a sanction or embargo program or of the FCPA or similar laws prohibiting certain payments to governmental officials, such as the U.K. Bribery Act, could subject us, and individual employees, to a regulatory enforcement action as well as significant civil and criminal penalties which could adversely impact our business and operations.
Regulation concerning consumer privacy may adversely affect our business.
Certain technologies that we currently support, or may in the future support, are capable of collecting personally-identifiable information. We anticipate that as mobile telephone software continues to develop, it will be possible to collect or monitor substantially moredistribution of this type of information. A growing body of laws designed to protect the privacy of personally-identifiable information, as well as to protect against its misuse, and the judicial interpretations of such laws, may adversely affect the growth of our business. In the United States, these laws could include the Federal Trade Commission Act, the Electronic Communications Privacy Act, the Fair Credit Reporting Act and the Gramm-Leach Bliley Act, as well as various state laws and related regulations. In addition, certain governmental agencies, like the Federal Trade Commission, have the authority to protect against the misuse of consumer information by targeting companies that collect, disseminate or maintain personal information in an unfair or deceptive manner. In particular, such laws could limit our ability to collect information related to users of our services, to store or process that information in what would otherwise be the most efficient manner, or to commercialize new products based on new technologies. The evolving nature of all of these laws and regulations, as well as the evolving nature of various governmental bodies’ enforcement efforts, and the possibility of new laws in this area, may adversely affect our ability to collect and disseminate or share certain information about consumers and may negatively affect our ability to make use of that information. If we fail to successfully comply with applicable regulations in this area, our business and prospects could be harmed.
Consumer avoidance of services which collect, store or use personally-identifiable data could adversely affect our business.
Consumer sentiment regarding privacy issues is constantly evolving. Such consumer sentiment may affect the buying public’s interest in our current or future service offerings. In some areas, consumer groups and individual consumers have already begun to vigorously lobby against, or otherwise express significant concern over, the collection, storage and/or use of personally-identifiable information. Accordingly, privacy concerns of consumers may influence mobile carriers to refrain from offering products that could harm the overall mobile telephone industry. Moreover, strong consumer attitudes often precipitate new regulations like the ones described above. If we fail to successfully monitor and consider the privacy concerns of consumers, our business and prospects would be harmed.
Potential product liability claims could affect our earnings and financial condition.
We face a potential risk of liability claims based on our products and services. Though we have product liability insurance coverage which we believe is adequate, we may not be able to maintain this insurance at reasonable cost and on reasonable terms. We also cannot assure that this insurance, if obtained, will be adequate to protect us against a product liability claim, should one arise. In the event that a product liability claim is successfully brought against us, it could result in a significant decrease in our liquidity or assets, which could result in the reduction or termination of our business.
Litigation generally could affect our financial condition and results of operations.
We generally may be subject to claims made by and required to respond to litigation brought by customers, former employees, former officers and directors, former distributors and sales representatives, former consultants and vendors and service providers. We have faced such claims and litigation in the past and we cannot assure that we will not be subject to claims in the future. In the event that a claim is successfully brought against us, considering our lack of material revenue and the losses our business has incurred for the period from our inception to December 31, 2015, this could result in a significant decrease in our liquidity or assets, which could result in the reduction or termination of our business.
As a public company, we are required to incur substantial expenses.
We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which requires, among other things, review, audit, and public reporting of our financial results, business activities, and other matters. The regulations of the Securities and Exchange Commission (the “SEC”), including regulations enacted as a result of the Sarbanes-Oxley Act of 2002, have also substantially increased the accounting, legal, and other costs related to compliance with SEC reporting obligations. If we do not have current information about our company available to market makers, they will not be able to trade our stock. The public company costs of preparing and filing annual and quarterly reports, and other information with the SEC will cause our expenses to be higher than they would be if we were privately-held.  These increased costs may be material and may include the hiring of additional employees and/or the retention of additional advisors and professionals. Our failure to comply with the federal securities laws could result in private or governmental legal action against us and/or our officers and directors, which could have a detrimental effect on our business and finances, the value of our stock, and the ability of security holders to resell their equity interests in the Company.
10

Risks Relating to our Intellectual Property
Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products, services and brand.
Our patents, trademarks, trade secrets, copyrights and all of our other intellectual property rights are important assets for us. There are events that are outside of our control that pose a threat to our intellectual property rights as well as to our products and services. For example, effective intellectual property protection may not be available in every country in which our products and services are distributed. The efforts we have taken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights could harm our business or our ability to compete. Protecting our intellectual property rights is costly and time consuming. Any increase in the unauthorized use of our intellectual property could make it more expensive to do business and harm our operating results. Although we seek to obtain patent protection for our innovations, it is possible we may not be able to protect some of these innovations. Given the costs of obtaining patent protection, we may choose not to protect certain innovations that later turn out to be important. There is always the possibility that the scope of the protection gained from one of our issued patents will be insufficient or deemed invalid or unenforceable. We also seek to maintain certain intellectual property as trade secrets. The secrecy could be compromised by third parties, or intentionally or accidentally by our employees, which would cause us to lose the competitive advantage resulting from these trade secrets.
Intellectual property litigation could harm our business.
Litigation regarding patents and other intellectual property rights is extensive in the biotechnology industry. In the event of an intellectual property dispute, we may be forced to litigate. This litigation could involve proceedings instituted by the U.S. Patent and Trademark Office (the “USPTO”) or the International Trade Commission, as well as proceedings brought directly by affected third parties. Intellectual property litigation can be extremely expensive, and these expenses, as well as the consequences should we not prevail, could seriously harm our business.
If a third party claims an intellectual property right to technology we use, we might need to discontinue an important product or product line, alter our products and processes, pay license fees or cease our affected business activities. Although we might, under these circumstances, attempt to obtain a license to this intellectual property, we may not be able to do so on favorable terms, or at all. Furthermore, a third party may claim that we are using inventions covered by the third party’s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. A court may decide that we are infringing on the third party’s patents and would order us to stop the activities covered by the patents. In addition, a court may order us to pay the other party damages for having violated the other party’s patents. The biotechnology industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods of use either do not infringe on the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires us to show clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our or our licensor’s issued patents or pending applications or that we or our licensors were the first to invent the technology. During the ordinary course of our business, we do not conduct “prior art” searches before filing a patent application. Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our or our licensors’ patent applications and could further require us to obtain rights to issued patents covering such technologies. If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions.
Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.  We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies.  The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.  We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules.  However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.  In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.
We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.  If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.
As is common in the technology industry, we employ individuals who were previously employed at other technology companies, including our competitors or potential competitors.  We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.  Litigation may be necessary to defend against these claims.  Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.
We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable.  However, trade secrets are difficult to protect.  We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information.  In addition, others may independently discover our trade secrets and proprietary information.  Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
Failure to secure trademark registrations could adversely affect our business.
If we seek to register any of our trademarks, our trademark applications may not be allowed for registration or our registered trademarks may not be maintained or enforced.  During trademark registration proceedings, we may receive rejections.  Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections.  In addition, in the USPTO and in comparable agencies in many other jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks.  Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.  If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.
Our confidential information may be disclosed by other parties.
We routinely enter into non-disclosure agreements with other parties, including but not limited to vendors, law firms, parties with whom we are engaged in negotiations, and employees. However, there exists a risk that those other parties will not honor their contractual obligations to not disclose our confidential information. This may include parties who breach such obligations in the context of confidential settlement offers and/or negotiations. In addition, there exists a risk that, upon such breach and subsequent dissemination of our confidential information, third parties and potential licensees may seek to use such confidential information to their advantage and/or to our disadvantage including in legal proceedings in which we are involved. Our ability to act against such third parties may be limited, as we may not be in privity of contract with such third parties.
Risks Related to Our Shares of Common Stock
We have outstanding shares of preferred stock with rights and preferences superior to those of our common stock.
The issued and outstanding shares of Series A Preferred Stock and Series B Preferred Stock grant the holders of such preferred stock anti-dilution, voting, dividend and liquidation rights that are superior to those held by the holders of our common stock.  In February 2016, we issued Series C Preferred Stock, which grants the holders of such preferred stock anti-dilution, voting, dividend and liquidation rights that are superior to those held by the holders of our common stock.  The issuance of shares of common stock in the future, issuances or deemed issuances of additional shares of common stock for a price below the applicable preferred stock conversion price will have the effect of diluting current stockholders.
If we fail to maintain an effective system of internal control, we may not be able to report our financial results accurately or prevent fraud.  Any inability to report and file our financial results accurately and timely could harm our reputation and adversely impact the trading price of our common stock.
Effective internal control is necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business and reputation with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely affect our financial condition, results of operation and access to capital. We have not performed an in-depth analysis to determine if historical un-discovered failures of internal controls exist and may in the future discover areas of our internal control that need improvement. 
Public company compliance may make it more difficult to attract and retain officers and directors.
The Sarbanes-Oxley Act of 2002 and rules implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these rules and regulations to increase our compliance costs in 2016 and beyond and to make certain activities more time consuming and costly. As a public company, we also expect that these rules and regulations may make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers, and to maintain insurance at reasonable rates, or at all.
Our operating results may fluctuate causing volatility in our stock price.
Our operating results may fluctuate as a result of a number of factors, many of which are outside of our control. The following factors may affect our operating results causing volatility in our stock price:
·Our ability to execute our business plan;
·Our ability to compete effectively;
·Our ability to continue to attract consumers;
·The amount and timing of operating costs and capital expenditures related to the maintenance and expansion of our business, operations and infrastructure;
·General economic conditions and those economic conditions specific to anti-counterfeiting industry; and
·Our ability to attract, motivate and retain top-quality employees.
Our stock price may be volatile.
The market price of our common stock is highly volatile and subject to wide fluctuations in price in response to various factors, some of which are beyond our control. These factors include:
·Changes in our industry;
·Competitive pricing pressures;
·Our ability to obtain working capital financing;
·Quarterly variations in our results of operations;
·Changes in estimates of our financial results;
·Investors’ general perception of us;
·Disruption to our operations;
·The emergence of new sales channels in which we are unable to compete effectively;
·Commencement of, or our involvement in, litigation;
·Any major change in our board of directors or management; and
·Changes in governmental regulations or in the status of our regulatory approvals.

We have not paid dividends in the past and do not expect to pay dividends in the future.  Any return on investment may be limited to the value of our common stock.
We have never paid cash dividends on our common stock and do not anticipate doing so in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant.    If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates , and may become worthless if a liquidation event occurs based on the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock preferences.
Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.
If our stockholders sell substantial amounts of our common stock in the public market, including shares issued in the private placement or upon the effectiveness of the registration statement required to be filed, or upon the expiration of any statutory holding period under Rule 144, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which, the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.
If we do not generate cash flow from operations, we may issue additional securities in the future, which could dilute your ownership.
If we do not generate substantial cash flow from operations necessary to carry out our business, of which there is no assurance, we may have to sell additional securities in order to generate the required capital. We may seek to raise capital through offering of our common stock, preferred stock, securities convertible into common stock, or rights to acquire such securities or our common stock. Under our articles of incorporation, we have additional authorized shares of common stock and preferred stock that we can issue from time to time at the discretion of our board of directors, without further action by the stockholders, except where stockholder approval is required by law. The issuance of any additional shares of common stock, preferred stock or convertible securities could be substantially dilutive to stockholders of our common stock. Holders of our shares of common stock have no preemptive rights that entitle them to purchase their pro-rata share of any offering of shares of any class or series and, therefore, our stockholders may not be permitted to invest in future issuances of our common stock and as a result will be diluted.
Our amended and restated articles of incorporation and amended and restated  bylaws may prevent a transaction you may favor or limit growth opportunities, which could cause the market price of our common stock to decline.
Certain provisions of our amended and restated articles of incorporation and amended and restated bylaws and applicable provisions of Nevada or federal law and regulations may delay, inhibit or prevent an organization or person from gaining control of us through a tender offer, business combination, proxy contest or some other method, even though you might be in favor of the transaction.
The ownership of our common stock is concentrated among a small number of stockholders, and each of these large stockholders may be able to significantly influence management and operations, which may prevent us from taking actions that may be favorable to other stockholders.  Furthermore, concentrated ownership of our common stock creates a risk of sudden changes in our share price.
As of December 31, 2015, 17 stockholders owned approximately 74.7% of our outstanding common stock on a fully-diluted basis (without giving effect to any applicable beneficial ownership limitation).  Those stockholders are able to significantly affect the election of directors as well as the outcome of most corporate actions requiring stockholder approval, such as the approval of mergers or other business combinations. Such concentration may also have the effect of delaying or preventing a change in control of our company. In some situations, the interests of each of these large stockholders, may be different from that of other stockholders.
Investors who receive our common stock may be subject to certain risks due to the concentrated ownership of our common stock. The sale by any of our stockholders who own a large amount of our common stock, of a significant portion of that stockholder’s holdings could have a material adverse effect on the market price of our common stock.
Our common stock price is below $5.00 per share and is treated as a “penny stock”, which places restrictions on broker-dealers recommending the stock for purchase.
Our common stock is defined as “penny stock” under the Exchange Act and its rules. The SEC has adopted regulations that define “penny stock” to include common stock that has a market price of less than $5.00 per share, subject to certain exceptions. These rules include the following requirements:
·broker-dealers must deliver, prior to the transaction, a disclosure schedule prepared by the SEC relating to the penny stock market;
·broker-dealers must disclose the commissions payable to the broker-dealer and its registered representative;
·broker-dealers must disclose current quotations for the securities; and
·broker-dealers must furnish its customers with monthly statements disclosing recent price information for all penny stocks held in the customer’s account and information on the limited market in penny stocks.
Additional sales practice requirements are imposed on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. For these types of transactions, the broker-dealer must make a special suitability determination for the purchaser and must have received the purchaser’s written consent to the transaction prior to sale. If our common stock remains subject to these penny stock rules these disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for our common stock. As a result, fewer broker-dealers may be willing to make a market in our stock, which could affect a shareholder’s ability to sell their shares.
Future sales by our stockholders may adversely affect our stock price and our ability to raise funds in new stock offerings.
Sales of our common stock in the public market following any prospective offering could lower the market price of our common stock. Sales may also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable. The current economic downturn has made the financings available to development-stage companies like us more dilutive in nature than they would otherwise be.
We currently intend to retain all of our future earnings rather than pay a cash dividend.
We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, for use in our business and therefore do not anticipate paying any cash dividends on our common stock in the foreseeable future.

This prospectus contains forward-looking statements.  All statements other than statements of historical facts contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements.  These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements include, among other things, statements about:

·our ability to continue as a going concern and our history of losses;

·our ability to obtain additional financing;

·our use of the net proceeds from this offering;

·our relatively new business model and lack of significant revenues;

·our ability to prosecute, maintain or enforce our intellectual property rights;

·disputes or other developments relating to proprietary rights and claims of infringement;

·the accuracy of our estimates regarding expenses, future revenues and capital requirements;

·the implementation of our business model and strategic plans for our business and technology;

·the successful development of our sales and marketing capabilities;

·the potential markets for our products and our ability to serve those markets;

·the rate and degree of market acceptance of our products and any future products;

·the success of competing products that are or become available;
·the loss ofour ability to retain key management personnel;

·regulatory developments and our compliance with applicable laws; and

·our liquidity.

These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under the section entitled “Risk Factors” and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, after the date of this prospectus, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

The forward-looking statements in this prospectus represent our views as of the date of this prospectus.  We anticipate that subsequent events and developments will cause our views to change.  However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law.  You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.

Industry and Market Data

This prospectus contains estimates made, and other statistical data published, by independent parties and by us relating to market size and growth and other data about our industry.  We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties.  This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries in which we operate that are inherently subject to a high degree of uncertainty and actual events or circumstances may differ materially from events and circumstances reflected in this information.  We caution you not to give undue weight to such projections, assumptions and estimates. While we believe that these publications, studies and surveys are reliable, we have not independently verified the data contained in them. In addition, while we believe that the results and estimates from our internal research are reliable, such results and estimates have not been verified by any independent source.

2
The selling security holders will receivePROSPECTUS SUMMARY

This summary highlights certain information appearing elsewhere in this prospectus. Because this is only a summary, it does not contain all of the proceedsinformation you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you make an investment decision, you should read this entire prospectus carefully, including the risks of investing in our securities discussed under the section of this prospectus entitled “Risk Factors” and similar headings. You should also carefully read our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

Business Overview

VerifyMe, Inc. (“VerifyMe,” the “Company,” “we” or “us”) is a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the patent pending VeriPAS™ software system in 2018 which covertly and overtly serializes products to track a product’s “life cycle” for brand owners. We believe VeriPAS™ is the only invisible covert serialization and authentication solution deployed through variable digital printing on HP Indigo printing systems with a smartphone tracking and authentication system. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the field – designed to allow investigators to quickly and efficiently authenticate product throughout the distribution chain, including warehouses, ports of entry, retail locations, and product purchased over the Internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and where they are deployed with geo location mapping and intelligent programable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of anyour RainbowSecure® technology.

Our brand protection technologies involve the utilization of our common stock offeredinvisible and color changing inks, which are compatible with today’s printing presses. In 2017, we signed a five-year contract with the Indigo Division of HP Inc. (“HP Indigo”) to print this technology on packages and labels on their 6000 series digital presses. In 2019, we entered into a strategic partnership with INX International Ink Company, the third largest producer of inks in this prospectus that is issued upon conversion of our outstanding Series C Preferred Stock or a cashless exercise of outstanding warrants held by the selling security holders. We will not receive any of the proceeds from any sale of the shares of common stock by selling security holders.  If the warrants that were issuedNorth America, to the selling security holdersco-develop inkjet inks to purchase an aggregate of 3,087,500 shares of common stock at an exercise price of $0.40 per share are exercised by payment of cash, we will receive proceeds of $1,235,000 from the selling security holders.  In such event, we intend to use the cash proceeds receivedbe used for general corporate purposes, additions to working capitalinkjet printing in combination with high speed, high volume label and capital expenditures.

When we refer to “selling security holders” in this prospectus, we mean those persons listed in the table below, and the pledgees, donees, permitted transferees, assignees, successors, and others who later come to hold any of the selling security holders' interests in shares of our common stock other than through a public sale.
The following table sets forth as of the date of this prospectus the name of each selling stockholder for whom we have registered shares of common stock for resale to the public and the number of shares of common stock that each selling stockholder may offer pursuant to this prospectus. The information set forth below is based on information known to us. The common stock being offered by the selling security holders consists of (i)  3,087,500 shares of common stock issuable upon conversion of the Series C Preferred Stock sold in our February 2016 offering, and (ii) 3,087,500 shares of common stock issuable upon exercise of the warrants sold in our February 2016 offering, which may be exercised at a price of $0.40 per share.
Based on information known to us or provided to us by each selling stockholder and as of the date the information was known to us or was provided to us, assuming that the selling security holders sell all of their shares of our common stock beneficially owned by them that have been registered by us and do not acquire any additional shares during the offering, each selling security holder will not own any shares other than those appearing in the column entitled “Beneficial Ownership of Common Shares Post-Offering.” We cannot advise you as to whether the selling security holders will in fact sell any or all of such shares of common stock.packaging printing presses. In addition, the selling security holdersinks may be used with certain printing systems such as offset, flexographic, silkscreen, gravure, and toner based laser printers. Based upon our experience, we believe that the ink technologies may be incorporated into existing manufacturing processes. Further, we believe that some of our patents may have non-security applications that we may attempt to commercialize in the future.

We believe that our brand protection will play a role in the supply chain management process. Our invisible ink can be used as a unique identifier in a digital serialization application.

Serialization or unique identification helps brand owners identify who manufactured the product, which wholesaler has sold transferredthe product to retailers or otherwise disposedhospitals and other pertinent information concerning the product’s supply chain.  The implementation of serialization and track and trace provides the ability to track and trace the lifecycle of products in the system end-to-end.  Our invisible ink is applied during the printing process of product labels and packaging and can be used as a unique invisible serialization identifying number or may sell, transfer or otherwise dispose of, at any timecode on labels and from time to time, the sharespackaging.   The invisibleness of our common stock in transactions exempt fromink acts as an additional layer of security since the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) after the date on which they provided the information set forth in the table below.

Beneficial ownership is determined in accordanceink needs to be revealed with SEC rulesspecial equipment.

A track and includes voting or investment power with respect to the securities. However, the Series C Preferred Stock and the warrants of the sellingtrace system improves security holders are subject to limitations upon conversion and exercise, respectively.  With respect to the Series C Preferred Stock, the most significant of these limitations is that the selling security holder may not convert its Series C Preferred Stock if the conversion would cause such holder's beneficial ownership of our common stock to exceed 4.99% of the outstanding shares of common stock.  The selling security holder is permitted to increase the 4.99% beneficial ownership limitation imposed upon its conversion of its Series C Preferred Stock up to a 9.99% beneficial ownership limitation upon notice to the Company, provided, that such increased beneficial ownership limitation shall not be effective until the 61st day after such notice is delivered to the Company.  Further, with respect to the warrants, the most significant of these limitations is that the selling security holder may not exercise its warrants if the exercise would cause such holder's beneficial ownership of our common stock to exceed 4.99% of the outstanding shares of common stock.  The selling security holder is permitted to increase the 4.99% beneficial ownership limitation imposed upon the exercise of its warrants up to a 9.99% beneficial ownership limitation upon notice to the Company, provided, that such increased beneficial ownership limitation shall not be effective until the 61st day after such notice is delivered to the Company. Therefore, although they are included in the table below, the number of shares of common stock for some listed persons may include shares that may not be purchased during a given 60-day period used for purposes of determining beneficial ownership.

Except for relationships noted in the selling security holder table, none of the selling security holders has, or within the past three years has had, any position, office or material relationship with us or any of our predecessors or affiliates.
 
Name of Investor
  
Beneficial
Ownership of
Common
Shares Prior
to Offering
(#)(1)
  Number of
Common
Shares
Underlying
Series C
Preferred
Stock Being
Registered
(#)(2)
   
Number of
Common
Shares
Underlying
Warrants
Being
Registered(3)
   
Beneficial
Ownership
of
Common
Shares Post-
Offering
(#)(4)
   
Percent of
Common
Shares
Beneficially
Owned Post-
Offering (%)(5)
 
Barry Honig  875,000   437,500   437,500   0   0%
Jordan S. Blickman  21,648   10,000   10,000   1,648   * 
Laurence J. Blickman SEP IRA  32,750   15,000   15,000   2,750   * 
Laurence J. Blickman Defined Benefit Plan  105,589   50,000   50,000   5,589   * 
2005 Blickman Family Trust  101,218   50,000   50,000   1,218   * 
Sandor Capital Master Fund  750,000   375,000   375,000   0   0%
Grander Holdings, Inc. 401k PSP  875,000(6)  312,500   312,500   0   0%
Horberg Enterprises LP  300,000   120,000   120,000   60,000   * 
Melechdavid, Inc.(7)
  500,000   250,000   250,000   0   0%
Robert A. Naify Living Trust  271,610   125,000   125,000   21,610   * 
Jeffrey K. Belk  250,000   125,000   125,000   0   0%
Intracoastal Capital, LLC(8)
  375,000   187,500   187,500   0   0%
Moishe Hartstein(9)
  250,000   125,000   125,000   0   0%
Oban Investments, LLC  125,000   62,500   62,500   0   0%
Michael Brauser  875,000(10)  125,000   125,000   0   0%
Stetson Capital Investments, Inc.  125,000   62,500   62,500   0   0%
FirstFire Global Opportunities Fund, LLC  500,000   250,000   250,000   0   0%
Russell L. Barnes  500,000   250,000   250,000   0   0%
(*) Less than 1%.
by:

(1)
Includes all shares·
Knowing the life cycle of common stock beneficially owned by the selling security holders as of April 14, 2016, including shares of common stock the selling security holder has the right to acquire within 60 days upon conversion of Series C Preferred Stocka product or prescription drug, from where it is manufactured, who is repackaging it, who is distributing it, when it is prescribed and exercise of warrants. Also includes all shares of common stock underlying the selling security holders' Series C Preferred Stock and warrants.
 (2)The numbers in the table reflect the actual number of shares of common stock issued or issuable to the selling security holder upon the conversion of the Series C Preferred Stock issued in our February 2016 offering.
(3)The numbers in the table reflect the actual number of shares of common stock issued or issuable to the selling security holder upon exercise of warrants to purchase common stock issued in our February 2016 offering in exchange for the exercise price.
(4)Assumes that all shares of Series C Preferred Stock are converted into common stock, a cash exercise of all warrants issued in our February 2016 offering, and that all such shares of common stock have beenwhen it is sold.
(5)Based on 6,586,711 shares of common stock issued and outstanding as of April 14, 2016.
(6)Includes (i) 125,000 shares of common stock underlying 125,000 shares of Series C Preferred Stock and (ii) 125,000 shares of common stock underlying a warrant, each held by Michael Brauser who is the trustee of Grander Holdings Inc. 401k PSP.
(7)This selling security holder failed to return its selling security holder questionnaire to the Company.  Therefore, the information provided in this table is based solely on the number of shares of common stock underlying the Series C Preferred Stock and warrants that such selling security holder purchased in the February 2016 offering.
(8)Michael P. Kopin (“Mr. Kopin”) and Daniel B. Asher (“Mr. Asher”), each of whom are managers of Intracoastal Capital LLC (“Intracoastal”), have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities reported herein that are held by Intracoastal.

 Mr. Asher, who is a manager of Intracoastal, is also a control person of a broker-dealer. As a result of such common control, Intracoastal may be deemed to be an affiliate of a broker-dealer. Intracoastal acquired the shares of common stock underlying the Series C Preferred Stock and the warrants being registered hereunder in the ordinary course of business, and at the time of the acquisition of the such shares of Series C Preferred Stock and warrants described herein, Intracoastal did not have any arrangements or understandings with any person to distribute such securities.
(9)3
This selling security holder has indicated that he is an affiliate of a broker-dealer.  However, such selling security holder has certified to the Company that the purchase of his Series C Preferred Stock and warrants was in the ordinary course of business and that, at the time of the purchase of such Series C Preferred Stock and warrants, he had no agreements or understandings, directly or indirectly, with any person to distribute the Series C Preferred Stock, the warrants or the common stock underlying his shares of Series C Preferred Stock and his warrants.
(10)Includes (i) 312,500 shares of common stock underlying 312,500 shares of Series C Preferred Stock and (ii) 312,500 shares of common stock underlying a warrant held by Grander Holdings Inc. 401k PSP of which Mr. Brauser is the trustee.
Each selling security holder and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on our principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling security holder may use any one or more of the following methods when selling securities:
·ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

·block tradesMeeting accurate regulatory and compliance requirement questions such as “What, Where, When and Who.”

·Locating product or batches and precisely where they are distributed.

·Enabling the option to recall a particular product or entire batches which are reported as having a product/batch failure or having not met standards.

·Identifying if the product or drug is counterfeit, stolen, contaminated, etc.

·Knowing about the multi-container packaging item level details.

·Identifying same code scan clusters by GPS location to identify possible counterfeiting.

Track and trace works in the following ways:

·Generate and print unique codes, serialization number or barcodes, on product labels and/or packaging during the printing process.

·Codes are purchased and then a digital file is generated for a digital printing press or digital ink jet device to print the variable numbers or codes contained in which the broker-dealer will attemptfile on labels and packaging.

·The unique codes are applied at the point of product fulfillment and scanned throughout the supply chain, including at the point of dispensing to sell the securities as agent but may positionconsumer, and resellultimately by the consumer to ensure it is authentic or engage the consumer for additional data and or marketing.

·Capture unique serialization number and store in centralized database (distributed or non-distributed).

·Update serialization data in electronic product code information services (“EPCIS”) centralized database.

·Distributors, wholesalers, repackagers and retail stores have the ability to validate the visible serialization when they use a portion of the block as principalsmart phone application to facilitate the transaction;perform authentication reviews, monitor product life cycle and/or transactions.

Each time a transaction for serialized drugs is carried out, the transaction drug history is updated in the e-pedigree system.

Our technologies include the following products:

RainbowSecure® technology was our first technology to be patented. It combines an invisible ink with a proprietary tuned laser to enable counterfeit products to be exposed. In 2017, we signed a five-year contract with HP Indigo to print this technology on packages and labels on their 6000 series digital presses. In December 2017, we signed a contract with Micro Focus International PLC (“Micro Focus”) to use RainbowSecure® in their Global Product Authentication, Track and Trace system (software). In May 2019, we entered into a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. The technology also features a unique double layer of security which remains entirely covert at all times and provides licensees with additional protection. RainbowSecure® is particularly well-suited to closed and controlled environments, such as casinos that want to verify transactions within a specific area, labels, packaging, textiles, plastics and metal products which need authentication. The specially formulated inks will enable these printing presses to print our RainbowSecure® invisible ink technology, which includes our variable VeriPAS™ serialization, track and trace technology. We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology.

VeriPASTMtechnology combines the covert identifier of RainbowSecure® with the Micro Focus Track and Trace software which provides brand owners geographical business intelligence on counterfeiting as well as the ability to authenticate labels, packaging and products. Based on our discussions with other serialization, track and trace software providers, we expect to add alternatives to clients beyond the Micro Focus Global Protected Authentication System (“GPAS”). This technology is currently being co-marketed with RainbowSecure® and our Smart Phone Authenticator™ product. Several clients are in the testing stage with this product. To date, we have not derived revenue from this technology.

4

SecureLight® technology was developed as a result of our investment in new proprietary color changing inks that could penetrate broader markets. During the past decade, we have refined our technology and its applications, and now have what we believe to be the easiest, most cost effective and efficient authentication technology available in the world today. Our technology, known as SecureLight®, takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in hundreds of new applications ranging from credit cards to driver’s licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technology can also be used to protect apparel, pharmaceuticals, and virtually any other physical product, such as fabrics, plastics, ceramics and metal. In 2018, we received notice that patents involving this technology were approved in various European nations. We are attempting to commercialize this product.

SecureLighttechnology combines the covert characteristics of RainbowSecure® and the overt characteristics of SecureLight®. This provides a solution which can be authenticated in two different ways - by proprietary tuned laser devices, and also by anyone with fluorescent lighting, including end consumers. In 2018, we received notice that patents involving this technology were approved in various European nations. SecureLight+® has been successfully deployed in one country’s drivers’ licenses and another country’s voter registration card program. We have begun to commercialize this product.

Smart Phone Authenticator™ technology is a piece of hardware with a built in lighting system and software that scans invisible RainbowSecure® codes. Product investigators attach their smart phone to this device which then reveals the hidden RainbowSecure® images on the smart phone screen which are then sent to the VeriPASTM software in the cloud for authentication and data submission. These devices have been commercialized and are being leased to customers. Leases are typically one year in length.

VerifyMe Beeper technology is an authentication tool which we are marketing to customers in conjunction with our RainbowSecure® ink pigment. Authentication is provided in the form of an LED indicator, a camera device which reveals the hidden serialization numbers and codes on a viewing screen and an audible beeping device when placed on a label, product or package containing the RainbowSecure® technology. The hand held beeping device is tuned to authenticate the unique frequency of our RainbowSecure® invisible ink and will broadcast a beeping sound to confirm the authenticity when placed on products, labels and packaging containing our RainbowSecure® ink technology. The VerifyMe Beeper is designed for use by customers who desire instant authentication on items, such as event tickets at an entry gate. Our customized beeper will only positively identify a product bearing our unique anti-counterfeit solution. This technology is being commercialized and leased to customers.

Our digital technologies involve the utilization of multiple authentication mechanisms, some of which we own and some of which we license. These mechanisms include biometric factors, knowledge factors, possession factors and location factors. Biometric factors include facial recognition with liveness detection, finger print and voice recognition. Knowledge factors include a personal gesture swipe and a safe and panic color choice. Possession factors include devices that the user has in their possession such as a smartphone, smart watch, and other wearable computing devices. The location factors geo-locate the user during a secure login. We surround these authentication mechanisms with proprietary systems that improve the usability and the security of the solutions. Our solutions allow the assessment and quantification of risk using a sophisticated heuristic scoring mechanism. We have specialized systems that perform ‘liveness’ detection to insure the subject of authentication is in fact a live human being. We also have systems that introduce learning capabilities into our solutions to improve the ease of use and flexibility. We are continuing to develop and market this technology but it has not yet been commercialized.

Recent Developments

Effective as of May 30, 2019, we entered into a contract with a Forbes Top 50 Private Company that sells nutrition, personal care, beauty and home care products around the globe. The brand owner prints its own packaging and labels using HP Indigo printing presses. They lease our equipment and software including VeriPAS™ technology products in conjunction with HP Indigo printing presses, our strategic partner.

On May 28, 2019, pursuant to a memorandum of understanding, we began a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. The specially formulated inks will enable these printing presses to print our RainbowSecure® invisible ink technology, which includes our variable VeriPAS™ serialization, track and trace technology.

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;5
Table of Contents ·an exchange distribution in accordance with the rules of the applicable exchange;
·privately negotiated transactions;
·settlement of short sales;
·in transactions through broker-dealers that agree with the selling security holders to sell a specified number of such securities at a stipulated price per security;
·through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
·a combination of any such methods of sale; or
·any other method permitted pursuant to applicable law.
The selling security holders may also sell securities under Rule 144 under the Securities Act if available, rather than under this prospectus.
Broker-dealers engaged by the selling security holders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling security holders (or, if any broker-dealer acts as agent

On May 3, 2019, we entered into a one year leasing contract with Identity Management Systems Co., Ltd., for the purchaserlease of securities, fromone of our new smartphone readers which includes the purchaser)VeriPAS™ technology. This lease is expected to allow us to introduce and sell our products and services to the markets in amountsEast Asia.

On April 24, 2019, we entered into a license agreement with Niagara Label Co. Inc. (“Niagara”), a western New York label manufacturer with 33 years’ experience. The license allows Niagara to offer our brand protection technology solutions to brand owners throughout the United States through the leasing of our smart phone authentication devices. These authentication devices read the invisible RainbowSecure® codes into the cloud and are recorded in our serialization, track and trace software platform, VeriPAS™.

On April 11, 2019, we entered into a one year reseller agreement with Arca Etichette (“Arca”), a leading label and packaging company based in Milan, Italy. Pursuant to the agreement, we offer our brand protection technology solutions to brand owners throughout Europe through the leasing of our patented smart phone authentication devices which read the invisible codes into the cloud and are recorded in the Company’s VeriPAS™ platform. Our devices are expected to be negotiated, but, except as set forthleased to brand owners by Arca in a supplement to this prospectus,exchange for recurring revenue.

Intellectual Property

Our current patent and trademark portfolios consist of 10 granted US patents and one granted European patent validated in four countries, four pending US and foreign patent applications, four registered US trademarks, one registered EU foreign registration, and eight pending US and foreign trademark applications.

 In addition, six patent applications were abandoned.  We plan on considering the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the salefiling for reinstatement on some of the securities or interests therein,abandoned patent applications.

Our registered patents expire between the selling security holders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short salesyears of the securities in the course of hedging the positions they assume. The selling security holders may also sell securities short2019 and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling security holders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The selling security holders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit2033. 

Listing on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling security holder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the selling security holders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling security holders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling security holders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling security holders or any other person. We will make copies of this prospectus available to the selling security holders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
Nasdaq Capital Market

Our common stock is currently quoted on the OTCBBOTCQB Market. In connection with this offering, we intend to apply to list our common stock and warrants offered in the offering on the Nasdaq Capital Market (“Nasdaq”) under the symbols “VRME” and “VRMEW”, respectively. If our listing application is approved, we expect to list our common stock and the warrants offered in the offering on Nasdaq upon consummation of the offering, at which point our common stock will cease to be traded on the OTCQB Market. No assurance can be given that our listing application will be approved. This offering will occur only if Nasdaq approves the listing of our common stock and warrants. Nasdaq listing requirements include, among other things, a stock price threshold. As a result, prior to effectiveness, we will need to take the necessary steps to meet Nasdaq listing requirements, including but not limited to a reverse split of our outstanding common stock. If Nasdaq does not approve the listing of our common stock, we will not proceed with this offering. There can be no assurance that our common stock will be listed on the Nasdaq.

Reverse Stock Split

On October 8, 2019, our Board of Directors (the “Board”) recommended that our stockholders, at the meeting of stockholders anticipated to be held on November 19, 2019, approve a reverse stock split of the common stock within the range of 1-for-25 to 1-for-120 of our issued and outstanding shares of common stock and authorize the Board, in its discretion, to determine the final ratio, effective date, and date of filing of the certificate of amendment to our articles of incorporation, as amended, in connection with the reverse stock split. The reverse stock split will not impact the number of authorized shares of common stock which will remain at 675,000,000 shares. Our Board has received the irrevocable proxy (the “Irrevocable Proxy”) of our former director, Laurence J. Blickman, that provides our Board, through December 4, 2019, with the right to vote Mr. Blickman’s shares on the reverse stock split proposal. See “Security Ownership of Certain Beneficial Owners and Management — Irrevocable Proxy.” All option, share and per share information in this prospectus does not give effect to the proposed reverse stock split.

6

Bridge Financing

On September 19, 2019, we completed the closing of $600,000 of secured convertible debentures (the “Debentures”) for gross proceeds of $540,000 after original issue discounts. Effective as of September 18, 2019 (the “Effective Date”), we entered into two substantially identical securities purchase agreements (the “Securities Purchase Agreements”) with two institutional investors (the “Purchasers”), which provided for the issuance of up to an aggregate of $1.2 million in principal amount of Debentures (the “Bridge Financing”) of which the first tranche of $600,000 have been issued. The Securities Purchase Agreements provided for the issuance of the Debentures due one year from the dates of issuance in two $600,000 tranches: the first tranche as described above, and the second tranche, at the discretion of the Purchasers and us, to occur any time after November 17, 2019. If, at any time after November 17, 2019, the Purchasers elect not to consummate the closing of the second tranche, then we may raise up to $600,000 from additional investors (including our affiliates) who will have a security interest on apari passu basis with the Purchasers in the first tranche, so long as such investors agree not to convert the securities received until the Purchasers in the first tranche have completely converted the Debentures or been fully repaid. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Bridge Financing” for the definition of Purchaser’s Securities and other information regarding the Bridge Financing.

Principal Risks

We are subject to various risks discussed in detail under “Risk Factors,” which include risks related to the following:

·our ability to continue as a going concern;
·our history of losses and our ability to raise capital;
·our ownership structure;
·our ability to compete;
·the ability of our products and services to function as expected;
·the ability of our products to gain market acceptance;
·our ability to retain key management personnel;
·our lack of business development resources;
·our ability to hire and retain an experienced sales team;
·our ability to manage growth effectively;
·the fact that a small number of customers account for our revenue;
·the success of our partners who integrate our solutions into their product offerings;
·our reliance on one printing press that has limited market share;
·our ability to commercialize our products;
·our ability to successfully protect our intellectual property rights, and claims of infringement by others;
·our compliance with data privacy requirements;
·our dependence on third-party vendors for key services;
·our ability to maintain an effective system of disclosure controls;
·the dilution of our shares as a result of the issuance of additional shares in connection with financing arrangements;
·the volatility of our stock price;
·the limited trading volume and price fluctuations of our stock;
·our ability to issue preferred stock without shareholder approval and other anti-takeover provisions;

7

·the immediate and substantial dilution of the net tangible book value of our common stock;
·the speculative nature of warrants;
·our ability to meet the listing requirements of the Nasdaq Capital Market;
·the trading liquidity of our common stock and warrants; and

·we intend to effect a reverse stock split of our outstanding common stock prior to this offering; however, the reverse stock split may not increase our stock price sufficiently and we may not be able to list our common stock on the Nasdaq Capital Market in which case this offering may not be completed.

Corporate Information

We were incorporated in Nevada on November 10, 1999 under the name LaserLock Technologies, Inc.  We changed our name to VerifyMe, Inc., effective July 23, 2015.  Our principal offices are located at 75 South Clinton Avenue, Suite 510, Rochester, New York 14604 and our telephone number is (585) 736-9400. Our website address is www.verifyme.com. We have not incorporated by reference into this prospectus the information included on or linked from our website and you should not consider it to be part of this prospectus.

8

Summary of the Offering

Issuer:VerifyMe, Inc.
Securities offered by us:$8,000,000 of Units, each Unit consisting of one share of our common stock and one warrant to purchase one share of our common stock. Each warrant will have an exercise price of $       per share (       % of the public offering price of the common stock), is exercisable immediately and will expire five (5) years from the date of issuance. The Units will not be certificated or issued in stand-alone form. The shares of our common stock and the warrants comprising the Units are immediately separable upon issuance and will be issued separately in this Offering.

Number of shares of common stock offered

by us:

          shares

Number of warrants offered by us:

          warrants to purchase          shares of common stock

Public offering price:

$           per Unit. 

Shares of common stock outstanding prior to the
offering(1)

110,115,860 shares.

Shares of common stock outstanding after the
offering(1):

          shares (assuming none of the warrants issued in this offering are exercised). 

Over-allotment option:We have granted a 45-day option to the underwriters to purchase up to        additional shares of common stock at a price of $     per share and/or     additional warrants at a price of $        per warrant less, in each case, the underwriting discounts payable by us, in any combination solely to cover over-allotments, if any. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be and the total proceeds to us, before expenses, will be $        .
Use of proceeds:

We estimate that we will receive net proceeds of approximately $7,196,000 from our sale of Units in this offering, after deducting underwriting discounts and estimated offering expenses payable by us. We intend to use the net proceeds of this offering to provide funding for the following purposes: sales force expansion, marketing and business development; repayment of outstanding Debentures issued in the Bridge Financing; potential acquisitions; research and development; and working capital purposes.  See “Use of Proceeds.” 

Description of the warrants:The exercise price of the warrants is $      per share, based on the public offering price of $      per Unit. Each warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock as described herein. A holder may not exercise any portion of a warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of the outstanding common stock after exercise, as such percentage ownership is determined in accordance with the terms of the warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. Each warrant will be exercisable immediately upon issuance and will expire on         , 2024 (five years after the initial issuance date). The terms of the warrants will be governed by a Warrant Agreement, dated as of the effective date of this offering, between us and West Coast Stock Transfer, Inc., as the warrant agent (the “Warrant Agent”). This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the warrants. For more information regarding the warrants, you should carefully read the section titled “Description of the Securities we are Offering—Warrants” in this prospectus.

9

Representative’s Warrants:The registration statement of which this prospectus is a part also registers for sale warrants (the “Representative’s Warrants”) to purchase                   shares of our common stock to Maxim Group LLC (the “Representative”), as the representative of the several underwriters, as a portion of the underwriting compensation payable to the underwriters in connection with this offering. The  Representative’s Warrants will be exercisable for a four and one-half year period commencing 180 days following the effective date of the registration statement of which this prospectus is a part at an exercise price of $         (110% of the public offering price of the Units). Please see “Underwriting — Representative’s Warrants” for a description of these warrants.
Potential sales to insiders:

It is possible that one or more of our directors or their affiliates or related parties could purchase common stock and warrants in this offering; however, these person or entities may determine not to purchase any shares or warrants in this offering, or the underwriters may elect not to sell any common stock or warrants in this offering to such persons or entities. The underwriter will receive a 5% underwriting discount and commissions on any shares and warrants purchased by these parties (and an 8% underwriting discount and commissions on any securities sold to all other parties). 

Trading symbol:

Our common stock is presently quoted on the OTCQB under the symbol “VRME.” We intend to apply to have our common stock and the warrants offered in the offering listed on the Nasdaq Capital Market under the symbols “VRME” and “VRMEW”, respectively. 

Reverse stock split:

On October 8, 2019, our Board recommended that our stockholders, at the meeting of stockholders anticipated to be held on November 19, 2019, approve a reverse stock split of the common stock within the range of 1-for-25 to 1-for-120 of our issued and outstanding shares of common stock and authorize the Board, in its discretion, to determine the final ratio. Upon approval of the stockholders, we intend to effectuate the reverse split of our common stock in a ratio to be determined by the Board prior to consummation of this offering. All option, share and per share information in this prospectus does not give effect to the proposed reverse stock split.

10

Risk factors:

Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See “Risk Factors” and the other information included and incorporated by reference into this prospectus for a discussion of risk factors you should carefully consider before deciding to invest in our securities. 

Lock-up Agreements:

We and our directors, officers and certain principal shareholders have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus. See “Underwriting” section on page 75.

(1)Unless we indicate otherwise, the number of shares of our common stock outstanding after this offering is based on 110,115,860 shares of common stock outstanding on September 30, 2019, does not give effect to the potential reverse stock split, and excludes the following:
·21,962,608 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $0.32 per share;
·20,113,529 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $0.14 per share;
·16,562,500 shares of our common stock that are reserved for equity awards that may be granted under our existing equity incentive plans;
·7,222,222 shares of common stock issuable upon conversion of our outstanding Series B Convertible Preferred Stock; and
·4,000,000 shares of common stock issuable upon exercise of Debentures in the principal amount of $600,000 issued in the Bridge Financing, assuming an exercise price of $0.15 per share.

Except as otherwise indicated, all information in this prospectus assumes:

·that the public offering price of our Units is $        per Unit (the assumed public offering price is $        per share of common stock and $0.01 per accompanying warrant);

·no exercise of the outstanding warrants described above;
·no exercise of the warrants included in the Units;
·no exercise of the Representative’s Warrants; and
·no exercise of the underwriters’ option to purchase additional shares and/or warrants from us in this offering.

11

RISK FACTORS

Any investment in our securities involves a high degree of risk. You should consider carefully the risks and uncertainties described below and all information contained in this prospectus, before you decide whether to purchase our securities. If any of the following risks or uncertainties actually occurs, our business, financial condition, results of operations and prospects would likely suffer, possibly materially. In addition, the trading price of our common stock could decline due to any of these risks or uncertainties, and you may lose part or all of your investment.

Risks Relating to our Business

Our ability to continue as a going concern is in doubt absent obtaining adequate new debt or equity financing and achieving sufficient sales levels.We anticipate that we will continue to lose money for the foreseeable future. Our continued existence is dependent upon generating sufficient working capital and obtaining adequate new debt or equity financing. Because of our continuing losses, we may have to continue to reduce our expenditures, without improvements in our cash flow from operations or new financing. Working capital limitations continue to impinge on our day-to-day operations thus contributing to continued operating losses. If we are unable to achieve or sustain profitability or to secure additional financing on acceptable terms, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our stockholders losing their entire investment. There is no guarantee that we will become profitable or secure additional financing on acceptable terms.

Our auditor has indicated in its report that there is substantial doubt about our ability to continue as a going concern and if we are unable to generate significant revenue or secure financing, we may be required to cease or curtail our operations.The report of our independent auditors dated April 1, 2019 on our financial statements for the year ended December 31, 2018 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. Our financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise additional capital and implement our business plan. The going concern paragraph in the independent auditor’s report emphasizes the uncertainty related to our business as well as the level of risk associated with an investment in our securities.

We are a developmental stage company with a history of losses and we may never achieve or maintain profitability. As a developmental stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating losses in each year due to costs incurred in connection with research and development activities and general and administrative expenses associated with our operations. We incurred a net loss of $1,178,962 and $2,932,462 for the six months ended June 30, 2019 and the year ended December 31, 2018, respectively. We expect to continue to incur substantial expenditures to develop and market our services and could continue to incur losses and negative operating cash flow. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Our ability to generate profits will depend, in part, on our expenses and our ability to generate revenue. If we fail to generate revenue and eventually become and remain profitable, or if we are unable to fund our continuing losses, our shareholders could lose all or part of their investments.

Our name and brand could be confused with brands that have similar names, and as a result, our brand value may be adversely affected by any confusion or negative publicity related to others that use a name similar to VerifyMe in their brand names. We have trademarked the VerifyMeTM brand in the United States and have pending applications with respect to our brand internationally. However, our name and brand could be confused with brands that have similar names, including but not limited to Verified.Me, a service offered to Canadians by SecureKey Technologies Inc. We have a pending application for the VerifyMe name in Canada but can make no assurances regarding its approval. Further, we have registered certain trademarks and service marks in the United States and foreign jurisdictions. We are aware of names and marks similar to our service marks being used from time to time by other persons. Although we oppose any such infringement, further or unknown unauthorized uses or other misappropriation of our trademarks or service marks may diminish the value of our brands and adversely affect our business.

12

We may be unable to meet our obligations pursuant to the Debentures and any default by us may adversely affect our financial condition and our ability to remain in business. The Debentures are senior secured obligations of ours secured by all of our assets. The first tranche of the Debentures will mature on September 18, 2020. Any principal or interest that is due under each of the Debentures, which is not paid by the respective maturity date, will bear interest at the rate of 18% per annum until it is satisfied in full. In the event of a default, the Purchaser can pursue certain actions that increase the principal amount outstanding under the applicable Debenture and accelerate the amounts outstanding. The exercise by the Purchasers of remedies provided under the Debentures in the event of a default may have a material adverse effect on our financial condition and results of operations, including the possibility we may cease to conduct operations.

Conversion of our Debentures into our common stock will result in dilution to our stockholders. The Debentures are convertible into shares of our common stock at a 30% discount to the price per share offered investors in this offering. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Bridge Financing.” Assuming the Purchasers convert the Debentures at the discounted price, the result would be immediate dilution to our stockholders.

Our competitors in the anti-counterfeiting industry have much greater financial resources than we do and more functional technology offerings than we currently have. Therefore, we may not be able to successfully compete with them.The market for protection from counterfeiting, diversion, theft and forgery is a mature industry dominated by a number of large, well-established companies. To compete effectively, we will need to expend significant resources in technology and marketing. Each of our competitors has substantially greater financial, human and other resources than we do and may develop superior technology or more cost-effective alternatives to our products and services. We may not have sufficient resources to develop and market our services effectively, if at all, and our primary digital technology is not currently fully functional. If we cannot bring this product to functionality or continue to develop competitive, cost-effective products and services, we may not be able to compete effectively, which will harm our operating results.

If our technologies do not work as anticipated once we achieve meaningful sales, we will not be successful.We believe that we have world class technologies and major businesses have tested our ink technology in trials. However, while we believe our ink business is just on the verge of market acceptance, without material sales and feedback from customers, we will not be successful. Further, we made a significant investment in our new authenticators. If customers do not find them useful or decline to lease them, our business may suffer. We can provide no assurances that the market will accept our products or that we will achieve any meaningful sales.

If our technology cannot be used successfully to prevent counterfeiting, we may not be able to generate material revenue.Our market is characterized by new and evolving technologies. Counterfeiting is constantly evolving in order to create items which appear to be legitimate and evade regulations which would seize counterfeit items and penalize counterfeiters. In order to stay competitive, our technologies will need to be sufficiently complex so that they cannot be reproduced or copied by counterfeiters. If we are unable to develop and integrate effective anti-counterfeiting technologies to address the increasingly sophisticated technological needs of our customers in a timely and cost-effective manner, we may not be successful in preventing counterfeiting and we may not be able to generate material revenue.

If the market does not accept or embrace our technologies or product offering, our business may fail. Our technologies and the products we are offering have not been tested in the market on a large-scale basis. As a result, we can only speculate as to the market acceptance of these products and services. No assurance can be given that the market will accept our technologies, products and services, or any of them. If the public fails to accept our technologies, products and services to a satisfactory degree, our business may fail.

Our technologies may not be successfully commercialized and generate revenues. Our eventual success and generation of positive cash flow will be dependent upon the extent of commercialization of products using our technology. Commercialization of new technology products often has a very long lead time. If we do not successfully commercialize our technologies, our business may not succeed. Additionally, even if we are able to commercialize our technologies or any products or services related to our technologies, it is not certain that they will result in profitability.

13

Our reliance on HP Indigo to qualify additional HP Indigo digital printing presses impacts our ability to sell our products and generate revenue. In 2017, we signed a five-year contract with HP Indigo to print our RainbowSecure® technology on packages and labels on their 6000 series digital presses. HP Indigo’s pace to qualify more HP Indigo digital printing presses that include our technology hinders our ability to sell our products. We believe that without further qualified HP Indigo presses, our ability to sell to a large part of the label and packaging print manufacturing market is impeded and as a result our business and revenues are adversely affected.

If we are unable to successfully develop and market an ink jet solution to address a large segment of the label and print manufacturing market used by major brands, our revenues and business will be negatively affected. We believe it is important to our business to successfully develop and market an ink jet solution to address the large segment of the label and print manufacturing market which is used by most major brands. In 2019, we entered into a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. There can be no assurances that we will successfully develop and market this technology. Without the successful development of the ink jet head utilizing our technology, we will be unable to provide our technology to most of the addressable market impacting our business, revenues and financial condition.

Our success depends on the efforts, abilities and continued service of Patrick White, our President and Chief Executive Officer, and if we are unable to continue to retain the services of Mr. White, we may not be able to continue our operations.Our success depends to a significant extent upon the continued service of Patrick White, our President and Chief Executive Officer.  Effective August 15, 2019, Mr. White’s employment agreement with us automatically renewed for one year. Loss of the services of Mr. White and any negative market or industry perception arising from such loss could significantly harm our business, future prospects and the price of our common stock.

Because we are relying on our small management team, we lack business development resources which may hurt our ability to increase revenue.We have a small management team that is focused on sales. In addition, our Chairman, who is not involved in sales, handles operational matters, legal compliance, board relationships and shareholder relations. Because we have only a few people dedicated to business development, we lack the resources to grow beyond certain levels. We cannot assure you that we will generate cash flow from operations or from a financings which will enable us to grow our revenues.

If we are unable to hire an experienced sales team, or our partners are not successful, we may not be able to generate material revenue. Presently our personnel consists of five employees. We have several outside partners and a licensed global label manufacturer who are working on sales of our products. Our agreement with a global label manufacturer (the “GLM”) allows the GLM to market our technologies to current and new clients. Our strategic partner agreements are individualized. We have a cross selling agreement that provides that the partner is able to sell and mark-up our technologies and we can sell and mark-up the strategic partner’s products. Another strategic partner is selling our products globally as well as providing marketing support, warehousing, shipping services, help desk services and billing for a fixed percentage of our sales. Our potential customers are large companies which do not impulsively enter into large contracts.  Accordingly, we may be required to hire sales persons.  If the efforts of our management team, the GLM, strategic partners, and any sales persons we hire are unsuccessful, we may be unable to generate material revenue and those outside sales channels may end their relationship with us thus ending their sales and services.

Severe price competition from similar ink technologies may hinder our ability to sell. Currently an ultra violet ink is being sold and supported by Hewlett-Packard for their line of digital presses known as Indigo. This ink has been in the security ink industry for many years and is therefore a wide-spread uncontrolled security product that sells for an extremely low cost. The same ultra violet ink has some similar properties as our RainbowSecure® ink technology but the cost is so low it is being selected by some clients based on price which limits our ability to sell RainbowSecure®. Ultra violet ink is also available in many forms and locations, including Amazon.com. This wide-spread availability also limits our ability to market and sell RainbowSecure®.

If we cannot manage our growth effectively, we may not become profitable.Businesses which grow rapidly often have difficulty managing their growth. If we continue to grow as rapidly as we anticipate, we will need to expand our management by recruiting and employing experienced executives and key employees capable of providing the necessary support. We cannot assure you that our management will be able to manage our growth effectively or successfully. Our failure to meet these challenges could cause us to lose money, and your investment could be lost.

14

Because a small number of customers account for all of our revenue, the loss of any of these customers would have a material adverse impact on our operating results and cash flows.We derive our revenue from a limited number of customers. Our revenue in each of the first six months of 2019 and the full year 2018 was nominal. Certain of our agreements with customers have short terms or can be terminated on short notice. Any termination of a business relationship with, or a significant sustained reduction in business received from, one of these customers could have a material adverse effect on our operating results and cash flows.

Our future growth will depend upon the success of our strategic partners who integrate our solutions into their product offerings.We rely on strategic partnerships with larger companies which integrate our technologies into their product offerings. This distribution strategy leaves us largely dependent upon the success of our partners. If any of our strategic partners who include our technology in their products cease to do so, or we fail to obtain other partners who will incorporate, embed, integrate or bundle our technology, or these partners are unsuccessful in their efforts, expanding deployment of our technology our business and future growth would be materially and adversely affected.

If we fail to protect or enforce our intellectual property rights, or if the costs involved in protecting and defending these rights are prohibitively high, our business and operating results may suffer.Our patent rights, trade secrets, copyrights, trademarks, domain names and other product rights are critical to our success. We strive to protect our intellectual property rights by relying on federal, state and common law rights, as well as contractual restrictions. We may enter into confidentiality and invention assignment agreements with our employees and confidentiality agreements with parties with whom we conduct business to limit access to, and disclosure and use of, our proprietary information. However, these contractual arrangements and the other steps we have taken to protect our intellectual property may not prevent the misappropriation of our proprietary information or deter independent development of similar technologies by others.

As management deems appropriate, we will pursue the registration of our domain names, trademarks, and service marks in the U.S. and in certain locations outside the U.S. We will seek to protect our trademarks, patents and domain names in an increasing number of jurisdictions, a process that is expensive and time-consuming and may not be successful or which we may not pursue in every location. We may, over time, increase our investment in protecting our innovations through increased patent filings that are expensive and time-consuming and may not result in issued patents that can be effectively enforced.

If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.  As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Sarbanes-Oxley Act of 2002 (“SOX”). We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems, and resources.

SOX requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will file with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. 

15

Our management concluded that our disclosure controls and procedures were not effective as of December 31, 2018 as the result of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2018. Other weaknesses in our disclosure controls and internal control over financial reporting may be identified in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. We have not yet been able to remediate the material weakness related to our internal control over financial reporting.

Additional material weaknesses in our internal control over financial reporting may be identified in the future.  Any failure to maintain existing or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional material weaknesses, cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial statements. If we are unable to effectively remediate material weaknesses in a timely manner, investors could lose confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on our stock price.

We may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse effect on our business. We are subject to the Foreign Corrupt Practice Act, or FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. persons and issuers as defined by the statute for the purpose of obtaining or retaining business. We have operations, agreements with third parties and make sales in jurisdictions which may experience corruption. These activities create the risk of unauthorized payments or offers of payments by one of the employees, consultants or agents of our company, because these parties are not always subject to our control. It is our policy to implement safeguards to discourage these practices by our employees. Also, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, sales agents or distributors of our company may engage in conduct for which we might be held responsible. Violations of the FCPA may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.

Cybersecurity incidents could adversely affect our business by causing a disruption to our operations, a compromise or corruption of our confidential information and/or damage to our business relationships, all of which could negatively impact our business, results of operations or financial condition. We rely on information technology networks and systems, including the internet, to process, transmit and store electronic information, and to manage or support a variety of business processes and activities. Additionally, we collect and store certain data, including proprietary business information, and may have access to confidential or personal information in certain of our businesses that is subject to privacy and security laws and regulations. These technology networks and systems may be susceptible to damage, disruptions or shutdowns due to failures during the process of upgrading or replacing software, databases or components; power outages; telecommunications or system failures; terrorist attacks; natural disasters; employee error or malfeasance; server or cloud provider breaches; and computer viruses or cyberattacks. Cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to information technology networks and systems to more sophisticated and targeted measures, known as advanced persistent threats, directed at us, our products, customers and/or our third-party service providers. Despite the implementation of cybersecurity measures, our information technology systems may still be vulnerable to cybersecurity threats and other electronic security breaches. It is possible for such vulnerabilities to remain undetected for an extended period, up to and including several years. In addition, it is possible a security breach could result in theft of trade secrets or other intellectual property or disclosure of confidential customer, supplier or employee information. Should we be unable to prevent security breaches or other damage to our information technology systems, disruptions could have an adverse effect on our operations, as well as expose us to litigation, liability or penalties under privacy laws, increased cybersecurity protection costs, reputational damage and product failure.

16

If we are required to sue third parties who we allege are violating our intellectual property rights, or if we are sued for violating a third party’s patents or other intellectual property rights, we may incur substantial expenses, and we could incur substantial damages, including amounts we cannot afford to pay.Litigation may be necessary to enforce our intellectual property rights, protect our trade secrets or determine the validity and scope of proprietary rights claimed by others. Patent and intellectual property litigation is extremely expensive and beyond our ability to pay. While third parties do, under certain circumstances, finance litigation for companies that file suit, we cannot assure you that we could find a third party to finance any claim we choose to pursue. Moreover, third parties do not finance companies that are sued. Any litigation of this nature, regardless of outcome or merit, could result in substantial costs, adverse publicity or diversion of management and technical resources, any of which could adversely affect our business and operating results. If we fail to maintain, protect and enforce our intellectual property rights, our business and operating results may be harmed.

From time-to-time, we may face allegations that we have infringed the trademarks, copyrights, patents and other intellectual property rights of third parties, including from our competitors and inactive entities. Patent and other intellectual property litigation may be protracted and expensive, and the results are difficult to predict. As the result of any court judgment or settlement, we may be obligated to cancel the launch of a new feature or product, stop offering certain features or products, pay royalties or significant settlement costs, purchase licenses or modify our products and features while we develop substitutes.

Evolving regulations concerning data privacy may result in increased regulation and different industry standards, which could prevent us from providing our current products to our users, or require us to modify our products, thereby harming our business.The regulatory framework for privacy issues worldwide is currently in flux and is likely to remain so for the foreseeable future. Practices regarding the collection, use, storage, transmission and security of personal information by companies operating over the Internet and mobile platforms have recently come under increased public scrutiny, and civil claims alleging liability for the breach of data privacy have been asserted against companies. The U.S. government, including the Federal Trade Commission and the Department of Commerce, has announced that it is reviewing the need for greater regulation for the collection of information concerning consumer behavior on the Internet, including regulation aimed at restricting certain targeted advertising practices. In addition, the European Union recently made sweeping reforms to its existing data protection legal framework, which resulted in a greater compliance burden for many companies with users who are European citizens. Various government and consumer agencies have also called for new regulation and changes in industry practices. In addition, our business could be adversely affected if laws or regulations are adopted, interpreted, or implemented in a manner that is inconsistent with our current business practices and that require changes to these practices, the design of our website, products, features or our privacy policy. Such changes may require us to modify our products and features, possibly in a material manner, and may limit our ability to develop new products and features that make use of the data that our users voluntarily share with us. We are, and will continue to be, dependent on certain third party vendors for the supply of raw materials and key services, and any disruptions in the supply of these materials or services could adversely affect our results of operations.

Because we are, and will continue to be, dependent on certain third-party vendors for key services, we are vulnerable to disruptions in the supply of these services which are beyond our control, and which could harm our operations.We are relying upon our business partners to assist us including the GLM, S-One and Micro Focus. These partners are larger companies and may not necessarily have the same goals as employees although they have key relationships, management, and staff support and greater financial resources than we do. We currently depend on a single vendor of pigment for the inks we sell, and we may continue to be dependent on a small number of third party suppliers in the future including services relating to our electronic technology. We cannot be certain that any of these providers will be willing or able to meet our evolving needs. Additionally, they could end our relationship in accordance with applicable contractual arrangements, some of which can be terminated on short notice. If our partners, vendors, or service providers fail to meet their obligations, provide poor, inaccurate or untimely service, or we are unable to make alternative arraignments for the supply of these services, we may fail, in turn, to provide our services or to meet our obligations to our users and our business, financial condition and operating results could be materially and adversely affected.

Risks Relating to our Common Stock 

Upon conversion of our outstanding warrants and Series B Convertible Preferred Stock we will be obligated to issue a substantial number of additional shares of common stock which will dilute our present shareholders.We are obligated to issue additional shares of our common stock in connection with our outstanding warrants and shares of our Series B Convertible Preferred Stock. Currently there are warrants and shares of Series B Convertible Stock outstanding, convertible into 21,962,608 and 7,222,222 shares of common stock, respectively. The exercise, conversion or exchange of warrants or convertible securities, including for other securities, will cause us to issue additional shares of our common stock and will dilute the percentage ownership of our shareholders. In addition, we have in the past, and may in the future, exchange outstanding securities for other securities on terms that are dilutive to the securities held by other shareholders not participating in such exchange.

17

Due to factors beyond our control, our stock price may be volatile.Any of the following factors could affect the market price of our common stock:

·The loss of one or more members of our management team;

·Our failure to generate material revenues;

·Regulatory changes including new laws and rules which adversely affect companies in our line of business;

·Our public disclosure of the terms of any financing which we consummate in the future;

·Our failure to become profitable;

·Our failure to raise working capital;

·Any acquisitions we may consummate;

·Announcements by us or our competitors of significant contracts, new services, acquisitions, commercial relationships, joint ventures or capital commitments;

·Cancellation of key contracts;

·A proxy contest a former director may launch;

·Our failure to meet financial forecasts we publicly disclose;

·The sale of large numbers of shares of common stock by former directors and their associates;

·Short selling activities; or

·Changes in market valuations of similar companies.

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management’s time and attention, which would otherwise be used to benefit our business.

Our common stock may be affected by limited trading volume and price fluctuations, which could adversely impact the value of our common stock.Until recently, there has been limited trading in our common stock and there can be no assurance that an active trading market in our common stock will either develop or be maintained. Our common stock has experienced, and is likely to experience in the future, significant price and volume fluctuations, which could adversely affect the market price of our common stock without regard to our operating performance. In addition, we believe that factors such as quarterly fluctuations in our financial results and changes in the overall economy or the condition of the financial markets could cause the price of our common stock to fluctuate substantially. These fluctuations may also cause short sellers to periodically enter the market in the belief that we will have poor results in the future. We cannot predict the actions of market participants and, therefore, can offer no assurances that the market for our common stock will be stable or appreciate over time.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.If our shareholders sell substantial amounts of our outstanding common stock, preferred stock, convertible notes issuable upon the exercise of outstanding warrants or other convertible securities, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common stock could fall. We have one large stockholder and former board member who has expressed an interest in selling his common stock, which may cause an overhang on our stock. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate. The shares of our restricted common stock will be freely tradable upon the earlier of: (i) effectiveness of any registration statement covering such shares and (ii) the date on which such shares may be sold without registration pursuant to Rule 144 (or other applicable exemption) under the Securities Act. If our existing stockholders seek to sell a substantial number of shares of our common stock, such selling efforts may cause significant declines in the market price of our common stock.

18

Because we may issue preferred stock without the approval of our shareholders and have other anti-takeover defenses, it may be more difficult for a third party to acquire us and could depress our stock price.In general, our Board may issue, without a vote of our shareholders, one or more additional series of preferred stock that have more than one vote per share, although the Company’s ability to designate and issue preferred stock is currently restricted by covenants under our agreements with prior investors. Without these restrictions, our Board could issue preferred stock to investors who support us and our management and give effective control of our business to our management. Additionally, issuance of preferred stock could block an acquisition resulting in both a drop in our stock price and a decline in interest of our common stock. This could make it more difficult for shareholders to sell their common stock. This could also cause the market price of our common stock shares to drop significantly, even if our business is performing well.

We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase, if any, of our share price.

Risks Relating to this Offering and our Reverse Stock-Split

Investors in this offering will experience immediate and substantial dilution in net tangible book value.  The public offering price will be substantially higher than the net tangible book value per share of our outstanding shares of common stock. As a result, investors in this offering will incur immediate dilution of $          per share, based on the assumed public offering price of $          per share. Investors in this offering will pay a price per share that substantially exceeds the book value of our assets after subtracting our liabilities. See “Dilution” for a more complete description of how the value of your investment will be diluted upon the completion of this offering.

Participation in this offering by certain of our directors and their affiliates would reduce the available public float for our shares. It is possible that one or more of our directors or their affiliates or related parties could purchase common stock and warrants in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, these persons or entities may determine not to purchase any shares or warrants in this offering, or the underwriter may elect not to sell any shares or warrants in this offering to such persons or entities. Any purchases by our directors or their affiliates or related parties would reduce the available public float for our shares because such shareholders would be restricted from selling the common stock and warrants by a lock-up agreement they have entered into with our underwriters and by restrictions under applicable securities laws. As a result, any purchase of common stock and warrants by such shareholders in this offering may reduce the liquidity of our common stock relative to what it would have been had these common stock and warrants been purchased by investors that were not affiliated with us.

Our management will have broad discretion over the use of proceeds from this offering and may not use the proceeds effectively. Our management will have broad discretion over the use of proceeds from this offering. We intend to use the net proceeds from this offering to provide funding for the following purposes: sales force expansion, marketing and business development; repayment of outstanding Debentures issued in the Bridge Financing; research and development; potential acquisitions; and working capital purposes. Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not improve our operating results or enhance the value of our securities.

Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including amount of cash used in our operations, which can be highly uncertain, subject to substantial risks and can often change. Our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering.

19

The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.

Warrants are speculative in nature.  The warrants offered in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of our common stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the warrants may exercise their right to acquire the common stock and pay an exercise price of          per share (          %]) of the public offering price of our common stock in this offering), prior to five years from the date of issuance, after which date any unexercised warrants will expire and have no further value. In addition, there is no established trading market for the warrants and we do not expect a market to develop.

Holders of the warrants will have no rights as a common stockholder until they acquire our common stock. Until holders of the warrants acquire shares of our common stock upon exercise of the warrants, the holders will have no rights with respect to shares of our common stock issuable upon exercise of the warrants. Upon exercise of the warrants, the holder will be entitled to exercise the rights of a common stockholder as to the security exercised only as to matters for which the record date occurs after the exercise.

There is no established market for the warrants to purchase shares of our common stock being offered in this offering. There is no established trading market for the warrants and we do not expect a market to develop. Although we have applied to list the warrants on the Nasdaq Capital Market there can be no assurance that there will be an active trading market for the warrants. Without an active trading market, the liquidity of the warrants will be limited.

Provisions of the warrants offered by this prospectus could discourage an acquisition of us by a third party. In addition to the discussion of the provisions of our amended and restated articles of incorporation, our amended and restated by-laws, certain provisions of the warrants offered by this prospectus could make it more difficult or expensive for a third party to acquire us. The warrants prohibit us from engaging in certain transactions constituting “fundamental transactions” unless, among other things, the surviving entity assumes our obligations under the warrants. These and other provisions of the warrants offered by this prospectus could prevent or deter a third party from acquiring us even where the acquisition could be beneficial to you.

If our planned reverse stock split does not result in a proportionate increase in the price of our common stock, we may not be able to list our common stock and the warrants on the Nasdaq Capital Market. We expect that the reverse stock split of our outstanding common stock will increase the market price of our common stock so that we will be able to meet the minimum bid price requirement of the listing rules of the Nasdaq Capital Market. However, the effect of a reverse stock split upon the market price of our common stock cannot be predicted with certainty, and the results of reverse stock splits by companies in similar circumstances have been varied. It is possible that the market price of our common stock following the reverse stock split will not increase sufficiently for us to be in compliance with the minimum bid price requirement. If we are unable meet the minimum bid price requirement, we may be unable to list our shares on the Nasdaq Capital Market, in which case this offering will not be completed.

Even if the reverse stock split achieves the requisite increase in the market price of our common stock, we cannot assure you that we will be able to continue to comply with the minimum bid price requirement of the Nasdaq Capital Market. Even if the reverse stock split achieves the requisite increase in the market price of our common stock to be in compliance with the minimum bid price of the Nasdaq Capital Market, there can be no assurance that the market price of our common stock following the reverse stock split will remain at the level required for continuing compliance with that requirement. It is not uncommon for the market price of a company’s common stock to decline in the period following a reverse stock split. If the market price of our common stock declines following the effectuation of the reverse stock split, the percentage decline may be greater than would occur in the absence of a reverse stock split. In any event, other factors unrelated to the number of shares of our common stock outstanding, such as negative financial or operational results, could adversely affect the market price of our common stock and jeopardize our ability to meet or maintain the Nasdaq Capital Market’s minimum bid price requirement.

20

Even if the reverse stock split increases the market price of our common stock, our stock price could fall and we could be delisted from the Nasdaq Capital Market.  The Nasdaq Capital Market requires that the trading price of its listed stocks remain above one dollar in order for the stock to remain listed. If a listed stock trades below one dollar for more than 30 consecutive trading days, then it is subject to delisting from the Nasdaq Capital Market. In addition, to maintain a listing on the Nasdaq Capital Market, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders’ equity, and certain corporate governance requirements. If we are unable to satisfy these requirements or standards, we could be subject to delisting. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would expect to take actions to restore our compliance with the listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the minimum bid price requirement, or prevent future non-compliance with the listing requirements.

If at any time in the future our shares of common stock are not listed for trading by Nasdaq and we trade again on an over-the-counter market, such as the OTCQB, trading in our securities will be subject to the SEC’s “penny stock” rules and, if we are not listing for trading by NASDAQ, it is anticipated that trading in our securities will continue to be subject to the penny stock rules for the foreseeable future. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser’s written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities.

The reverse stock split may decrease the liquidity of the shares of our common stock. The liquidity of the shares of our common stock may be affected adversely by the reverse stock split given the reduced number of shares that will be outstanding following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split. In addition, the reverse stock split may increase the number of shareholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such shareholders to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.

Following the reverse stock split, the resulting market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve. Although we believe that a higher market price of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.

Even if we meet the initial listing requirements of the Nasdaq Capital Market, there can be no assurance that we will be able to comply with the continued listing standards of the Nasdaq Capital Market. Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a de-listing of our common stock. Even if we meet the initial listing requirements of the Nasdaq Capital Market, we cannot assure you that we will be able to comply with the other standards that we are required to meet in order to maintain a listing of our common stock on the Nasdaq Capital Market. If after listing we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements or the minimum stockholder's equity requirement, the Nasdaq Capital Market may take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock and would impair our shareholders' ability to sell or purchase our common stock when they wish to do so. In the event of a de-listing, we would take actions to restore our compliance with the Nasdaq Capital Market's listing requirements, but we can provide no assurance that any action taken by us would result in our common stock becoming listed again, or that any such action would stabilize the market price or improve the liquidity of our common stock.

21

There is no assurance that once listed on the Nasdaq Capital Market we will not continue to experience volatility in our share price. The OTCQB Venture Market, where our common stock is currently quoted, is an inter-dealer, over-the-counter market that provides significantly less liquidity than the Nasdaq Capital Market. Our stock is thinly traded due to the limited number of shares available for trading on the OTCQB Venture Market thus causing large swings in price. As such, investors and potential investors may find it difficult to obtain accurate stock price quotations, and holders of our common stock may be unable to resell their securities at or near their original offering price or at any price. Our public offering price per unit may vary from the market price of our common stock after the offering. If an active market for our stock develops and continues, our stock price may nevertheless be volatile. If our stock experiences volatility, investors may not be able to sell their common stock at or above the public offering price per unit. Sales of substantial amounts of our common stock, or the perception that such sales might occur, could adversely affect prevailing market prices of our common stock and our stock price may decline substantially in a short period of time. As a result, our shareholders could suffer losses or be unable to liquidate their holdings. No assurance can be given that the price of our common stock will become less volatile when listed on the Nasdaq Capital Market.

Market prices for our common stock will be influenced by a number of factors, including:

·the issuance of new equity securities pursuant to a future offering,
·including issuances of preferred stock;
·the introduction of new products or services by us or our competitors;
·the acquisition of new direct selling businesses;
·changes in interest rates;
·significant dilution caused by the anti-dilutive clauses in our financial agreements;
·competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;
·variations in quarterly operating results;
·change in financial estimates by securities analysts;
·a limited amount of news and analyst coverage for our company;
·the depth and liquidity of the market for our shares of common stock;
·sales of large blocks of our common stock, including sales by our major stockholder, any executive officers or directors appointed in the future, or by other significant shareholders;
·investor perceptions of our company and the direct selling segment generally; and
·general economic and other national and international conditions.

Market price fluctuations may negatively affect the ability of investors to sell our shares at consistent prices.

22

USE OF PROCEEDS

We estimate that the net proceeds from this offering will be approximately $7,196,000 after deducting estimated underwriting discounts and estimated offering expenses payable by us. If the underwriters’ over-allotment option is exercised in full, we estimate that our net proceeds will be approximately $8,300,000. We intend to use the net proceeds from this offering, and any proceeds from the exercise of warrants, for the following purposes:

Proceeds:   
Gross Proceeds $8,000,000 
Fees and Expenses  (804,000)
Net Proceeds $7,196,000 
     
Uses:    
Research and Development $1,800,000 
Sales Force Expansion, Marketing, Business Development and Potential Acquisitions  2,700,000 
Repayment of outstanding Debentures issued in the Bridge Financing(1)  660,000 
Working Capital  2,036,000 
Total Uses $7,196,000 

(1) We will be required to repay amounts outstanding under the Debentures issued in the Bridge Financing, including any applicable redemption premium, if the Purchasers do not elect to convert the Debentures within three days of consummation of this offering into common stock at a 30% discount to the price offered investors in this offering,. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Bridge Financing.”

The actual allocation of proceeds realized from this offering will depend upon our operating revenues and cash position and our working capital requirements and may change.

Therefore, as of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. Accordingly, we will have discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the proceeds of this offering.

Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. We anticipate that the proceeds from this offering will enable us to become cash flow from operations positive.

A $0.50 increase (decrease) in the assumed public offering price of $          per unit would increase (decrease) the expected net proceeds of the offering to us by approximately $          million, assuming that the number of shares of common stock sold by us remains the same. We may also increase or decrease the number of units we are offering. An increase (decrease) of 500,000 in the number of units sold in this offering would increase (decrease) the expected net proceeds of the offering to us by approximately $          million, assuming that the assumed combined public offering price per unit remains the same.

23

CAPITALIZATION

The following table sets forth our capitalization as of June 30, 2019:

·on an actual basis;
·on a pro forma basis to reflect the $540,000 of net cash proceeds received in the Bridge Financing and the issuance of the Debentures (assuming repayment of 110% of the sum of the principal amount outstanding under the Debentures);
·on a pro forma as-adjusted basis to reflect the adjustments reflected above, the repayment of the Debentures, and the issuance and sale by us of           Units in this offering at the assumed public offering price of
$                per Unit, after deducting underwriting discounts and commissions and estimated offering expenses payable by us and the receipt by us of the proceeds of such sale.

You should consider this table in conjunction with “Use of Proceeds” above as well as our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the notes to those financial statements incorporated by reference in this prospectus.

 As of June 30, 2019 
 Unaudited,
Actual
  Unaudited,
 Pro Forma
  

 

Unaudited,

Pro Forma

As Adjusted(1)

 
Cash and cash equivalents $585,193  $1,125,193    
Debentures  --   600 000    
Stockholders’ Equity:            
Series B Convertible Preferred Stock, $0.001 par value,
85 shares authorized; 0.85 shares issued and outstanding
  --   --     
Common Stock, $0.001 par value; 675,000,000
authorized; 109,672,373 issued and 109,321,833 shares
outstanding as of June 30, 2019, and               pro
forma, as adjusted
  109,322   109,322     
Additional paid-in capital  61,186,990   61,186,990    
Accumulated deficit  (60,442,512)  (60,442,512)   
Treasury stock as cost (350,540 shares at June 30,
2019)
  (113,389)  (113,389)    
Total Stockholders’ Equity $740,411  $740,411     

(1) The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

Each $0.50 increase (decrease) in the assumed public offering price of $           per unit would increase (decrease) cash and cash equivalents, working capital, total assets, total liabilities, additional paid-in capital and total stockholders’ (deficit) equity by $           , assuming that the number of units offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 500,000 units offered by us would increase (decrease) each of cash and cash equivalents, working capital, total assets, additional paid-in capital and total stockholders’ (deficit) equity by
$           , assuming the assumed public offering price of $           per unit remains the same, and after deducting the estimated underwriting discounts and commissions.

The above discussion and table are based on 109,321,833 shares of common stock outstanding as of June 30, 2019, and does not give effect to the potential reverse stock split or include, as of that date:

·22,126,088 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $0.32 per share as of June 30, 2019;
·19,613,529 shares of our common stock issuable upon exercise of outstanding options at a weighted average exercise price of $0.14 per share;
·17,062,500 shares of our common stock that are reserved for equity awards that may be granted under our existing equity incentive plans; and
·4,000,000 shares of common stock issuable upon exercise of Debentures in the principal amount of $600,000 issued in the Bridge Financing, assuming an exercise price of $0.15 per share.

24

DETERMINATION OF OFFERING PRICE

        The offering price of the Units has been negotiated between the Underwriter and us considering our historical performance and capital structure, prevailing market conditions, and overall assessment of our business. Our common stock is currently quoted on the OTCQB under the ticker symbol “VRME”.“VRME.”  On April 11, 2016,October 9, 2019, the last reported sale price of our common stock was $0.58$0.11 per share.  All prices have been retroactively adjusted to reflect the 1-for-85 reverse stock split that was effected on July 23, 2015, but do not account for any fractional shares.

The following table sets forth the range of high and low bid prices of our common stock for the periods indicated as reported by the OTC Markets.
Fiscal Year Ending December 31, 2016HighLow
Quarter ended March 31, 2016$2.50$0.35 
Fiscal Year Ending December 31, 2015HighLow
Quarter ended March 31, 2015$3.74$0.85
Quarter ended June 30, 2015$8.08$0.54
Quarter ending September 30, 2015$6.20$2.10
Quarter ending December 31, 2015$1.95$0.85
Fiscal Year Ended December 31, 2014HighLow
Quarter ended March 31, 2014$8.50$4.25
Quarter ended June 30, 2014$8.50$3.40
Quarter ended September 30, 2014$10.20$3.40
Quarter ended December 31, 2014$4.25$0.85

Stockholders
As of April 14, 2016, there were approximately 1,325 stockholders of record of our 6,586,711  outstanding shares of common stock.  This does not reflect persons or entities that hold their stock in nominee or “street” name through various brokerage firms.
Dividend Policy

DIVIDEND POLICY

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.  We intend to retain all available funds and any future earnings to fund the development and expansion of our business.  Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

25
23

DILUTION

If you invest in our units in this offering, your interest will be diluted to the extent of Contents

the difference between the assumed public offering price per share of common stock that is part of the unit and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering.

Our net tangible book value is the amount of our total tangible assets less our total liabilities. Our net tangible book value as of June 30, 2019 was $        , or $        per share of common stock. Pro forma net tangible book value gives effect to receipt of $540,000 net cash proceeds from the Bridge Financing and the issuance of the Debentures in the aggregate principal amount of $600,000. Our pro forma net tangible book value as of June 30, 2019, giving effect to the Bridge Financing would have been approximately $        , or $        per share of our as adjusted outstanding common stock.

Pro forma as adjusted net tangible book value is our pro forma net tangible book value, the repayment of Debentures plus the effect of the sale of units in this offering at the assumed public offering price of $        per unit and after deducting the underwriting discounts and commissions and other estimated offering expenses payable by us. Our pro forma as adjusted net tangible book value as of June 30, 2019 would have been approximately $        , or $        per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value of approximately $        per share to our existing stockholders, and an immediate dilution of $        per share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors.

The following table sets forth our selected financial data forillustrates this per share dilution:

Assumed public offering price per share (attributing no value to the warrants)$
Net tangible book value per share as of June 30, 2019$

Increase in as adjusted net tangible book value per share attributable to the

Bridge Financing

$
Pro forma net tangible book value per share as of June 30, 2019$

Increase in pro forma as adjusted net tangible book value per share after this

offering

$

Pro forma as adjusted net tangible book value per share after giving effect to

this offering

$

Dilution in pro forma as adjusted net tangible book value per share to new

investors

$

Each $0.50 increase (decrease) in the periods andassumed public offering price of $          per unit would increase (decrease) the pro forma as of the dates indicated.  You should read the following selected financial data in conjunction with our audited and unaudited financial statementsadjusted net tangible book value per share by $          , and the related notes thereto included elsewheredilution per share to new investors in this offering by $          , assuming the number of units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Each increase of 500,000 in the number of units sold in this offering would increase (decrease) our pro forma as adjusted net tangible book value by approximately $          and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of this prospectus.

The statement of operations data for the years ended 2014 and 2015, and the balance sheet data as of December 31, 2015 and 2014, are derived from our audited financial statements included elsewheredilution per share to new investors in this prospectus.
Our historical results areoffering by $          , assuming that the assumed public offering price per unit remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

The information above assumes that the Representative does not necessarily indicativeexercise its over-allotment option. If the Representative exercises its over-allotment option in full, the pro forma as adjusted net tangible book value will increase to $           per share, representing an immediate increase to existing stockholders of the results that may be expected in the future$           per share and interim results are not necessarily indicativean immediate dilution of results$           per share to be expected for any other period or the full year.

  December 31, 
  2014  2015 
       
  
(in thousands)
 
Cash and cash equivalents $64  $4 
Total assets $562  $337 
         
Accounts payable, accrued expenses and other
liabilities
 $5,261  $   653 
Deferred revenue  17   -- 
Warrant liability  6,371   1,802 
Notes payable  927   50 
Common and preferred stock  637   6 
Additional paid-in capital  25,047   39,779 
Treasury stock  (113)  (113)
Deferred compensation  --   1,842 
Accumulated deficit  (37,696)  (39,998)
Total stockholders’ deficit  (12,126)  (2,168)
Total liabilities and stockholders’ deficit $562  $337 


  Year  Year 
  Ended  Ended 
  December 31,  December 31, 
  2014  2015 
TOTAL NET REVENUE $124,598  $217,268 
COST OF SALES  113,024   65,723 
GROSS PROFIT  11,574   151,545 
OPERATING EXPENSES        
      General and administrative  811,916   449,483 
      Legal and accounting  344,903   458,801 
      Payroll expenses  1,611,376   1,875,488 
      Research and development  10,590,271   2,412,833 
      Sales and marketing  218,443   197,430 
    Total operating expenses  13,576,909   5,394,035 
LOSS BEFORE OTHER INCOME  (13,565,335)  (5,242,490)
OTHER INCOME (EXPENSE)        
Interest expense  (199,364)  (61,438)
Gain (loss) on extinguishment of debt  (82,000)  332,523 
Change in fair value of warrants  5,128,204   2,669,520 
Change in fair value of embedded derivative liability  800,000   - 
   5,646,840   2,940,605 
NET LOSS $(7,918,495) $(2,301,885)
LOSS PER SHARE        
  BASIC $(2.22) $(0.47)
  DILUTED $(2.22) $(0.47)
You should read the followingnew investors. 

The foregoing discussion and analysistable do not take into account further dilution to new investors that could occur upon the exercise of our financial condition and results of operations together with “Selected Financial Data” and our financial statements andoutstanding warrants having a per share exercise or conversion price less than the related notes appearing elsewhereper share offering price to the public in this prospectus.  In additionoffering.

We may choose to historical information, this discussion and analysis contains forward-looking statementsraise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that involve risks, uncertainties and assumptions.  Our actual results may differ materially from those discussed below.  Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

Overview
VerifyMeadditional capital is a technology pioneer in the anti-counterfeiting industry. This broad market encompasses counterfeiting of physical and material goods and products, as well as counterfeiting of identity in digital transactions. We deliver security solutions for identification and authentication of people, products, packaging and material goods for a variety of applications in the security field for both digital and physical transactions. Our products can be used to manage and issue secure credentials, including national identification documents, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications.
Recent Developments
In connection with our February 2016 offering, we issued in the aggregate 3,087,500 shares of Series C Preferred Stock at a purchase price of $0.40 per share with gross proceeds to us of $1,235,000. In connection withraised through the sale of equity or convertible debt securities, the Series C Preferred Stock, we issuedissuance of these securities could result in further dilution to our stockholders.

The above discussion and table are based on 109,321,833 shares of common stock outstanding as of June 30, 2019, and does not give effect to the purchasers warrants to purchase in the aggregate 3,087,500potential reverse stock split or include, as of that date:

·     22,126,088 shares of our common stock issuable upon exercise of outstanding warrants at ana weighted average exercise price of $0.40$0.32 per share. Each share as of Series C Preferred Stock is convertible into one share of common stock, subject to adjustment.

On June 12, 2015, we entered into definitive agreements to restructure the overall capitalization of our company.  The transaction involved the conversion of several outstanding debts owed to various holders of promissory notes previously executed by us into30, 2019;

·     19,613,529 shares of our common stock and shares of our newly-created Series B Preferred Stock; the conversion of warrants previously issued concurrently with the promissory notes for shares of our common stock; and the conversionissuable upon exercise of outstanding royalty payments owed by us into shares of newly-created Series B Preferred Stock.  In addition, we received cash investments from multiple investors in exchange for the issuance of shares of our Series A Preferred Stock and shares of our common stock.

On July 14, 2015, we filed Articles of Amendment to our amended and restated articles of incorporation with the Secretary of State of the State of Nevada reflecting a name change from LaserLock Technologies, Inc. to VerifyMe, Inc.  The name change was effective as of 12:00 am on July 23, 2015.  The name change was effected in accordance with the provisions of our organizational documents and the corporate laws of the State of Nevada.
Simultaneously with the name change, we effected a reverse stock split of our currently issued and outstanding common stock, par value $0.001 per share, and currently issued and outstanding Series A Preferred Stock and Series B Preferred Stock, par value $0.001 per share,options at a split ratioweighted average exercise price of 1-for-85.  The reverse stock split was effective as of 12:00 am on July 23, 2015.  As a result of the reverse stock split, every 85 pre-split$0.14 per share;

·     17,062,500 shares of our common stock and preferred stock issued and outstanding immediately prior to July 23, 2015, were automatically exchangedthat are reserved for one post-split share ofequity awards that may be granted under our capital stock with any fractional shares resulting from the reverse stock split being rounded up to the nearest whole share. The total number of authorized shares of our capital stock remains unchanged at its current total of 750,000,000, with 675,000,000 designated as common stockexisting equity incentive plans; and 75,000,000 designated as preferred stock.

Furthermore, we have made several recent changes to our management team.  Effective May 5, 2015, Paul Donfried was appointed as our Chief Executive Officer, replacing our former Chief Executive Officer Neil S. Alpert. In addition, we recently appointed two new members to our management team.  On June 12, 2015, Sandy Fliderman was appointed our Chief Technology Officer.  Mr. Fliderman commenced his position with us on June 16, 2015.  We have entered into an employment letter with Mr. Fliderman, dated June 16, 2015, which governs the terms of his employment.  On July 9, 2015, Ben Burrell commenced his position with us as our Chief Operating Officer.  We entered into an offer letter with Mr. Burrell, dated June 12, 2015, which governs the terms of his employment.
Additionally, we have recently had new directors appointed to our board of directors.  Our board of directors appointed Lawrence Schafran to a vacant seat on our board of directors on September 30, 2015, whereby Mr. Schafran is to serve as a director until our next annual meeting and until his successor is duly elected and qualified.  Mr. Schafran was appointed as the chair of our audit committee and as a member of the compensation committee and nominating and corporate governance committee. Furthermore, our board of directors appointed Michael Madon to a vacant seat on our board of directors on February 29, 2016.  Mr. Madon is to serve as a director until our next annual meeting and until his successor is duly elected and qualified.  Mr. Madon was also appointed as chairman of the board of directors.
Results of Operations
Comparison of the Years Ended December 31, 2015 and 2014
The following discussion analyzes our results of operations for the years ended December 31, 2015 and 2014. The following information should be considered together with our financial statements for such periods and the accompanying notes thereto.
Revenue/Net Loss
We have not generated significant revenue since our inception. For the years ended December 31, 2015 and 2014, we generated revenues of $217,268 and $124,598. Our net loss was $2,301,885 for the year ended December 31, 2015, a decrease of $5,616,610 from a net loss of $7,918,495 for the year ended December 31, 2014, primarily as a result of closing our Washington, D.C. office, a reduction in share-based compensation and other cost conservation measures.
Cost of Sales
For the years ended December 31, 2015 and 2014, we incurred proprietary technology costs of sales of $65,723 and $113,024. Cost of sales is significantly lower for the year end December 31, 2015, since we receive a commission on the number of units produced and our customer was able to produce more units with less of our product.
General and Administrative Expenses
General and administrative expenses were $449,483 for the year ended December 31, 2015 compared to $811,916 for the year ended December 31, 2014, a decrease of $362,433. The decrease is attributable to the closing of the office in Washington, D.C., the reduction in staff and associated costs as well as a concentrated effort to contain costs. However the Company incurred additional cost during the year ended December 31, 2015, including, bad debt write off of $62,125 of receivables and increases in public company filing costs.
Legal and Accounting
Legal and accounting fees increased $113,898 to $458,801 for the year ended December 31, 2015 from $344,903 for the year ended December 31, 2014. The increase in legal and accounting fees between the periods was related to the Recapitalization Transaction (as defined hereinafter) in June 2015, and the settlement of old accounts payable.
Payroll Expenses
Payroll expenses increased to $1,875,488 for the year ended December 31, 2015 from $1,611,376 for the year ended December 31, 2014, an increase of $264,112. The majority of the increase was the expense of the fair market value of options issued to the Board and the officers of the Company aggregating approximately $1,260,000 in 2015, compared to $860,000 in 2014.
Research and Development
Research and development expenses decreased $8,177,438 to $2,412,833 for the year ended December 31, 2015 from $10,590,271 for the year ended December 31, 2014. The decrease in research and development expenses was due to warrants and shares issued, with a fair value of $10,236,089, for the year ended December 31, 2014 related to the Patent and Technology License Agreement entered into on December 31, 2012 as compared to $2,000,000 in 2015.
Sales and Marketing
Sales and marketing expenses for the year ended December 31, 2015 were $197,430 as compared to $218,443 for the year ended December 31, 2014, a decrease of $21,013. The Company has reduced expenditures such as sales related travel and certain advertising programs that it has concluded were not generating revenue.
Interest Expense
During the year ended December 31, 2015, we incurred interest expense of $61,438, as compared to $199,364 for the year ended December 31, 2014, a decrease of $137,926. The decrease in interest expense relates to the conversion of notes payable and accrued interest into common stock as part of the Recapitalization Transaction in June 2015.
Gain (Loss) on Extinguishment of Debt
The gain from extinguishment of debt was $332,523 for the year ended December 31, 2015, compared to a loss of $82,000 for the year ended December 31, 2014. The gain on extinguishment of debt was a result of the excess fair value of the notes payable and accrued interest over the value of the common stock issued, and accrued interest thereon, that were part of the Recapitalization Transaction in June 2015.
Change in Fair Value of Warrants
During the year ended December 31, 2015, the Company incurred a change in the fair value of warrants of $2,669,520 as compared to $5,128,204 for the year ended December 31, 2014. The change resulted from the re-valuation of warrants associated with the Investment Agreement entered into on December 31, 2012, the Subscription Agreement entered into on January 31, 2013 and the notes payable issued during 2014. The value of the warrant liability has decreased because most of the warrants were converted to common stock as part of the Recapitalization Transaction in June 2015. Additionally, as part of the Recapitalization Transaction, certain warrants were converted to     4,000,000 shares of common stock and the associated liabilityissuable upon exercise of $1,867,417 was reclassified to additional paid-in capital.
Change in Fair Value Embedded Derivative Liability
During the year ended December 31, 2015, the Company incurred $0 for the change in fair value of the embedded derivative liability as compared to a gain of $800,000 for the year ended December 31, 2014. The change derived from the common stock price decreasing below the value of the conversion option associated with the Subscription Agreement entered into on January 31, 2013 for the year ended December 31, 2014. Because the Series A Preferred Stock was converted into shares of common stock with the Recapitalization Transaction in June 2015, the embedded derivative liability no longer exists and no valuation or adjustment will be neededDebentures in the future as a result.
Liquidity and Capital Resources
Net cash used in operating activities decreased $524,702 to $1,495,315 for the year ended December 31, 2015 as compared to $2,020,017 for the year ended December 31, 2014.  The decrease resulted primarily from reductions in accounts payable.
Net cash used in investing activities was $2,532 for the year ended December 31, 2015, materially unchanged from $0 for the year ended December 31, 2014. 
Net cash provided by financing activities increased by $640,043 to $1,438,043 for the year ended December 31, 2015 from $798,000 for the year ended December 31, 2014.  Cash provided by financing activities during the year ended December 31, 2015, consisted of our Series A Preferred Stock offering and Common Stock offering which raised $1,328,501 in June 2015.
Since our inception, we have focused on developing and implementing our business plan. Our business plans are dependent on our ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through future public offering of our securities.  In June 2015, as part of the Recapitalization Transaction, we raised approximately $1,328,000 as described in detail below. In our February 2016 offering, the Company$600,000 issued 3,087,500 shares of Series C Preferred Stock at a purchase price of $0.40 per share with gross proceeds to the Company of $1,235,000. In connection with the sale of the Series C Preferred Stock, the Company issued to the purchasers warrants to purchase in the aggregate 3,087,500 shares of the Company’s common stock atBridge Financing, assuming an exercise price of $0.40$0.15 per share. Each share of Series C Preferred Stock is convertible into one share of common stock, subject to adjustment.

26
Even with this infusion of capital, we do not believe that our existing cash resources will be sufficient to sustain our operations during the next twelve months,

OUR BUSINESS

Overview

 We are a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and we may need to raise additional funds in the future. We intend to raise such financing through private placements and/or the sale of debttrace features for labels, packaging and equity securities, of which there is no assurance.products. The issuance of additional equity would result in dilution to our existing shareholders. If we are unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms favorable to us, we may be unable to execute upon our business plan or pay our costs and expensesCompany was formed as they are incurred, which could have a material, adverse effect on our business, financial condition and results of operations.

Even if we are successful in raising sufficient capital, in order to continue in business as a viable going concern our revenues need to reach a level that sustains our business operations. While it is impossible to predict the amount of revenues, if any, that we may receive from our products, we presently believe, based solely on our internal projections, that we will generate revenues sufficient to fund our planned business operations if the products are marketed effectively in accordance with our plans. There can be no assurance that we will raise sufficient proceeds, or any proceeds, for us to implement fully our proposed business plan. Moreover there can be no assurance that even if our products are marketed effectively, that we will generate revenues sufficient to fund our operations. In either situation, we may not be able to continue our operations and our business might fail.
As of March 30, 2016 we had cash resources of approximately $670,000.
As we have not realized significant revenues since our inception, we have financed our operations through public and private offerings of debt and equity securities. We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution. The following sets forth our primary sources of capital during the previous two years.
On or about June 12, 2015, the Company entered into definitive agreements to restructure the overall capitalization of the Company (the “Recapitalization Transaction”). To effectuate the Recapitalization Transaction, the Company entered into a Master Acquisition Agreement (the “Master Agreement”) with OPC Partners LLC, a Delaware limited liability company (“OPC”), VerifyMe Inc., a Texas corporation (“VFM”), ZaahLaserLock Technologies, Inc., a Delaware corporation (“Zaah”), and an additional private investor (the “Private Investor”).
Pursuant to the Master Agreement, the Company entered into several other material definitive agreements (collectively, the “Transaction Documents”) required to consummate the Recapitalization Transaction. A brief summary of the Transaction Documents is included below. Each of the Transaction Documents was entered into effective as of June 12, 2015, upon the closing of the Recapitalization Transaction.
Note Conversion Agreement. The Company entered into various Note Conversion Agreements with various holders of promissory notes executed by the Company (the “Noteholders”), pursuant to which the Noteholders converted $731,426 of outstanding notes and accrued interest (net of gain on conversion of $297,370) into 57,265,030 shares (pre-Reverse Stock Split) of restricted non-trading common stock of the Company at a conversion rate of one (1) share of common stock per $0.018 of outstanding principal and interest.
Warrant Conversion Agreement. The Company entered into various Warrant Conversion Agreements with various holders of warrants for the Company’s common stock (the “Warrantholders”), pursuant to which the Warrantholders converted 3,700,000 outstanding common stock warrants into 3,700,000 shares (pre-Reverse Stock Split) of restricted non-trading common stock of the Company at a conversion ratio 1:1.
Preferred Stock Conversion Agreement. The Company and VFM entered into a Preferred Stock Conversion Agreement, pursuant to which VFM converted 21,111,111 shares (pre-Reverse Stock Split) of Series A Preferred Stock of the Company that it currently owns into shares of common stock of the Company on a 1:1 basis (pre-Reverse Stock Split).
Patent and Technology License Termination Agreement. Pursuant to a Patent and Technology License Termination Agreement, the Company and VFM terminated that certain Patent and Technology License Agreement, dated as of December 31, 2012, by and between the Company and VFM (the “License”), and VFM agreed to receive eighty five (85) shares (pre-Reverse Stock Split) of Series B Preferred Stock in complete satisfaction of $4,500,000 in past due license payments and $2,000,000 exclusivity payments owed by the Company under the License.
Termination of Registration Rights. Pursuant to a Registration Rights Termination Agreement, the Company and VFM have terminated that certain Registration Rights Agreement, dated as of December 31, 2012, by and between the Company and VFM.
Termination of Technology and Services Agreement. Pursuant to a Technology and Services Agreement Termination Agreement, the Company and VFM terminated that certain Technology and Services Agreement, dated as of December 31, 2012, by and between the Company and VFM.
Termination of Investment Agreement. Pursuant to an Investment Agreement Termination Agreement, the Company and VFM terminated that certain Investment Agreement, dated as of December 31, 2012, by and between the Company and VFM.
Patent Purchase Agreement. The Company and VFM entered into and consummated a Patent Purchase Agreement, transferring and assigning over to the Company all of VFM’s rights, title and interest into certain U.S. patents and pending U.S. patent applications.
Termination of Zaah Technology and Services Agreement. Pursuant to a Technology and Services Agreement Termination Agreement, the Company and Zaah terminated that certain Technology and Services Agreement, dated as of December 31, 2012, by and between the Company and Zaah.
Series A Preferred Stock Subscription Agreement. The Company entered into a Subscription Agreement with OPC, pursuant to which the Company issued 37,564,767 shares (pre-Reverse Stock Split) of Series A Preferred Stock to OPC for a cash investment $1,278,501, plus the conversion of deferred compensation, notes payable and accrued interest amounting to $171,813, into the Company by OPC.
Common Stock Subscription Agreement. The Company entered into a Subscription Agreement with the Private Investor, pursuant to which the Company issued 25,906,736 shares (pre-Reverse Stock Split) of restricted non-trading common stock to the Private Investor for a cash investment of $50,000 into the Company by the Private Investor.
Series B Preferred Stock Subscription Agreement. In connection with the termination of the License with VFM, the Company entered into a Subscription Agreement with VFM, pursuant to which to the Company issued 85 shares (pre-Reverse Stock Split) of Series B Preferred Stock to VFM.
The foregoing description of the Master Agreement and the related Transaction Documents is a summary, and does not purport to be a complete description of the Master Agreement and the related Transaction Documents, and is qualified in its entirety by reference to the Master Agreement and the related Transaction Documents, copies of which are filed as Exhibits 10.1, 10.2 and 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on June 18, 2015.
Off-Balance Sheet Arrangements
As of December 31, 2015, we did not have any relationships with unconsolidated entities or financial partners, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.
Critical Accounting Policies
Our financial statements are impacted by the accounting policies used and the estimates and assumptions made by management during their preparation. A complete summary of these policies is included in note 1 of the notes to our financial statements included elsewhere herein. We have identified below the accounting policies that are of particular importance in the presentation of our financial position, results of operations and cash flows and which require the application of significant judgment by management.
Stock-based Compensation
We account for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
We account for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options at the end of each period.
Revenue Recognition
In accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition (Codified in FASB ASC 605), we recognize revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
Recently Issued Accounting Pronouncements
Recently issued accounting pronouncements are discussed in Note 1 of the Notes to Financial Statements contained elsewhere in this registration statement.
Overview
VerifyMe, Inc. was incorporated in Nevada on November 10, 1999 under1999. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the name LaserLock Technologies, Inc.patent pending VeriPAS™ software system in 2018 which covertly and overtly serializes products to track a product’s “life cycle” for brand owners. We changed our name to VerifyMe, Inc. effective July 23, 2015.  VerifyMebelieve VeriPAS™ is the only invisible covert serialization and authentication solution deployed through variable digital printing on HP Indigo printing systems with a technology pioneersmartphone tracking and authentication system. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the anti-counterfeitingfield – designed to allow investigators to quickly and digital authentication industries. These broad markets encompass counterfeitingefficiently authenticate product throughout the distribution chain, including warehouses, ports of material goods,entry, retail locations, and product purchased over the Internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and packaging, as well as counterfeitingwhere they are deployed with geo location mapping and intelligent programable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of identity in digital transactions.engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We deliver security solutions forhave not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the identification and authenticationsale of people, products and packaging inour RainbowSecure® technology.

We believe the context of both digital and physical transactions. Our productsbrand protection technologies we own, once fully developed, can be used to manage and issue secure credentials, including national identification documents, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications.

The challenges associated with digital access control and identity authentication are problems that are highly relevant in the world today. Consumers, citizens, employees, governments and employers demand comprehensive solutions that are reliable but not intrusive. The current widespread use of passwords or PINs for authentication has been proven insecure and inadequate. Individuals increasingly expect anywhere-anytime experiences—whether they are making purchases, crossing borders, accessing services or logging into online accounts or corporate resources. They expect those experiences to ensure the protection of their privacy and to provide uncompromising confidentiality.
We believe that the digital technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from identitybrand protection, product diversion and authentication to the management of legacy passwords and PINs. We empower our customers to take advantage of the full capabilities of smart mobile devices and provide solutions that are both simple to use and deliver the highest level of security. These solutions can be applied to corporate networks, financial services, e-gov services, digital wallets, mobile payments, online entertainment, subscription services, and social media.
Our digital technologies involve the utilization of multiple authentication mechanisms, some of which we own and some of which we license.  These mechanisms include biometric factors, knowledge factors, possession factors and location factors.   Biometric factors include facial recognition with liveness detection and fingerprint on supported devices.  Knowledge factors include a personal gesture swipe and a secret color. The secret color contains a unique safety feature which allows the user to select either their normal, safe color when they willingly participate in a transaction or they can select their duress color, if they are under form of coercion. Possession factor includes devices that the user has in their possession such as a smartphone, smart watch, and other wearable computing devices.  The location factor geo-locates the user during a secure login.  We surround these authentication mechanisms with proprietary systems that improve the usability and the security of the solutions. Our solutions allow the assessment and quantification of risk using a sophisticated heuristic scoring mechanism.  We have specialized systems that perform ‘liveness’ detection to insure the subject of authentication is in fact a live human being. We have systems that introduce learning capabilities into our solutions to improve the ease of use and flexibility.

Brand owners, government agencies, professional associations, and others all share in the challenge of responding to counterfeit goods and product protection issues. Counterfeit goods span across all most every industry including currency, tax stamps, lottery tickets, passports, ID cards, pharmaceuticals, apparel, accessories, music, software, food, beverages, tobacco, automobile and airplane parts, consumer goods, toys and electronics. Described by the U.S. Federal Bureau of Investigation as the crime of the twenty-first century, product counterfeiting accounts for an estimated 5% of global trade and wreaks dire global health, safety and economic consequences on individuals, corporations, government and society.
We believe that the physical technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from counterfeit identification to employee or customer monitoring. Potential applications of our technologies are available in different types of products and industries—e.g., banking, gaming, apparel, tobacco, fragrances, pharmaceuticals,cosmetics, food, beverages, plastics, metal, event and transportation tickets, manufactured goods, fabrics, parts, driver’s licenses, insurance cards, passports, computer software, and credit cards. We generatehave commercial generating sales through licensesre-seller agreements of our technology orand through direct sales of our technology.
technology to global brand owners, label and packaging printers. 

Our physicalbrand protection technologies involve the utilization of invisible and/or color changing/shifting pigment,changing inks, which when incorporated into inks, dyes & resins are compatible and printed with today’s digital and standard printing machines and other manufacturing technologies. Expressed aspresses. The inks they may be used with certain printing systems such as digital, offset, flexographic, silkscreen, gravure, inkjet and digital.toner based laser printers. The inks can be printed in both a static image and variable image utilizing digital printing presses and third party digital inkjet systems which are attached to traditional printing presses. Our invisible ink can be a fixed image, variable image or a serialized code, bar code or QR code. We have developed a product which attaches to a smart-phone that reads our invisible ink codes into sophisticated cloud based track and trace software. We also have a product that informs users that our invisible ink is present for authentication. Based upon our experience, we believe that the ink technologies canmay be incorporated into most existing manufacturing processes.

2018 was a year of continued product development and early stage revenue generation. Prior to such time, we were primarily engaged in the research and development of our technologies. In order to penetrate the security printing market, we modernized our invisible ink technology, called RainbowSecure®. We created the ability to utilize RainbowSecure® as an invisible code that contained data that could be read into sophisticated software that resides in the cloud. To accomplish this task, we created a device that attaches to a smart phone, our Smart Phone Authenticator™. After several prototypes, this device was successfully tested in 2018 and is now being manufactured. The first units have been leased to one customer in Taiwan and one customer in the United States and are ready for leasing to brand owners, inspectors and print service providers around the world.

In conjunction with the new smart phone reading device, we finalized our VeriPASTM software which is based in the cloud and gives brand owners the ability to monitor, control and protect their products life cycle. This software resides in the cloud and brand owners access it over the internet. The software generates serialization codes which the brand owner purchases from us. These codes are then printed on labels and packaging in both visible codes for consumers to engage and invisible codes known as RainbowSecure® which trained brand inspectors review with our reading device.

We signed three contracts with print service providers in 2018. In February 2018, we entered into a reseller agreement with the GLM. This particular label printer began printing our technology in July 2018 and has major brand owners as clients which can utilize our technologies to protect their product labels and packaging from counterfeiting and product diversion. This label printer owns and operates printers and manufacturing equipment which can implement our technology. This reseller also has manufacturing facilities around the globe.

In 2018, we entered into two other reseller agreements with print service providers (“PSP”). One of these PSPs is testing for a global consumer products company.

Additionally, in March 2018, we entered into a strategic partnership with S-One Labels and Packaging LLC, a division of S-One LP (“S-One”). S-One provides companies with product and sales channels, technical and marketing support, digital development support, and distribution channels through the other companies which have partnered with S-One. S-One has agreed to provide us with global sales, distribution, and promotion support for our products and will employ a representative that will be solely dedicated to promoting our products. Under the terms of our agreement with S-One, S-One will act as a sales and marketing contractor for our printed products and services on a global basis and will assist us in fulfilling our obligations under our signed current and future reseller agreements with global and domestic print providers and brand owners. 

27

We believe revenue will continue to grow in 2019 due to the development and leasing of our new smart phone reading devices, the addition of our new VP of Business Development who was hired in late 2018, the completed training of our marketing and sales partner, S-One, and the installation of our products into the HP Experience Centers located in Tel Aviv, Israel, Singapore, Barcelona, Spain and Alpharetta, Georgia, where customers can perform tests and get hands on experience with our technologies.

Recent Developments

Effective as of May 30, 2019, we entered into a leasing agreement and purchase agreement with a Forbes Top 50 Private Company that sells nutrition, personal care, beauty and home care products around the globe. This is our first direct contract with a brand owner who prints its own packaging and labels using HP Indigo printing presses. They lease our equipment and software including VeriPAS™ technology products in conjunction with HP Indigo printing presses, our strategic partner. This one year leasing agreement can be terminated by either party upon 90 days’ prior notice.

On May 28, 2019, pursuant to a memorandum of understanding, we began a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. The specially formulated inks will enable these printing presses to print our RainbowSecure® invisible ink technology, which includes our variable VeriPAS™ serialization, track and trace technology. Pursuant to the memorandum of understanding, either party may termination the strategic partnership at any time after September 1, 2019.

On May 3, 2019, we entered into a one year leasing contract with Identity Management Systems Co., Ltd., for the lease of one of our new smartphone readers which includes the VeriPAS™ technology. This lease is expected to allow us to introduce and sell our products and services to the East Asia markets. The contract can be terminated by either party with 90 days’ prior notice.

On April 24, 2019, we entered into a license agreement with Niagara, a western New York label manufacturer with 33 years’ experience. The license allows Niagara to offer our brand protection technology solutions to brand owners throughout the United States through the leasing of our smart phone authentication devices. These authentication devices read the invisible RainbowSecure® codes into the cloud and are recorded in our serialization, track and trace software platform, VeriPAS™. This license has a one year term that automatically renews for successive one year terms unless 90 days’ prior notice of non-renewal is given by either party. The agreement can also be terminated by either party with 90 days’ prior notice.

On April 11, 2019, we entered into a one year reseller agreement with Arca, a leading label and packaging company based in Milan, Italy. Pursuant to the agreement, we offer our brand protection technology solutions to brand owners throughout Europe through the leasing of our patented smart phone authentication devices which read the invisible codes into the cloud and are recorded in the Company’s VeriPAS™ platform. Our devices are expected to be leased to brand owners by Arca in exchange for recurring revenue. The agreement can be terminated by either party with 90 days’ prior notice.

Brand Protection Printing Technology

In September 2017, we announced a five-year contract with HP Indigo, a leader in manufacturing digital printing presses.  These presses print both static and variable high-quality images such as personalized labels and packaging for major brand owners.  Our technology was tested and approved by HP Indigo for use on the HP Indigo 6000 series press models. It is currently being qualified for the larger HP Indigo 30,000 series.

This press is mainly used to print labels and packaging for major world-wide brand owners.  HP Indigo and VerifyMe incorporate VerifyMe's pigment products with HP Indigo's ElectroInk to be used for packaging, label authentication, anti-counterfeiting, anti-diversion and covert item level serialization for supply chain and distribution security.

This solution is marketed as RainbowSecure® powered by HP Indigo and sold globally by us to HP Indigo customers. The solution includes a HP Indigo security ElectroInk as well as our readers and authentication tools that can be used in conjunction with the security ElectroInk. Both companies provide support to HP Indigo customers that use the RainbowSecure® solution on HP Indigo's digital printing presses.

The HP Security ElectroInk containing RainbowSecure® is in an ink canister that is mounted into the digital Indigo printing press along with the other traditional ink stations.  Since the HP Indigo is a digital press, the RainbowSecure® technology prints covert serialization numbers, codes or images either fixed or variable mainly on labels and packaging which are revealed when using our hand-held authentication devices.

28

As an add-on track and trace feature of our RainbowSecure® covert imaging, we have contracted with Micro Focus International PLC, a global software developer to utilize their visible QR code system, GPAS, which is printed on labels and packaging along with our covert RainbowSecure® to store our hidden covert serial number in the cloud for product diversion investigators to authenticate with a proprietary app on a mobile device.  The Micro Focus GPAS allows customers to use their smartphone to scan a product’s QR code or send the code via a text message. Immediate results help verify whether the product is real or counterfeit. This helps save customers from potential physical harm and businesses from facing lawsuits, loss of revenue and brand erosion.  In addition to the anti-counterfeiting image, the Micro Focus Track and Trace software has a “big data” gathering system with real-time analytics which geographically locate and identify counterfeiting activity by using an easily configured rules engine. Our covert or invisible RainbowSecure® system works as an extra layer of protection for the GPAS system.  When a professional product investigator scans the Micro Focus visible QR code with a special app on a smart phone it brings him or her to our secure cloud application to see what the hidden serialization number printed by the HP Indigo is for that particular label or package.  The product investigator then uses the RainbowSecure® reading device to compare the hidden serialization number against the cloud number to prove authenticity.

Under the contract with Micro Focus, VerifyMe has a re-seller agreement where we sell the combined Micro Focus GPAS system with our RainbowSecure® identifier under our own trademarked name, VeriPASTM.

Under the terms of our agreement with GLM, GLM will be able to create and print labeling containing the RainbowSecure® ink technology.

HP has their own QR code track and trace system called, “HP Link Technology.”  HP Link competes with the Micro Focus GPAS system.  We are in continuing discussions to build a similar covert serialization number layer utilized in the Micro Focus GPAS system into HP Indigo’s Link system. Additional software development efforts will be required and we expect to continue the integration discussion with HP Link.

We also have a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. The specially formulated inks will enable these printing presses to print our RainbowSecure® invisible ink technology, which includes our variable VeriPAS™ serialization, track and trace technology.

In addition, effective as of May 30, 2019, we entered into a contract with a Forbes Top 50 Private Company that sells nutrition, personal care, beauty and home care products around the globe. The brand owner prints its own packaging and labels using HP Indigo printing presses. They lease our equipment and software including VeriPAS™ technology products in conjunction with HP Indigo printing presses, our strategic partner. This one year leasing agreement can be terminated by either party upon 90 days’ prior notice.

 We believe that the brand protection security technologies we own, once fully developed and coupled with our contract with HP Indigo, can be used to enable brand owners to securely prevent counterfeiting, prevent product diversion and authenticate labels, packaging and products and alleviate the brand owner’s liability from counterfeit products which physically harm consumers. Our covert technologies give the brand owner the ability to control, monitor and protect their products life cycle. Also, our technologies allow the brand owner to prove whether the product causing an issue is authentic or made by a counterfeiter. Our goal is to generate revenue through licenses and royalties of our technology and through direct sales of our technology.

In addition to packaging and labels, our brand protection security printing technologies can be applied to authenticate important credentials such as driver’s licenses, plastics, metal, apparel, birth certificates, immigration documents, gaming, apparel, currency, event and transportation tickets, passports, computer software, and credit cards.

29

Anti-Counterfeiting Technologies and Products

Recent developments in copying and printing technologies have made it easier to counterfeit a wide variety of documents and products.  Currency,We have organized the current state of counterfeiting into two types.  The first type is what we call “Traditional Counterfeiting” that includes mainly paper type documents and instruments such as bank checks, birth certificates, credentials, identification documents, stock certificates, currency, lottery tickets, credit cards, driver’s licenses, event and transportation tickets, casino slot tickets,coupons, and travelers’ checkschecks.  Most of the Traditional Counterfeiting targets are all susceptiblemainly paper type instruments which can be traditionally copied, scanned, color copied, hand drawn, etc., by both professionals and consumers alike.  The other type of counterfeiting we call “Modern Counterfeiting.”  Although Traditional Counterfeiting targets are extremely important and cause mainly financial harm, “Modern Counterfeiting” targets on the other hand are much more sophisticated.  Organized crime, consumers, small and large businesses, and even governments partake in Modern Counterfeiting.  Modern Counterfeiting consists of the actual counterfeiting of major brand owner’s products such as expensive luxury items like jewelry, purses, military items (sabotage), drug manufacturing, consumables like tobacco, alcohol, golf clubs and even food and beverages.  Not only is the packaging and labeling counterfeited, the actual products are counterfeited.  There are even reports of whole companies being counterfeited.

Not only are consumers at risk, brand owners are also at risk.  Normally brand owners are financially impacted when someone is selling or diverting their products.  The financial impact seems to counterfeiting.be the lesser of the risk factors.  We believe the additional, more impactful risk, facing brand owners and drug manufacturers is the liability issue.  A brand owner may be called to a court room to prove that a product is authentic or counterfeit to avoid major liability exposure in the form of judgements and fines, as well as the extremely severe negative marketing exposure for such issues.

Brand owners do not want their products published under the name of a product that injured or harmed a consumer.  Our covert RainbowSecure® technology can be utilized by brand owners to authenticate products, labels and packaging in those circumstances.  We believe that losses and liability from such counterfeiting have increasedis increasing substantially with improvements in counterfeiting technology. Counterfeiting has long caused losses to manufacturers of brand name products, and we believe that these losses have increasedtechnology as well as the counterfeitingproliferation of labelinghighly skilled and packaging has become easier.

well-funded counterfeiters.  It is therefore imperative that all brand owners, beverages, food and drug manufacturers utilize the best counterfeit prevention technologies available for their products.

We believe that our physical and material goodsbrand protection security anti-counterfeit technologies may be useful to businesses desiring to authenticate a wide variety of materials and products. The best solution for brand owners and manufacturers is to layer as many technologies as they can to protect their products.  Our technologies include (1)(i) a covert technology utilizing invisible ink taggant that can be revealed by use of a special calibrated laser lightslight for authentication purposes, (ii) an ink technology, which allows invisible codes to be printed, and authentication devices, (2)  an overt(iii) a color shiftingchanging technology that changes color under differentis activated by certain types of readily available lighting. These two differentlights. All of those technologies cannot be copied or scanned by the counterfeiter. We believe the useful life of our technologies on a label or package is at least 20 years.  Our technologies can be combinedprinted on labels and packaging and can also be applied to metals, plastics and textiles. Other possible variations of our laser-based technology involve multiple color responses from a common laser, visible marks of one color that turn another color with a second laser, or visible and invisible marks that turn into one solution and customized for individual customers & products.a multicolored image. These technologies provide users with the ability to authenticate products and detect counterfeit items not bearing these features.documents. Applications include the authentication of documents having intrinsic value, such as currency, checks, travelers’ checks, gift certificates and event tickets, and the authentication of product labeling and packaging. When applied to product labeling and packaging, alsoour technologies can be used to detect counterfeit products with labels and/or in packaging that do not contain the authenticating marks invisibly printed on the packaging or labels of legitimate products, as well as to combat product diversion (i.e., the sale of legitimate products through unauthorized distribution channels or in unauthorized markets). We believe that our technologies also could be used in a manner that permits manufacturers and distributors to track the movement or pinpoint geographically where counterfeiting of products is occurring.  We can track and trace from production to ultimate consumption when coupled with our VeriPASproprietary software.

30
In the past, we have focused on the widespread problem of counterfeiting in the gaming industry. We have incorporated our technology into traditional gaming accessories such as playing cards, casino chips, and dice as well as gaming-based machinery such as slot machines with cashless gaming systems. This is accomplished during the regular manufacturing and/or printing processes. Our products are incorporated in ink that is used for printing playing cards. Our products are also incorporated in resins used to manufacture dice and casino chips that can be authenticated with multiple low cost devices to verify the authenticity of the item.

Physical

Brand Protection and Material Goods Anti-Counterfeit Industry — Overview

Currency, passports, ID cards and other high-value documents have historically been subject to counterfeiting and forgery and continue to be today. Many consumer industries such as pharmaceutical, luxury goods and auto parts are also subject to significant counterfeiting. In the last 15 years, the counterfeiting of goods has increased significantly on a global basis and has become a major threat to brand owners in most industries. Major brands, whether national or multinational, are being systematically attacked, by sophisticated criminals. Furthermore, counterfeiting and forgery have filtered down to the level of small criminal groups due to the availability of digital scanning and copying technologies.
The U.S. is projected to remain the largest single consumer of security services and products in the world. One

We believe one of the most important new areas of expansionfor our technology is in the area of authentication, which is the act of confirming that objects such as currency, passports, casino chips, credit cards, stock certificates, pharmaceuticals, stamps, identification cards, lottery tickets, and so forth, are real and not forgeries. With the advent of the digital age,new technologies, including the color copier and other newprinting technologies and templates available onand the web, thieves and forgersavailability of the Internet, counterfeiters have been ablehad access to technologies which make near identical copiesit easier to produce counterfeit items. Counterfeiters are often located in foreign nations where counterfeiting is subject to little or no viable threat of almost any printed item, which has resulted in major financial losses to business and, importantly, has compromised security at critical installations. One particular problem is many of those engaging in such activities are overseas and far from the reach of U.S. law enforcement.

prosecution.

While some currency and credit cards have introduced holograms, seals, and embedded strips in order to add a level of protection, most such methodologies are expensive and, in some cases involve a time-consuming in the production process. In other instances, such as when printing packagingcigarette tax stamps or hundreds of millions of pieces used in high volume consumer goods industries,a popular restaurant chain’s contest game pieces, the authentication process must be extremely inexpensive and easy to use or it will not be rejected. Volumescost effective. Currently many national currencies lack a sufficient layer of protection to deter counterfeiting and can easily be counterfeited. 

Two Major Trends

We believe major shifts are occurring in these industrieshow counterfeit products enter the hands of consumers. Many consumers are purchasing counterfeit products online. In addition, biometric technology is becoming increasingly popular which can reach billions of unitstie individuals to their documents and transactions. We have multi-factor technology using biometrics in our digital verification technology. Our entry into the incremental costs for security features to authenticate genuine product have to be in the pennies or fraction of a cent. Our solutions meet all of these requirements.

Counterfeiting, product diversion, piracybiometrics technology business is further described below under “Digital Authentication Technologies and forgery create significant and growing problems to companies in a wide range of industries as well as governments and individuals worldwide. Products.”

Counterfeiting is a global problem, and it is a problem that appears to be increasing.  In March 2015, the International Chamber of Commerce’s (“ICC”) Business Action to Stop Counterfeiting and Piracy (“BASCAP”) issued a report on the “Roles and Responsibilities of Intermediaries: Fighting counterfeiting and piracy in the supply chain” that estimates the globalcontinuously evolving economic and social impacts of counterfeiting and piracy at $1.7 trillion annually.

Counterfeiting is one of the fastest growing economic crimes of modern times.crime. It presents companies, governments and individuals with a unique set of problems. What was once a cottage industryproblems and has now become a highly sophisticated network of organized crime that has the capacity to threaten the very fabric of national economies, endanger safety and threatens lives.  Itcounterfeiting.  Counterfeiting devalues corporate reputations, hinders investment, funds terrorism, and imposes costs hundreds of thousands ofupon many people their livelihood every year.

The Size of the Market Opportunity

Based on technology, the label and packaging market, including the anticounterfeit packaging industry, has been segmented as follows:

·Coding & printing technology (Track and Trace)

·Radio Frequency Identification (“RFID”)

·Hologram

·Security labels

·Packaging design

·Others (digital mass sterilization, digital mass encryption, and surveillance technologies)

The anti-counterfeiting industry is segmented into four general categories: (i) Optical technologies - use of light, i.e. holograms; (ii) Electronic - magnetic strips and smart cards; (iii) Biotechnologies - uses characteristics of biological proteins such as antibodies, enzymes and DNA; and (iv) Chemical technologies - includes photochromic (or light-reactive) and thermochromic (or heat-reactive) inks.

We operate in the chemical technologies and security ink sectors of the industry. Products in this industry change color when exposed to either heat or light and revert to their original color when exposed again. Generally, the effect is reversible as often as required. Inks have also been developed that are invisible to the human eye, but which can be read by bar-code scanners. These have been used in the fragrance and pharmaceutical industries to authenticate products. Other reactive inks change color when brought into contact with specific substances, such as ink from a felt-tipped pen.

We operate in the coding and printing technology, security labels segments in the anti-counterfeit packaging industry.

Recent developments in printing technologies have made it easier to counterfeit a wide variety of documents. Lottery tickets, gift certificates, event and transportation tickets and travelers’ checks are all susceptible to counterfeiting, and we believe that losses from such counterfeiting have increased substantially due to improvements in technology. Counterfeiting has long caused losses to manufacturers of brand name products, and we believe that these losses have increased as the counterfeiting of labeling and packaging has become easier.

31
According to the U.S. Department of Homeland Security seizure statistics, in the fiscal year 2014 the number of Intellectual Property Rights seizures was 23,140. The manufacturer’s suggested retail price (MSRP) of the goods had they been genuine was $1,226,347,540.

The Organization for Economic Cooperation and Development, has concludedin its published study in 2019, estimated that global trade related counterfeiting accounts for 3.3% of world trade or approximately $509 billion. They also conclude that millions of consumers are risking their lives by using unsafe and ineffective counterfeit products unknowingly.

Identification Cards

Printing and Secure Documents

Governments are increasingly vulnerable to counterfeiting, terrorism and other security threats at least in part because currencies, identity and security cards and other official documents can be counterfeited with relative ease. For instance, Havocscope, a company that collects black market intelligence and identifies security threats, reports that the value of counterfeit identification and passports is currently $100 million. Governments must also enforce the various anti-counterfeiting and anti-piracy regimes of their respective jurisdictions, which becomes increasingly difficult with the continued expansion of global trade. Our overt and covert ink pigment platform can provide secure, forensic, and cost-effective anti-counterfeiting, anti-piracy and identification solutions to local, state, and federal governments as well as the defense contractors and the other companies that do business with them. Our pigment solution cans be used for all types of identification and official documents, such as:
·passports;
·permanent resident, or “green” cards and visas;
·drivers’ licenses;
·Social Security cards;
·military identification cards;
·national transportation cards;
·security cards for access to sensitive physical locations; and
·other important identity cards, official documents and security-related cards.

Pharmaceuticals
The pharmaceutical industry faces major problems relative to counterfeit, diluted, or falsely labeled drugs that make their way through healthcare systems worldwide, posing a health threat to patients and a financial threat to producers and distributors. Counterfeit prescription pharmaceuticals are a growing trend, widely recognized as a public health risk and a serious concern to public health officials, private companies, and consumers. In January 2016, the World Health Organization (the “WHO”) published an updated Fact Sheet on substandard, spurious, falsely labelled, falsified and counterfeit (“SSFFC”) medical products. The key facts were as follows:

·SSFFC medical products may cause harm to patients and fail to treat the diseases for which they were intended.
·They lead to loss of confidence in medicines, healthcare providers and health systems.
·They affect every region of the world.
·SSFFC medical products from all main therapeutic categories have been reported to WHO including medicines, vaccines and in vitro diagnostics.
·Anti-malarials and antibiotics are amongst the most commonly reported SSFFC medical products.
·Both generic and innovator medicines are falsified including very expensive products for cancer to very inexpensive products for treatment of pain.
·They can be found in illegal street markets, via unregulated websites through to pharmacies, clinics and hospitals.

 In 2013, the WHO launched a global surveillance and monitoring system to encourage member states to report SSFFC incidents in a structured and systematic format. Over 920 medical products have so far been reported representing all main therapeutic categories and representing both innovator and generic medicines.
Based on this growing threat, many countries have started to address vulnerabilities in the supply chain by enacting legislation which, among other things, requires the implementation of a comprehensive system designed to combat counterfeit, diluted or falsely labelled pharmaceuticals.  These systems are often referred to as serialization, or in the United States as e-Pedigree (electronic pedigree).  One jurisdiction that has enacted such regulations is the state of California, which passed legislation requiring that 50% of all “dangerous drugs” (defined as all prescription drugs) that are distributed in California must be serialized and have an electronic pedigree in a phased approach from 2015 through 2017.
We believe that ePedigree and serialization requirements will likely be implemented in all aspects of the pharmaceutical supply chain, from the manufacturer to the packager, wholesaler, distributor and final dispensing entity. The ePedigree provides an “audit trail,” or documented evidence, to help to identify and catch counterfeiting and diversion. Serialization requires manufacturers, or third-party packagers in some virtual supply chains, to establish and apply to the smallest saleable unit package or immediate container a “unique identification number.” Our unique pigments embedded in the ink of a unique serialized barcode can provide a layered security foundation for a customer solution in this market.
Food and Beverage
Counterfeit food threats are becoming more common as supply chains become more global and as imaging and manufacturing technology become more accessible. Numerous reports of counterfeit foods have been reported, including long-grain rice labelled and sold as basmati rice, Spanish olive oil bottled and sold as Italian olive oil, and mixtures of industrial solvents and alcohol sold as vodka. Although many of these stories have emerged from the U.K. and Europe, the fake-food problem is also relevant in the United States.
On March 30, 2016, INTERPOL announced that more than 10,000 tonnes and one million litres of hazardous fake food and drink were seized in operations across 57 countries in an INTERPOL-Europol coordinated initiative to protect public health and safety. We believe our pigments and authentication tools can help in the battle against counterfeit foods and beverages.
Consumer Goods Packaging
Counterfeit items are a significant and growing problem with all kinds of consumer packaged goods, especially in the luxury retail and apparel industries.

Counterfeiting in packaging has greatly intensified in recent years, causing concerns for consumers and financial concern for businesses worldwide. As a result, the global anti-counterfeit packaging market is estimated to reach approximately $128.6 billion by the year 2019, according to Markets and Markets.  Billions of dollars per year are at stake for companies as they seek ways to ensure that the products sold with their logos and brandingbrands are authorized and authentic. The proliferation of counterfeiting requires brand owners and their converter/printer partners to work together to create a multi-layered protection plan so that their packaging and labels protect their brands and deter those trying to profit at their (and their reputation’s) expense.

Counterfeiters have become so good at their unlawful activity that spotting the difference between legitimate and counterfeit products can be daunting. Counterfeiters have many ways to subvert legitimate brands. These may include taking an out-of-date product and selling it in packaging and labels that have been forged; sometimes, the packaging, labels and product itself are all counterfeited. Counterfeiters might also use legitimate packaging coupled with fake products. We believe our pigment security systems are a cost-effective solution for printer and packagers and are easily integrated into their existing manufacturing process.

The Opportunity

As counterfeiting continues to increase and losses to manufacturers and others continue to escalate, we believe that those entities will seek better technologies to minimize their exposure. These technologies, however, must also be cost-effective, easy to integrate, and highly resistant to counterfeiting themselves.

We offer products in two related market segments. We offer security ink taggants in the anti-counterfeiting/authentication industry and we offer a software product called VeriPASTM in the identifier/track and trace industry.

Our Solutions

In the areas of authentication and serialization of physical goods, we offer clients the following products as anti-counterfeit systems:

·RainbowSecure™;RainbowSecure®

·SecureLight™;VeriPASTM Global Product Identifier, Track and Trace System

·SecureLight®

·SecureLight+™; and®

·Authentication tools.Smart Phone Authenticator™
RainbowSecureTM

·VerifyMe Beeper

RainbowSecure®technology was our first technology to be patented. It combines an invisible ink with a proprietary tuned laser to enable counterfeit products to be exposed. It has been widely acceptedIn 2017, we signed a five-year contract with HP Indigo to print this technology on packages and labels on their 6000 series digital Presses.  In December 2017, we signed a contract with Micro Focus to use RainbowSecure® in the gaming industry, where the technology has been used by casinos to protect their chips, dice,Global Product Authentication, Track and playing cards from fraud.Trace system (software). The technology also features a unique double layer of security which remains entirely covert at all times and provides licensees with additional protection. RainbowSecure™RainbowSecure® is particularly well-suited to closed and controlled environments, such as casinos that want to verify transactions within a specific area, as well as labels, packaging, textiles, plastics and metal products which need authentication. In May 2019, we entered into a strategic partnership with INX International Ink Company, the third largest producer of inks in North America, to co-develop inkjet inks to be used for inkjet printing in combination with high speed, high volume label and packaging printing presses. The specially formulated inks will enable these printing presses to print our RainbowSecure® invisible ink technology, which includes our variable VeriPAS™ serialization, track and trace technology. We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology.

32

VeriPAS™ technology combines the covert identifier of RainbowSecure® with the Micro Focus Track and Trace software which provides brand owners geographical business intelligence on counterfeiting as well as the ability to authenticate labels, packaging and products. We are not interested in outside public verification by consumers. Thespeaking with other serialization, track and trace software providers and expects to add alternatives to clients beyond the Micro Focus GPAS system. This technology is also appropriate for anti-counterfeit protection of tagscurrently being co-marketed with RainbowSecure® and labelsour Smart Phone Authenticator™ product. Several clients are in the apparel industry, where it can be applied to a variety of different materials in the form of dyes.

SecureLightTMtesting stage with this product. To date, we have not derived revenue from this technology.

SecureLight® technology was developed as a result of our investment in new proprietary color changing inks that could penetrate broader markets and result in far greater revenues.markets. During the past nine years,decade, we have refined our technologiestechnology and theirits applications, and now have what we believe to be the easiest, most cost effective and efficient authentication technologiestechnology available in the world today. Our technology, known as SecureLight™SecureLight®, takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in hundreds of new applications ranging from credit cards to driver’s licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologiestechnology can also be used to protect apparel, pharmaceuticals, and virtually any other physical product, such as fabrics, plastics, ceramics and metal. In 2018, we received notice that patents involving this technology were approved in various European nations. We are attempting to commercialize this product.

SecureLight+TM

SecureLighttechnology combines the covert characteristics of RainbowSecureRainbowSecure® and the overt characteristics of SecureLight.SecureLight®. This provides a solution which can be authenticated in two different ways - by proprietary tuned laser devices, and also by anyone with fluorescent lighting, including end consumers.

Authentication tools In 2018, we received notice that patents involving this technology were approved in various European nations. SecureLight+® has been successfully deployed in one country’s drivers’ licenses and another country’s voter registration card program. We have begun to commercialize this product.

Smart Phone Authenticator™ technology is a piece of hardware with a built in lighting system and software that scans invisible RainbowSecure® codes. Product investigators attach their smart phone to this device which then reveals the hidden RainbowSecure® images on the smart phone screen which are then sent to the VeriPASTM software in the cloud for authentication and data submission. These devices have been developedcommercialized and are being leased to customers. Leases are typically one year in length.

VerifyMe Beeper technology is an authentication tool which we sellare marketing to customers in conjunction with pigments and are tuned to authenticate the unique frequency of each batch. This allows for customers to instantly authenticate items with a customized beeper which will only positively identify a product bearing their unique anti-counterfeiting solution. This authenticationour RainbowSecure® ink pigment. Authentication is provided in the form of an LED indicator, a camera device which reveals the hidden serialization numbers and codes on a viewing screen and an audible ‘beep’.beeping device when placed on a label, product or package containing the RainbowSecure® technology. The hand held beeping device is tuned to authenticate the unique frequency of our RainbowSecure® invisible ink and will broadcast a beeping sound to confirm the authenticity when placed on products, labels and packaging containing our RainbowSecure® ink technology. The VerifyMe Beeper is designed for use by customers who desire instant authentication on items, such as event tickets at an entry gate. Our customized beeper will only positively identify a product bearing our unique anti-counterfeit solution. This technology is being commercialized and leased to customers.

Identification Cards and Secure Documents

Governments are increasingly vulnerable to counterfeiting, terrorism and other security threats at least in part because currencies, identity and security cards and other official documents can be counterfeited with relative ease. Governments must also enforce the various anti-counterfeiting and anti-piracy regimes of their respective jurisdictions which becomes increasingly difficult with the continued expansion of global trade. Our overt and covert ink pigment platform can provide secure, forensic, and cost-effective anti-counterfeiting, anti-piracy and identification solutions to local, state, and federal governments as well as the defense contractors and the other companies that do business with them. Our pigment solution can be used for many types of identification and official documents, such as:

33

·Passports;

·Permanent resident, or “green” cards and visas;

·Drivers’ Licenses;

·Social Security cards;

·Military identification cards;

·National transportation cards;

·Security cards for access to sensitive physical locations; and

·other important identity cards, official documents and security-related cards.

In connection with the development of our Smart Phone Authenticator™, we are currently seeking to expand our business in this market but have not yet generated sales in this area.

Pharmaceuticals

The pharmaceutical industry faces major problems relative to counterfeit, diluted, or falsely labeled drugs that make their way through healthcare systems worldwide, posing a health threat to patients and a financial threat to producers and distributors. We receivedbelieve counterfeit prescription pharmaceuticals are a U.S. patentgrowing trend, widely recognized as a public health risk and a serious concern to public health officials, private companies, and consumers. Counterfeiting can apply to both branded and generic products and counterfeit pharmaceuticals may include products with the correct ingredients but fake packaging, with the wrong ingredients, without active ingredients or with insufficient active ingredients.

Based on this threat, many countries have started to address vulnerabilities in the supply chain by enacting legislation which, among other things, requires the implementation of a comprehensive system designed to combat counterfeit, diluted or falsely labelled pharmaceuticals.  These systems are often referred to as serialization, or in the United States as e-Pedigree (electronic pedigree).

e-Pedigree and the Federal Drug Administration (“FDA”) mandated serialization requirements were implemented in November 2018 and are now required in all aspects of the pharmaceutical supply chain, from the manufacturer to the packager, wholesaler, distributor and final dispensing entity. The e-Pedigree provides an “audit trail,” or documented evidence, to help identify and catch counterfeiting and diversion. Serialization requires manufacturers, or third-party packagers in some virtual supply chains, to establish and apply to the smallest saleable unit package or immediate container a “unique identification number.” Our unique pigments embedded in the ink of a unique serialized barcode can provide a layered security foundation for a customer solution in this market.

The FDA implemented Title II of the Drug Quality and Security Act, entitled the “Drug Supply Chain Security Act.” This regulation requires drug manufactures to add product identifiers to certain prescription drug packages beginning in November 2018. We expect all pharmaceutical companies will eventually comply with the legislation at some point in the future. Our RainbowSecure® technology as well as our VeriPAS™ track and trace system can address the need for product identifiers. We plan on selling directly to detectthe pharmaceutical industry and authenticatetheir printers. We also expect to engage third party marketing and sales companies to present our solutions to the drug and pharmaceutical industry.

We have entered into a strategic partnership to assist us with marketing our products to the pharmaceutical industry.

Consumer Products

        Counterfeit items are a significant and growing problem with all kinds of consumer-packaged goods, especially in the luxury retail and apparel industries.  Our unique ink pigments can be incorporated in dyes and used by manufacturers in these industries to combat counterfeiting and piracy of actual physical goods. Our pigments expressed as inks can also be used on packaging, as well as to track products that have been lost in transit, whether misplaced or stolen. We currently have a contract to assist with securing certain cosmetic products.

34

Food and Beverage

Counterfeit food threats are becoming more common as supply chains become more global and as imaging and manufacturing technology become more accessible. There have been numerous reports of counterfeit foods, including long-grain rice labelled and sold as basmati rice, Spanish olive oil bottled and sold as Italian olive oil, and mixtures of industrial solvents and alcohol sold as vodka. Although many of these stories have emerged from the U.K. and Europe, the fake-food problem is also relevant in the United States.

We believe the fake-food problem is often due to product laundering, dilution and intentionally false labeling. We believe our pigments using a smartphone.and authentication tools can help in the battle against counterfeit foods and beverages. We are currently marketing our products in the process of developing this application and expect to have it in production this year. This will provide a very simple and inexpensive way for brand owners, supply chain/distribution chain and consumers to verify the authenticity of products, packaging and any material goods.


market.

Our Raw Material Suppliers

Our security pigments are manufactured from naturally occurring inorganic rare earth materials. The manufacturing process includes both chemical and mechanical elements. In many cases, we produce pigments that are unique to a particular customer or product line. This uniqueness can be achieved through a variety of techniques, including custom formulation or combination of our proprietary pigments and/or incorporation of other specialized taggents.

taggants.

There are many manufacturers of these types of specialized pigments and we intend to maintain multiple simultaneous relationships to ensure ample sources of supply.

Distribution

We currently distribute pigments directly to our customers. We are in discussions with an existing channel partner regarding an arrangement to use their secure facilities to house inventory and fulfill customer orders.

We provide pigment mixing instructions for the specific uses of each client based on their existing equipment and processes. We maintain policies and procedures to monitor, track and log access to and disposition of all pigment. Our customers are also required to agree to and implement these policies and procedures.

The company has also developed relationships with ink suppliers for formulation and mixing of inks and coatings, which can be provided directly to customers. Typically, inks and coatings are formulated and mixed individually for specific printing equipment and applications for different substrates. We have worked with ink suppliers to optimize the formulation of inks and coatings incorporating our pigments. Our ready supply of finished inks and coatings allows for customers to easily utilize our solutions.

Digital Authentication Technologies and Products

We believe accurate identification of human beings in electronic transactions, also known as Digital Identity Management, will continue to be a large and rapidly growing market. As more electronic transactions incorporateIn today’s world the exchange of value and money, theneed for verification of the unique identity of human beings participating in those transactions becomeshas become more important. In general, every electronic transaction has a least two actors – a subject and a relying party. The relying party has a business need to eliminate or reduce risk associated with the identification of the subject.

Electronic financial theft and electronic theft of private information often make headlines almost every day -according to a 2015 Identity Fraud Study released by Javelin Strategy & Research, in 2014, $16 billion was stolen from 12.7 million U.S. consumers. Theheadlines. We believe the majority of this harm can be traced to weak authentication systems, such as Username/Password,username/password, yet these weak systems continue to be used in most of the world’s transactional systems.

Cybersecurity is a growing threat requiring continuously evolving forms of electronic security.

Historically, stronger authentication solutions, such as biometric, two-factor and multi-factor solutions have been difficult to use and expensive to deploy and operate. The extraordinary proliferation of smart phones and tablets provide an infrastructure for disruptive solutions that leverage the mobile nature of these devices and the multi-sensor computing capabilities.

The authentication market continues to become more fragmented with new authentication devices and mechanisms emerging every day. Fingerprint sensors in smartphones, IR retina scanning cameras in smartphones, wearable’s like fitbit, iWatch, etc. All of these make the strong authentication decision for enterprises much more difficult – which technology(s) do they support, which will become the next standard. This is one of the key value propositions of

VerifyMe Authenticator – our ability to support any authentication mechanism and our patented risk scoring engine insult the enterprise from these risks and insure that whatever technologies become entrenched they will be able to use them and delight their customers.

VerifyMe Authenticator is a digital identity management software platform that provides extensible authentication mechanisms that can be dynamically invoked to achieve a specified degree of identity assurance. The Authenticator platform incorporates a risk engine that associates individual risk parameters and scores with every unique authentication mechanism. The risk engine then generates aggregate risk scores based on the specific combination of individual authentication mechanisms used to confirm the identity of the human being.

35

We are now enhancing this product and getting it ready for deployment into the financial services industry.  We cannot assure you we will generate any revenues from these efforts.

Digital Authentication Technology

We believe that the digital technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from identity and authentication to the management of legacy passwords and PINs. We empower our customers to take advantage of the full capabilities of smart mobile devices and provide solutions that are both simple to use and deliver the highest level of security. These solutions can be applied to corporate networks, financial services, e-gov services, digital wallets, mobile payments, entertainment, subscription services, and social media.

The challenges associated with digital access control and identity theft are problems that are highly relevant in the world today. Consumers, citizens, employees, governments and employers demand comprehensive solutions that are timely, reliable but not intrusive. The current widespread use of passwords and personal identification numbers, or PINs for authentication has proven to be unsecure and inadequate. Individuals increasingly expect anywhere-anytime experiences—whether they are making purchases, crossing borders, accessing services or logging into online accounts or corporate resources. They expect those experiences to ensure the protection of their privacy and to provide uncompromising confidentiality.

Verification is the front door of all access and transactions. The most fundamental action is to identify “who the person is and how you identify yourself.” We believe our VerifyMe digital authentication is the building block that answers that question. Our verification technology ensures that users are who they say they are.  Our technology becomes their virtual credentials which are protected from fraud and theft.  There are hundreds of millions of identities stolen annually. It is absolutely crucial to know which users have the right to access particular information or transactions, and whether or not unauthorized users have been prevented from accessing those same critically important items.

In today’s world we have global workforces, customers, systems and data.  Unfortunately, we have the same global sophisticated cybercrime.   Therefore, vetting users and access also means asking important questions about authentication, such as which authentication method is most appropriate given a resource, channel or specific risk factor.

We believe that our digital verification technology meets user expectations for ease of use, privacy and overall experiences especially in financial and healthcare enterprises. For connected organizations, the authentication process is like the front door. To users, it’s important not only to smoothly reach the systems or data they need, but to know that their own account access and data is secured. Authentication is crucial, but it needs to be frictionless to avoid frustrating users whether they are customers, partners, or employees.

Passwords are no longer enough. It has been proven time and time again that even strong credentials can be stolen, cracked or coaxed from end users. Given today’s threat landscape, good security requires strong authentication practices, one of which is multi-factor authentication (“MFA”). Our MFA system requires no passwords at all.

By using multiple independent factors VerifyMe’s verification system significantly increases the effort that cybercriminals must exert to break in and access the protected transaction or data.  Also attempts that fail for lack of additional factors raises immediate red flags to end users and their financial or data system administrators.

Additionally, our MFA does not use tokens or complicated, tiered passwords. Passwords are replaced by our MFA technology. Passwords are lost, stolen, forgotten, constantly changed, etc. Our MFA removes the need for passwords. The person’s biometrics combined with other non-password factors become their password.

Our digital technologies involve the utilization of multiple authentication mechanisms, some of which we own. These mechanisms include biometric factors, knowledge factors, possession factors and location factors. Biometric factors include facial recognition with liveness detection, finger print and voice recognition. Knowledge factors include a personal gesture swipe and a safe and panic color choice. Possession factor includes devices that the user has in their possession such as a smartphone, smart watch, and other wearable computing devices. The location factor geo-locates the user during a secure login. We surround these authentication mechanisms with proprietary systems that improve the usability and the security of the solutions. Our solutions allow the assessment and quantification of risk using a sophisticated patented heuristic scoring mechanism. We have specialized systems that perform ‘liveness’ detection to insure the subject of authentication is in fact a live human being. We have software systems that introduce learning capabilities into our solutions to improve the ease of use and flexibility.

36

We believe that by using a host of factors, our proprietary scoring system gives a 99% assurance that the person behind the transaction is the person they say they are.

The digital technologies we own will enable businesses and consumers to reconstruct their overall approaches to security—from identity and authentication to the management of legacy passwords and PINs. We empower our customers to take advantage of the full capabilities of smart mobile devices and provide solutions that are both simple to use and deliver the highest level of security.

Our digital multi-factor verification software solutions can be applied to:

·Cryptocurrencies

·Blockchain Authentication

·Corporate Networks

·Digital Drop Box Access

·Physical Access

·Banking

·Financial Transaction Services

·Medical Insurance

·Gaming

·Retail

·Digital Wallets

·Legal

·Government (e-gov services)

·Military

·Pharmaceutical

·Immigration

·Entertainment

·Social Media

·Mobile Payments

·Purchaser Authentication

·Notary Authentication

·Electronic Forms

·Voting Systems

·Subscription services

·Employee Time Systems

Digital Authentication Industry Background

The growth in internet banking and internet commerce and the increasing use and reliance upon proprietary or confidential information that is remotely accessible by many users by businesses, government and educational institutions, has made information security a paramount concern. We believe that enterprises are seeking solutions that will continue to allow them to expand access to data and financial assets while maintaining network security.

37

A vendor in the user authentication market delivers on-premises software/hardware or a cloud-based service that makes real-time authentication decisions for users who utilize an arbitrary endpoint device (that is, not just Windows PCs or Macs) to access one or more applications, systems or services in a variety of use cases. Where appropriate to the authentication methods supported, a vendor in this market also delivers client-side software or hardware that end users utilize to make those real-time authentication decisions.

The market is mature, with several vendors offering products that have been continuously offered during the past three decades (although ownership has changed over that time). However, new methods and vendors continue to emerge, with the most rapid growth occurring within the past decade in response to the changing market needs for different trade-offs among trust, user experience (“UX”) and total cost of ownership (“TCO”).ownership. The greater adoption of user authentication over a wider variety of use cases, the impact of mobile, cloud and big data analytics, and the emergence of innovative methods continue to be disruptive.

While over 100 authentication vendors currently operate in the market, the vast majority deliver two-factor authentication solutions. Even the few vendors that market biometric solutions simply combine them with a password for two-factor security.

We are providing more granular access to the different elements of VerifyMe Authentication. Specifically we will introduce a 2 factor authentication solution that provides a direct alternative to existing 2 factor authentication solutions at substantially lower TCO with a simple a seamless upgrade path to 3+ factor authentication incorporating biometrics.

Internet and Enterprise Security.  With the advent of personal computers and distributed information systems in the form of wide area networks, intranets, local area networks and the Internet, as well as other direct electronic links, many organizations have implemented applications to enable their workforce and third parties, including vendors, suppliers and customers, to access and exchange data and perform electronic transactions. As a result of the increased number of users having direct and remote access to such enterprise applications, data and financial assets have become increasingly vulnerable to unauthorized access and misuse.

Individual User Security.  In addition to the need for enterprise-wide security, the proliferation of personal computers, personal digital assistants and mobile telephones in both the home and office settings, combined with widespread access to the Internet, have created significant opportunities for electronic commerce by individual users such as electronic bill payment, home banking and home shopping.

The continued reliance by most enterprises on passwords and PINs has resulted in daily identity theft and data breaches, with massive attacks being announced almost every week. The companies that have been attacked and compromised private data include top brands in finance, retail, entertainment, technology and governments.

Strong Authentication Market

A strong authentication market has emerged, initially led by two-factor authentication solutions. Two-factor authentication solutions combine a password with a second factor, which typically involves proving possession of some object which may includethrough a one-time password token that generates rotating secret codes, a telephone call via a callback or a SMS message, or an email address via emailing a secret code.

According to Markets We believe three-, four- and Markets, the global multi-factor authentication (“MFA”) market was valued at USD $3.60 billion in 2014five-step methods are expensive and is expected to reach USD $9.60 billiontypically used by 2020, at an estimated CAGR of 17.7% from 2015 to 2020. Two-factor authentication is the most widely used MFA model followed by three-factor authentication models, wherein smartcard with PINbanks and one time password (“OTP”) is the most popular technique. Biometric based MFA models are growing athigh-level government operations. We believebiometric technology will play a fast rate. North America and Europe covers most of the market, whereas the Asia-Pacific region is the fastest growing region. This growth can be attributed to the rise of biometric security services, such as fingerprint, retina and facial scanning.
larger role.

Password Manager/Digital Wallet Market

2012 was the year of password theft, according to SecurityCoverage. The security software company says that in the first six months of 2012, online password breaches increased 300% over the same period in 2011. Since then, this growth rate has continued. In the case of the recent data breach of dating service Ashley Madison, it is expected that the exposed personally identifiable information of over 30 million people will directly lead to the compromise of other password based accounts and services.

Until companies figure out a better way to protect their data in the cloud, we believe that the best solution is to enforce higher security with password managers.  Password managers provide tools to encrypt text files that can store passwords that are not Web based, such as Windows and Outlook passwords, Lotus Notes passwords, administration passwords including local and domain accounts, BIOS passwords, encrypted hard drive passwords, cell phone and voicemail passwords and iPad and iPhone passwords.  Password managers promise greater security while improving the user experience.

38

The best password managers sync to the cloud across all dominant platforms and require multi-factor authentication. There are currently no password managers that utilize more than two-factor authentication and none that incorporate additional biometric mechanisms.

The Opportunity

As identity theft and data breaches continue to increase and losses to service providers and individuals continue to escalate, we seebelieve both enterprises and consumers seekingwill seek better solutions to protect their interests. These solutions must be cost effective, easy to integrate, and simple to use.

Any transaction or action which requires authentication of an individual is a potential opportunity for a strong multi-factor solution such as VerifyMe Authenticator. ThisWe believe this is a very large market opportunity, within which we are focused on fourfive specific segments:

·Subscription services market, where revenue is commonly lost due to multiple individuals sharing user credentials to access information and services;

·Online gaming market, where financial transactions are performed and also geo-location is very important to complymaintaining compliance with state/country regulations;

·Financial services market, where there is a large financial risk to identity theft and fraud;fraud, including banking, purchases, mobile payments, and digital wallets

·Physical accessAccess control market, where the identity of individuals is key to allow access to buildings.buildings as well as digital access to data

·Social Media Market to identify people versus robots or imposters

Our Solution

VerifyMe Authenticator delivers an electronic authentication solution for identifying individual human beings. When a subject attempts to access an internet resource and asserts an identity, VerifyMe Authenticator attempts to authenticate the asserted identity insuring that it corresponds to the unique human being that originally registered.identity. It does this utilizing multiple strong authentication mechanisms, involving at least three independent factors.  VerifyMe Authenticator can deliver identity assurance consistent with National Institute of Standards and Technology (NIST) Level 4 authentication requirements as specified in Special Publication 800-63-1.

VerifyMe Authenticator is based around mobile apps that incorporate a password manager and single sign on (“SSO”) capability. In addition to facilitating strong authentication during the logon process to the enterprise resource or service, VerifyMe Authenticator also lets the user conveniently integrate and protect all of their legacy username and passwords.

Fast and Easy to Use

VerifyMe Authenticator replaces passwords and PINs with a quick, intuitive and user-friendly interface. Our customers are able tocan authenticate end users in multiple ways (multi-factor) in the same timeframe as a conventional password login. The Serviceservice is platform agnostic (available for IOS, Android, Mac and PC), and scalable for use withon wearable personal devices.

Support for Any Authentication Method

VerifyMe Authenticator has the ability to authenticate individuals using facial recognition, fingerprint, voice scanning, retina scanning, swipe pattern recognition, secret color, location detection and other mechanisms.approved IP detection. We believe that Authenticator can provide the highest levels of confidence, security and account protection to a businesses’ customers, all within seconds. VerifyMe Authenticator is not limited to specific authentication factors. Our platform can support any available authentication mechanism, including those that require policy-driven mechanisms.  We are continuing to add new authentication mechanisms, including mechanisms suitable for wearable devices and new forms of biometrics.

39

Multi-Factor Confidence Scores

Depending on the desired level of confidence, different online and mobile application accounts can require varying quality scores. As the desired level of security increases, so does the required quality score to complete a sign-in transaction. As the quality score increases, additional authentication factors are added to the sign-in process.

Secure Platform, Easy to Integrate

VerifyMe Authenticator can be delivered either as a managed service from our secure cloud or as licensed software which can be operated on-premise with existing infrastructure.  VerifyMe Authenticator also features the following benefits:

·Available to be white-labeled and integrated into existing digital platforms;

·Non-Stop, audited, monitored, private cloud service;

·Three independent, fault tolerant, redundant data centers (“Rackspace”);centers;

·Global load balancing and traffic management;

·High level commercial API’s can be integrated in hours; and

·Complete audit information, including fresh biometrics.

The three factors VerifyMe Authenticator utilize include, but are not limited to, the following:

Factor 1 – Something you have – a possession device – typically this is a registered mobile device, which we can authenticate either via SMS or email round robin protocol.

Factor 2 – Something you know – a knowledge factor – we currently utilize a color gesture swipe. This requires the subject to confirm their secret color and appropriately connect dots on a matrix consistent with their registered gesture pattern.

Factor 3 – Something you are – we utilize facial recognition to authenticate images captured in real-time using the registered device’sdevices built in camera, with images that were stored in the subject’s profile during registration.

Our platform can be distinguished from competitors in that it is not limited to any of the above authentication mechanisms; VerifyMe Authenticator currently supports many more authentication mechanisms and we intend to continue expanding this list.  For example, our platform is not limited to facial recognition as a biometric mechanism. It currently supports voice, fingerprint and other mechanisms.

In addition, VerifyMe Authenticator includes a risk-scoring engine that is able to enforce complex, customer specific authentication policies and shield them from the underlying complexity of evaluating multiple, independent authentication mechanisms. This risk engine allows us to constantly add new authentication mechanisms as they emerge. We see the emerging market of wearable devices as providing new authentication mechanisms that will be very simple and reliable for the end-user. Because our risk engine insulates the enterprise from the complexity of having to interface with all these different platforms, they are available to benefit from and insure their customers can utilize these devices to their full potential.

VerifyMe Authenticator is platform agnostic (available for IOS, Android, Mac, Linux and Windows) and scalable for use on wearable personal devices. The digital platform is an enterprise solution, which combines multiple independent authentication factors and can also determine geo-location utilizing a number of mechanisms including GPS, cell tower triangulation and IP/WIFI address. Because the service utilizes biometrics and liveness detection, it eliminates the possibility that users might share their authentication credentials, or that user accounts can be accessed by other individuals. The combination of biometrics and geo-location provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction.

40

The VerifyMe Smart Phone Authenticator™ technology is being commercialized and leased to customers. We spent approximately $24,000 on hosting of our MFA software and $0.3 million on software and hardware development. We had no sales in 2018 in relation to our MFA technologies due to further refinement to address new smart phone capabilities. Our MFA can now work of both Apple IOS and Android phone systems. In 2018, we developed applications (“APPs”) which are used in conjunction with the MFA technology. These APPS are now fully functional except we expect to enhance and upgrade the visual appearance and functionality of the APP to enhance a customer’s experience.

VerifyMe Authenticator Marketing and Sales

We are seeking business partners with revenue and proven business models. To date we have had no sales however, in 2019, we are investing in sales channels and pursuing opportunities.

Our Technology

and Intellectual Property

Intellectual property is important to our business. The current patent and trademark portfolios consist of 10 granted US patents and one granted European patent validated in four countries, four pending US and foreign patent applications, four registered US trademarks, one registered EU foreign registration, and eight pending US and foreign trademark applications.

 In addition, six patent applications were abandoned.  We plan on considering the filing for reinstatement on some of the abandoned patent applications.

Our registered patents expire between the years of 2019 and 2033. 

We have attempted to achieve sufficient flexibility in our products and technologies so as to provide cost-effective solutions to a wide variety of counterfeiting problems. We intend to generate revenues primarily by selling pigment to manufacturers who incorporate our technologies into their manufacturing processes and their products as well as through licensing fees where we are providing unique or custom solutions.

Our Intellectual Property
Intellectual property is important to our business. Our current patent portfolio consists of ten granted patents and six applications pending.

While some of our granted patents are commercially ready, we believe that others may have commercial application in the future but will require additional capital and/or a strategic partner in order to reach the potential markets. All of our patents are related to the inventions described above. Our registered patents begin to expire between the years of 2019 and 2031.

2033. The expiration date of a pending application that matures into a registration depends upon the issuance date and any adjustment under 35 U.S.C. 154(b).

It is cost prohibitive to register patents in every country.  We continue to develop new anti-counterfeiting technologies and towe apply for patent protection for these technologies wherever possible.in countries with the most market potential and strong patent enforcement tools.  When a new product or process is developed, we may seek to preserve the economic benefit of the product or process by applying for a patent in each jurisdiction in which the product or process is likely to be exploited.

The issuance of a patent is considered prima facie evidence of validity.  The granting of a patent does not prevent a third party from seeking a judicial determination that the patent is invalid. Such challenges to the validity of a patent are not uncommon and are occasionallycan be successful. There can be no assurance that a challenge will not be filed to one or more of our patents, if granted, and that if filed, such a challenge will not be successful.

We have trademarked the VerifyMeTM brand in the United States and have pending applications with respect to our brand internationally. However, our name and brand could be confused with brands that have similar names, including but not limited to Verified.Me, a service offered to Canadians by SecureKey Technologies Inc. We have a pending application for the VerifyMe name in Canada but can make no assurances regarding its approval. We are aware of names and marks similar to our service marks being used from time to time by other persons that could result in confusion and may diminish the value of our brands and adversely affect our business.

41

The following tables provide information with respect to our current patent and trademark portfolio:

Patents:

JurisdictionPatent No.Issue DateTitleExpiration Date
US6,483,57611/19/2002Counterfeit detection system

12/10/2019

US6,861,01203/01/2005Latent inkjet formulation and method

03/10/2021

US6,672,71801/06/2004

Aqueous latent image printing method and aqueous latent image printing ink for use therewith

 07/23/2022
US7,939,23905/10/2011

Illumination sources and subjects having distinctly matched and mismatched narrow spectral bands

03/03/2028 (subject to payment of all maintenance fees)
US8,551,68310/08/2013

Illumination sources and subjects having distinctly matched and mismatched narrow spectral bands

11/02/2024 (subject to payment of all maintenance fees)
US9,250,66002/02/2016

"Home" button with integrated user biometric sensing and verification system for mobile device

11/14/2032 (subject to payment of all maintenance fees)
US8,841,06309/23/2014

Illumination sources and subjects having distinctly matched and mismatched narrow spectral bands

5/20/2024 (subject to

payment of all maintenance fees)

EuropeEP175664911/28/2018

Illumination sources and subjects having distinctly matched and mismatched narrow spectral bands

2/11/2025 (subject to payment of all annuity fees in each of France, Germany, Great Britain, and Italy)

US9,485,23611/01/2016

System and method for verified social network profile

11/14/2032 (subject to payment of all maintenance fees)

US9,183,68811/10/2015Characteristic Verification System

02/19/2033 (subject to payment of all maintenance fees)

US9,159,01610/13/2015System and method for providing tangible medium with electromagnetic security marker

03/14/2033 (subject to payment of all maintenance fees)

USUS20190138868A1

Published 05/09/2019

Dual code authentication process

Pending application

PCTWO2019/094274

Published 05/16/2019

Dual code authentication process

Pending application
US----Device and method for authentication

Pending application

PCT----Device and method for authentication

Pending application

42

Trademarks:

JurisdictionTrademark No.Issue DateTitleExpiration Date/Status
US4,302,45503/12/2013VERIFYME

Registered; Renewal due 03/12/2023

Australia----VERIFYME

Pending application

Canada----VERIFYME

Pending application

Colombia----VERIFYME

Pending application

Europe----VERIFYME

Pending application

Japan----VERIFYME

Pending application

Mexico----VERIFYME

Pending application

Singapore----VERIFYME

Pending application

South Korea----VERIFYME

Pending application

US5,725,79504/16/2019SECURELIGHT

Registered; Section 8 Affidavit due 04/16/2024 to 04/16/2025

US5,725,79404/16/2019RAINBOWSECURE

Registered; Section 8 Affidavit due 04/16/2024 to 04/16/2025

US5,725,79604/16/2019SECURELIGHT+

Registered; Section 8 Affidavit due 04/16/2024 to 04/16/2025

US----VERIPAS

Pending application

Research and Development

We have been involved in research and development since our inception and intend to continue our research and development activities, funds permitting. Until January 1, 2013, our research and development focused on pigment technologies. Since January 1, 2013, we have allocated research and development efforts between digital and physicalpigment technologies. We hope to expand our technology into new areas of implementation and to develop unique customer applications. We spent approximately $2.4$6,251 and $28,429 in the six months ended June 30, 2019 and 2018, respectively, and $0.2 million and $10.6$0.1 million on research and development during the years ended December 31, 20152018 and 2014, respectively.

2017, respectively, on research and development.

Our Revenue Model

To date, we have not generated significantmaterial revenue. We believe that creatingour recent contract with HP Indigo will create demand for our productsRainbowSecure® and servicesVeriPASTM products.  Working with HP Indigo and S-One, we are creating co-marketing programs to effectively reach all 6000 series HP Indigo owners.   We also will require a marketing program that effectively reaches potential customers. In developingreach out to brand owners and make them aware of our most recent marketing approach, we have attempted to achieve sufficient flexibility in our products and technologies so as tobrand protection security solutions which can provide cost-effective solutions to a wide variety of counterfeiting problems.brand owners counterfeit prevention protection. We intend to generate revenues primarily by collecting license fees based on usage fees generated from HP Indigo 6000 series users as well as non-digital press technology usage.  Our revenue is derived utilizing a royalty rate based on the volume of a particular label or package printed with our RainbowSecure® technology (e.g. a royalty on each impression). We believe we will also have revenue that will be generated with the leasing of authentication devices to manufacturers who incorporate our technologies into their manufacturing processes and user authentication protocols, as well as through the sale of pigments to be incorporated withinin inks and dyes and the sale of authentication tools.

43
42

Our VeriPASTM technology product is an identifier, track and trace system which generates revenue from a contracted usage fee per impression rate based on the number of Contents

codes which are purchased for application on labels and packages printed with the technology.

Our VerifyMe Digital Authentication technology is a software system.  The revenue to be generated from this product will be in the form of a contracted per transaction fee and or a monthly service fee.

Sales and Marketing Strategy:

Brand Protection Security Technology Marketing Strategy

We plan on marketing directly with HP Indigo 6000 series owners, as well as the label and packaging printing industry, including both traditional and digital printers and users to address their clients’ needs for our covert serialization. Those printers will market and resell our technologies to both current and future brand owner clients.

In addition to the printing industry we will be marketing directly to all brand owners who utilize labels and packaging for their products. Brand owners can be licensed directly by VerifyMe and direct their personal printer to print their labels and packaging with the VerifyMe printing technologies.  The brand owner will therefore pay their royalties directly to VerifyMe based on the number of labels and packages units that their printer applied the technology to.

In addition, we will engage third parties to market, sell and support our brand protection security technologies on a global basis for a contracted fee based on their sales.  Our targeted third parties will already have a successful track record in supporting HP Indigo owners as well as traditional printing clients.

As discussed above, in March 2018, we entered into a strategic partnership with S-One. S-One provides VerifyMe with global sales, distribution, and promotion support for the Company’s products and will employ a representative that will be solely dedicated to promoting the Company’s products. Under the terms of the Company’s agreement with S-One, S-One acts as a sales and marketing contractor for the Company’s printed products and services on a global basis and assists the Company in fulfilling the Company’s obligations under the Company’s signed current and future reseller agreements with various global and domestic print providers and brand owners.

The FDA implemented the identifier track and trace portion of the Title II of the Drug Quality and Security Act in November 2018, entitled the “Drug Supply Chain Security Act.” This regulation requires drug manufactures to add product identifiers, such as our RainbowSecure® technology as well as our VeriPASTM track and trace system, to certain prescription drug packages beginning in November 2018. Re-packagers must begin adding product identifiers in November 2018. We expect to engage third party marketing and sales companies to present our solutions to the drug and pharmaceutical industry. The FDA intends to continue implementing the Drug Supply Chain Security Act to ensure that a full electronic identification system for prescription drugs is implemented by 2023.

In addition, our track and trace partner, Micro Focus is contracted to cross sell our technologies as part of their Global Product Authentication System called “GPAS”.  We are also contracted with Micro Focus to re-sell their GPAS product with our RainbowSecure® technology under our own trademarked name, VeriPASTM which stands for VerifyMe Global Product Authentication System.

An additional marketing strategy at multiple target groups as follows:

is to incorporate our technology into the high-speed inkjet hardware that traditional Flexo and Commercial Printers use to add a variable data feature for their clients.

44
Consumer Product Security
· Pharmaceuticals
· Luxury goods
· Tobacco
· Alcohol
· Auto parts
· Aviation parts
· Any other packaging requirements
Table of Contents  

Some of the major brand segments that need our type of label, packaging and serialization identifier products are:

Consumer Product Security

Documents of Value
·
Pharmaceuticals

·Food

·Beverages

·Luxury goods

·Cosmetics

·Alcohol

·Auto parts

·Aviation parts

·Any other label/ packaging requirements

Documents of Value

·Currency

·Stock certificates and bonds

·Event tickets

·Lottery tickets

Homeland Security

·Passports

Homeland Security
·Passports
· 
ID cards

·Driver’s licenses

·Visas

·Container seals

·Pallet security

Military

·Uniforms

Gaming
·Online gaming sites
· Casino chips
· Dice
· Playing cards
· E-proms/critical memory devices
· Lottery tickets
Weapons

·Ammunition

Product Diversion Tracking

Product Diversion Tracking
·
Pharmaceuticals

·Apparel/licensed merchandise

·Cosmetics and fragrances

·Watches and jewelry

Financial Services and Products

Financial Services and Products
·
· Consumer login credentials

·Online transaction approval

·Credit cards

·Bank checks

·Financial documents/promissory notes

 
Two-Factor Alternative
· Consumer login credentials
· Lower cost
· Upgrade to stronger authentication - configuration changes - no new integration
45 
Subscription Service
Table of Contents
· Consumer login credentials
· Uniquely identify human beings
· No ability to share credentials
· Subscriptions/Licenses specific to one individual

We plan for our sales and marketing strategy to include an outreach program and sales programs that tailor the product to the governmental body or merchant, as well as key partnerships with authorities and merchants whose products or audiences can be complementary to our own. In particular, we will focus on building relationshiprelationships with key partners who can deliver our products to their existing and prospective customers in target markets - i.e., printer/packagers, plastic card manufacturers and financial services intermediaries.

demonstrations and trade shows.

Our initial targeted market segment is the financial services industry.  This includes both the traditional banking and crypto financial transaction industries.  Our second targeted market segment is expected to be the healthcare industry.  The third targeted market is expected to the gaming industry.   The fourth target market segment we expect to market to will be governments.  Governments can be both foreign and domestic as well as federal, state and local levels.

We anticipate that all of these market outreaches will be made directly by us and we also plan to use third party marketing vendors who specialize in software sales.

Competition

The market for protection from counterfeiting, diversion, theft and forgery is a mature 25-year-oldmore than 25-year old industry dominated by a number of large, well-established companies, particularly in the area of traditional overt security technologies.technologies where repeating static produced images are commonly used. This is due to the fact that security printing for currency production for example, began in Europe over a century ago and has resulted in the establishment of old-line security printers which have branched out into brand and product protection as well. In North America, brand protection products, such as tamper-resistant packaging, security labels, and anti-theft devices are readily available and utilized on a widespread basis. In recent years, however, demand has increased for more sophisticated overt and covert security technologies.technologies with a strong desire for technologies that can provide variable images and data. Competitors can be segregated into the following groups: (i) Security Ink Manufacturers.Manufacturers: These are generally well-established companies such as SICPA and Sun Chemical, whose core business is manufacturing and selling printing inks; (ii) System Integrators.Integrators: These companies have often evolved from other sectors in the printing industry, mainly security printing manufacturers, technology providers, or packaging and label manufacturers. These companies offer a range of security solutions, enabling them to provide a complete suite of solutions tailored to the customer’s specific needs and requirements. The companies in this space include 3M, DuPont, Opsec, Honeywell, and Avery Dennison; (iii) System Consultancy Groups.Groups: These companies offer a range of technologies from several different providers and tailor specific solutions to end-users; (iv) Traditional Authentication Technology Providers.Providers: These purveyors include companies like American Banknote Holographics, Crown Roll Leaf and Digimarc, which provide holograms and digital watermarking, respectively; (iv)(v) Product Diversion Tracking Providers. Applied DNA Sciences Next-Generation Technology Providers LLC falls into this group, along with several companies such as Applied DNA Sciences, Authentix, DNA Technologies, and Identif, Kodak Traceless, which provide on-product and in-product tagging technologies; (v)(vi) Traditional Security Printers.Printers: This group includes traditional security printers such as Thomas de la Rue, Canadian Banknote, and Banknote Corporation of America, and Portals, whose core products are printing the world’s currencies; and (vi)(vii) Biometric Solution Providers.Providers: These companies offer biometric authentication capabilities to be integrated with existing mobile device authentication, such as OT-Morpho and ImageWare Systems.

Amazon is now an official competitor with their new “Project Zero” Brand protection system utilizing their “Transparency” serialization product. Amazon’s product serialization service provides a unique code for every unit that is manufactured, and the brand puts these codes on its products as part of its manufacturing process, which Amazon scans and verifies. This differs from our covert luminescent pigment which is incorporated in the labeling process and our invisible covert serialization and authentication solution.

46

Also HP Indigo, is now selling a yellow ultra violet ink as a security product for an inexpensive price that directly competes with our products. There are a number of providers of inexpensive ultra violet inks in the marketplace, however, we believe these inexpensive ultra violet inks do not provide the level of security and safety that our products provide.

New types of security competition is also increasing, such as retail website monitoring, brand investigations, RFID and near field communications (“NFC”) products using low powered radio signals.

To compete effectively, we are seeking to establish key relationships with major digital solution equipment and distribution providers as we have done with HP Indigo.  While leveraging these relationships, we still expect that we will need to expend significant resources in technology and marketing. EachMany of our competitors hashave substantially greater financial, human and other resources than we have. As a result, we may not have sufficient resources to develop and market our services to the market effectively, if at all.

effectively.

We expect competition with our products and services to continue and intensify in the future. We believe competition in our principal markets is primarily driven by:

·product performance, features and liability;

·price; new laws and regulations;

·product innovation and timing of new product introductions;

·ability to develop, maintain and protect proprietary products and technologies;

·sales and distribution capabilities;

·technical support and service;

·brand loyalty;

·applications support; and

·breadth of product line.

If a competitor develops superior technology or cost-effective alternatives to our products, our business, financial condition and results of operations could be significantly harmed.

Major Customers/Vendors

During the yearsyear ended December 31, 2015 and 2014, three2018, four customers accounted for 100% of total revenue.sales. There were no sales during the year ended December 31, 2017. Generally, a substantial percentage of our revenuesales has been made to a small number of customers and is typically on an open account basis.

In 2018, we announced two re-seller contracts for our RainbowSecure® technology.  One of these contracts was with a global billion dollar label printer.  We also signed a similar contract for our RainbowSecure® technology with a leading RFID technology label group.  Both of these customers have clients in the consumer products industry.

On September 6, 2017, we announced a five-year contract with HP to supply HP Indigo Digital press ink canisters containing our technology pigment for use by HP Indigo digital press owners who print our security feature on labels and packages for their brand owners. In 2018, our customers began using our technology to print product labels using HP RainbowSecure® technology.

In December 2017, we entered into an agreement with Micro Focus, a public global software developer.  Micro Focus will be offering our technology to their track and trace clients requiring an identifier to accompany Micro Focus Track and Trace system.  VerifyMe also can sell GPAS which is printed on labels and packaging along with our covert to store our hidden covert serial number in the cloud for product diversion investigators to authenticate with a proprietary app on a mobile device.

47
44

In March 2018, we entered into a strategic partnership with S-One. S-One provides companies with product and sales channels, technical and marketing support, digital development support, and distribution channels through the other companies which have partnered with S-One. S-One will provide the VerifyMe with global sales, distribution, and promotion support for the Company’s products and will employ a representative that will be solely dedicated to promoting the Company’s products. Under the terms of Contents

the Company’s agreement with S-One, S-One will act as a sales and marketing contractor for the Company’s printed products and services on a global basis and will assist the Company in fulfilling the Company’s obligations under the Company’s signed current and future reseller agreements with various global and domestic print providers and brand owners.

During the years ended December 31, 20152018 and 2014,2017, we purchased 100% of our pigment from one vendor.

VerifyMe utilizes multiple vendors including the pigment vendor Phosphur Technologies.

for engineered RainbowSecure® authentication devices.

Facilities

Our principal offices are located in temporary office space at 12 West 21st Street,75 S. Clinton Avenue, Suite 1525, Rochester, New York NY1001014604, where we lease and occupy approximately 300 square feet of space. Theoffice space for $1,179 per month under a lease for our office is month-to-month.

that expires on January 31, 2020. We believe that our office is suitable and adequate for our current needs but weneeds. We do anticipate seeking more permanent office facilities in New York City.
not own or operate, and have no plans to establish, any manufacturing facilities.

Employees

As of September 30, 2019, we had two full time employees and two part time employees.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this prospectus.  In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. See the “Cautionary Statement Regarding Forward-Looking Statements” above.  Our actual results may differ materially from those discussed below.  Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

Overview

We are a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products. We were formed as LaserLock Technologies, Inc., in Nevada on November 10, 1999. With the addition of our current chief executive officer in 2017 and new management, we transitioned from a research and development company to focus more on the commercialization efforts of our security solutions for identification and authentication of packaging, labels and products in a variety of applications. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the patent pending VeriPAS™ software system in 2018 which covertly and overtly serializes products to track a product’s “life cycle” for brand owners. We believe VeriPAS™ is the only invisible covert serialization and authentication solution deployed through variable digital printing on HP Indigo printing systems with a smartphone tracking and authentication system. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the field – designed to allow investigators to quickly and efficiently authenticate product throughout the distribution chain, including warehouses, ports of entry, retail locations, and product purchased over the Internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and where they are deployed with geo location mapping and intelligent programable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology.

48

Results of Operations

Comparison of the three months ended June 30, 2019 and 2018

The following discussion analyzes our results of operations for the three months ended June 30, 2019 and 2018.

Revenue

We generated revenue of $40,479 for the three months ended June 30, 2019 compared to $6,799 for the three months ended June 30, 2018. The revenue primarily related to security printing with our authentication serialization technology for a large global brand owner. For the three months ended June 30, 2019, three customers represented 100% of revenues.

General and Administrative Expenses

General and administrative expenses decreased by $107,565 to $418,195 for the three months ended June 30, 2019 from $525,760 for the three months ended June 30, 2018. The decrease resulted primarily from a decrease in non-cash charges related to restricted stock awards and stock options of approximately $40,000 while the remaining positive impact was a result of continued efficiencies within the Company.

Legal and Accounting

Legal and accounting fees decreased by $95,435 to $68,335 for the three months ended June 30, 2019 from $163,770 for the three months ended June 30, 2018. The decrease related primarily to a decrease in attorney fees.

Payroll Expenses

Payroll expenses were $101,786 for the three months ended June 30, 2019, an increase of $1,983 from $99,803 for the three months ended June 30, 2018. The increase relates to non-cash stock-based compensation.

Research and Development

Research and development expenses were $2,608 and $16,233 for the three months ended June 30, 2019 and 2018, respectively. The decline is primarily due to investments in developing our VeriPASTM Mobile Authenticator technology in 2018 while in the three months ended June 30, 2019, our products are nearly completely developed.

Sales and Marketing

Sales and marketing expenses were $109,158 and $25 for the three months ended June 30, 2019 and 2018, respectively. The increase in sales and marketing expenses related to the hiring of our VP of Global Business Development and our increased participation in trade shows.

Net Loss

Our net loss decreased by $129,539 to $665,656 for the three months ended June 30, 2019 from $795,195 for the three months ended June 30, 2018. The decrease primarily related to a decrease in non-cash share-based compensation which amounted to $89,085.

49

Comparison of the six months ended June 30, 2019 and 2018

The following discussion analyzes our results of operations for the six months ended June 30, 2019 and 2018.

Revenue

We generated revenue of $86,933 for the six months ended June 30, 2019 compared to $6,799 for the six months ended June 30, 2018. The revenue primarily related to security printing with our authentication serialization technology for a large global brand owner. For the six months ended June 30, 2019, three customers represented 100% of revenues.

General and Administrative Expenses

General and administrative expenses decreased by $370,457 to $650,877 for the six months ended June 30, 2019 from $1,021,334 for the six months ended June 30, 2018. The decrease resulted primarily from a decrease in non-cash charges related to restricted stock awards and stock options of approximately $300,000 while the remaining variance was due to efficiencies within the Company.

Legal and Accounting

Legal and accounting fees decreased by $166,775 to $130,699 for the six months ended June 30, 2019 from $297,474 for the six months ended June 30, 2018. The decrease related primarily to a decrease in legal fees.

Payroll Expenses

Payroll expenses were $206,575 for the six months ended June 30, 2019, an increase of $14,721 from $191,854 for the six months ended June 30, 2018. The increase relates to non-cash stock-based compensation.

Research and Development

Research and development expenses were $6,251 and $28,429 for the six months ended June 30, 2019 and 2018, respectively. The decline is primarily due to investments in developing our VeriPASTM Mobile Authenticator technology in 2018, while in the six months ended June 30, 2019, we did not significantly invest in the development of our technology.

Sales and Marketing

Sales and marketing expenses were $252,301 and $8,067 for the six months ended June 30, 2019 and 2018, respectively. The increase in sales and marketing relates to the hiring of our VP of Global Business Development and our increased participation in trade shows.

Settlement agreement with shareholders

In the first half of 2018 we made a strategic decision to end a future revenue sharing program resulting in settlement expenses of $779,000 with certain of our shareholders (the “Settlement Agreement”).

Net Loss

Our net loss decreased by $739,866 to $1,178,962 for the six months ended June 30, 2019, from $1,918,828 for the six months ended June 30, 2018. The decrease related primarily to the Settlement Agreement with shareholders which occurred in the six months ended March 31, 2018 resulting in a total expense of $779,000.

Comparison of the Years Ended December 31, 2015,2018 and 2017

The following discussion analyzes our results of operations for the years ended December 31, 2018 and 2017. The following information should be considered together with our financial statements for such periods and the accompanying notes thereto.

50

Revenue/Net Loss

We have not generated material revenue since our inception. For the years ended December 31, 2018 and 2017, we generated revenues of $74,844 and $0, respectively. Our net loss was $2,932,462 for the year ended December 31, 2018, a decrease of $452,878 from a net loss of $3,385,340 for the year ended December 31, 2017.  Net loss included non-cash charges of $1,107,203 for the year ended December 31, 2018, in comparison to non-cash charges of $1,800,181 for the year ended December 31, 2017. The increase in our net loss excluding non-cash charges, was primarily a result of a settlement agreement with two shareholders which resulted in a cash payment of $500,000 and a non-cash charge of $279,000 related to common stock issuance. The remaining increases related to an increase in research and development and sales and marketing expenses related to activities that we expect will expand our operations.

Cost of Sales

For the years ended December 31, 2018 and 2017, we incurred proprietary technology costs of sales of $28,802 and $0. Cost of sales was lower for the year ended December 31, 2017, since we had fiveno sales during the year.

General and Administrative Expenses

General and administrative expenses were $1,585,329 for the year ended December 31, 2018 compared to $1,689,883 for the year ended December 31, 2017, a decrease of $104,554. The decrease is attributable primarily to a decrease in non-cash stock-based compensation for consultants.

Legal and Accounting

Legal and accounting fees increased $170,252 to $416,772 for the year ended December 31, 2018 from $246,520 for the year ended December 31, 2017. In the beginning of 2017 we had released our then attorneys and hired our current attorneys in the second quarter of 2017. Thus, charges in 2018 for legal feels include a full time employees. Noneyear, in comparison to half year charges in 2017.

Payroll Expenses

Payroll expenses decreased to $316,837 for the year ended December 31, 2018 from $767,257 for the year ended December 31, 2017, a decrease of $450,420. The majority of the decrease was the result of lower non-cash charges related to stock-based compensation.

Research and Development

Research and development expenses increased $59,611 to $187,655 for the year ended December 31, 2018 from $128,044 for the year ended December 31, 2017.  

Sales and Marketing

Sales and marketing expenses for the year ended December 31, 2018 were $135,290 as compared to $3,800 for the year ended December 31, 2017, an increase of $131,490. The increase was related to the hiring of our employees are represented byVP of Sales, and expenses for travel and costs related to various trade shows and other sales and marketing activities.

Interest Expense

During the year ended December 31, 2018, we earned interest income of $6,664, as compared to a union or covered bynet interest expense of $218,316 for the year ended December 31, 2017, a collective bargaining agreement.variance of $224,980.  The variance is related to the settlement of notes payable in the second quarter of 2017.

51

Gain on derecognition of note payable and accrued interest

Gain on derecognition of note payable and accrued interest was $83,667 and $0 for the year ended December 31, 2018 and 2017, respectively. The release related to a note payable that had matured in 2011. We believe that our relationswere not able to contact the holder, nor had the holder reached out us.

Gain on Accounts Payable Forgiveness

Gain on Accounts Payable Forgiveness was $352,008 and $0 for the year ended December 31, 2018 and 2017, respectively and consisted of primarily a settlement reached with our previous attorneys.

Settlement agreement with shareholders

In the first half of 2018, we made a strategic decision to end a future revenue sharing program resulting in settlement expenses of $779,000.

Loss on Settlement of Related Party Notes Payable

During the year ended December 31, 2017, we settled related party notes payable outstanding as of June 30, 2017, by issuing common stock and warrants to issue common stock exercisable at $0.15.  The fair value of the warrants resulted in a non-cash loss on settlement of related party notes payable of $0 and $331,912 for the years ended December 31, 2018 and 2017, respectively.

Liquidity and Capital Resources

Six Months Ended June 30, 2019 Compared to Six Months Ended June 30, 2018

Our operations used $1,013,238 of cash during the six months ended June 30, 2019, compared to $1,623,303 during the comparable period in 2018, primarily due to a $500,000 payment made related to the Settlement Agreement during the six months ended June 30, 2018.

Cash used in investing activities was $74,770 during the six months ended June 30, 2019, compared to $825 during the six months ended June 30, 2018, which was attributed primarily to software costs related to our products during the six months ended June 30, 2019.

Cash provided by financing activities during the six months ended June 30, 2019 was nil compared to $3,247,428 during the six months ended June 30, 2018. During the six months ended June 30, 2018, we sold common stock for gross proceeds of $1,154,211. Additionally, we raised $2,093,217 from the exercise of warrants during the six months ended June 30, 2018.

Since our inception, we have focused on developing and implementing our business plan. Our business plans are dependent on our ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through future public offerings of our securities. As of August 9, 2019, we had cash resources of approximately $450,000, a decrease from our December 31, 2018 cash balance, primarily due to the manufacturing and deployment of authenticators and beepers which account for $0.2 million of the spend. Our existing cash resources are not sufficient to sustain our operations during the next 12 months unless we have material increase in revenue and collections of any revenue. Management's plans include efforts to increase sales and raising additional capital through incurrence of debt and the sale of equity securities, including through this offering. On September 19, 2019, we received net proceeds of $540,000 from the Bridge Financing. Our business plans are dependent on the ability to raise capital through this offering, through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through additional future public offerings of our securities. However, we cannot provide any assurances that we will be successful in accomplishing any of our plans. As a result of the Bridge Financing, we believe our existing cash resources will be sufficient to sustain our operations through the December 2019, and, assuming the successful closing of the offering, we expect to fund our cash flow needs and resolve our ability to operate as a going concern for the next 12 months.

52

Year Ended December 31, 2018 Compared to Year Ended December 31, 2017

Net cash used in operating activities increased by $1,440,796 to $2,376,714 for the year ended December 31, 2018 as compared to $935,918 for the year ended December 31, 2017.  The increase resulted primarily from a settlement payout with shareholders of $500,000 and from operational changes discussed previously.

Net cash used in investing activities was $108,735 for the year ended December 31, 2018, compared to $2,650 for the year ended December 31, 2017.  Increase investing activities relates to the purchase of patents which is vital for our business, and for software costs related to the development of our products.

Net cash provided by financing activities increased by $1,856,724 to $3,465,649 for the year ended December 31, 2018 from $1,608,925 for the year ended December 31, 2017.  Cash provided by financing activities during the year ended December 31, 2018, and 2017 consisted primarily of the private placement and our warrant discount program authorized in the year ended December 31, 2018.

Bridge Financing

On September 19, 2019, we completed the closing of $600,000 of Debentures for gross proceeds of $540,000 after original issue discounts. As of the Effective Date, we entered into two substantially identical Securities Purchase Agreements with two Purchasers, which provided for the issuance of up to an aggregate of $1.2 million in principal amount of Debentures of which the first tranche of $600,000 have been issued. The Securities Purchase Agreements provided for the issuance of the Debentures due one year from the dates of issuance in two $600,000 tranches: the first tranche as described above, and the second tranche, at the discretion of the Purchasers and us, to occur any time after November 17, 2019. If, at any time after November 17, 2019, the Purchasers elect not to consummate the closing of the second tranche, then we may raise up to $600,000 from additional investors (including our affiliates) who will have a security interest on apari passu basis with the Purchasers in the first tranche, so long as such investors agree not to convert the securities received until the Purchasers in the first tranche have completely converted the Debentures or been fully repaid.

In connection with the Bridge Financing, each of the Purchasers received a commitment fee of $5,000 and 500,000 restricted shares (the “Commitment Shares”) of our common stock. The Representative served as placement agent for the Bridge Financing and received a cash fee of 8% of the gross proceeds received at each closing and is entitled to receive warrants for 5% of the total number of securities issued in connection with the Bridge Financing. These warrants will be exercisable at a price per share equal to 110% of the price of the securities paid by the Purchasers and will expire in five years. See “Underwriting — Other.”

The first tranche of the Debentures will mature on September 18, 2020, and may be redeemed by us prior to the maturity date as described below. All unpaid principal due and payable on the maturity date will be paid in the form of common stock. Any principal or interest that is due under each of the Debentures, which is not paid by the respective maturity date, will bear interest at the rate of 18% per annum until it is satisfied in full.

The Debentures are senior secured obligations of ours secured pursuant to the terms of security agreements dated as of September 18, 2019 (the “Security Agreements”) by all of the assets of us and our subsidiaries.

Each Purchaser is entitled, at any time, to convert all or any portion of the outstanding principal amount of its Debenture(s) plus any accrued interest into restricted shares of common stock. If we consummate a public offering within 180 calendar days of the Effective Date, then the conversion price will be the lesser of (a) $0.15 or (b) 70% multiplied of the price per share of the common stock we issue in the public offering (the “QPI Discounted Price”), subject to further adjustment as provided in the Debenture as well as subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. Further, if we consummate a public offering of common stock which results in us receiving gross proceeds of at least $5 million within 180 calendar days of the Effective Date then we are obligated to repay the outstanding amounts owed under the Debentures, to the extent they are not converted and including the applicable redemption premium then in effect, within three days of consummation of such an offering.

53

If any portion of the Debentures are outstanding on the 181st calendar day after the Effective Date, then the conversion price shall equal the lesser of (a) $0.15, (b) the QPI Discounted Price, or (c) 70% of the lowest volume-weighted average price (as reported by Bloomberg LP) of the common stock on any trading day during the 20 trading days immediately preceding the date of conversion of the Debenture (provided, further, that if either we are not DWAC operational at the time of conversion, the common stock is traded on the OTC Pink at the time of conversion, or the Conversion Price is less than $0.01 per share, then 70% will automatically adjust to 60%).

The Debentures are subject to a “conversion blocker” such that the each of the Purchasers cannot convert the Debentures to the extent that the conversion would result in the Purchaser and its affiliates holding more than 4.99% of the outstanding common stock (which the Purchaser can increase to 9.99% upon at least 61 days prior written notice to us).

So long as no event of default has occurred and is continuing under the Debentures, we may at our option call for redemption all or part of the Debentures prior to the maturity date, upon not more than two calendar days written notice, for an amount equal to: (i) if the redemption date is 90 calendar days or less from the date of issuance of the Debentures, 110% of the sum of the principal amount; (ii) if the redemption date is greater than or equal to 91 calendar days from the date of issuance of the Debentures and less than or equal to 150 calendar days from the date of issuance of the Debentures, 120% of the sum of the principal amount; (iii) if the redemption date is greater than or equal to 151 calendar days from the date of issuance of the Debentures and less than or equal to 180 calendar days from the date of issuance of the Debentures, 125% of the sum of the principal amount; and (iv) if either (1) the Debentures are in default but the holder consents to the redemption notwithstanding such default or (2) the redemption date is greater than or equal to 181 calendar days from the date of issuance of the Debentures, 130% of the sum of the principal amount.

The Debentures include an adjustment provision that, subject to certain exceptions, reduces, at the Purchaser’s option, the conversion price if we issue common stock or common stock equivalents (including in variable rate transactions) at a price lower than the then-current conversion price of the Debentures. Any reverse stock split of our outstanding shares will also result in an adjustment of the conversion price of the Debentures.

The Securities Purchase Agreements contain customary representations, warranties and covenants. In addition, pursuant to the Securities Purchase Agreements, the Purchasers were granted piggy-back registration rights such that, from September 18, 2019 until the earlier of March 18, 2021 or the date the Debentures have been converted and/or repaid in the entirety, if we contemplate making an offering of our common stock or securities convertible into our common stock registered for sale under the Securities Act, or propose to file a registration statement covering any of our securities (other than a registration statement filed by us within 45 days of the signing closing date with the Representative acting as the underwriter), then each of the Purchasers will have the right to include all or a pro rata share of its Commitment Shares, the common stock issuable upon conversion of the Debentures (the “Conversion Shares”), and, to the extent applicable, any other shares of capital stock or other securities of ours that are issued upon exchange of Conversion Shares and/or restricted stock held by the Purchaser (collectively, the “Purchaser’s Securities”).

Off-Balance Sheet Arrangements

None.

Going Concern

The report of our independent auditors dated April 1, 2019 on our financial statements for the year ended December 31, 2018 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. We have suffered recurring losses from operations and negative cash flows from operations raising substantial doubt about our ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, we will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by the sale of common shares, including through the offering. On September 19, 2019, we received net proceeds of $540,000 from the Bridge Financing. Our business plans are dependent on the ability to raise capital through this offering, through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through additional future public offerings of our securities. However, we cannot provide any assurances that we will be successful in accomplishing any of our plans. As a result of the Bridge Financing, we believe our existing cash resources will be sufficient to sustain our operations through December 2019, and, assuming the successful closing of the offering, we expect to fund our cash flow needs and resolve our ability to operate as a going concern for the next 12 months.

54

Critical Accounting Policies

Our financial statements are impacted by the accounting policies used and the estimates and assumptions made by management during their preparation. We have identified below the accounting policies that are of particular importance in the presentation of our financial position, results of operations and cash flows and which require the application of significant judgment by management.

Revenue Recognition

We account for revenues according to ASC Topic 606, “Revenue from Contracts with Customers” which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity's contracts to provide goods or services to customers.

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

·identify the contract with a customer;

·identify the performance obligations in the contract;

·determine the transaction price;

·allocate the transaction price to performance obligations in the contract; and

·recognize revenue as the performance obligation is satisfied.

Stock-based Compensation

We account for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation,” which requires the measurement and recognition of compensation expense for all stock-based awards made to employees consultants and contractorsdirectors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.

Effective January 1, 2019, we adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on our financial statements.

Recently Issued Accounting Pronouncements

Recently issued accounting pronouncements are good.discussed in Note 1 of the notes to financial statements.

55
AND BOARD OF DIRECTORS

Executive Officers and Directors

The following table sets forth certain information about our executive officers and directors as of April 14, 2016:

October 9, 2019:

Name
Age
Age
Position(s)
Executive Officers:  
Paul DonfriedPatrick White5466President, Chief Executive Officer and Director
Benjamin BurrellMargaret Gezerlis3738Chief Financial Officer
Keith Goldstein51Chief Operating Officer
Sandy Fliderman

Non-Employee Directors:

39Chief Technology Officer
Scott McPherson54Chief Financial Officer
   
Non-Employee Directors:Norman Gardner 77Chairman and Director
Claudio BallardChris Gardner5765Director
Michael MadonMarshall Geller4380Director
Lawrence SchafranHoward Goldberg7774Director
Jonathan WeinbergerArthur Laffer3979Director

Executive Officers

Paul Donfried
Paul Donfried

Patrick White - Mr. White has served as a director of the Company since July 12, 2017. Mr. White founded Document Security Systems, Inc. (NYSE:DSS), a technology company, serving as its chief executive officer and director from August 2002 until December 2012 and as its business consultant from 2012 to March 2015. He has been a director of Box Score Brands, Inc. (formerly, U-Vend, Inc.) since 2009. Mr. White was appointeda Financial Adviser for the Monroe County Government from April 2016 until May 2017. Mr. White worked as an independent consultant from March 2015 until March 2016. Mr. White was a consultant to the Board of Directors on April 22, 2015, andCompany from June 2017 through August 2017, when he was appointed as President, Chief Executive Officer and SecretaryPresident. Mr. White was appointed to our Board for his experience with previously serving as the chief executive officer of VerifyMe, Inc. on May 5, 2015.a public company.

Keith Goldstein - Mr. Donfried joined VerifyMe as Chief Technology Officer in 2013. He was responsible for leading the development of innovative, resilient and easy-to-use solutions for meeting the anti-counterfeiting and brand protection needs of our customers. In his role as CTO, Mr. Donfried was also responsible for IT services, b oth internal and external.  Prior to his current role at VerifyMe, Inc., Mr. Donfried spent four years as CTO - Identity and Access Management for Verizon, responsible for the strategy, engineering and marketing direction of the company’s portfolio of enterprise identity services. He led Verizon’s strategic alignment of cloud-based identity technologies across market segments, helping deliver a new generation of identity services that enable organizations to address the complex challenges of authenticating and managing user identities.  Prior to his role at Verizon, Mr. Donfried was Vice President of SAIC Identity & Access Management Solutions for two years, where his responsibilities included overall strategy, product development and the introduction of identity technologies. Earlier in his career, Mr. Donfried worked for Apple, General Electric and The Bank of Montreal.  A recognized expert in the fields of identity life cycle and risk management, Mr. DonfriedGoldstein has led the development of numerous industry organizations including SAFE-BioPharma and Identrust. He is a frequent speaker on the role of trusted e-commerce and its application in heavily regulated industries and the federal government. As a member of the Open Identity Exchange (OIX), Mr. Donfried provides leadership on the creation of trust frameworks and the protection of critical infrastructure. Mr. Donfried received a Bachelor of Science in computer science from Rensselaer Polytechnic Institute and holds multiple patents for identity, authentication, attributes and digital signing systems.

Our board of directors believes Mr. Donfried’s perspective and experience as our President and CEO, as well as his depth of operating and senior management experience in our industry and educational background, provide him with the qualifications and abilities to serve as a director.
Benjamin Burrell
On July 15, 2015, Ben Burrell was appointedserved as the Chief Operating Officer of VerifyMe, Inc.  Prior to his current role with the Company since September 2017. Mr. Burrell was the Vice President—Americas, Head of Middle Office Operations for Clearing, Collateral Management and Execution at JPMorgan Chase & Co., a global leader in investment banking, financial services, commercial banking, financial transaction processing, asset management and private equity. In his role at JPMorgan Chase & Co., Mr. Burrell coordinated the operational delivery of technology-based financial services products to over 400 institutional clients. Prior to that, Mr. Burrell held various senior positions in the Worldwide Securities Services division of JPMorgan Chase & Co. spanning 15 years, including roles relating to Sales, Securities Operations Management and Client Relationship Management. Mr. Burrell began his career with Barclays Bank Plc in London and has also worked as Director of Business Development for a boutique investment bank, New Vernon Financial LLC.
Sandy Fliderman
On June 12, 2015, Sandy Fliderman was appointed as the Chief Technology Officer (“CTO”) of VerifyMe, Inc.  Prior to his current role with the Company, Mr. FlidermanGoldstein was the Chief InformationExecutive Officer at VEEDIMS, LLC, an Internet of Things technology company specializing in data collectionInfinacom, a provider of biometric based security solutions, from April 2018 until March 2019. He was previously Chief Executive Officer of ABCorp., North America, a supplier of secure payment, retail and distribution in the aerospaceidentification cards, vital record and marine industries. In addition, in the areas of Information Technology (“IT”)/Information Systems, Researchtransaction documents, systems and Developmentservices to governments and Operations, Mr. Fliderman lead the chargefinancial institutions, from 2011 until April 2017, and has provided professional sales and advisory services to attain the AS9100 and ISO9001:2008 certifications needed to do business in the aerospace markets. Prior to that Mr. Fliderman was the co-founder and CTO of Zaah. Zaah is a full service digital media company that creates big brand websites, mobile apps, games, and develops social media content and strategy. As CTO of Zaah, Mr. Fliderman directed a team of over 200 personnel and oversaw Zaah’s strategy and development teams in New York, Florida and India. While CTO at Zaah, Sandy was co-inventor on a number of patents and created the technology behind VerifyMe. A software management veteran with over 22 years of experience, Mr. Fliderman began his business career at J.P. Morgan & Co. on the bank’s IT team. He spent his first 5 years in IT on the trading floor on Wall Street.
Scott McPherson
Scott McPhersonABCorp. since April 2017.

Margaret Gezerlis - Ms. Gezerlis has served asbeen our Chief Financial Officer (“CFO”) since December 1,May 2018. In November 2018, Ms. Gezerlis became our employee. Ms. Gezerlis was previously an employee of the CFO Squad LLC from February 2018 until November 2018, where she worked as an independent contractor for the Company. Previously, Ms. Gezerlis was a Financial Reporting Manager at Bankrate.com from March 2017 until February 2018. Prior to her position at Bankrate.com, Ms. Gezerlis was a financial reporting manager for Westport Fuel Systems Inc. (Nasdaq:WPRT) from March 2014 to November 2016 and a performance services manager for Workiva Inc. (NYSE:WK) from June 2012 to March 2014. Ms. Gezerlis holds an international accounting qualification from the Association of Chartered Certified Accountants.

Non-Employee Directors

Norman Gardner- Mr. McPhersonGardner, the Company’s founder, was appointed as Chairman of the Board in January 2017. Mr. Gardner was previously served as our Chief Financial Officera director and Vice-Chairman of the Company from December 2012 to Octoberthe Company’s inception in November 1999 until January 2013. Mr. McPherson is currently the CFO of Virtual Piggy, Inc. Mr. McPherson also served as CFO of Cannlabs from April 2014 to June 2015. He alsoGardner served as Chief Executive Officer of Cannlabsthe Company from April 2015 to June 2015. Prior to his tenure with us,November 1999 until January 2013, and from January 2017 until August 2012 through November 2012,2017. Mr. McPherson served as the Chief Financial Officer of Virtual Piggy, Inc. Virtual Piggy, Inc. isGardner has been a public company that has increased market interest towards the security aspects of online gaming and social networking and has focused its efforts towards delivering a platform technology designed to manage the under-18 age group’s online experience in a secure manner. Mr. McPherson currently serves as Chief Financial Officer of Virtual Piggy, Inc. In January 2005, Mr. McPherson formed McPherson, CPA, PLLC which he continues to manage today. The firm performs accounting and tax services for numerous clients in various industries. The firm also performs litigation support services, primarily involving clients in class action lawsuits and other lawsuits involving accounting malpractice or manipulation. The firm has successfully assisted small public companies by developing procedures for them to implement in order to initially comply and maintain compliance with the Sarbanes-Oxley Act. All of these services are conducted under the direction of Mr. McPherson. Mr. McPherson has managed McPherson, CPA, PLLC since its founding. Priorconsultant to the formationCompany since June 2017 and was previously a consultant to the Company from January 2013 until January 2017. As our Chairman and founder, Mr. Gardner brings to the Board extensive knowledge of McPherson, CPA, PLLC, the Company’s products, structure, history, major stockholders and culture.

56

Chris Gardner -Mr. McPherson served in a regional certified public accounting firm as a partner in the Merger and Acquisition, SEC and Litigation Support departments of a regional certified public accounting firm.

Non-Employee Directors
Claudio R. Ballard
Claudio R. BallardGardner has served as a director on our board of directors since March 30, 2013. He currently serves as the Chairman, Founder and one of the Managing MembersCompany since May 2019. He has been a Senior Advisor to Wisdom Tree Investments, Inc. (NASDAQ:WETF), an exchange-traded fund, since June 2018. From October 2010 until April 2016, he was the Ambassador of VEEDIMS, where he has served since April 2011. In 2010,Happyness for AARP, a nonprofit organization dedicated to empowering Americans age 50 and older. Mr. BallardGardner is an international best-selling author and award-winning film producer. Mr. Gardner established the institutional brokerage firm of Gardner Rich and Company in 1989 that closed in December 2012. Mr. Gardner was named “Inventorselected to serve on the Board for his entrepreneurial experience and network of relationships which the Year” by the United States Business and Industry Council, in recognition of his founding of Iconic Motors and VEEDIMS as well as the creation of the DataTreasury Global Repository Platform, a patent protected electronic transaction system licensed by banks to process digital checks. Mr. Ballard has over 37 years of experience in computer technology, software and business development. In 1979, he founded FORTEX Corporation, which in 1981 became the world’s first ORACLE Value-Added Reseller and Systems Integrator by delivering the earliest known commercially viable production mission critical application software and supporting development tools that initially ran on ORACLE and eventually ran on other database platforms. By the late 1980s, Mr. Ballard’s team had built sophisticated, mission critical systems for more than 30 Fortune 500 companies, including Kidder Peabody, General Electric (14 Divisions), Standard & Poor’s, CitiBank, Philip Morris, Boeing, McDonnell Douglas and AT&T Bell Labs, Pfizer, and Novartis (formally Ciba-Geigy), as well as government agencies that included the U.S. Army, U.S. Air Force, U.S. Navy, the Food and Drug Administration (7 departments at the FDA) and the Central Intelligence Agency. In 1994, Mr. Ballard invented the DataTreasury System, the sophisticated repository and online biometrics system that enables banks to quickly verify identity and process a myriad number of financial transactions. In 1998, Mr. Ballard founded DataTreasury Corporation and launched the core technology that ledBoard believes are valuable assets to the development of the check-imaging platform. Today, over 50 banks throughout the U.S. representing approximately 70% of U.S. check processing volume use this technology through a licensing arrangement.
Our board of directors believes Company and its growth. Chris Gardner is not related to Norman Gardner. 

Marshall Geller - Mr. Ballard is qualified to serveGeller has served as a director of the Company since July 2017. Mr. Geller has been a director and a member of the audit committee of GP Strategies Corporation (NYSE:GPX) since 2002. Mr. Geller was a director of Wright Investors’ Service Holdings Inc. (OTCMKT:WISH) from January 2015 until October 2018. Mr. Geller was a founder of St. Cloud Capital, a Los Angeles based on his manyprivate equity fund, and Senior Investment Advisor from December 2001 until September 2017. He has spent more than 50 years in corporate finance and investment banking, including 21 years as a Senior Managing Partner of professional experienceBear, Stearns & Co., with oversight of all operations in Los Angeles, San Francisco, Chicago, Hong Kong and the board of directors also believes, based on his professional experience that,Far East. Mr. Ballard possesses particular knowledge and experience that strengthen the board’s collective qualifications, skills and experience.

Michael Madon
Michael Madon was appointed as the Chairman of the Board of VerifyMe, Inc. on February 29, 2016.  Mr. MadonGeller is a senior strategy leader in cyber security and financial intelligence with nearly 20 years of a proven track record and expertise in leading cross-functional teams to develop and create results-oriented solutions at the intersection of government and business processes, people management, and information technology. Mr. Madon currently serves as the CEO and co-founder of Ataata, the next generation learning and engagement platform for the 21st century workforce. Before founding Ataata, Mr. Madon served as Vice President, Business Development for RedOwl, a behavioral analytics software company that addresses insider security risks. Mr. Madon also served on the Board of Directors of TeleCommunication Systems (NASDAQ: TSYS), a world leader in secureUCLA Health System and highly reliable wireless communication technology. In February 2016, Comtech Telecommunications Corp. acquired TeleCommunication Systems, Inc. for $430.8 million in a strategic and cash accretive transaction.  From September 2009 to May 2014, Mr. Madon served as Deputy Assistant Secretary in the Office of Intelligence and Analysis of the Treasury Department where he developed strategies to help the department identify and mitigate cyber risks and vulnerabilities within both the department and financial sector. In recognition of his service, Mr. Madon was awarded the National Intelligence Distinguished Service Medal—the Intelligence Community’s highest award. In addition, he received the U.S. Department of the Treasury’s Distinguished Service Award.  Mr. Madon has focused on cyber information issues in areas as diverse as attack, remediation, and preservation, as well as threats to critical infrastructure and supply chains. A recognized expert in the fields of cyber security and financial intelligence, he has testified before Congress on the global cyber threat and been profiled in an arrayBoard of industry publications. He currently serves on Intelligence & National Security Alliance (INSA) and is an active memberGovernors of INSA’s Subcommittee on Insider Threat. HeCedars Sinai Medical Center, Los Angeles. Mr. Geller also serves on the Dean's Advisory Council for the College of Business & Economics at California State University, Los Angeles. Mr. Geller was appointed to the Company’s Board of Advisors of the Foundation for Defense of Democracies’ Center on Sanctionshis financial and Illicit Finance and is an active member of the Armed Forces Communications and Electronics Association.  Mr. Madon served as an active duty officer in the U.S. Army and remains an active member of the Army Reserves as an Intelligence Officer supporting the Joint Chiefs of Staff (J2, Intelligence). He has held leadership positions in Airborne, Mechanized and Military Intelligence Units stateside and overseas. He is a recipient of the Bronze Star.
Mr. Madon holds a M.B.A. from the Wharton School of the University of Pennsylvania, a Certificate of Graduation from the Command and General Staff College, a Master of International Affairs from Columbia University, and a B.A. from Cornell University.
Our board of directors believes Mr. Madon is qualified to servebusiness experience as a director based onmanaging partner of a private equity fund and his many years of professional experience includingand expertise as an investor in and adviser to companies in various sectors as well as his experience inwith serving on the cybersecurity industry and the boardboards of directors also believes, based on his professional experience that,of other public and private corporations. 

Howard Goldberg - Mr. Madon possesses particular knowledge and experience that strengthen the board’s collective qualifications, skills and experience.

Lawrence Schafran
Lawrence G. SchafranGoldberg has served as a director on our board of directorsthe Company since September 30, 2015.July 2017. Mr. Schafran, age 77, was chosenGoldberg served as a memberdirector of Winthrop Realty Trust from 2003 until August 2016 when it was converted to Winthrop Realty Liquidating Trust. Since August 2016,Mr. Goldberg has served as a trustee of the Company’sWinthrop Realty Liquidating Trust.  Mr. Goldberg was a director of New York REIT, Inc. from March 2017 until October 2018, when it converted to a limited liability company called New York REIT LLC. Since October 2018, Mr. Goldberg has been a manager of New York REIT LLC. He has been retired since 1994 after a long career as a lawyer. He provided consulting services to the Company through December 2017. Mr. Goldberg was appointed to the Board becausefor his experience with being a director of his extensive business skills and experiencesother public companies and his financial literacy andlegal expertise. Mr. Schafran also possesses a broad range of experiences and skill garnered from the various leadership positions and from his service on other public company boards and committees. Since 2006, Mr. Schafran

Arthur Laffer - Dr. Laffer has served as a director of the Company since March 2019. Dr. Laffer is the founder and chairman of the audit committeeLaffer Associates, an institutional economic research and member of the compensation committee of Wright Investors’ Service Holdings, Inc., a provider ofconsulting firm, as well as Laffer Investments, an institutional investment and financial services. Mr. Schafran was previously a director, audit committee chairman and member of the compensation committee of SecureAlert, Inc., now Track Group, a manufacturer and distributor of tracking systems, from 2006 to 2013. Between 2006 and 2011, Mr. Schafran also served as a director and board committee member for other public companies, including Subaye, Inc., New Frontier Energy, Inc., America’s Suppliers, Inc., and SulphCo, Inc. Mr. Schafranmanagement firm utilizing diverse investment strategies. Dr. Laffer has also served as a director of several private companies, including Cupcake Digital,EVO Transportation & Energy Services, Inc., (OTCPINK:EVOA) since August 2018, GEE Group Inc. (NYSE American:JOB) since January 2015, and NexPoint Residential Trust Inc. (NYSE:NXRT) since May 2015. Dr. Laffer’s economic acumen and influence in triggering a creatorworld-wide tax-cutting movement in the 1980s have earned him the distinction in many publications as “The Father of Supply-Side Economics.” Dr. Laffer was a member of President Reagan’s Economic Policy Advisory Board for both of his two terms (1981-1989). Dr. Laffer also advised Prime Minister Margaret Thatcher on fiscal policy in the UK during the 1980s. In the early 1970s, Dr. Laffer was the first to hold the title of Chief Economist at the Office of Management and distributorBudget under George Shultz. Additionally, Dr. Laffer served as Charles B. Thornton Professor of children’s educational and entertainment applications (2014 to present); Glasstech, Inc., an automotive glass manufacturer (2002 to present),Business Economics at the University of Southern California and as Associate Professor of Business Economics at the managing directorUniversity of Providence Capital, an investment and advisory firm (2003 to 2012).

Our boardChicago. In June 2019, Dr. Laffer received the Presidential Medal of directorsFreedom. The Board believes Mr. SchafranDr. Laffer is qualified to serve on the Board because of his expertise in economics and his experience as a director based on his many years of professional experience and the board of directors also believes, based on his professional experience that, Mr. Schafran possesses particular knowledge and experience that strengthen the board’s collective qualifications, skills and experience.multiple companies.

57
Jonathan Weinberger
Jonathan R. Weinberger has served as a director on our board of directors since November 21, 2012. Mr. Weinberger is an experienced, accomplished, and well-respected member of the Washington D.C. legal, government, technology, and business communities. He currently serves as the first ever Vice President of Innovation and Technology at the Alliance of Automobile Manufacturers, based in Washington D.C. The Alliance is the leading advocacy group for the auto industry and represents 77% of all car and light truck sales in the United States. He previously served as President and Executive Vice President of a revolutionary technology company called Veedims, LLC, based in Fort Lauderdale, Florida. He also acted as a senior advisor to the owners of the private holding company that owns Veedims. Prior to joining Veedims, Mr. Weinberger served directly under six cabinet members in various positions, including service at the Department of State on the staffs of both Secretary Albright and Secretary Powell. At the U.S. Treasury, Mr. Weinberger served as the youngest Executive Secretary of the Treasury in the department’s history. He also served as the Executive Secretary and Deputy Chief of Staff at the Office of the United States Trade Representative at the White House. Mr. Weinberger has served as Associate General Counsel, where he was in charge of issues with respect to foreign investment in the United States and led the litigation team on various high-level trade disputes with China. Through his service in the government, Mr. Weinberger has developed a superb skill for executive management at the largest scale, an eye for efficient operation, and a rare entrepreneurial mindset that allowed for the streamlining of multitudes of bureaucratic structures and processes. Mr. Weinberger received his Bachelor’s Degree in International Affairs and Italian from The Johns Hopkins University. He also earned a Master’s Degree in U.S. Foreign Policy from the Elliott School of International Affairs at George Washington University, a Juris Doctor degree from the Washington College of Law at American University, and a Masters of Law (LL.M.) in international finance and national security law, with distinction, from Georgetown University Law Center.
Our board of directors believes Mr. Weinberger is qualified to serve as a director based on his many years of professional experience and the board of directors also believes, based on his professional experience that, Mr. Weinberger possesses particular knowledge and experience in information technology that strengthen the board’s collective qualifications, skills and experience.

Composition of our Board of Directors

Our board of directors currently consists of five members, four of whom are non-employee directors.six members. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. There are no family relationships among any of our directors or executive officers.

Director Independence

Based upon information requested from

With the exception of Norman Gardner and provided by eachPatrick White, our Board determined that all of our present directors and our former director concerning their background, employmentare independent, in accordance with standards under the Nasdaq Listing Rules. Our Board determined that, under the Nasdaq Listing Rules, Norman Gardner is not an independent director as a result of being a consultant to the Company, and affiliations, including family relationships, our boardPatrick White is not an independent director because he is an employee of directorsthe Company.

Our Board has determined that Michael Madon, Lawrence SchafranMarshall Geller and Jonathan WeinbergerHoward Goldberg are independent under the applicable rules and regulations of the NASDAQ Stock Market.Nasdaq Listing Rules’ independence standards for Audit Committee members. Our board of directorsBoard has also determined that Jonathan Weinberger, who is chairman of our nominatingMarshall Geller, Howard Goldberg and corporate governance committee, satisfiesChris Gardner are independent under the Nasdaq Listing Rules independence standards for such committees established by the SecuritiesCompensation Committee members and Exchange Commissionfor Governance and the NASDAQ Marketplace Rules, as applicable. However, Claudio Ballard, who is chairman of our compensationNominating committee does not satisfy the standards for such committees established by the Securities and Exchange Commission and the NASDAQ Marketplace Rules, as applicable. With respect to our audit committee, our board of directors has determined that Lawrence Schafran satisfies the independence standards for such committee established by Rule 10A-3 under the Exchange Act, the Securities and Exchange Commission and the NASDAQ Marketplace Rules, as applicable. In making such determinations, the board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances the board of directors deemed relevant in determining their independence.

Board Diversity
Our nominating and corporate governance committee is responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and has individual members. In evaluating the suitability of individual candidates (both new candidates and current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, takes into account many factors, including the following:
·diversity of personal and professional background, perspective, experience, age, gender, ethnicity and country of citizenship;
·personal and professional integrity and ethical values;
·experience in one or more fields of business, professional, governmental, scientific or educational endeavors, and a general appreciation of major issues facing public companies similar in scope and size to us;
·experience relevant to our industry or with relevant social policy concerns;
·relevant academic expertise or other proficiency in an area of our operations;
·objective and mature business judgment and expertise; and
·any other relevant qualifications, attributes or skills.

Committees of the Board of Directors

Our board

Audit Committee

The Audit Committee is composed of directors has established an audit committee, a compensation committeetwo independent directors: Howard Goldberg and a nominating and corporate governance committee. Each committee operates under a charter approved byMarshall Geller. Eugene Robin, our board of directors. The composition and function of each of these committees are described below.

Audit Committee. Our audit committee is comprised of Lawrence Schafran, Jonathan Weinberger, and Claudio Ballard, Mr. Schafran is the chairpersonformer independent director, served as Chair of the committee. Our boardAudit Committee until his resignation in September 2019. Each member of directors has determined that Mr. Schafranthe Audit Committee is an audit committee financial expert,independent director as defined by the rules of the SecuritiesSEC and Exchange Commission,Nasdaq. The Board expects to recommend for election an additional director who is anticipated to serve on the Audit Committee.

The Audit Committee has the sole authority and satisfiesresponsibility to select, evaluate and engage independent auditors for the Company. The Audit Committee reviews with the auditors and with the Company’s financial sophistication requirementsmanagement all matters relating to the annual audit of applicable NASDAQ Marketplace Rules.

the Company.

The Audit Committee monitors the integrity of our financial statements, monitors the independent registered public accounting firm’s qualifications and independence, monitors the performance of our internal audit function and the auditors, and monitors our compliance with legal and regulatory requirements. The Audit Committee also meets with our auditors to review the results of their audit and review of our annual and interim financial statements.

The Audit Committee meets at least on a quarterly basis to discuss with management the annual audited financial statements and quarterly financial statements and meets from time to time to discuss general corporate matters.

Audit Committee Financial Expert

Our board of directors hasBoard determined that Eugene Robin, our former director, was qualified as an Audit Committee Financial Expert, as that term is defined by the rules of the SEC, in compliance with the Sarbanes-Oxley Act of 2002. The Board expects to recommend for election an additional director who is anticipated to serve on the Audit Committee and expected to qualify as an Audit Committee Financial Expert.

Compensation Committee

The Compensation Committee, which currently consists of Marshall Geller (Chair), Howard Goldberg, and Chris Gardner shall consist of at least three members, each of whom shall be independent directors. Among other things, the audit committee membersCompensation Committee reviews, recommends and approves salaries and other than Claudio Ballard is an independent director under the NASDAQ Marketplace Rules and Rule 10A-3compensation of the Exchange Act.

Our audit committee is authorized to:
Company’s executive officers, and administers the Company’s equity incentive plans (including reviewing, recommending and approving stock option and other equity incentive grants to executive officers).

 ·58approve and retain the independent auditors to conduct the annual audit of our financial statements;

The Compensation Committee will meet in executive session to determine the compensation of the Chief Executive Officer of the Company. In determining the amount, form, and terms of such compensation, the Committee considers the annual performance evaluation of the Chief Executive Officer conducted by the Board in light of company goals and objectives relevant to Chief Executive Officer compensation, competitive market data pertaining to Chief Executive Officer compensation at comparable companies, and such other factors as it deems relevant, and is guided by, and seeks to promote, the best interests of the Company and its shareholders.

In addition, subject to existing agreements, the Compensation Committee determines the salaries, bonuses, and other matters relating to compensation of the executive officers of the Company using similar parameters. It sets performance targets for determining periodic bonuses payable to executive officers. It also reviews and makes recommendations to the Board regarding executive and employee compensation and benefit plans and programs generally, including employee bonus and retirement plans and programs (except to the extent specifically delegated to a Board appointed committee with authority to administer a particular plan). In addition, the Compensation Committee approves the compensation of non-employee directors and reports it to the full Board.

The Compensation Committee also reviews and makes recommendations with respect to shareholder proposals related to compensation matters.

They administer the Company’s equity incentive plans, including the review and grant of stock

options and other equity incentive grants to executive officers and other employees and consultants.

The Compensation Committee may, in its sole discretion and at the Company’s cost, retain or obtain the advice of a compensation consultant, legal counsel or other adviser. The Compensation Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel and other adviser retained by the committee.

Governance and Nominating Committee

The Governance and Nominating Committee, which consists of Marshall Geller (Chair), Howard Goldberg, and Chris Gardner will have no fewer than three members, each of whom shall meet the independence requirements of all other applicable laws, rules and regulations governing director independence, as determined by the Board.

The Governance and Nominating Committee identifies individuals qualified to become members of the Board, consistent with criteria approved by the Board; recommends to the Board the director nominees for the next annual meeting of stockholders or special meeting of stockholders at which directors are to be elected; recommends to the Board candidates to fill any vacancies on the Board; develops, recommends to the Board, and reviews the corporate governance guidelines applicable to the Company; and oversees the evaluation of the Board and management.

In recommending director nominees for the next annual meeting of shareholders, the Governance and Nominating Committee ensures the Company complies with its contractual obligations, if any, governing the nomination of directors. It considers and recruits candidates to fill positions on the Board, including as a result of the removal, resignation or retirement of any director, an increase in the size of the Board or otherwise. The Committee conducts, subject to applicable law, any and all inquiries into the background and qualifications of any candidate for the Board and such candidate’s compliance with the independence and other qualification requirements established by the Committee. The Committee also recommends candidates to fill positions on

committees of the Board.

In selecting and recommending candidates for election to the Board or appointment to any committee of the Board, the Committee does not believe that it is appropriate to select nominees through mechanical application of specified criteria. Rather, the Committee shall consider such factors at it deems appropriate, including, without limitation, the following: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; experience in the Company’s industry; experience as a board member of another publicly-held company; diversity of expertise and experience in substantive matters pertaining to the Company’s business relative to other directors of the Company; practical and mature business judgment; and composition of the Board (including its size and structure).

review the proposed scope and results of the audit;59

The Committee develops and recommends to the Board a policy regarding the consideration of director candidates recommended by the Company’s stockholders and procedures for submission by stockholders of director nominee recommendations.

In appropriate circumstances, the Committee, in its discretion, will consider and may recommend the removal of a director, in accordance with the applicable provisions of the Company’s certificate of incorporation and bylaws. If the Company is subject to a binding obligation that requires director removal structure inconsistent with the foregoing, then the removal of a director shall be governed by such instrument.

The Committee oversees the evaluation of the Board and management. It also develops and recommends to the Board a set of corporate governance guidelines applicable to the Company, which the Committee shall periodically review and revise as appropriate. In discharging its oversight role, the Committee is empowered to investigate any matter brought to its attention.

Finance and Uplisting Committee

The Finance and Uplisting Committee, which consists of Marshall Geller (Chair), Howard Goldberg and Arthur Laffer, is required to review the business of the Company and make recommendations to the Board concerning the Company’s prospects regarding uplisting to a national securities exchange.

Board Diversity

While we do not have a formal policy on diversity, the Board considers diversity to include the skill set, background, reputation, type and length of business experience of the Board members as well as a particular nominee’s contributions to that mix.  The Board believes that diversity brings a variety of ideas, judgments and considerations that benefit the Company and its shareholders.  Although there are many other factors, the Board seeks individuals with experience on operating and growing businesses.

Board Leadership Structure

Norman Gardner serves as the Chairman of the Board and actively interfaces with management, the Board and counsel regularly. We believe that this Board leadership structure is the most appropriate for the Company and its stockholders at this time because it allows the Chief Executive Officer to focus on generating sales, overseeing sales and marketing, and managing the Company while leveraging the experience and perspectives of the Chairman, who is our founder, and offers an additional channel of communication for other directors, investors and employees.

The Board has also created the position of Lead Director to facilitate the communications between management and the Board and to promote effective governance standards. The Board elects a Lead Director from our independent directors. Howard Goldberg currently serves as our Lead Director.

Board Risk Oversight

The Company’s risk management function is overseen by the Board. The Company’s management keeps the Board apprised of material risks and provides its directors access to all information necessary for them to understand and evaluate how these risks interrelate, how they affect us, and how management addresses those risks. Norman Gardner works closely together with the other members of the Board once material risks are identified on how to best address such risks. If the identified risk poses an actual or potential conflict with management, the Company’s independent directors may conduct the assessment. Presently, the primary risk affecting us is the Company’s ability to generate revenue.

review and pre-approve audit and non-audit fees and services;60
Table of Contents ·review accounting and financial controls with the independent auditors and our financial and accounting staff;
·review and approve transactions between us and our directors, officers and affiliates;
·recognize and prevent prohibited non-audit services;
·establish procedures for complaints received by us regarding accounting matters;
·oversee internal audit functions, if any; and
·prepare the report of the audit committee that the rules of the Securities and Exchange Commission require to be included in our annual meeting proxy statement.

Compensation Committee. Our compensation committee is comprised

Code of Claudio Ballard, Lawrence Schafran and Jonathan Weinberger. Mr. Ballard is the chairman of the compensation committee. Our compensation committee is authorized to:

·review and recommend the compensation arrangements for management, including the compensation for our chief executive officer;
·administer our stock incentive plans; and
·prepare the report of the compensation committee that the rules of the Securities and Exchange Commission require to be included in our annual meeting proxy statement.

Nominating and Corporate Governance Committee. Our nominating and corporate governance committee is comprised of Jonathan Weinberger, Claudio Ballard and Lawrence Schafran. Mr. Weinberger is the chairman of the nominating and corporate governance committee. Our nominating and corporate governance committee is authorized to:

·identify and nominate members of the board of directors;
·develop and recommend to the board of directorsEthics

The Board has adopted a set of corporate governance principles applicable to our company; and

·oversee the evaluation of our board of directors.

Code of Business Conduct and Ethics
We have adopted a code (the “Code of business conduct and ethicsEthics”) that will applyapplies to all of ourthe Company’s employees, officersincluding the Company’s Chief Executive Officer and directors,Chief Financial Officer. Although not required, the Code of Ethics also applies to the Company’s directors. The Code of Ethics provides written standards that we believe are reasonably designed to deter wrongdoing and promote honest and ethical conduct, including those officers responsible for financial reporting.  the ethical handling of actual or apparent conflicts of interest between personal and professional relationships, full, fair, accurate, timely and understandable disclosure and compliance with laws, rules and regulations and the prompt reporting of illegal or unethical behavior. The code of business conduct and ethics is available on ourthe Company’s website at http:https://www.verifyme.com/#intro.  We expect that any amendments to the code, or any waivers of its requirements, will be disclosed on our website.
Board Leadership Structure and Board’s Role in Risk Oversight
The positions of chairman of the board and chief executive officer are presently separated at our company.  We believe that separating these positions allows our chief executive officer to focus on our day-to-day business, while allowing our chairman of the board to lead the board of directors in its fundamental role of providing advice to, and independent oversight of, management.  Our board of directors recognizes the time, effort and energy that the chief executive officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our chairman, particularly as the board of directors’ oversight responsibilities continue to grow.  Our board of directors also believes that this structure ensures a greater role for the independent directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our board of directors.  This leadership structure also is preferred by a significant number of our stockholders.  Our board of directors believes its administration of its risk oversight function has not affected its leadership structure. Michael Madon is the Chairman of the Board of Directors
While our amended and restated by-laws and corporate governance guidelines do not require that our chairman and chief executive officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Risk is inherent with every business, and how well a business manages risk can ultimately determine its success.  We face a number of risks, including risks relating to product candidate development, technological uncertainty, dependence on collaborative partners and other third parties, uncertainty regarding patents and proprietary rights, comprehensive government regulations, having no commercial manufacturing experience, marketing or sales capability or experience and dependence on key personnel.  Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management.  In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed.
Our board of directors is actively involved in oversight of risks that could affect us.  This oversight is conducted primarily through committees of the board of directors, but the full board of directors has retained responsibility for general oversight of risks.  Our board of directors satisfies this responsibility through full reports by each committee chair regarding the committee’s considerations and actions, as well as through regular reports directly from officers responsible for oversight of particular risks within our company as our board of directors believes that full and open communication between managementcode-of-conduct and the board of directors is essential for effective risk management and oversight.
Limitation of Directors’ and Officers’ Liability and Indemnification
The corporate laws of the state of Nevada authorize corporationsCompany will provide a copy, without charge, to limit or eliminate, subjectanyone that requests one in writing to specified conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach of their fiduciary duties.  Our amended and restated articles of incorporation limit the liability of our directors to the fullest extent permitted by Nevada law.
We have obtained director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us.  Our amended and restated articles of incorporation and amended and restated by-laws also provide that we will indemnify and advance expenses to any of our directors and officers who, by reason of the fact that he or she is one of our officers or directors, is involved in a legal proceeding of any nature.  We will repay certain expenses incurred by a director or officer in connection with any civil, criminal, administrative or investigative action or proceeding, including actions by us or in our name.  Such indemnifiable expenses include, to the maximum extent permitted by law, attorney’s fees, judgments, fines, ERISA excise taxes, penalties, settlement amounts and other expenses reasonably incurred in connection with legal proceedings.  A director or officer will not receive indemnification if he or she is found not to have acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interest.
 The company intends to enter into separate agreements with its directors and officers.  Pursuant to such agreements, the company intends to agree to indemnify, defend and hold harmless each director to the fullest extent of the law of the State of Nevada and in accordance with the Company’s amended and restated articles of incorporation and amended and restated by-laws.  The Company expects for such indemnification to apply to any actions taken in the director’s official capacity as a director, as well as those actions that relate to the company’s business while the director holds office.  Further, the Company expects for such indemnification to not apply to matters arising out of the director’s gross negligence or willful misconduct.  The Company expects for such indemnification of its directors to cover payment for or reimbursement of expenses, including legal fees and expenses.  Additionally, the company intends to agree to maintain directors’ and officers’ insurance throughout the terms of such agreements and for a period of six years thereafter. We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and officers.
52

VerifyMe, Inc., 75 S. Clinton Ave., Suite 510 Rochester, NY 14604 Attention: Corporate Secretary.

Table of Contents

Such limitation of liability and indemnification does not affect the availability of equitable remedies.  In addition, we have been advised that in the opinion of the SEC, indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act and is therefore unenforceable.
There is no pending litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required or permitted.  We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.

Summary Compensation Table

The following table sets forthinformation is related to the compensation earnedpaid, distributed or accrued by the Company’s principal executive officer and named executive officers duringus for the years ended December 31, 20152018 and 2014.

         Stock  Option  All Other    
   Salary  Bonus  
Awards(1)
  
Awards(1)
  Compensation  Total 
Name and Principal PositionYear ($)  ($)  ($)  ($)  ($)  ($) 
Neil Alpert, Former Chief2015  6,667   -   -   -   -   6,667 
  Executive Officer2014  200,000*   -   -   -   -   200,000 
Paul Donfried, Chief Executive Officer,2015  151,107**   -   280,000   405,342   -   836,449 
  President and Secretary(a)
2014  300,000***   -   -   -   -   300,000 
Ben Burrell, Chief Operating Officer(b)
2015  68,055****   -   918,000   1,502,219   -   2,488,274 
 2014  -   -   -   -   -   - 
Scott McPherson, Chief Financial Officer2015  79,350*****   -   692,400   1,107,857   -   1,879,607 
 2014  -   -   -   -   -   - 
Sandy Fliderman, Chief Technology Officer(c)
2015  74,948******   -   191,250   304,003   -   570,201 
 2014  -   -   -   -   -   - 
(1)  2017 to our Named Executive Officers.

Summary Compensation Table

Name and          Option  All Other  Total 
Principal    Salary  Stock  Awards  Compensation  Compensation 
Position Year  ($)  Awards ($)  ($)(1)  ($)(2)  ($) 
                   
Patrick White (3)  2018   200,000(4)  16,240(5)  48,466   14,400   279,106 
CEO  2017   75,291(4)  --   240,631   25,000   340,922 
                         
Keith Goldstein(6)  2018   145,000   --   271,745   14,400   431,145 
COO  2017   41,000   --   318,818   1,000   359,818 

(1) Represents the grant date fair value of the option award, or stock award, as applicable, calculated in accordance with FASB Accounting Standard Codification 718, “Compensation – Stock Compensation,” or ASC 718. The assumptions used in calculating the grant date fair value of the option awards are set forth in Note 1 of the Financial Statements to our Form 10-K for the year ended December 31, 2018.

(2)The amounts shown in this column reflect amounts paid by us to or on behalf of each named executive officer for medical insurance reimbursement.For 2017, the amounts for Mr. White also included his consulting fees.

(3) Mr. White served as a consultant to us during 2017 and was appointed our Chief Executive Officer on
August 15, 2017.

(4) Pursuant to Mr. White’s employment agreement, $50,000 of his annual salary was deferred for each year of the two-year term beginning August 15, 2017, for a total deferred salary of $100,000. This amount was subsequently deferred for another year. See “Named Executive Officer Employment and Compensation Agreements” below.

(5)Represents the aggregate grant date fair value of the restricted stock awards granted to Mr. White for his service as a director, calculated in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the optionrestricted stock awards are set forth in Note 13 of1 to our Consolidated Financial Statements.audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.

(6) Mr. Goldstein was appointed Chief Operating Officer on September 1, 2017. The sum of salary represents consulting fees paid to POC Advisory Group, LLC, of which Mr. Goldstein is the managing member.

(a) – Mr. Donfried was appointed Chief Executive Officer, President and Secretary on April 22, 2015.61

Named Executive Officer Employment and Compensation Agreements

We have employment agreements with each of our executive officers.

In August 2019, the Company entered into an amendment to the employment agreement, dated August 15, 2017, with Patrick White, the Chief Executive Officer of the Company, which employment agreement automatically renewed on July 16, 2019, effective on August 15, 2019. Pursuant to the amendment, the term was set at one year and Mr. White agreed to defer receipt of sums due him to improve the Company’s liquidity. Mr. White was due to receive $100,000 on August 15, 2019 representing deferred salary (the “Deferral Amount”) that he had previously agreed to defer over the two years of the initial term of his employment agreement. Pursuant to the amendment, Mr. White agreed to extend receipt of the Deferral Amount until August 15, 2020. In addition, he agreed to continue deferring 25% of his base salary (set at $200,000 per year) over the one-year term until August 15, 2020. In connection with entering into the amendment, the Company granted Mr. White immediately vesting incentive stock options under the Company’s 2017 Equity Incentive Plan for 500,000 shares of common stock that expire five-years from the date of grant with an exercise price of $0.14 per share.

On August 1, 2017, Mr. White received a grant of a five year option to purchase 5,000,000 shares of our common stock at an exercise price of $0.07 per share of which 3,000,000 vested upon execution of our standard Stock Option Agreement and the remaining 2,000,000 vest annually, in equal increments over a two year period. On April 17, 2018, Mr. White received an additional grant of a five year option to purchase 2,000,000 shares of our common stock at an exercise price of $0.07 per share. Both the August 2017 and April 2018 option grants were issued pursuant to Section 4(a)(2) of the Act and are therefore “restricted securities” as such term is used in Rule 144 of the Act. In the event of termination of Mr. White’s employment agreement without cause, Mr. White is entitled to receive any unpaid salary and expenses, a payment equal to 12 months of his salary at the rate in effect on the date of such termination, and a continuation of benefits for a period of six-months. Additionally, in the event of termination, all options granted to Mr. White shall immediately vest and he shall be entitled to exercise those options for a period of one-year from the date of termination. In the event Mr. White is terminated or his title as chief executive officer changes within 12 months following a change in control, Mr. White will be entitled to receive any unpaid salary and expenses, a payment equal to 18 months of his salary at the rate in effect on the date of such termination, and a continuation of benefits for a period of 18 months.

On September 1, 2017, the Company entered into a six-month Consulting Agreement with Keith Goldstein pursuant to which Mr. Goldstein served as our Chief Operating Officer and received a monthly fee of $10,000 per month plus 4% of any sales made by Mr. Goldstein on behalf of the Company. Mr. Goldstein was granted options to purchase 2,000,000 shares of our common stock with an exercise price of $0.04 per share and a five-year term that vested in equal monthly increments over the initial six-month term.

On March 1, 2018, the Company amended the Consulting Agreement with an entity controlled by Mr. Goldstein, our Chief Operating Officer, for a one-year term which expired on February 28, 2019, under which Mr. Goldstein received a monthly fee of $12,500 per month. The amendment provided Mr. Goldstein with additional options to purchase 1,000,000 shares of our common stock with an exercise price of $0.2102 per share that have a five-year term. Options with respect to 500,000 shares vested upon execution of the amendment and options with respect to the remaining 500,000 shares vested on February 28, 2019. The amendment also terminated Mr. Goldstein’s right to the 4% sales commission. In February 2019, the Company agreed to renew Mr. Goldstein’s agreement on a month-to-month basis on the terms of the amendment, pending Board approval of a new agreement. On April 9, 2019, we entered into a Second Amendment to Consulting Agreement. The key provisions of the second amendment to the Consulting Agreement include the following:

·Mr. Burrell was appointed Chief Operating OfficerGoldstein receives a monthly consulting fee of $14,500 for services provided;

·Mr. Goldstein received a grant of stock options under the 2017 Equity Incentive Plan to purchase 1,000,000 shares of our common stock with an exercise price of $0.195 per share. The options vest annually in equal increments over a two-year period with the first vesting date being March 1, 2020, subject to Mr. Goldstein performing services for the Company as of each applicable vesting date and executing the Company’s standard Stock Option Agreement. Any unvested options will vest immediately upon a change of control;
·the second amendment is for a two-year term beginning March 1, 2019 and expiring on July 15, 2015.March 1, 2021.

62
(c)Table of Contents – Mr. Fliderman was appointed Chief Technology Officer on June 12, 2015.
As

The Consulting Agreement, as amended, may be terminated at any time by the Company for cause. If terminated without cause, Mr. Goldstein is entitled to any unpaid fees and any unpaid and accrued expenses. The Consulting Agreement, as amended, contains non-compete provisions prohibiting Mr. Goldstein from competing with us during the term of December 31, 2015, employees have accrued the following:


** $4,167
**** $3,245
***** $6,000
******  $3,245
AsConsulting Agreement and for one year after termination.

Other Consulting Agreement

On June 29, 2017, the Company entered into a Consulting Agreement with Norman Gardner. Under the terms of December 31, 2014, employees had accrued the following:

$38,827
*** $76,000
$12,500 over a three-year term beginning June 30, 2017. The Consulting Agreement provides that the Company will reimburse Mr. Gardner for up to $1,000 a month for health insurance and other medical expenses and will provide Mr. Gardner with a grant of 10,000,000 stock options exercisable at $0.07 per share which are fully vested and exercisable over a five-year term. In the event of termination without cause, Mr. Gardner is entitled to receive any unpaid salary and expenses, a payment equal to 12 months of his consulting fee, and a continuation of benefits for a period of six-months. The Consulting Agreement further provides for 12 months of severance and health insurance reimbursement if it is terminated without cause and 18 months of severance and health insurance reimbursement upon a change of control if Mr. Gardner terminates the Agreement within one year of the change of control.

Outstanding Equity Awards At December 31, 2015

equity awards at fiscal year-end

The following table sets forth the outstanding equity awards for each named executive officer, information regarding unexercised options, stock that had not vested, and equity incentive plan awardsour Named Executive Officers as of the end of our fiscal year ended December 31, 2015.


  Option awards  Stock awards 
 
 
 
 
 
 
 
 
 
 
 
 
Name
 
 
 
 
 
 
 
Number of
securities
underlying
unexercised
options
(#)
exercisable
  
 
 
 
 
 
Number of
securities
underlying
unexercised
options
(#)
unexercisable
(a)
   
 
 
 
Equity
incentive
plan awards:
Number of
securities
underlying
unexercised
unearned
options
(#)
  
 
 
 
 
 
 
 
 
 
Option
Exercise
Price
($)
  
 
 
 
 
 
 
 
 
 
 
Option
Expiration
Date
  
 
 
 
 
 
 
Number of
shares or
units of
stock that
have not
vested
(#)
  
 
 
 
 
 
Market
value of
shares or
units of
stock that
have not
vested
($)
  
 
 
Equity
incentive
plan awards:
Number of
unearned
shares, units
or other
rights that
have not
vested
(#)
  
Equity
incentive
plan awards:
Market or
payout
value of
unearned
shares, units
or other
rights that
have not
vested
($)
 
Neil Alpert  -   -    -   -   -   -   -   -   - 
Paul Donfried  5,882   -    -   4.25  3/28/2024   -   -   -   - 
   125,000   375,000 (1)  -   0.85  6/12/2020   -   -   -   - 
   -   -    -   -   -   -   -   300,000   750,000 
Ben Burrell  31,250   343,750 (2)  -   0.85  7/9/2020   -   -   -   - 
   -   -    -   -   -   -   -   225,000   562,500 
Scott McPherson  16,667   183,333 (3)  -   5.77  8/10/2020   -   -   -   - 
   -   -    -   -   -   -   -   20,000   50,000 
   -   -    -   -   -   -   -   100,000   250,000 
Sandy Fliderman  62,500   312,500 (4)  -   0.85  6/12/2020   -   -   -   - 
   -   -    -   -   -   -   -   225,000   562,500 
2018. 

   Option Awards   Stock Awards 
Name  Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
   Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
   

Option
Exercise
Price

($)

   Option
Expiration
Date
   

Number of
Shares of
Restricted
Stock That
Have Not
Vested

(#)

   

Market Value
of Shares of
Restricted
Stock That
Have Not
Vested

($)

 
Patrick White  6,000,000   1,000,000(1)  0.07   8/15/2022   75,000(2)  16,500(3)
                         
Keith Goldstein  2,000,000(4)     0.04   09/01/2022       
   500,000   500,000(5)  0.21   03/01/2023       

(1) 62,500Vested on August 9, 2019.

(2) Vested every three months over a one year period that commenced on June 27, 2018.

(3) Based on $0.22 per share, the closing price of the Company’s common stock as of December 28, 2018.

(4) These options vested on March 12, 2016, andare held by POC Advisory Group LLC, of which Mr. Goldstein is the remainder vest quarterly through June 12, 2017.

(2)   31,250 of the options vested on January 9, 2016, and the remainder vest quarterly through July 9, 2018.
(3)   16,667 of the options vestedmanaging member.

(5) Vested on February 10, 2016, and28, 2019.

Director Compensation for the remainder vest quarterly through August 10, 2018.

(4)   31,250 of the options vested on March 12, 2016, and the remainder vest quarterly through September 25, 2017.


Narrative Disclosure to Summary Compensation Table and Outstanding Equity Awards Table
Employment Agreements
Pursuant to the terms of the offer letter agreed to between the Company and Mr. Donfried, Mr. Donfried is an “at-will” employee of the Company and receives an annual salary of $200,000. Mr. Donfried will also receive 42,500,000 options (post reverse split 500,000 options) to purchase shares of common stock of the Company, with an exercise price of $0.01. The options vest quarterly over three years. In addition, Mr. Donfried will receive 25,500,000 (post reverse split 300,000 RSUs) shares of restricted stock, vesting over a three year period, with 1/3 vesting the first year and 1/6 vesting ratably semi-annually thereafter. Mr. Donfried will receive a standard benefits package that includes health insurance and paid vacation time.
Pursuant to the terms of the offer letter agreed to between the Company and Mr. Burrell, Mr. Burrell is an “at-will” employee of the Company and receives an annual salary of $150,000. Mr. Burrell received 31,875,000 options (post reverse split 375,000 options) to purchase shares of common stock of the Company, with an exercise price of $0.01. The options will vest quarterly over three years. In addition, Mr. Burrell received 19,125,000 (post reverse split 225,000 RSUs) shares of restricted stock, vesting over a three-year period, with one-third vesting the first year and 1/12 vesting ratably on a quarterly basis thereafter. Mr. Burrell receives a standard benefits package that includes health insurance and paid vacation time.
Pursuant to the terms of the offer letter agreed to between the Company and Mr. Fliderman, Mr. Fliderman is an “at-will” employee of the Company and receives an annual salary of $150,000. Mr. Fliderman received 31,875,000 options (post reverse split 375,000 options) to purchase shares of common stock of the Company, with an exercise price of $0.01. The options vest quarterly over three years. In addition, Mr. Fliderman received 19,125,000 (post reverse split 225,000 RSUs) shares of restricted stock, vesting over a three year period, with 1/3 vesting the first year and 1/12 vesting ratably on a quarterly basis thereafter. Mr. Fliderman receives a standard benefits package that includes health insurance and paid vacation time.
Director Compensation
Nonqualified
Non-equity incentivedeferred
Fees Earned orStockOptionplancompensationAll Other
paid in cashawardsawardscompensationearningsCompensationTotal
Name(2)
($)($)
($)(1)
($)($)($)($)
Claudio Ballard--
 60,801(5)
---60,801
Lawrence G. Schafran--
155,003(6)
---155,003
Jonathan Weinberger--
141,870(7)
---141,870
Paul Klapper(3)
-------
Connie Harriman(4)
-------

(1)Represents the grant date fair value of the option award, calculated in accordance with FASB Accounting Standard Codification 718, “Compensation – Stock Compensation,” or ASC 718. The assumptions used in calculating the grant date fair value of the option awards are set forth in Note 13 of our Consolidated Financial Statements.
(2)Neil Alpert and Paul Donfried who were directors in 2015 are not included in this table as they were employee directors who did not receive additional compensation for their service as directors. Mr. Madon did not serve as a director in 2015 and therefore did not receive any compensation to be reported in this table.
(3)Mr. Klapper resigned as a director of the Company on February 26, 2015. He was not paid any compensation for his services as a director in 2015.
(4)Ms. Harriman resigned as a director of the Company on February 15, 2015. She was not paid any compensation for her services as a director in 2015.
(5)Mr. Ballard held 75,000 options at year end, of which 25,000 options had vested, and 50,000 options remained unvested, as of December 31, 2015.
(6)
Mr. Schafran held 75,000 options at year end, of which 25,000 options had vested, and 50,000 options remained unvested, as of December 31, 2015.
(7)
Mr. Weinberger held 175,000 options at year end, of which 58,333 options had vested, and 116,667 options remained unvested,as of December 31, 2015.
Narrative Disclosure to Directors Compensation Table
We did not pay an annual fee to any of our directors during 2015 or 2014. Each member of our board of directors receives reimbursement of expenses incurred in connection with his or her services as a member of our board or board committees.
Fiscal Year ended 2018

Our non-employee directors are eligible to receive options, restricted stock and other equity linked grants under our 2013 Omnibus Equity Compensation Plan (the “2013 Plan”).

Equity Incentive Plan
In 2013, the board of directors and the holders of at least majority of our then-outstanding capital stock approved and adopted our 2013 Plan.
The material terms of the 2013 Plan are summarized below.
General.  The 2013 Plan provides that grants may be made in any of the following forms: 
equity incentive plans. Board compensation is determined on an annual basis.

 ·63Incentive stock options
Table of Contents ·Nonqualified stock options
·Stock units
·Stock awards
·Stock appreciation rights (“SARs”)
·Dividend equivalents
·Other stock-based awards

The 2013 Plan authorizesfollowing table sets forth information about the compensation earned by or paid to our directors during our fiscal year ended December 31, 2018. Please refer to the “Summary Compensation Table” above for compensation earned by Mr. White as a member of the Board of Directors.

  Stock  All Other  Total 
  Awards(1)  Compensation  Compensation 
Name ($)  ($)  ($) 
Norman Gardner  16,240   162,000(2)   178,240 
Carl Berg(3)  81,318   -   81,318 
Laurence Blickman(3)  31,585     30,000(4)   61,585 
Harvey Eisen(3)  108,236   -   108,236 
Marshall Geller  28,337   -   28,337 
Howard Goldberg  36,457   -   36,457 
Lawrence G. Schafran(3)  6,143   -   6,143 

(1) Represents grants of restricted common stock in June 2018, vesting quarterly over a one-year period, subject to continued service as a director and the portion vesting in 2018 for restricted common stock granted in August 2017. The following table presents the number of shares of restricted common stock outstanding and the aggregate number of outstanding options for each of our directors as of December 31, 2018.

Name Shares of Restricted Common Stock  Stock Options 
Carl Berg  495,000   -- 
Laurence Blickman  535,000   -- 
Harvey Eisen  510,000   -- 
Norman Gardner  150,000   4,500,000 
Marshall Geller  505,000   -- 
Howard Goldberg  580,000   -- 

(2) Mr. Gardner receives a monthly consulting fee of $12,500 and is reimbursed up to $1,000 a month for health insurance and other medical expenses. Please see “Other Consulting Agreement” above.

(3) Former director.

(4) On April 25, 2018, the Company approved the payment of $30,000 to Mr. Blickman for the services he rendered in connection with the negotiating and resolving the transactions pertaining to the settlement agreement with shareholders.

 Equity compensation plan information

During 2013, the Board adopted, and our shareholders approved, a new comprehensive incentive compensation plan (the “2013 Plan”) which served as the successor incentive compensation plan to a 2003 Stock Option Plan covering (i) 20,000,000 new shares of our common stock, for issuance equal to the sum of the following:  (i) 20,000,000 new shares, plus (ii) the number of shares of our common stock subject to outstanding grants under ourthe 2003 Stock Option Plan (the “2003 Plan”) as of the date of the 2013 Plan was approved by our stockholdersAnnual Meeting, plus (iii) the number of shares of our common stock remaining available for issuance under the 2003 Plan but not subject to previously exercised, vested or paid grants as of the date of  2013 Plan was approved by our stockholders, in each case, subject to adjustment in certain circumstances as described below. As of December 31, 2015, 300,000 shares of our common stock were subject to outstanding awards and 19,700,000 shares of our common stock remained availablePlan. Outstanding options for future issuance.

The 2013 Plan provides that the maximum aggregate number of shares of our common stock with respect to which grants may be made to any individual during any calendar year is 4,000,000 shares, subject to adjustment in certain circumstances as described below.  If dividend equivalents are granted, a grantee may not accrue more than $500,000 of such dividend equivalents during any calendar year.
If and to the extent options (including options granted under the 2003 Plan) and SARs granted under the 2013 Plan terminate, expire or are cancelled, forfeited, exchanged or surrendered without being exercised or if any stock awards, stock units, or other stock-based awards (including stock awards or stock units granted under the 2003 Plan), are forfeited, terminated, or otherwise not paid in full, the shares subject to such grants will become available again for purposes of the 2013 Plan. Shares surrendered in payment of the exercise price of an option and shares withheld or surrendered for payment of taxes will be available again for issuance or transfer under the 2013 Plan. If any grants are paid in cash, and not in shares of our common stock, any shares of our common stock subject to such grants will also be available for future grants. Upon the net exercise of an option or the exercise of a SAR, then both for purposes of calculating the number of7,990,000 shares of common stock remaining available for issuancehave been issued under the 2013 Plan and the number2013 Plan will no longer be used for future grants.

On November 14, 2017, the Board adopted and in 2018 our shareholders ratified the Company’s 2017 Equity Incentive Plan (the “2017 Plan”) which provides for the issuance of awards covering 13,000,000 shares of common stock remainingunder the Plan. Awards granted under the Plan may be Incentive Stock Option, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock or Restricted Stock Units which are awarded to employees, consultants, officers and directors of the Company. As of September 30, 2019, there were 9,900,000 shares available for exercisegrant under the option or SAR, the number2017 Plan.

64

Equity compensation plan information as of such shares will be reduced by the net number of shares for which the option or SAR is exercised, and without regardDecember 31, 2018

  (a)  (b)  (c) 
Plan category  Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
   Weighted-average exercise
price of outstanding options,
warrants and rights
   Number of securities remaining
available for future issuance under
equity compensation plans
(excluding securities reflected in
column (a))
 
Equity
compensation
plans
approved by
security holders(1)
  9,590,000  $0.20   18,062,500 
             
Equity
compensation
plans not-
approved by
security holders
  9,023,529  $0.07   -- 
             
Total  18,613,529  $0.14   18,062,500 

(1) Includes awards pursuant to any cash settlement of a SAR.

Administration.  The 2013 Plan will be administered and interpreted by the Compensation Committee.  Ministerial functions may be performed by an administrative committee of our employees appointed by the Compensation Committee.
The Compensation Committee has the authority to (i) determine the individuals to whom grants will be made under the 2013 Plan (ii) determineand the type, size,2017 Plan.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In addition to Employment and Consulting Agreements disclosed elsewhere, we engaged in a number of transactions with our executive officers and directors.

 In January 2018, we issued 1,749,683 shares and 1,749,683 warrants to purchase common stock at an exercise price of $0.15 per share to entities controlled by Paul Klapper, a former member of our Board, relating to a note payable conversion that took place in June 2017 prior to the time he became a director.

On February 19, 2018, we authorized a warrant reduction program (the “Program”) permitting warrant holders of our outstanding $0.15 warrants to exercise their warrantsfor $0.10 (the “Reduced Price”) under the terms and conditions of the grants, (iii) determine when grants will be madeProgram. We received total gross proceeds of approximately $2,079,345 from the exercise of warrants under the Program at the Reduced Price. Included in the above amounts are gross proceeds of $1,205,458 from then directors including $572,000 from Carl Berg, $110,000 from Marshall Geller, $71,500 from Harvey Eisen, and $451,958 from Laurence Blickman.

On March 31, 2018, we entered into the Settlement Agreement with Paul Klapper, who was at the time a member of our Board, and certain other parties named in the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, we (i) paid a total of $500,000 (the “Settlement Amount”) to a fund controlled by Paul Klapper and an additional party and (ii) issued a total of 1,000,000 shares of our common stock to  the fund and the durationthird party (the “Settlement Shares”). The Settlement Agreement provides for the cancellation of any applicable exercise or restriction period, including the criteria for exercisabilitycertain revenue sharing agreements, as of March 31, 2018, between us and Mr. Klapper (or an affiliate) and the acceleration of exercisability, (iv) amend the termsthird party, and conditions of any previously issued grant, subjectterminates our obligation to the limitations described below and (v) deal with any other matters arising under the 2013 Plan.  

Eligibility for Participation.  Allissue Mr. Klapper or affiliates warrants to purchase 3,700,000 shares of our employees, non-employeecommon stock at an exercise price of $0.40 per share.  As a condition of entering into the Settlement Agreement, we accelerated the vesting of 150,000 shares of restricted common stock held by Mr. Klapper which were part of a 300,000 share grant on August 2017. Mr. Klapper joined the Board on July 14, 2017 and resigned as of March 31, 2018. 

On July 31, 2018, our former director, Laurence Blickman, exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929.

65

In 2017, we authorized a private placement with a maximum offering amount of $2,100,000 allowing investors to purchase units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share. In January 2018, we approved an increase in the offering. The following directors consultants and advisors who perform services for us and our subsidiaries are eligible to receive grants underor former directors of ours purchased the 2013 Plan. As of April 14, 2016, approximately 10 persons are eligible as employees, non-employee directors, consultants and advisors to receive grants underfollowing securities in connection with the 2013 Plan. offering:

·Carl Berg - $400,000 for 5,720,000 shares and 5,720,000 warrants;

·LaurenceBlickman $291,777 for 4,172,411 shares and 4,172,411 warrants;

·Harvey Eisen - $50,000 for 715,000 shares and 715,000 warrants;

·Marshall Geller -  $250,000 for 3,575,000 shares and 3,575,000 warrants;

·Howard Goldberg - $115,000 for 1,644,500 shares and 1,644,500 warrants;

·Larry Schafran - $115,000 for 1,644,500 shares and 1,644,500 warrants (including shares issued to a member of Schafran’s household);

·Paul Klapper - $26,000 for 371,800 shares and 371,800 warrants.

66

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The Compensation Committee is authorized to select the persons to receive grants from among those eligible and will determinefollowing table sets forth the number of shares of our common stock that are subjectand Series B Convertible Preferred Stock beneficially owned as of September 30, 2019, by (i) those persons known by us to be owners of more than 5% of its common stock, (ii) each grant.

Vesting. The Compensation Committee determines the vesting of awards granted under the 2013 Plan.
Types of Awards.
Stock Options
The compensation committee may grant options intended to qualify as incentive stock options (“ISOs”) within the meaning of section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) or “nonqualified stock options” that are not intended to so qualify (“NQSOs”) or any combination of ISOs and NQSOs. Anyone eligible to participatedirector, (iii) our named executive officers (as disclosed in the 2013 Plan may receiveSummary Compensation Table), and (iv) our executive officers and directors as a grant of NQSOs.  Only our employees and employees of our subsidiaries may receive a grant of ISOs.
The Compensation Committee will fixgroup. Unless otherwise specified in the exercise price per share of options onnotes to this table, the date of grant. The exercise price of options granted under the 2013 Plan will not beaddress for each person is: VerifyMe, Inc., 75 South Clinton Avenue, Suite 510, Rochester, New York 14604.

Beneficial

Owner

 

Amount of

Beneficial

Ownership of

Common
Stock
(1)

  

Percent of
Common Stock

Beneficially
Owned
(1)

 Amount of
Beneficial
Ownership of
Series B
Convertible
Preferred Stock
  Percent of
Series B
Convertible
Preferred
Stock
 
Named Executive 
Officers:
               
Patrick White(2)  7,650,000   6.50%        
Keith Goldstein(3)  3,000,000   2.65%        
                
Directors:               
Norman Gardner(4)  8,964,469   7.79%        
Chris Gardner  240,000   *        
Marshall Geller(5)  7,895,000   7.01%        
Howard Goldberg(6)  4,306,755   3.85%        
Arthur Laffer  240,000   *        
All current directors and
executive officers as a group
(8 persons)
  32,396,224(7)  24.97%        
                
 5% Shareholders:               
Carl Berg(8)  11,837,000   10.75%        
Laurence Blickman(9)  8,394,367   7.62%        
Estate of Claudio Ballard(10)  --(10)  --  0.85(10)  100%

* indicates less than the fair market value1%

(1)Based on 110,115,860 shares of common stock issued and outstanding as of September 30, 2019 adjusted for stock options vested or vesting within 60 days and conversion of outstanding warrants into shares of common stock. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power with respect to securities. A person is deemed to be the beneficial owner of securities that can be acquired by such person within 60 days whether upon the exercise of options, warrants or conversion of notes. Unless otherwise indicated in the footnotes to this table, we believe that each of the shareholders named in the table has sole voting and investment power with respect to the shares of common stock indicated as beneficially owned by them. This table does not include any unvested stock options except for those vesting within 60 days. As for the 5% shareholders, we are relying upon reports filed by each 5% shareholder with the SEC.

(2)Includes 7,000,000 and 500,000 shares of common stock underlying stock options exercisable at $0.07 per share and $0.14 per share, respectively.

(3)Includes 2,000,000 shares of common stock underlying stock options exercisable at $0.04 per share and 1,000,000 shares of common stock underlying stock options exercisable at $0.2102 per share held by POC Advisory Group LLC. Mr. Goldstein is the managing member and primary owner of POC Advisory Group LLC.

(4)Includes 165,000 shares of common stock underlying stock options exercisable at $0.11 per share, 250,000 shares of common stock underlying stock options exercisable at $0.25 per share, and 4,500,000 shares of common stock underlying stock options exercisable at $0.07 per share. Does not include Mr. Gardner’s minority ownership of an entity that holds 44,820 of our common stock.

67

(5)Includes 4,975,000 shares of common stock held by the Marshall & Patricia Geller Living Trust (the “Geller Trust”) which are beneficially owned by Mr. Geller, and 2,475,000 shares of common stock underlying warrants exercisable at $0.15 per share held by the Geller Trust.

(6)Includes 1,644,500 shares of common stock underlying warrants exercisable at $0.15 held by Mr. Goldberg. Mr. Goldberg’s shares are held directly in a pledged account with Merrill Lynch, but as of September 30, 2019, no debt is outstanding in this account.

(7)Includes options to purchase an aggregate of 100,000 shares of common stock for an executive officer who is not a named executive officer.

(8)Consists of 397,500 shares of common stock held directly by Mr. Berg and 11,440,000 shares of common stock held by Berg & Berg Enterprises, LLC (“BB”), which are beneficially owned by Mr. Berg, the managing member and primary owner of BB. The address for Mr. Berg and BB is 10050 Bandley Dr., Cupertino, CA 95014.

(9)Includes (i) 2,417,341 shares owned by Laurence J. Blickman 1991 Trust, of which Mr. Blickman is the trustee, (ii) 778,557 shares owned by Laurence J. Blickman SEP IRA, and (iii) 5,198,469 shares owned by Laurence J. Blickman Profit Sharing Plan. The address for Mr. Blickman is 233 Alameda de las Pulgas, Atherton, CA 94027. Mr. Blickman has provided the Company with the Irrevocable Proxy to vote his shares of common stock of the Company with certain exceptions, however, Mr. Blickman retains all power over the disposition of these shares. See “— Irrevocable Proxy” below.

(10)Includes 250,000 shares of common stock underlying stock options exercisable at $0.25 per shares and 75,000 shares of common stock underlying stock options exercisable at $0.11 per share. Also includes 7,222,222 shares of common stock issuable upon the conversion of the 0.85 share of Series B Convertible Preferred Stock held by Mr. Ballard’s estate. The address for Mr. Ballard’s estate is 265 S. Federal Highway, Suite 354, Deerfield Beach, FL 33441-4151.

(11)Mr. Ballard’s estate holds 0.85 share of Series B Convertible Preferred Stock that is convertible into 7,222,222 shares of our common stock. The Series B Convertible Preferred Stock is subject to a 4.99% beneficial ownership limitation. The address for Mr. Ballard’s estate is c/o Shepard Lane, Esq., 2 Park Avenue, 21st Floor, New York, NY 10016. See “Description of Capital Stock — Preferred Stock — Series B Convertible Preferred Stock.”

Irrevocable Proxy

Laurence J. Blickman, a former director, executed the Irrevocable Proxy that, during the period of September 5, 2019 through December 4, 2019, gives our Board of Directors voting rights for the common stock on the date of grant. However, if the grantee of an ISO is a person who holds more than 10% of the total combined voting power of all classes of our outstanding stock, the exercise price per share of an ISO granted to such person must be at least 110% of the fair market value of our common stock on the date of grant.

The Compensation Committee will determine the term of each option which will not exceed 10 years from the date of grant. Notwithstanding the foregoing, if the grantee of an ISO is a person who holds more than 10% of the combined voting power of all classes of our outstanding stock, the term of the ISO may not exceed five years from the date of grant. To the extent that the aggregate fair market value of shares of our common stock, determined on the date of grant,owned directly or indirectly by Mr. Blickman with respect to which ISOs become exercisable forall matters that require shareholder approval however, Mr. Blickman has the first time by a grantee during any calendar year exceeds $100,000, such ISOs will be treated as NQSOs. The maximum aggregate number of shares of our common stock with respectright to which ISOs may be granted under the 2013 Plan is 10,000,000, subject to adjustment in accordance with the terms of the 2013 Plan.
The Compensation Committee will determine the terms and conditions of options, including when they become exercisable. The Compensation Committee may accelerate the exercisability of any options. Except as provided in the grant instrument or as otherwise determined by the Compensation Committee, an option may only be exercised while a grantee is employed by or providing service to us or our subsidiaries or during an applicable period after termination of employment or service.
A grantee may exercise an option by delivering notice of exercise to us. The grantee will pay the exercise price and any withholding taxes for the option: (i) in cash, (ii) in certain circumstances as permitted by the Compensation Committee, by the surrender of shares of our common stock with an aggregate fair market value on the date the option is exercised equal to the exercise price, (iii) by payment through a broker in accordance with the procedures permitted by Regulation T of the Federal Reserve Board, (iv) if permitted by the Compensation Committee, by surrender of the vested portion of the option to us for an appreciation distribution payable in shares of our common stock with a fair market value at the time of the option surrender equal to the dollar amount by which the then fair market value ofsell the shares of our common stock subject to the surrendered portion exceeds the aggregate exercise price, or (v) by another method approved by the Compensation Committee.
Stock Awards
The Compensation Committee may grant stock awards to anyone eligible to participate in the 2013 Plan. The Compensation Committee may require that grantees pay consideration for the stock awardsIrrevocable Proxy and may impose restrictions on the stock awards. If restrictions are imposed on stock awards, the Compensation Committee will determine whether they will lapse over a period of time or according to such other criteria, including the achievement of specific performance goals, as the Compensation Committee determines.
The Compensation Committee will determine the number of shares of our common stock subject to the grant of stock awards and the other terms and conditions of the grant including whether the grantee willwe have theno right to vote shares of our common stock and to receive dividends paid on such shares during the restriction period. Unless the Compensation Committee determines otherwise, all unvested stock awards are forfeited if the grantee’s employment or service is terminated for any reason.
Stock Units
The Compensation Committee may grant stock units to anyone eligible to participate in the 2013 Plan. Each stock unit provides the grantee with the right to receive a share of our common stock or an amount based on the value of a share of our common stock at a future date. The Compensation Committee will determine the number of stock units that will be granted, whether stock units will become payable based on achievement of performance goals or other conditions, and the other terms and conditions applicable to stock units.
Stock units may be paid at the end of a specified period or deferred to a date authorized by the Compensation Committee. If a stock unit becomes payable, it will be paid to the grantee in cash, in shares of our common stock, or in a combination of cash and shares of our common stock, as determined by the Compensation Committee. All unvested stock units are forfeited if the grantee’s employment or service is terminated for any reason, unless the Compensation Committee determines otherwise.
The Compensation Committee may grant dividend equivalents in connection with grants of stock units made under the 2013 Plan. Dividend equivalents entitle the grantee to receive amounts equal to ordinary dividends that are paid on the shares underlying a grant while the grant is outstanding. The Compensation Committee will determine whether dividend equivalents will be paid currently or credited to a bookkeeping account as a dollar amount or in the form of stock units. Dividend equivalents may be paid in cash, in shares of our common stock or in a combination of the two. The terms and conditions of dividend equivalents will be determined by the Compensation Committee.
Stock Appreciation Rights
The Compensation Committee may grant Stock Appreciation Rights, or SARs, to anyone eligible to participate in the 2013 Plan. SARs may be granted in connection with, or independently of, any option granted under the 2013 Plan. Upon exercise of a SAR, the grantee will be paid an amount equal to the excess of the fair market value of our common stock on the date of exercise over the base amount for the SAR. Such payment to the grantee will be in cash, in shares of common stock, or in a combination of cash and shares of common stock, as determined by the Compensation Committee. The Compensation Committee will determine the term of each SAR, which will not exceed 10 years from the date of grant.
The base amount of each SAR will be determined by the Compensation Committee and will be equal to the per-share exercise price of the related option or, if there is no related option, an amount that is equal to or greater than the fair market value of our common stock on the date the SAR is granted. The Compensation Committee will determine the terms and conditions of SARs, including when they become exercisable. The Compensation Committee may accelerate the exercisability of any SARs.
Other Stock-Based Awards
The Compensation Committee may grant other stock-based awards, which are grants other than options, SARs, stock units, and stock awards. The Compensation Committee may grant other stock-based awards to anyone eligible to participate in the 2013 Plan. These grants will be based on or measured by shares of our common stock, and will be payable in cash, in shares of our common stock, or in a combination of cash and shares of our common stock. The terms and conditions for other stock-based awards will be determined by the Compensation Committee.
Qualified Performance-Based Compensation.  The 2013 Plan permits the Compensation Committee to impose objective performance goals that must be metconsent with respect to grants of stock units, stock awards, other stock-based awards or dividend equivalents granted to employees(i) shares which are publicly sold by Mr. Blickman under Rule 144 under the 2013 Plan,Securities Act; (ii) shares which are sold by Mr. Blickman to an unaffiliated third party in order fora private offering; or (iii) any proposal with respect to a merger or consolidation, the grants to be considered qualified performance-based compensation for purposessale of section 162(m)all or substantially all of the Code (see “Federal Income Tax Consequencesour assets, our dissolution or winding up, any increase of the 2013 Plan” below). Prior to,our capital stock or soon after the beginning of, the performance period, the Compensation Committee will establish in writing the performance goalsany proposal that must be met, the applicable performance period, the amounts to be paid if the performance goals are met, and any other conditions.
The performance goals, to the extent designed to meet the requirements of section 162(m) of the Code, will be based ondisproportionately favors one or more shareholders or one or more classes of the following measures: earnings or earnings growth (including but not limited to earnings per share or net income); economic profit; stockholder value added or economic value added; return on equity, assets or investment; revenues; expenses; stock price or total stockholder return; regulatory compliance; satisfactory internal or external audits; improvement of financial or credit ratings; achievement of balance sheet or income statement objectives, including, without limitation, capital and expense management;  market share; productivity ratios; or achievement of risk management objectives. Such performance goals may also be particular to an employee or the division, department, line of business, subsidiary orshareholders over other unit in which the employee works, or may be based on attaining a specified absolute level of the performance goal, or a percentage increase or decrease in the performance goal compared to a pre-established target, previous years’ results, or a designated market index or comparison group, all as determined by the Compensation Committee.
Deferrals.  The Compensation Committee may permit or require grantees to defer receipt of the payment of cash or the delivery of shares of our common stock that would otherwise be due to the grantee in connection with any stock units or other stock-based awards under the 2013 Plan. The Compensation Committee will establish the rules and procedures applicable to any such deferrals and may provide for interest or other earnings to be paid on such deferrals.
Adjustment Provisions.  In connection with stock splits, stock dividends, recapitalizations and certain other events affecting our common stock, the Compensation Committee will make adjustments as it deems appropriate in the maximum number of shares of our common stock reserved for issuance as grants, the maximum number of shares of our common stock that any individual participating in the 2013 Plan may be granted in any year, the number and kind of shares covered by outstanding grants, the kind of shares that may be issued or transferred under the 2013 Plan, and the price per share or market value of any outstanding grants. Any fractional shares resulting from such adjustment will be eliminated. In addition, in the event of a change of control, the provisions applicable to a change in control will apply. Any adjustments to outstanding grants will be consistent with section 409A or 422 of the Code, to the extent applicable.
Change of Control.  Upon a change of control, the Compensation Committee may determine that effective upon the date of the change of control:
shareholders.

 68All outstanding options and SARs will automatically accelerate and become fully exercisable;
Table of Contents The restrictions and conditions on all outstanding stock awards will immediately lapse; and
All stock units, dividend equivalents and other stock-based awards will become fully vested and will be paid at their target value, or in such greater amounts as the Compensation Committee may determine.
Notwithstanding the foregoing, in the event of a change of control, the Compensation Committee may also take any of the following actions with respect to any or all outstanding grants under the 2013 Plan:
Require that grantees surrender their options and SARs in exchange for payment by us, in cash or shares of our common stock as determined by the Compensation Committee, in an amount equal to the amount by which the then fair market value of the shares subject to the grantees’ unexercised options and SARs exceeds the exercise price of the options or the base amount of the SARs, as applicable;
After giving grantees the opportunity to exercise their options and SARs, terminate any or all unexercised options and SARs at such time as the Compensation Committee deems appropriate; or
Determine that outstanding options and SARs that are not exercised will be assumed by, or replaced with comparable options or rights by, the surviving corporation (or a parent or subsidiary of the surviving corporation), and other outstanding grants that remain in effect after the change of control will be converted to similar grants of the surviving corporation (or a parent or subsidiary of the surviving corporation).
In general terms, a change of control under the 2013 Plan occurs:
If a person, entity or affiliated group (with certain exceptions) acquires more than 30% of our then outstanding voting securities;
If we merge into another entity, unless the holders of our voting shares immediately prior to the merger have at least 50% of the combined voting power of the securities in the merged entity or its parent;
If we sell or dispose of all or substantially all of our assets;
If we are liquidated or dissolved; or
If at least a majority of the board of directors at any time does not consist of individuals who were elected, or nominated for election, by directors in office at the time of such election or nomination.
For any grants subject to the requirements of Section 409A (discussed below) that will become payable on a change of control, the transaction constituting a change of control must also constitute a change of control even for purposes of Section 409A.
Transferability of Grants.  Only the grantee may exercise rights under a grant during the grantee’s lifetime. A grantee may not transfer those rights except by will or the laws of descent and distribution; provided, however, that a grantee may transfer a grant other than an ISO pursuant to a domestic relations order. The Compensation Committee may also provide, in a grant agreement, that a grantee may transfer NQSOs to his or her family members, or one or more trusts or other entities for the benefit of or owned by such family members, consistent with applicable securities laws, according to such terms as the Compensation Committee may determine.
Participants Outside of the United States.  If any individual who receives a grant under the 2013 Plan is subject to taxation in a country other than the United States, the Compensation Committee may make the grant on such terms and conditions as the Compensation Committee deems appropriate to comply with the laws of the applicable country.
No Repricing of Options.  Except as set forth in the 2013 Plan, neither our board of directors nor the Compensation Committee can amend the price of outstanding options or SARs under the 2013 Plan to reduce the exercise price or cancel such options or SARs in exchange for cash or other awards of options or SARs with an exercise price that is less than the exercise price of the original options or SARs, without prior stockholder approval.
Clawback Policy.  All grants made under the 2013 Plan are subject to any compensation, clawback or recoupment policy that may be applicable to employees of the Company, as such policy may be in effect from time to time, whether or not approved before or after the effective date of the 2013 Plan.
Amendment and Termination of the 2013 Plan.  Our board of directors may amend or terminate the 2013 Plan at any time, subject to stockholder approval if such approval is required under any applicable laws or stock exchange requirements.
Stockholder Approval for Qualified Performance-Based Compensation.  If stock awards, stock units, other stock-based awards or dividend equivalents are granted as qualified performance-based compensation under section 162(m) of the Code, the 2013 Plan must be re-approved by our stockholders no later than the first stockholders meeting that occurs in the fifth year following the year in which our stockholders previously approved the 2013 Plan.
Federal Income Tax Consequences of the 2013 Plan
The federal income tax consequences of grants under the 2013 Plan will depend on the type of grant. The following description provides only a general description of the application of federal income tax laws to grants under the 2013 Plan. This discussion is for information purposes only and does not constitute tax guidance to grantees, as the consequences may vary with the types of grants made, the identity of the grantees and the method of payment or settlement. The summary does not address the effects of other federal taxes (including possible “golden parachute” excise taxes) or taxes imposed under state, local, or foreign tax laws.
From the grantees’ standpoint, as a general rule, ordinary income will be recognized at the time of delivery of shares of our common stock or payment of cash under the 2013 Plan. Future appreciation on shares of our common stock held beyond the ordinary income recognition event will be taxable as capital gain when the shares of our common stock are sold. The tax rate applicable to capital gain will depend upon how long the grantee holds the shares. We, as a general rule, will be entitled to a tax deduction that corresponds in time and amount to the ordinary income recognized by the grantee, and we will not be entitled to any tax deduction with respect to capital gain income recognized by the grantee.
Exceptions to these general rules arise under the following circumstances:
·If shares of our common stock, when delivered, are subject to a substantial risk of forfeiture by reason of any employment or performance-related condition, ordinary income taxation and our tax deduction will be delayed until the risk of forfeiture lapses, unless the grantee makes a special election to accelerate taxation under section 83(b) of the Code.
·If an employee exercises a stock option that qualifies as an ISO, no ordinary income will be recognized, and we will not be entitled to any tax deduction, if shares of our common stock acquired upon exercise of the stock option are held until the later of (A) one year from the date of exercise and (B) two years from the date of grant. However, if the employee disposes of the shares acquired upon exercise of an ISO before satisfying both holding period requirements, the employee will recognize ordinary income at the time of the disposition equal to the difference between the fair market value of the shares on the date of exercise (or the amount realized on the disposition, if less) and the exercise price, and we will be entitled to a tax deduction in that amount.  The gain, if any, in excess of the amount recognized as ordinary income will be long-term or short-term capital gain, depending upon the length of time the employee held the shares before the disposition.
·A grant may be subject to a 20% tax, in addition to ordinary income tax, at the time the grant becomes vested, plus interest, if the grant constitutes deferred compensation under section 409A of the Code and the requirements of section 409A of the Code are not satisfied.

Section 162(m) of the Code generally disallows a publicly held corporation’s tax deduction for compensation paid to its chief executive officer or certain other officers in excess of $1 million in any year.  Qualified performance-based compensation is excluded from the $1 million deductibility limit, and therefore remains fully deductible by the corporation that pays it. We intend that options and SARs granted under the 2013 Plan will be qualified performance-based compensation. Stock units, stock awards, dividend equivalents, and other stock-based awards granted under the 2013 Plan may be structured to meet the qualified performance-based compensation exception under section 162(m) of the Code if the Compensation Committee determines to condition such grants on the achievement of specific performance goals in accordance with the requirements of section 162(m) of the Code.
We have the right to require that grantees pay to us an amount necessary for us to satisfy our federal, state or local tax withholding obligations with respect to grants. We may withhold from other amounts payable to a grantee an amount necessary to satisfy these obligations. The Compensation Committee may permit a grantee to satisfy our withholding obligation with respect to grants paid in shares of our common stock by having shares withheld, at the time the grants become taxable, provided that the number of shares withheld does not exceed the individual’s minimum applicable withholding tax rate for federal, state and local tax liabilities.
Rule 10b5-1 Plans
Our directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis.  Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them.  The director or officer may amend or terminate the plan in some circumstances.  Our directors and executive officers may also buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.
In addition to the director and executive officer compensation arrangements discussed above in “Executive and Director Compensation,” since January 1, 2014, we have engaged in the following transactions in which the amount involved exceeded $120,000 and in which any director, executive officer or holder of more than 5% of our voting securities, whom we refer to as our principal stockholders, or affiliates or immediate family members of our directors, executive officers and principal stockholders had or will have a material interest.  We believe that all of these transactions were on terms as favorable as could have been obtained from unrelated third parties.
At June 12, 2015, three stockholders of the Company, Harvey Goldberg, Robert Bast and Clydesdale Partners II, held $317,000 of the senior secured convertible notes payable and were owed accrued interest of $42,713. The notes and accrued interest were converted into 234,735 shares (19,952,489 pre-reverse stock split) of common stock.  These transactions were considered arms-length transactions as they were on similar terms with transactions included in the restructuring transaction on June 12, 2015.

Director and Executive Officer Compensation
Please see “Executive and Director Compensation” for information regarding compensation of directors and executive officers.
Employment Agreements
For descriptions of compensation paid to our named executive officers for acting in such capacities, see “Executive and Director Compensation — Narrative Disclosure to Summary Compensation Table and Outstanding Equity Awards Table — Employment Agreements.”
Indemnification Agreements
We intend to enter into agreements with each of our directors and officers, which will contain indemnification provisions. Our amended and restated articles of incorporation and amended and restated by-laws currently require us to indemnify our directors and officers to the fullest extent permitted by Nevada law. See “Management — Limitation of Directors’ and Officers’ Liability and Indemnification.”
The following table sets forth certain information with respect to the beneficial ownership of our common stock as of April 14, 2016 for (a) each stockholder known by us to own beneficially more than 5% of our common stock (b) our named executive officers, (c) each of our directors, and (d) all of our current directors and executive officers as a group.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of April 14, 2016 pursuant to the exercise of options, warrants or the vesting of restricted stock units to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 6,586,711 shares of common stock outstanding on April 14, 2016.

Title of  Name and address of
beneficial
 
Amount and nature of
beneficial
  Percent of 
class  owner ownership +  class 
5% Beneficial Owners          
Common  Robert Bast       
   110 Spruce Lane       
   Ambler, PA  19002  334,396(1)   5.1%
Common  Clydesdale Partners II LLC         
   201 Spear Street, Suite 1750         
   San Francisco, CA  94105  679,394(2)   10.3%
Common  Nob Hill         
   c/o Stephen Ray         
   100 V Embarcadero PH         
   San Francisco, CA  94105  385,312(3)   5.8%
             
Executive Officers and Directors(4)
            
Michael Madon     50,000(5)   * 
Claudio Ballard     25,000(6)   * 
Jonathan Weinberger     58,333(7)   * 
Lawrence Schafran     25,000(8)   * 
Paul Donfried     345,775(9)   5.0%
Ben Burrell     93,750(10)   1.4%
Scott McPherson     70,000(11)   1.1%
Sandy Fliderman     93,750(12)   1.4%
Neil Alpert(13)
     11,675(14)   * 
All officers and directors as a group            
   (9 people)     773,283    10.4%
Less than 1 percent
+In accordance with SEC rules, options, warrants and other securities exercisable for or convertible into shares of our common stock that were exercisable as of April 14, 2016, or would become exercisable within 60 days thereafter, are deemed to be outstanding and beneficially owned by the person holding such options, warrants or other securities for the purpose of computing such person’s percentage ownership, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. This table has been prepared based on 6,586,711 shares of our common stock outstanding on April 14, 2016.
(1)Consists of 334,396 shares of common stock.
(2)Consists of 568,805 shares of common stock and 110,589 shares of PFK Acquisition Group II LLC, which is under common control.
(3)Consists of 385,312 shares of common stock.
(4)Unless otherwise indicated, the business address of all the individuals and entities is c/o VerifyMe, Inc., 12  West 21st Street, 8th Floor, New York, New York 10010.
(5)Consists of 50,000 shares of common stock underlying options exercisable at $0.60 per share.
(6)Consists of 25,000 shares of common stock underlying options exercisable at $0.85 per share.
(7)Consists of 58,333 shares of common stock underlying options exercisable at $0.85 per share.
(8) Consists of 25,000 shares of common stock underlying options exercisable at $2.55 per share.
(9)Consists of 5,882 shares of common stock underlying options exercisable at $4.25 per share, 187,500 shares of common stock underlying options at $0.85 per share, and 7,620 shares of Series A Preferred Stock held by OPC Partners, LLC for the benefit of Paul Donfried that are convertible into 152,393 shares of common stock.
(10)Consists of 93,750 shares of common stock underlying options exercisable at $0.85 per share.
(11)Consists of 20,000 shares of restricted stock and 50,000 shares of common stock underlying options at $5.77 per share.
(12)Consists of 93,750 shares of common stock underlying options exercisable at $0.85 per share.
(13)
Mr. Alpert’s last known address is 1080 Wisconsin Avenue, NW, #104, Washington, DC. 20007
(14)Consists of 11,765 shares of common stock.



The following is a summary of our capital stock and provisions of our amended and restated articles of incorporation and amended and restated by-laws.  For more detailed information, please refer to our amended and restated articles of incorporation and amended and restated by-laws, which are filed, or incorporated by reference, as exhibits to the registration statement of which this prospectus forms a part.  The descriptions of our common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering.

Our authorized capital stock consists of 675,000,000 shares of common stock, $0.001 par value per share, and 75,000,000 shares of preferred stock, $0.001 par value per share. As of April 14, 2016,September 30, 2019, there are 6,586,711110,115,860 shares of common stock outstanding; 427,218outstanding, and 0.85 shares of Series AB Convertible Preferred Stock outstanding, convertible into 8,544,369 shares of common stock; 0.97 shares of Series B Preferred Stock outstanding, convertible into 8,204,952 shares of common stock; and 3,087,500 shares of Series C Preferred Stock outstanding, convertible into 3,087,5007,222,222 shares of common stock.  Assuming the conversion of all of our preferred stock, as of April 14, 2016,September 30, 2019, we would have had outstanding, an aggregate of 26,423,531117,338,082 shares of common stock, consisting of (i) 6,856,711110,115,860 shares of common stock outstanding on such date and (ii) 19,836,8207,222,222 shares of common stock into which all of our preferred stock outstanding as of such date would have been converted, which were held of record by 1,349 stockholders.one shareholder.  In addition, as of April 14, 2016,September 30, 2019, there were outstanding options to purchase 2,357,35320,113,529 shares of common stock, outstanding warrants to purchase 21,962,608 shares of common stock, and two Debentures outstanding warrants to purchase 4,499,451convertible into 4,000,000 shares of common stock.

assuming a $0.15 per share conversion price.

Common Stock

Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders,shareholders, and do not have cumulative voting rights.  Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of funds legally available for dividend payments.  All outstanding, shares of common stock are fully paid and nonassessable, and the shares of common stock to be issued upon completion of this offering will be fully paid and nonassessable.  The holders of common stock have no preferences or rights of cumulative voting, conversion, or pre-emptive or other subscription rights.  There are no redemption or sinking fund provisions applicable to the common stock.  In the event of any liquidation, dissolution or winding-up of our affairs, holders of common stock will be entitled to share ratably in any of our assets remaining after payment or provision for payment of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock, if any.

Preferred Stock

Our preferred stock includes our Series A Preferred Stock, Series B Preferred Stock and  Series CConvertible Preferred Stock.  Our board of directors has the authority, without further stockholdershareholder authorization, to issue from time to time shares of preferred stock in one or more series and to fix the terms, limitations, relative rights and preferences and variations of each series.  Although we have no present plans to issue additional shares of preferred stock, the issuance of shares of preferred stock, or the issuance of rights to purchase such shares, could decrease the amount of earnings and assets available for distribution to the holders of common stock, could adversely affect the rights and powers, including voting rights, of the common stock, and could have the effect of delaying, deterring or preventing a change of control of us or an unsolicited acquisition proposal.

Series AB Convertible Preferred Stock and Series B Preferred Stock.

Holders of our Series A Preferred Stock and Series B Convertible Preferred Stock are entitled to participate pro rata with holders common stock with respect to dividends and other distributions, including the distribution of assets upon liquidation.  Each share of Series A Preferred Stock is convertible at any time into twenty shares of common stock; provided, that holders of Series A Preferred Stock are prohibited from converting Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding.  Each share of Series B Convertible Preferred Stock is convertible at any time into 8,496,732 shares of common stock;provided, that holders of Series B Convertible Preferred Stock are prohibited from converting Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding.  Holders of our Series A Preferred Stock and Series B Convertible Preferred Stock are not entitled to vote, except (i) as otherwise required by law and (ii) that each issued and outstanding share of Series A Preferred Stock and Series B Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which each such share of Series A Preferred Stock or Series B Convertible Preferred Stock is convertible in connection with (A) certain fundamental transactions or (B) the issuance by the Company, directly or indirectly, in one or more related transactions or series of related transactions, of shares of common stock, options or convertible securities if, in the aggregate, the number of such shares of common stock together with the number of shares of common stock issuable upon the conversion or exercise, as applicable, of such options and convertible securities is more than 20% of the number of shares of common stock issued and outstanding prior to any such issuance.

69
Series C Preferred Stock.

Our Series C Preferred Stock, which was sold in our February 2016 offering, is senior in rank to all shares of capital stock of the Company with respect to all dividends, distributions and payments upon liquidation. The holders of our Series C Preferred Stock are entitled to dividends when and as declared by our board of directors. Except as otherwise expressly required by law, each holder of Series C Preferred Stock is entitled to vote on all matters submitted to shareholders of the Company and is entitled to the number of votes for its Series C Preferred Stock equal to the number of shares of common stock into which the Series C Preferred Stock is convertible, but not in excess of the conversion limitations set forth in the Certificate of Designation for the Series C Preferred Stock.  Except as otherwise required by law, the holders of the Series C Preferred Stock vote together with the holders of common stock on all matters and not as a separate class.

Each share of Series C Preferred Stock is convertible at any time into one share of common stock; provided, that holders of Series C Preferred Stock are prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding.  However, any holder of Series C Preferred Stock may increase or decrease such percentage to any other percentage not in excess of 9.99% provided that (i) any such increase will not be effective until the 61st day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to such holder sending such notice and not to any other holder of Series C Preferred Stock.  The Series C Preferred Stock provides for certain adjustments that may be made to the conversion price and the number of shares of common stock issuable upon conversion due to future corporate events or otherwise.

If the Company grants, issues or sells options, convertible securities or rights to purchase capital stock (“Purchase Rights”) to the record holders of the common stock, the holders of Series C Preferred Stock have certain rights to acquire such Purchase Rights.

In the case of certain fundamental transactions affecting the Company, the holders of Series C Preferred Stock have the right to receive, (i) such securities or other assets to which such holder would have been entitled if the Series C Preferred Stock had been converted or (ii) in lieu of the shares of common stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of common stock in connection with the consummation of such fundamental transaction in such amounts as such holder would have been entitled to receive had the Series C Preferred Stock held by such holder initially been issued with conversion rights for the form of such consideration (as opposed to shares of common stock) at a conversion rate for such consideration commensurate with the conversion rate set forth in the Certificate of Designation for the Series C Preferred Stock.

Warrants

The Company has 4,502,393 warrants outstanding to purchase an aggregate of 4,499,45121,962,608 shares of common stock.  The exercise prices range from $0.40$0.15 to $12.75 per share and expire beginning February 2019June 2022 through February 2023.

Registration Rights
In connection withprincipal amount of Debentures are outstanding. These Debentures will mature on September 18, 2020, and may be redeemed by us prior to the February 2016 offering, we entered into a Registration Rights Agreement with certain holdersmaturity date as described below. All unpaid principal due and payable on the maturity date will be paid in the form of our Series C Preferred Stock (the "Registration Rights Agreement"). Undercommon stock. Any principal or interest that is due under each of the Debentures, which is not paid by the respective maturity date, will bear interest at the rate of 18% per annum until it is satisfied in full. The Debentures are senior secured obligations of ours secured pursuant to the terms of the Registration Rights Agreement, we agreedSecurity Agreements by all of the assets of us and our subsidiaries.

Each Purchaser is entitled, at any time, to register for resale byconvert all or any portion of the investors under the Securities Act theoutstanding principal amount of its Debenture(s) plus any accrued interest into restricted shares of common stock. If we consummate a public offering within 180 calendar days of the Effective Date, then the conversion price will be the lesser of (a) $0.15 or (b) 70% multiplied of the price per share of the common stock issuable uponwe issue in the public offering (the “QPI Discounted Price”), subject to further adjustment as provided in the Debenture as well as subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. Further, if we consummate a public offering of common stock which results in us receiving gross proceeds of at least $5 million within 180 calendar days of the Effective Date then we are obligated to repay the outstanding amounts owed under the Debentures, to the extent they are not converted and including the applicable redemption premium then in effect, within three days of consummation of such an offering.

If any portion of the Debentures are outstanding on the 181st calendar day after the Effective Date, then the conversion price shall equal the lesser of (a) $0.15, (b) the QPI Discounted Price, or (c) 70% of the lowest volume-weighted average price (as reported by Bloomberg LP) of the common stock on any trading day during the 20 trading days immediately preceding the date of conversion of the Series C Preferred Stock and exerciseDebenture (provided, further, that if either we are not DWAC operational at the time of conversion, the common stock is traded on the OTC Pink at the time of conversion, or the Conversion Price is less than $0.01 per share, then 70% will automatically adjust to 60%).

The Debentures are subject to a “conversion blocker” such that the each of the warrants soldPurchasers cannot convert the Debentures to the extent that the conversion would result in our February 2016 offering.

           We agreed to file such registration statement within 45 calendar days of February 29, 2016, the closingPurchaser and its affiliates holding more than 4.99% of the February 2016 offering (the "Filing Deadline"). We are requiredoutstanding common stock (which the Purchaser can increase to use9.99% upon at least 61 days prior written notice to us).

So long as no event of default has occurred and is continuing under the Debentures, we may at our best efforts to haveoption call for redemption all or part of the Registration Statement declared effective as soon as practicable. We will incur certain liquidated damages if: (i) the registration statement is not filed on orDebentures prior to the Filing Deadline; (ii)maturity date, upon not more than two calendar days written notice, for an amount equal to: (i) if the Company fails to file a request for accelerationredemption date is 90 calendar days or less from the date of issuance of the registration statementDebentures, 110% of the sum of the principal amount; (ii) if the redemption date is greater than or equal to 91 calendar days from the date of issuance of the Debentures and less than or equal to 150 calendar days from the date of issuance of the Debentures, 120% of the sum of the principal amount; (iii) if the redemption date is greater than or equal to 151 calendar days from the date of issuance of the Debentures and less than or equal to 180 calendar days from the date of issuance of the Debentures, 125% of the sum of the principal amount; and (iv) if either (1) the Debentures are in accordance with Rule 461 promulgated bydefault but the SEC pursuantholder consents to the Securities Act within five tradingredemption notwithstanding such default or (2) the redemption date is greater than or equal to 181 calendar days from the date of issuance of the dateDebentures, 130% of the sum of the principal amount.

The Debentures include an adjustment provision that, the Company is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement will not be “reviewed” or will not be subject to further review;  (iii) prior tocertain exceptions, reduces, at the effective datePurchaser’s option, the conversion price if we issue common stock or common stock equivalents (including in variable rate transactions) at a price lower than the then-current conversion price of the registration statement, the Company fails to file a pre-effective amendment and otherwise respondDebentures. Any reverse stock split of our outstanding shares will also result in writing to comments made by the SEC in respect of such registration statement within eighteen (18) calendar days after the receipt of comments by or notice from the SEC that such amendment is required in order for such registration statement to be declared effective, (iv) the registration statement is not declared effective by the SEC on or prior to the 60th day after the closingan adjustment of the February 2016 offering (or the 120th day after the closingconversion price of the February 2016 offering if the SEC determines to review the registration statement), and (v) after the effective date of the registration statement, such registration statement ceases for any reason to remain continuously effective as to all registrable securities included in such registration statement, or the holders of the registrable securities are otherwise not permitted to utilize the prospectus therein to resell such registrable securities, for more than ten (10) consecutive trading days or more than an aggregate of twenty (20) trading days (which need not be consecutive trading days) during any 12-month period (each such failure is referred to herein as an "Event").Debentures.

70
On each date that an Event occurs and on each monthly anniversary of such date, we must pay to each holder of registrable securities an amount in cash equal to 1.0% multiplied by the aggregate subscription amount paid by such holder of registrable securities, up to a maximum of 6.0%. If we fail to pay such amount when due, we must pay interest thereon at a rate of 18% per annum.
We agreed to keep any registration statements required by the Registration Rights Agreement effective until the date that all registrable securities covered by such registration statement (i) have been sold thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company's transfer agent and affected holders.

Our Amended and Restated Articles of Incorporation and Amended and Restated By-Laws

Amended and Restated Articles of Incorporation, as amended, and Amended and Restated By-Laws.

Provisions of our amended and restated articles of incorporation, as amended, and our amended and restated by-laws may delay or discourage transactions involving an actual or potential change of control or change in our management, including transactions in which stockholdersshareholders might otherwise receive a premium for their shares, or transactions that our stockholdersshareholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock.

Board of Directors; Removal of Directors for Cause.  Our amended and restated articles of incorporation and amended and restated by-laws provide for the election of directors to one-year terms at each annual meeting of the stockholders.shareholders.  All directors elected to our board of directors will serve until the election and qualification of their respective successors or their earlier resignation or removal.  The board of directors is authorized to create new directorships, subject to the amended and restated articles of incorporation, and to fill such positions so created.created by a majority vote of the directors.  Members of the board of directors may only be removed with or without cause and only by the affirmative vote of the holders of not less than two-thirds of the voting power of our issued and outstanding stock entitled to vote generally in the election of directors.

Advance Notice Provisions for StockholderShareholder Proposals and StockholderShareholder Nominations of Directors.  Our amended and restated by-laws provide that, for nominations to the board of directors or for other business to be properly brought by a stockholdershareholder before a meeting of stockholders, the stockholder must first have given timelyshareholders, written notice of the proposal in writing to our Secretary.  For an annual or special meeting, a stockholder’s notice generallynomination must be deliveredreceived by us not lessearlier than 60120 days nor moreand not later than 90 days prior to the anniversary date of the immediately preceding annual meeting.  Detailed requirements as to the form of the notice and information required in the notice are specified in the amended and restated by-laws.  If it is determined that business was not properly brought before a meeting in accordance with our by-law provisions, such business will not be conducted at the meeting.

Special Meetings of StockholdersShareholders.  Special meetings of the stockholdersshareholders may be called only by our chairman of the board of directors pursuant to the requirements of our amended and restated by-laws.

Blank-Check Preferred Stock.  Our board of directors will be authorized to issue, without stockholdershareholder approval, preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve.

Series A Convertible Preferred Stock

Pursuant to our amended and restated articles of incorporation, we are authorized to issue 37,564,767 shares of Series A Convertible Preferred Stock. As of September 30, 2019, we have no shares of Series A Convertible Preferred Stock outstanding.

Nevada Anti-Takeover Statutes

The following provisions of the Nevada Revised Statutes (“NRS”) could, if applicable, have the effect of discouraging takeovers of our company.

Transactions with Interested Stockholders.The NRS prohibits a publicly-traded Nevada company from engaging in any business combination with an interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless, prior to that date, the board of directors of the corporation approved either the business combination itself or the transaction that resulted in the stockholder becoming an interested stockholder.

An “interested stockholder” is defined as any entity or person beneficially owning, directly or indirectly, 10% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, controlling, or controlled by any of these entities or persons. The definition of “business combination” is sufficiently broad to cover virtually any type of transaction that would allow a potential acquirer to use the corporation’s assets to finance the acquisition or otherwise benefit its own interests rather than the interests of the corporation and its stockholders.

71

In addition, business combinations that are not approved and therefore take place after the three year waiting period may also be prohibited unless approved by the board of directors and stockholders or the price to be paid by the interested stockholder is equal to the highest of (i) the highest price per share paid by the interested stockholder within the 3 years immediately preceding the date of the announcement of the business combination or in the transaction in which he or she became an interested stockholder, whichever is higher; (ii) the market value per common share on the date of announcement of the business combination or the date the interested stockholder acquired the shares, whichever is higher; or (iii) if higher for the holders of preferred stock, the highest liquidation value of the preferred stock.

Acquisition of a Controlling Interest.The NRS contains provisions governing the acquisition of a “controlling interest” and provides generally that any person that acquires 20% or more of the outstanding voting shares of an “issuing corporation,” defined as Nevada corporation that has 200 or more stockholders at least 100 of whom are Nevada residents (as set forth in the corporation’s stock ledger); and does business in Nevada directly or through an affiliated corporation, may be denied voting rights with respect to the acquired shares, unless a majority of the disinterested stockholder of the corporation elects to restore such voting rights in whole or in part.

The statute focuses on the acquisition of a “controlling interest” defined as the ownership of outstanding shares sufficient, but for the control share law, to enable the acquiring person, directly or indirectly and individually or in association with others, to exercise (i) one-fifth or more, but less than one-third; (ii) one-third or more, but less than a majority; or (iii) a majority or more of the voting power of the corporation in the election of directors.

The question of whether or not to confer voting rights may only be considered once by the stockholders and once a decision is made, it cannot be revisited. In addition, unless a corporation’s articles of incorporation or bylaws provide otherwise (i) acquired voting securities are redeemable in whole or in part by the issuing corporation at the average price paid for the securities within 30 days if the acquiring person has not given a timely information statement to the issuing corporation or if the stockholders vote not to grant voting rights to the acquiring person’s securities; and (ii) if voting rights are granted to the acquiring person, then any stockholder who voted against the grant of voting rights may demand purchase from the issuing corporation, at fair value, of all or any portion of their securities.

The provisions of this section do not apply to acquisitions made pursuant to the laws of descent and distribution, the enforcement of a judgment, or the satisfaction of a security interest, or acquisitions made in connection with certain mergers or reorganizations.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is InterwestWest Coast Stock Transfer, Inc.

DESCRIPTION OF THE SECURITIES WE ARE OFFERING

In this offering, we are offering our Units, with each Unit consisting of one share of our common stock and a warrant to purchase one share of our common stock. Our Units will not be certificated and the shares of our common stock and the warrants part of such Units are immediately separable and will be issued separately in this Offering. We are also registering the shares of common stock issuable upon exercise of the warrants. These securities are being issued pursuant to an underwriting agreement between us and the underwriters. You should review the underwriting agreement and the form of warrant, each filed as exhibits to the registration statement of which this prospectus is a part, for a complete description of the terms and conditions applicable to the warrants. The following brief summary of the material terms and provisions of the warrants is subject to, and qualified in its entirety by, the form of warrant.

Units

We are offering units in this offering at an assumed initial offering price of $        per unit. Each unit consists of one share of our common stock and a warrant to purchase one share of our common stock at an exercise price equal to $     , which is     % of the public offering price of the units. Our Units will not be certificated and the shares of our common stock and the warrants part of such Units are immediately separable and will be issued separately in this offering.

72

Common Stock

The material terms and provisions of our common stock are described under the caption “Description of Capital Stock” in this prospectus.

Warrants

Warrants to Be Issued in the Offering

Overview

The following summary of certain terms and provisions of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the warrant agent agreement between us the Warrant Agent, and the form of warrant, both of which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the warrant agent agreement, including the annexes thereto, and form of warrant.

The warrants issued in this offering entitle the registered holder to purchase one share of our common stock at a price equal to $ per share, subject to adjustment as discussed below, immediately following the issuance of such warrant and terminating at 5:00 p.m., New York City time, five (5) years after the closing of this offering. As described below, we have applied to list the warrants on the Nasdaq Capital Market under the symbol “VRMEW.”

The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including in the event of a stock dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of common stock at prices below its exercise price.

Exercisability. The warrants are exercisable at any time after their original issuance and at any time up to the date that is five (5) years after their original issuance. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. Under the terms of the Warrant Agreement, we must use our best efforts to maintain the effectiveness of the registration statement and current prospectus relating to common stock issuable upon exercise of the warrants until the expiration of the warrants. If we fail to maintain the effectiveness of the registration statement and current prospectus relating to the common stock issuable upon exercise of the warrants, the holders of the warrants shall have the right to exercise the warrants solely via a cashless exercise feature provided for in the warrants, until such time as there is an effective registration statement and current prospectus.

Exercise Limitation. A holder may not exercise any portion of a warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of the outstanding common stock after exercise, as such percentage ownership is determined in accordance with the terms of the warrant, except that upon prior notice from the holder to us, the holder may waive such limitation up to a percentage not in excess of 9.99%.

Exercise Price.The exercise price per whole share of common stock purchasable upon exercise of the warrants is $         per share (based on an assumed public offering price of $         per unit) or         % of public offering price of the common stock. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.

73

Fractional Shares. No fractional shares of common stock will be issued upon exercise of the warrants. If, upon exercise of the warrant, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise price. If multiple warrants are exercised by the holder at the same time, we shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.

Transferability.Subject to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.

Exchange Listing.We have applied to list our warrants on the Nasdaq Capital Market under the symbol “VRMEW”. No assurance can be given that our listing application will be approved.

Warrant Agent; Global Certificate. The warrants will be issued in registered form under a warrant agent agreement between the Warrant Agent and us. The warrants shall initially be represented only by one or more global warrants deposited with the Warrant Agent, as custodian on behalf of The Depository Trust Company Inc.(DTC) and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

Fundamental Transactions. In the event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants will be entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction.

Rights as a Stockholder.The warrant holders do not have the rights or privileges of holders of common stock or any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

Governing Law. The warrants and the warrant agent agreement are governed by New York law.

Representative’s Warrants

The registration statement of which this prospectus is a part also registers for sale the Representative’s Warrants, as a portion of the underwriting compensation payable to the underwriters in connection with this offering. The Representative’s Warrants will be exercisable for a four and one-half year period commencing 180 days following the effective date of the registration statement of which this prospectus is a part at an exercise price of $     (     % of the public offering price of the Units). Please see “Underwriting — Representative’s Warrants” for a description of the warrants we have agreed to issue to the representative of the underwriters in this offering, subject to the completion of the offering. We expect to enter into a warrant agreement in respect of the Representative’s Warrants prior to the closing of this offering.

74

UNDERWRITING

Maxim Group LLC is acting as the representative of the underwriters of the offering (the “Representative”). We have entered into an underwriting agreement dated         , 2019 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below and each underwriter named below has severally and not jointly agreed to purchase from us, at the public offering price per Unit less the underwriting discounts set forth on the cover page of this prospectus, the number of Units listed next to its name in the following table:

UnderwriterNumber
of Units
Maxim Group LLC
Total

The underwriting agreement provides that the obligation of the underwriters to purchase all of the Units being offered to the public is subject to specific conditions, including the absence of any material adverse change in our business or in the financial markets and the receipt of certain legal opinions, certificates and letters from us, our counsel and the independent auditors. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may be increased or the offering may be terminated. Subject to the terms of the underwriting agreement, the underwriters will purchase all of the Units being offered to the public, other than those covered by the over-allotment option described below, if any of these Units are purchased.

The underwriters are offering the Units, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

Over-Allotment Option

We have granted to the Representative an option, exercisable not later than 45 days after the date of this prospectus, to purchase from us up to an (i) additional       shares of common stock at a price of $ per share and/or (ii) additional        warrants to purchase        shares of common stock at a price of $0.01 per warrant (15% of the shares of common stock and warrants included in the Units sold in this offering), in each case, less the underwriting discounts and commissions set forth on the cover of this prospectus in any combination thereof to cover over-allotments, if any. To the extent that the Representative exercises this option, each of the underwriters will become obligated, subject to conditions, to purchase approximately the same percentage of these additional shares of common stock and/or warrants as the number of Units to be purchased by it in the above table bears to the total number of Units offered by this prospectus. We will be obligated, pursuant to the option, to sell these additional shares of common stock and/or warrants to the underwriters to the extent the option is exercised. If any additional shares of common stock and/or warrants are purchased, the underwriters will offer the additional shares of common stock and/or warrants on the same terms as those on which the other Units are being offered hereunder. If this option is exercised in full, the total offering price to the public will be $        and the total net proceeds, before expenses and after the credit to the underwriting commissions described below, to us will be $       .

Discounts and Commissions; Expenses

The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of the over-allotment option.

Per UnitTotal
Without
Over-
Allotment
Option
Total With
Full Over-
Allotment
Option
Public offering price$$$
Underwriting discount (8%)$$$
Proceeds, before expenses, to us$$$
Non-accountable expense allowance (1%)(1)$$$

(1)The non-accountable expense allowance will not payable with respect to any exercise of the over-allotment option by the Representative.

The underwriters propose to offer the Units offered by us to the public at the public offering price per Unit set forth on the cover of this prospectus. In addition, the underwriters may offer some of the Units to other securities dealers at such price less a concession of $ per Unit. After the initial offering, the public offering price and concession to dealers may be changed.

75

We have paid an expense deposit of $25,000 to the Representative, which will be applied against the accountable expenses that will be paid by us to the Representative in connection with this offering. The $25,000 expense deposit will be returned to us to the extent not actually incurred. The underwriting agreement also provides that in the event the offering is terminated, the $25,000 expense deposit paid to the Representative will be returned to us to the extent that offering expenses are not actually incurred by the Representative in accordance with FINRA Rule 5110(f)(2)(C).

In addition to the 1.0% non-accountable expense allowance, we have also agreed to reimburse the underwriters for reasonable out-of-pocket expenses not to exceed $100,000 in the aggregate. We estimate that total expenses payable by us in connection with this offering, other than the underwriting discount and non-accountable expense allowance referred to above, will be approximately $       . 

Discretionary Accounts

The underwriters do not intend to confirm sales of the Units offered hereby to any accounts over which they have discretionary authority.

Indemnification

We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.

Lock-Up Agreements

We and our officers and directors and the holders of 3% or more of the outstanding shares of our common stock (other than Carl Berg and Laurence Blickman) as of the effective date of the Registration Statement, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any shares of our common stock or any securities convertible into or exchangeable for our common stock either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the Representative. We and the Representative may, in our sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements. 

Pricing of this Offering

Prior to this offering, there has not been an active market for our common stock and there has been no public market for our warrants. The public offering price for our Units will be determined through negotiations between us and the underwriters. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriter believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.

We offer no assurances that the public offering price of our Units will correspond to the price at which our common stock will trade in the public market subsequent to this offering or that an active trading market for our common stock and warrants will develop and continue after this offering. 

Representative’s Warrants

We have agreed to issue to the Representative (or its permitted assignees) warrants to purchase up to a total of         shares of common stock (6% of the Units sold in this offering, excluding the over-allotment, if any). The warrants will be exercisable at any time, and from time to time, in whole or in part, during the four and one-half year period commencing 180 days from the effective date of the registration statement of which this prospectus is a part, which period shall not extend further than three years from the effective date of the registration statement of which this prospectus is a part in compliance with FINRA Rule 5110(f)(2)(G)(i). The warrants are exercisable at a per share price equal to $ per share, or 110% of the public offering price per Unit in the offering (based on the public offering price of $ per Unit). The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The Representative (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the effective date of the registration statement of which this prospectus is a part. In addition, the warrants provide for registration rights upon request, in certain cases. The sole demand registration right provided will not be greater than five years from the effective date of the registration statement of which this prospectus is a part in compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration rights provided will not be greater than seven years from the effective date of the registration statement of which this prospectus is a part in compliance with FINRA Rule 5110(f)(2)(G)(v). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the warrants other than underwriting commissions incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price.

76

Right of First Refusal

Subject to the closing of this offering and certain conditions set forth in the underwriting agreement, until
twelve months from the closing date of this offering, the Representative shall have a right of first refusal to act as lead investment banker, lead book-runner and/or lead placement agent, at its sole discretion, for each and every of our future public or private equity, equity-linked or debt (excluding commercial bank debt) offerings during such twelve month period for us, or any of our successors or subsidiaries, on terms customary to the Representative. The Representative in conjunction with us, shall have the sole right to determine whether or not any other broker-dealer shall have the right to participate in any such offering and the economic terms of any such participation.

Trading; NASDAQ Capital Market Listing

Our common stock is presently quoted on the OTCQB market under the symbol “VRME.” We intend to apply to have our common stock and the warrants offered in the offering listed on the Nasdaq Capital Market under the symbols “VRME” and “VRMEW”, respectively. No assurance can be given that our listing application will be approved by the Nasdaq Capital Market.

Price Stabilization, Short Positions and Penalty Bids

In connection with this offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance with Regulation M under the Exchange Act:

Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum.
Over-allotment involves sales by the underwriters of securities in excess of the number of securities the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option and/or purchasing securities in the open market.
Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which they may purchase securities through the over-allotment option. A naked short position occurs if the underwriters sell more securities than could be covered by the over-allotment option. This position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in this offering.

Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when securities originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of the securities. As a result, the price of our shares of common stock and warrants may be higher than the price that might otherwise exist in the open market. These transactions may be discontinued at any time.

Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our shares of common stock and warrants. In addition, neither we nor the underwriters make any representation that the underwriters will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.

Electronic Distribution

This prospectus in electronic format may be made available on websites or through other online services maintained by the underwriters, or by their affiliates. Other than this prospectus in electronic format, the information on the underwriters’ websites and any information contained in any other websites maintained by the underwriters is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors.

77

Other

From time to time, the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services it has received and, may in the future receive, customary fees. Except for the services provided in connection with this offering and other than as described below, the underwriters have not provided any investment banking or other financial services during the 180-day period preceding the date of this prospectus.

On September 19, 2019, we received gross proceeds of $600,000 and net proceeds of $540,000 from the Bridge Financing. The Representative acted as the placement agent in connection with the Bridge Financing and received a cash fee of 8% of the gross proceeds received at each closing and is entitled to receive warrants for 5% of the total number of securities issued in connection with the Bridge Financing, if converted, or upon redemption (if not converted). These warrants will be exercisable at a price per share equal to 110% of the price of the common stock issued upon conversion of the Debentures, if converted, paid by the Purchasers in the Bridge Financing and will expire in five years.

Notice to Prospective Investors in Canada

This prospectus constitutes an “exempt offering document” as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this prospectus or on the merits of the securities and any representation to the contrary is an offence.

Canadian investors are advised that this prospectus has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts (“NI 33-105”). Pursuant to section 3A.3 of NI 33-105, this prospectus is exempt from the requirement that the Company and the underwriter(s) provide Canadian investors with certain conflicts of interest disclosure pertaining to “connected issuer” and/or “related issuer” relationships that may exist between the Company and the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.

Resale Restrictions

The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement that the Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the securities outside of Canada.

Representations of Purchasers

Each Canadian investor who purchases securities will be deemed to have represented to the Company, the underwriters and to each dealer from whom a purchase confirmation is received, as applicable, that the investor is (i) purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii) an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii) is a “permitted client” as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.

Taxation and Eligibility for Investment

Any discussion of taxation and related matters contained in this prospectus does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.

Rights of Action for Damages or Rescission

Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum (such as this prospectus), including where the distribution involves an “eligible foreign security” as such term is defined in Ontario Securities Commission Rule 45-501 Ontario Prospectus and Registration Exemptions and in Multilateral Instrument 45-107 Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a “misrepresentation” as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defenses under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor.

78

Language of Documents

Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only.Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu’il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d’achat ou tout avis) soient rédigés en anglais seulement.

Offers Outside the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

LEGAL MATTERS

Certain legal matters in connection with the securities have been passed upon by Baker, Donelson, Bearman, CaldwellHarter Secrest & Berkowitz, PC.

Emery LLP, Rochester, New York. Gracin & Marlow LLP is acting as counsel for the Underwriter in this offering.

EXPERTS

The

Our financial statements of VerifyMe, Inc. as of December 31, 20142018 and December 31, 2015 and for each of the years in the two-year period ended December 31, 20152017 have been so included in reliance on the report of Morison CogenMaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

firm.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You may read and copy any document that we file at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549, on official business days during the hours of 10:00 am and 3:00 pm. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. All filings we make with the SEC are also available on the SEC’s web site at http://www.sec.gov. You may also request a copy of these filings, at no cost, by writing us at 12 West 21st Street, 8th Floor,75 S. Clinton Ave., Suite 510, Rochester, New York NY 1001014604 or contacting us at (212) 994-7002.

(585) 736-9400.

We are subject to the periodic reporting requirements of the Exchange Act, and we will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying aton the public reference room and website of the SEC referred to above. We maintain a website at http://www.verifyme.com/#intro.www.verifyme.com. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge or at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. We have not incorporated by reference into this prospectus the information contained in, or that can be accessed through, our website, and you should not consider it to be a part of this prospectus.

79

INDEX TO FINANCIAL STATEMENTS

VERIFYME, INC.

Financial Statements
for the Three and Six Months Ended June 30, 2019 and 2018 (unaudited)

Page
Balance Sheets (unaudited) as of June 30, 2019 and December 2018F-2
Statements of Operations (unaudited) for the Three and Six Months Ended June 30, 2019 and 2018F-3
Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2019 and 2018F-4
Statement of Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2019 and 2018
(Unaudited)

F-5

Notes to Financial StatementsF-7

Financial Statements

For the Fiscal Years Ended December 31, 2018 and 2017

Page
Report of Independent Registered Public Accounting FirmF-15
Balance Sheets as of December 31, 2018 and 2017F-16
Statements of Operations for the Years Ended December 31, 2018 and 2017F-17
Statements of Cash Flows for the Years Ended December 31, 2018 and 2017F-18
Statement of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2018 and 2017F-20
Notes to Financial StatementsF-21

F-1

VerifyMe, Inc.

Balance Sheets

  As of 
  June 30, 2019  December 31, 2018 
  (Unaudited)    
       
ASSETS      
       
CURRENT ASSETS      
Cash and cash equivalents $585,193  $1,673,201 
Accounts Receivable  22,024   30,373 
Deposits on Equipment  163,090   - 
         
Prepaid expenses and other current assets  29,981   25,781 
         
Inventory  43,266   41,982 
         
TOTAL CURRENT ASSETS  843,554   1,771,337 
         
         
INTANGIBLE ASSETS        
Patents and Trademarks, net of accumulated amortization of        
$269,929 and $258,294 as of June 30, 2019 and December 31, 2018  225,988   209,049 
Capitalized Software Costs  116,427   70,231 
         
TOTAL ASSETS $1,185,969  $2,050,617 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
         
CURRENT LIABILITIES        
Accounts payable and other accrued expenses $351,722  $411,211 
Accrued Payroll  93,836   69,041 
TOTAL CURRENT LIABILITIES  445,558   480,252 
         
STOCKHOLDERS' EQUITY        
Series A Convertible Preferred Stock, $.001 par value, 37,564,767 shares        
authorized; 0 shares issued and outstanding as of June 30, 2019 and        
304,778 shares issued and outstanding as of December 31, 2018  -   305 
         
Series B Convertible Preferred Stock, $.001 par value; 85 shares        
authorized; 0.85 shares issued and outstanding as of June 30, 2019 and
December 31, 2018
  -   - 
         
Common stock of $.001 par value; 675,000,000 authorized;
109,672,373 and 102,553,706 issued, 109,321,833 and 102,203,166
shares outstanding as of June 30, 2019 and December 31, 2018
  109,322   102,203 
         
Additional paid in capital  

61,186,990

   60,844,796 
         
Treasury stock as cost (350,540 shares at June 30, 2019 and  December
31, 2018)
  (113,389)  (113,389)
         
Accumulated deficit  (60,442,512)  (59,263,550)
         
STOCKHOLDERS' EQUITY  740,411   1,570,365 
         
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $1,185,969  $2,050,617 

The accompanying notes are an integral part of these unaudited financial statements.

F-2

VerifyMe, Inc.

Statements of Operations

(Unaudited)

  Three months ended  Six months ended 
  June 30, 2019  June 30, 2018  June 30, 2019  June 30, 2018 
             
             
NET REVENUE            
Sales $40,479  $6,799  $86,933  $6,799 
                 
COST OF SALES  7,085   2,000   21,852   2,000 
                 
GROSS PROFIT  33,394   4,799   65,081   4,799 
                 
OPERATING EXPENSES               
General and administrative (a)  418,195   525,760   650,877   1,021,334 
Legal and accounting  68,335   163,770   130,699   297,474 
Payroll expenses (a)  101,786   99,803   206,575   191,854 
Research and development  2,608   16,233   6,251   28,429 
Sales and marketing (a)  109,158   25   252,301   8,067 
Total Operating expenses  700,082   805,591   1,246,703   1,547,158 
                 
LOSS BEFORE OTHER INCOME (EXPENSE)  (666,688)  (800,792)  (1,181,622)  (1,542,359)
                 
OTHER (EXPENSE) INCOME                
Interest income (expenses), net  1,032   1,074   2,660   283 
Settlement agreement with shareholders  -   -   -   (779,000)
Gain on accounts payable forgiveness  -   4,523   -   402,248 
   1,032   5,597   2,660   (376,469)
                 
NET LOSS $(665,656) $(795,195) $(1,178,962) $(1,918,828)
                 
LOSS PER SHARE                
BASIC $(0.01) $(0.01) $(0.01) $(0.02)
DILUTED $(0.01) $(0.01) $(0.01) $(0.02)
                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING                
BASIC  

97,520,779

   95,910,130   

96,434,361

   86,488,400 
DILUTED  

97,520,779

   95,910,130   

96,434,361

   86,488,400 

(a)Includes share-based compensation of $259,923 and $349,008 for the three and six months ended June 30, 2019 and $215,810 and $505,713 for the three and six months ended June 30, 2018.

The accompanying notes are an integral part of these unaudited financial statements.

69
F-3

VerifyMe, Inc.

Statements of Cash Flows

(Unaudited)

  Six months ended 
  June 30, 2019  June 30, 2018 
CASH FLOWS FROM OPERATING ACTIVITIES      
     Net loss $(1,178,962) $(1,918,828)
     Adjustments to reconcile net loss to net cash used in        
        operating activities:        
Stock based compensation  15,000   44,119 
Fair value of options and warrants issued in exchange for services  249,788   226,188 
Fair value of restricted stock and restricted stock units issued in exchange
for services
  84,220   235,406 
Gain on accounts payable forgiveness  -   (402,248)
Share-based payment for settlement agreement with shareholders  -   279,000 
         
Amortization and depreciation  11,635   10,894 
Changes in operating assets and liabilities:        
Accounts Receivable  8,349   (5,667)
Deposit on Equipment  (163,090)  - 
Inventory  (1,284)  (11,769)
Prepaid expenses and other current assets  (4,200)  - 
Accounts payable and accrued expenses  (34,694)  (80,398)
Net cash used in operating activities  (1,013,238)  (1,623,303)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of Patents  (28,574)  (825)
Capitalized Software Costs  (46,196)  - 
Net cash used in investing activities  (74,770)  (825)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from exercise of warrants  -   2,093,217 
Proceeds from sale of common stock  -   1,154,211 
         
Net cash provided by financing activities  -   3,247,428 
         
NET (DECREASE) INCREASE IN CASH AND        
CASH EQUIVALENTS  (1,088,008)  1,623,300 
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD  1,673,201   693,001 
         
CASH AND CASH EQUIVALENTS - END OF PERIOD $585,193  $2,316,301 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid during the period for:        
Interest $-  $- 
            Income taxes $-  $- 
         
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING
ACTIVITIES
        
         
Series A Convertible Preferred Stock converted to common stock $6,096  $400 
Series B Convertible Preferred Stock converted to common stock $-  $599 
Cashless Exercise of Stock Options $-  $4,028 
Cashless Exercise of Warrants $72  $- 
Common Stock and Warrants Issued for Common Stock Payable $-  $122,478 

The accompanying notes are an integral part of these unaudited financial statements.

F-4

VerifyMe, Inc.

Statement of Contents

Stockholders' Equity (Deficit)

(Unaudited)

  Series A  Series B                   
  Convertible  Convertible                   
  Preferred  Preferred  Common             
  Stock  Stock  Stock  Additional          
  Number of     Number of     Number of     Paid-In  Treasury  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Deficit  Total 
                               
Balance at April 1, 2018  304,778   305   0.85   -   92,945,925   92,944   59,481,371   (113,389)  (57,454,721)  2,006,510 
Exercise of Warrants  -   -   -   -   6,257,277   6,258   609,904   -   -   616,162 
Fair value of stock option  -   -   -   -   -   -   20,219   -   -   20,219 
Restricted Stock awards and Restricted Stock Units  -   -   -   -   1,912,500   1,913   182,203   -   -   184,116 
Common stock and warrants issued for services  -   -   -   -   49,500   50   11,425   -   -   11,475 
Net loss  -   -   -   -   -   -   -   -   (795,195)  (795,195)
Balance at June 30, 2018  304,778   305   0.85   -   101,165,202   101,165   60,305,122   (113,389)  (58,249,916)  2,043,287 

  Series A  Series B                   
  Convertible  Convertible                   
  Preferred  Preferred  Common             
  Stock  Stock  Stock  Additional          
  Number of     Number of     Number of     Paid-In  Treasury  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Deficit  Total 
                               
Balance at April 1, 2019  264,778   265   0.85   -   103,643,166   103,643   60,932,481   (113,389)  (59,776,856)  1,146,144 
Conversion of Series A Convertible Preferred Stock  (264,778)  (265)  -   -   5,295,569   5,296   (5,031)  -   -   - 
Fair value of stock option  -   -   -   -   -   -   126,077   -   -   126,077 
Restricted Stock awards and Restricted Stock Units  -   -   -   -   240,000   240   118,606   -   -   118,846 
Cashless Exercise of Warrants  -   -   -   -   

71,774

   72   (72)  -   -   - 
Common stock issued for services  -   -   -   -   71,324   71   14,929   -   -   15,000 
Net loss  -   -   -   -   -   -   -   -   (665,656)  (665,656)
Balance at June 30, 2019  -   -   0.85   -   

109,321,833

   

109,322

   

61,186,990

   (113,389)  (60,442,512)  740,411 

The accompanying notes are an integral part of these unaudited financial statements.

F-5

VerifyMe, Inc.

Statement of Stockholders' Equity (Deficit)

(Unaudited) 

  Series A  Series B                   
  Convertible  Convertible                   
  Preferred  Preferred  Common             
  Stock  Stock  Stock  Additional          
  Number of     Number of     Number of     Paid-In  Treasury  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Deficit  Total 
                                         
Balance at December 31, 2017  324,778   325   0.92   -   53,523,332   53,522   56,198,126   (113,389)  (56,331,088)  (192,504)
Conversion of Series A
Convertible Preferred Stock
  (20,000)  (20)  -   -   400,000   400   (380)  -   -   - 
Conversion of Series B
Convertible Preferred Stock
  -   -   (0.07)  -   599,362   599   (599)  -   -   - 
Sale of common stock  -   -   -   -   16,513,311   16,513   1,137,698   -   -   1,154,211 
Settlement Agreement  -   -   -   -   1,000,000   1,000   278,000   -   -   279,000 
Conversion of notes payable  -   -   -   -   1,749,683   1,750   120,728   -   -   122,478 
Exercise of Warrants  -   -   -   -   20,969,736   20,970   2,072,247   -   -   2,093,217 
Cashless Exercise of Stock
Options
      -   -   -   4,027,778   4,028   (4,028)  -   -   - 
Fair value of stock option  -   -   -   -   -   -   226,188   -   -   226,188 
Restricted Stock awards and
Restricted Stock Units
  -   -   -   -   2,212,500   2,213   233,193   -   -   

235,406

 
Common stock and warrants
issued for services
  -   -   -   -   169,500   170   43,949           44,119 
Net loss  -   -   -   -   -   -   -   -   (1,918,828)  (1,918,828)
Balance at June 30, 2018  304,778   305   0.85   -   101,165,202   101,165   60,305,122   (113,389)  (58,249,916)  2,043,287 

  Series A  Series B                   
  Convertible  Convertible                   
  Preferred  Preferred  Common             
  Stock  Stock  Stock  Additional          
  Number of     Number of     Number of     Paid-In  Treasury  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Deficit  Total 
                               
Balance at December 31, 2018  304,778   305   0.85   -   102,203,166   102,203   60,844,796   (113,389)  (59,263,550)  1,570,365 
Conversion of Series A
Convertible Preferred Stock
  (304,778)  (305)  -   -   6,095,569   6,096   (5,791)  -   -   - 
Fair value of stock option  -   -   -   -   -   -   249,788   -   -   249,788 
Restricted Stock awards and
Restricted Stock Units
  -   -   -   -   880,000   880   83,340   -   -   84,220 
Cashless Exercise of Warrants  -   -   -   -   

71,774

   72   (72)  -   -   - 
Common stock issued for
services
  -   -   -   -   71,324   71   14,929   -   -   15,000 
Net loss  -   -   -   -   -   -   -   -   (1,178,962)  (1,178,962)
Balance at June 30, 2019  -   -   0.85   -   

109,321,833

   

109,322

   

61,186,990

   (113,389)  (60,442,512)  740,411 

The accompanying notes are an integral part of these unaudited financial statements.

F-6
SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Table of Contents
Insofar

VerifyMe, Inc.

Notes to Financial Statements

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of the Business

The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in Rochester, New York and its common stock, par value $0.001 per share, is traded on the over-the-counter market and quoted on the OTCQB.

The Company is a developmental stage technology solutions provider specializing in brand protection functions such as indemnificationcounterfeit prevention, authentication, serialization, track and trace features for liabilities arising underlabels, packaging and products. We deliver security solutions for identification and authentication of packaging, labels and products in a variety of applications. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the Securities Act may be permittedpatent pending VeriPAS™ software system in 2018, which covertly and overtly serializes products to directors, officers or persons controllingtrack a products “life cycle” for brand owners. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the registrantfield – allowing investigators to quickly and efficiently authenticate product throughout the distribution chain, including warehouses, ports of entry, retail locations, and product purchased over the internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and where they are deployed with geo location mapping and intelligent programmable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology.

The accompanying unaudited interim financial statements (the “Interim Statements”) have been prepared pursuant to the foregoing provisions,rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U. S. generally accepted accounting principles (“GAAP”) for complete financial statements are not included herein. The Interim Statements should be read in conjunction with the registrant has been informed thatfinancial statements and notes thereto included in the opinion ofCompany’s latest Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission such indemnification is against public policy as expressed(the “SEC”) on April 1, 2019.  The accompanying Interim Statements are unaudited; however, in the Securities Actopinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The interim results for the three and is therefore unenforceable.

70

Tablesix months ended June 30, 2019 are not necessarily indicative of Contentsthe results to be expected for the year ending December 31, 2019 or for any future interim periods.

The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding for working capital and to further develop the Company’s intellectual property.

Basis of Presentation

The accompanying financial statements are presented in accordance with GAAP.

Revenue Recognition

The Company accounts for revenues according to ASC Topic 606, “Revenue from Contracts with Customers” which establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity's contracts to provide goods or services to customers.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·identify the contract with a customer;
·identify the performance obligations in the contract;
·determine the transaction price;
·allocate the transaction price to performance obligations in the contract; and
·recognize revenue as the performance obligation is satisfied.

VerifyMe, Inc.

Notes to Financial Statements

During the three and six months ended June 30, 2019, the Company’s revenues consisted of revenue generated from customer’s printing labels utilizing the Company’s technology.

Basic and Diluted Net Income per Share of Common Stock

The Company follows FASB ASC 260, “Earnings Per Share,” when reporting earnings per share resulting in the presentation of basic and diluted earnings per share.  Because the Company reported a net loss for each of the periods presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same.

For the three and six months ended June 30, 2019 and 2018, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented. For the three and six months ended June 30, 2019 there were approximately 48,877,000 anti-dilutive shares consisting of 19,614,000 shares issuable upon exercise of options, 22,041,000 shares issuable upon exercise of warrants and 7,222,000 shares issuable upon conversion of preferred stock. For the three and six months ended June 30, 2018 there were approximately 42,703,000 anti-dilutive shares consisting of 18,014,000 shares relating to options, 11,375,000 shares relating to warrants and 13,314,000 shares relating to preferred share agreements.

Going Concern

The Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by the sale of common shares. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through future public offering of our securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The Company’s existing cash resources are sufficient to sustain the Company’s operations through the third quarter of 2019. The Company needs to raise additional funds in the future in order to remain operational past that date. 

Recently Adopted Accounting Pronouncements

Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on the Company’s financial statements.

NOTE 2 – INTANGIBLE ASSETS

Patents and Trademarks

The current patent and trademark portfolios consist of 10 granted US patents and 1 granted European patent validated in 4 countries, 4 pending US and foreign patent applications, 4 registered US trademark, and 9 pending US and foreign trademark applications. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 19 years.During the six months ended June 30, 2019 and 2018, the Company capitalized $28,574 and $825 of patent and trademarks costs. Amortization expense for patents and trademarks was $5,928 and $5,860 for the three months ended June 30, 2019 and 2018, and $11,635 and $10,984 for the six months ended June 30, 2019 and 2018, respectively.

F-8

VerifyMe, Inc.

Notes to Financial Statements

Capitalized Software

Costs incurred in connection with the development of software related to our proprietary digital products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985 “Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market. Amortization of capitalized software development costs begins once the product is available to the market. Capitalized software development costs are amortized over the estimated life of the related product, generally three years, using the straight-line method. The Company will evaluate its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company had Capitalized Software of $116,427 and $70,231 as of June 30, 2019 and December 31, 2018, respectively. The Company has not incurred a depreciation charge as the software was not available for use as of June 30, 2019. 

NOTE 3 – CONVERTIBLE PREFERRED STOCK

The Company is authorized to issue Series A Convertible Preferred Stock, par value of $0.001 per share (the “Series A”) and Series B Convertible Preferred Stock, par value of $0.001 per share (the “Series B”). As of June 30, 2019, there were no shares of Series A outstanding and 0.85 of a share of Series B outstanding. Each share of Series A and Series B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and Series B are subject to beneficial ownership limitations.

Series A Convertible Preferred Stock

During the six months ended June 30, 2019,304,778shares of Series A were converted into6,095,569shares of the Company’s common stock.


During the six months ended June 30, 2018, 20,000 shares of Series A were converted into 400,000 shares of the Company’s common stock.

Series B Convertible Preferred Stock

During the six months ended June 30, 2018, 0.07 of a share of Series B was converted into 599,362 shares of the Company’s common stock.

NOTE 4 – STOCKHOLDERS’ EQUITY

For the three and six months ended June 30, 2019 the Company expensed $0 relative to restricted stock units.For the three and six months ended June 30, 2018 the Company expensed $248 and $8,625 relative to restricted stock units.

During the six months ended June 30, 2019, the Company granted a total of 1,200,000 restricted stock awards to five directors of the Company for their services. The restricted stock awards vest in equal quarterly installments over a one-year period. On February 27, 2019 three directors resigned from the Company’s Board of Directors, effective March 1, 2019. This resulted in a cancellation of 320,000 shares related to the portion of the unvested restricted stock awards these directors had received.

The Company expensed $118,846 and $84,220 in costs related to restricted stock awards for the three and six months ended June 30, 2019.For the three and six months ended June 30, 2018, the Company expensed $183,866 and $226,781 relative to restricted common stock.

During the six months ended June 30, 2019, the Company issued 71,324 shares of restricted common stock for a total expense of $15,000 related to consulting services. During the six months ended June 30, 2018, the Company issued 169,500 shares of restricted common stock for a total expense of $44,119 related to consulting services.

During the six months ended June 30, 2018, 37,500 restricted stock units vested in relation to a consulting services agreement and a total of $8,625 was expensed.

F-9

VerifyMe, Inc.

Notes to Financial Statements

During the six months ended June 30, 2018, the Company granted a total of Contents


Torestricted common stock awards to two directors of the Company, each receiving 300,000 shares of restricted common stock, for joining the Board of Directors.On April 25, 2018, the Company approved the immediate vesting of all of the Company’s outstanding restricted common stock issued in 2017 and 2018 to non-employee directors of the Company.

During the three months ended June 30, 2018, the Company granted a total of 1,425,000 shares of restricted common stock to the directors and the Chief Executive Officer of the Company for their services and 150,000 shares to one attorney, that vested quarterly over a one-year period.

In 2017, the Company authorized a private placement with a maximum offering amount of $2,100,000 allowing investors to purchase units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share. In January 2018 the Company’s Board of Directors increased the size of the private placement by an additional amount beyond the $2,100,000 limit. During the six months ended June 30, 2018, the Company raised gross proceeds of $1,154,211 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants. Of these amounts, gross proceeds of $530,777 for the purchase of 7,590,111 shares of common stock and 7,590,111 warrants related to purchases by directors and relatives of the directors of the Company.

In January 2018, the Chairman of the Board of Directors, made a cashless exercise of 5,000,000 options related to services rendered in 2017, resulting in the issuance of 4,027,778 shares of common stock, see Note 5.

On January 30, 2018, the Company authorized a 30-day offer, beginning on February 20, 2018, to the holders of the Company’s outstanding warrants exercisable at $0.15 to exercise their warrants at $0.10 per share.  This authorization was extended until the latter of 30 days after the receipt of all Investment Letters, as defined below, in connection with the Settlement Shares, as defined below, or June 30, 2018.  For the six months ended June 30, 2018, 20,764,860 shares of warrants were exercised and a total of 20,764,860 shares of common stock were issued for gross proceeds of $2,076,486. Included in the above amounts are gross proceeds of $1,205,458 from directors which resulted in 12,054,576 warrants converted into the issuance of 12,054,576 common stock. The offer to exercise $0.15 warrants at $0.10 per share expired on June 30, 2018 and the Company did not extend the offer.

In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731.

On March 31, 2018, the Company entered into a Confidential Settlement Agreement (the “Settlement Agreement”) with Paul Klapper, a member of the Company’s Board at that time, and certain other parties named in the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the Company (i) paid a total of $500,000 (the “Settlement Amount”) to a fund controlled by Paul Klapper and an additional party, and (ii) issued a total of 1,000,000 shares of the Company’s common stock to the fund and the third party (the “Settlement Shares”). The shares were valued at $279,000 whereby $139,500 related to common stock issued to a related party and $139,500 related to common stock issued to a third party. The Settlement Agreement provides for cancellation as of March 31, 2018 of certain revenue sharing agreements between the Company and each of Mr. Klapper (or an affiliate) and the third party, and terminates the Company’s obligation to issue warrants to purchase 3.7 million shares of the Company’s common stock at an exercise price of $0.40 per share. Mr. Klapper joined the Board of Directors on July 14, 2017 and resigned as of March 31, 2018.

In January 2018, the Company issued 1,749,683 shares of common stock and 1,749,683 warrants with an exercise price of $0.15 to Mr. Klapper relating to the Note payable conversion that took place in June 2017.

 On March 28, 2018, the Company accelerated the vesting of 150,000 shares of restricted common stock owned by Mr.  Klapper.

In April 2018, the former Chief Executive Officer of the Company exercised his warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares.

F-10

VerifyMe, Inc.

Notes to Financial Statements

NOTE 5 – STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS

During 2013, the Company adopted an incentive compensation plan (the “2013 Plan”). Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of 20,000,000 shares of common stock. The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as incentive stock options. All options granted under the 2013 Plan, which are not intended to qualify as incentive stock options are deemed to be non-statutory stock options. The 2013 Plan is no longer used for future grants.

On November 14, 2017, the Executive Committee of the Company’s Board of Directors adopted the 2017 Equity Incentive Plan (the “2017 Plan”) which covers the potential issuance of 13,000,000 shares of common stock. The 2017 Plan provides that directors, officers, employees, and consultants of the Company will be eligible to receive equity incentives under the 2017 Plan at the discretion of the Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The Compensation Committee may adopt rules and regulations to carry out the terms of the 2017 Plan. The Plan terminates on November 14, 2027 unless sooner terminated.

The 2017 Plan is administered by the Compensation Committee which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the 2017 Plan.

In connection with incentive stock options issuable under the 2017 Plan, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).

Incentive stock options under all plans of the Company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to first exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be non-statutory stock options, including prices, duration, transferability and limitations on exercise.

The Company issued non-statutory stock options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided.

Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments.

During the six months ended June 30, 2019 and 2018, the Company expensed $249,788 and $226,188, respectively, with respect to options.

The following table presents the weighted-average assumptions used to estimate the fair value of the stock options granted during the six months ended June 30, 2019:

    
    
Risk Free Interest Rate  2.14%
Expected Volatility  424.69%
Expected Life (in years)  5.0 
Dividend Yield  0%
Weighted average estimated fair value of    
options during the period $0.27 

F-11

VerifyMe, Inc.

Notes to Financial Statements

 Options Outstanding 
      Weighted -    
     Average  Aggregate 
     Remaining  Intrinsic 
   Weighted-  Contractual  Value 
 Number of  Average  Term  (in 000’s) 
 Shares  Exercise Price  (in years)  (1) 
Balance as of December 31, 2018  18,613,529  $0.14         
                 
Granted  1,000,000   0.20         
                 
Balance June 30, 2019  19,613,529  $0.14         
                 
Exercisable at June 30, 2019  17,230,196  $0.13   3.5  $937 

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for options that were in-the-money at each respective period. 

The following table summarizes the activities for the Company’s unvested stock options for thesix months ended June 30, 2019:

 Unvested Options 
    
   Weighted - Average 
 Number of Unvested  Grant Date 
 Options  Exercise Price 
Balance December 31, 2018  2,016,666  $0.18 
         
Granted  1,000,000   0.20 
         
Vested  (633,333)  0.24 
         
Balance June 30, 2019  2,383,333  $0.17 

F-12

VerifyMe, Inc.

Notes to Financial Statements

During the six months ended June 30, 2019, the Company amended the Consulting Agreement it has with its Chief Operating Officer and granted him options to purchase 1,000,000 shares of common stock with an exercise price of $0.195 that vest annually in equal increments over a two-year period.  

The following table summarizes the activities for the Company’s warrants for thesix months ended June 30, 2019:

  Warrants Outstanding 
  Number of
Shares
  

Weighted-

Average

Exercise

Price

  

Weighted -

Average

Remaining

Contractual

Term

in years)

  

Aggregate

Intrinsic

Value

(in 000's)
(1)

 
             
             
Balance, December 31, 2018  22,240,833  $0.31         
                 
Granted  

85,255

   0.15         

 

Exercised

  (200,000)  0.15         
                 
                 
Balance, June 30, 2019  22,126,088  $0.32         
                 
Exercisable at June 30, 2019  22,126,088  $0.32   3.2  $231 

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.14 for our common stock on June 30, 2019.

During the six months ended June 30, 2019, the Company recorded 85,255 warrants related to past issuances.

In May 2019, a former director made a cashless exercise of 200,000 warrants, whereby the warrant holder disposed of 128,226 shares of common stock to the Company as part of this exercise, amounting to an issuance of 71,774 shares of common stock.

NOTE 6 – CONCENTRATIONS

Revenue

For the three and six months ended June 30, 2019, three customers represented 100% of revenues.

Accounts Receivable

As of June 30, 2019, two customers represented 100% of accounts receivable.

NOTE 7 – SUBSEQUENT EVENTS

In July 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relation services.

In August 2019, the Company granted 200,000 shares of restricted common stock in relation to consulting services. 

In August 2019, the Company granted 400,000 shares of restricted common stock in relation to consulting services.

F-13

VerifyMe, Inc.

Notes to Financial Statements

In August 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relation services.

In August 2019, the Company entered into an amendment (the “Amendment���) to the Employment Agreement, dated August 15, 2017, with Patrick White, the Chief Executive Officer of the Company (the “Employment Agreement”), which Employment Agreement automatically renewed on July 16, 2019, effective on August 15, 2019. Pursuant to the Amendment, the term was reduced to one year and Mr. White agreed to defer receipt of sums due him to improve the Company’s liquidity. Mr. White was due to receive $100,000 on August 15, 2019 representing deferred salary (the “Deferral Amount”) that he had previously agreed to defer over the two years of the initial term of his Employment Agreement. In the Amendment, Mr. White agreed to extend receipt of the Deferral Amount until August 15, 2020. In addition, he agreed to continue deferring 25% of his base salary over the one-year term until August 15, 2020. In connection with entering into the Amendment, the Company granted Mr. White 500,000 five-year fully vested incentive stock options under the Company’s 2017 Equity Incentive Plan exercisable at $0.14 per share.

In September 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relation services.

On September 18, 2019, a Board Member provided his resignation as member of the Company’s Board of Directors, effective immediately. This resulted in a cancellation of 120,000 shares of common stock related to the portion of the unvested restricted stock awards granted to this director.

On September 19, 2019, we completed the closing of $600,000 of Debentures for gross proceeds of $540,000 after original issue discounts. As of the Effective Date, we entered into two substantially identical Securities Purchase Agreements with two Purchasers, which provided for the issuance of up to an aggregate of $1.2 million in principal amount of Debentures of which the first tranche of $600,000 have been issued. The Securities Purchase Agreements provided for the issuance of the Debentures due one year from the dates of issuance in two $600,000 tranches: the first tranche as described above, and the second tranche, at the discretion of the Purchasers and us, to occur any time after November 17, 2019. If, at any time after November 17, 2019, the Purchasers elect not to consummate the closing of the second tranche, then we may raise up to $600,000 from additional investors (including our affiliates) who will have a security interest on apari passu basis with the Purchasers in the first tranche, so long as such investors agree not to convert the securities received until the Purchasers in the first tranche have completely converted the Debentures or been fully repaid.

In connection with the Bridge Financing, each of the Purchasers received a commitment fee of $5,000 and 500,000 restricted shares (the “Commitment Shares”) of our common stock. The Representative served as placement agent for the Bridge Financing and received a cash fee of 8% of the gross proceeds received at each closing and is entitled to receive warrants for 5% of the total number of securities issued in connection with the Bridge Financing. These warrants will be exercisable at a price per share equal to 110% of the price of the securities paid by the Purchasers and will expire in five years. See “Underwriting — Other.”

The first tranche of the Debentures will mature on September 18, 2020, and may be redeemed by us prior to the maturity date as described below. All unpaid principal due and payable on the maturity date will be paid in the form of common stock. Any principal or interest that is due under each of the Debentures, which is not paid by the respective maturity date, will bear interest at the rate of 18% per annum until it is satisfied in full.

The Debentures are senior secured obligations of ours secured pursuant to the terms of security agreements dated as of September 18, 2019 (the “Security Agreements”) by all of the assets of us and our subsidiaries.

Each Purchaser is entitled, at any time, to convert all or any portion of the outstanding principal amount of its Debenture(s) plus any accrued interest into restricted shares of common stock. If we consummate a public offering within 180 calendar days of the Effective Date, then the conversion price will be the lesser of (a) $0.15 or (b) 70% multiplied of the price per share of the common stock we issue in the public offering (the “QPI Discounted Price”), subject to further adjustment as provided in the Debenture as well as subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. Further, if we consummate a public offering of common stock which results in us receiving gross proceeds of at least $5 million within 180 calendar days of the Effective Date then we are obligated to repay the outstanding amounts owed under the Debentures, to the extent they are not converted and including the applicable redemption premium then in effect, within three days of consummation of such an offering.

F-14

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of

VerifyMe, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of VerifyMe, Inc. (the “Company”) as of December 31, 20152018 and 20142017, and the related statements of operations, changes in stockholders’ deficit,equity (deficit), and cash flows for the years then ended. ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Matter

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has negative cash flows from operations that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on thesethe Company’s financial statements based on our audits.

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included considerationAs part of our audits we are required to obtain an understanding of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’sCompany's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supportingregarding the amounts and disclosures in the financial statements, assessingstatements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ MaloneBailey, LLP

www.malonebailey.com

We have served as the Company's auditor since 2018.

Houston, Texas

April 1, 2019

F-15
In our opinion the financial statements referred to above present fairly, in all material respects, the financial position
Table of Contents

VerifyMe, Inc. as of December 31, 2015 and 2014, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.


The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 2 to the financial statements, the Company has incurred significant losses and experienced negative cash flow from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ MORISON COGEN LLP 
Blue Bell, Pennsylvania
March 30, 2016
VerifyMe, Inc.
  December 31, 2015  December 31, 2014 
       
ASSETS      
       
CURRENT ASSETS      
Cash and cash equivalents $4,152  $63,956 
Inventory  28,687   97,360 
Prepaid expenses  -   181,086 
         
TOTAL CURRENT ASSETS  32,839   342,402 
         
PROPERTY AND EQUIPMENT        
Capital equipment, net of accumulated depreciation of $230,621 and $161,205 as of December 31, 2015 and December 31, 2014  7,838   74,821 
         
OTHER ASSETS        
Deposits  37,197   37,197 
Patents and Trademark, net of accumulated amortization of $135,315 and $118,502 as of December 31, 2015 and December 31, 2014  259,294   107,586 
   296,491   144,783 
         
TOTAL ASSETS $337,168  $562,006 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
         
CURRENT LIABILITIES        
Accounts payable and accrued expenses $652,973  $5,217,770 
Accrued interest - related parties  -   43,215 
Deferred revenue  -   16,667 
Senior secured convertible notes payable - related parties  -   114,000 
Notes payable  50,000   812,553 
         
TOTAL CURRENT LIABILITIES  702,973   6,204,205 
         
LONG-TERM LIABILITIES        
Warrant liability  1,802,375   6,370,709 
Accrued interest - related parties  -   112,885 
         
TOTAL LONG-TERM LIABILITIES  1,802,375   6,483,594 
         
TOTAL LIABILITIES  2,505,348   12,687,799 
         
CONTINGENCIES        
         
STOCKHOLDERS' DEFICIT        
         
Series A Convertible Preferred Stock, $ .001 par value; 37,564,767 shares authorized; 441,938 shares issued and outstanding        
   as of December 31, 2015 and 75,000,000 shares authorized; 248,366 issued and outstanding as of December 31, 2014  442   633,333 
         
Series B Convertible Preferred Stock, $.001 par value; 85 shares authorized; 1 share issued and outstanding        
   as of December 31, 2015 and 0 shares authorized; 0 issued and outstanding as of December 31, 2014  -   - 
         
Common stock, $ .001 par value; 675,000,000 shares authorized; 6,259,727 and 3,969,106 shares issued, and 5,977,030        
  and 3,618,566 shares outstanding at December 31, 2015 and December 31, 2014  5,977   3,618 
         
Additional paid in capital  39,779,414   25,047,050 
         
Treasury stock, at cost (350,540 shares at December 31, 2015 and December 31, 2014)  (113,389)  (113,389)
         
Deferred compensation  (1,842,334)  - 
         
Accumulated deficit  (39,998,290)  (37,696,405)
         
STOCKHOLDERS' DEFICIT  (2,168,180)  (12,125,793)
         
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $337,168  $562,006 

  As of 
  December 31, 2018  December 31, 2017 
ASSETS      
       
CURRENT ASSETS      
Cash and cash equivalents $1,673,201  $693,001 
Accounts Receivable  30,373   - 
Prepaid expenses and other current assets  25,781   18,668 
Inventory  41,982   - 
TOTAL CURRENT ASSETS  1,771,337   711,669 
         
OTHER ASSETS        
Patents and Trademarks, net of accumulated amortization of        
$258,294 and $237,331 as of December 31, 2018 and December 31, 2017  209,049   191,507 
Capitalized Software Costs  70,231   - 
         
TOTAL ASSETS $2,050,617  $903,176 
         
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)        
         
CURRENT LIABILITIES        
Accounts payable and other accrued expenses $411,211  $923,202 
Accrued Payroll $69,041  $- 
Notes payable  -   50,000 
Common Stock payable  -   122,478 
TOTAL CURRENT LIABILITIES  480,252   1,095,680 
         
STOCKHOLDERS' EQUITY (DEFICIT)        
Series A Convertible Preferred Stock, $.001 par value, 37,564,767 shares        
 authorized; 304,778 shares issued and outstanding as of December 31, 2018 and        
324,778 shares issued and outstanding as of December 31, 2017  305   325 
         
Series B Convertible Preferred Stock, $.001 par value; 85 shares        
  authorized; 0.85 shares issued and outstanding as of December 31, 2018 and        
  0.92 shares issued and outstanding as of December 31, 2017  -   - 
         
Common stock of $.001 par value; 675,000,000 authorized; 102,553,706 and
53,873,872 issued, 102,203,166 and 53,523,332 shares outstanding as of
December 31, 2018 and December 31, 2017
  102,203   53,522 
         
Additional paid in capital  60,844,796   56,198,126 
         
Treasury stock as cost (350,540 shares at December 31, 2018 and  December
31, 2017)
  (113,389)  (113,389)
         
Accumulated deficit  (59,263,550)  (56,331,088)
         
STOCKHOLDERS' EQUITY (DEFICIT)  1,570,365   (192,504)
         
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $2,050,617  $903,176 

The accompanying notes are an integral part toof these financial statements.

F-16


VerifyMe, Inc.

Statements of Operations

For

  Year Ended 
  December 31, 2018  December 31, 2017 
NET REVENUE      
Sales $74,884  $- 
         
COST OF SALES  28,802   - 
         
GROSS PROFIT  46,082   - 
         
OPERATING EXPENSES        
General and administrative (a)  1,585,329   1,689,883 
Legal and accounting  416,772   246,520 
Payroll expenses (a)  316,837   767,257 
Research and development  187,655   128,044 
Sales and marketing  135,290   3,800 
Total Operating expenses  2,641,883   2,835,504 
         
LOSS BEFORE OTHER INCOME (EXPENSE)  (2,595,801)  (2,835,504)
         
OTHER (EXPENSE) INCOME        
Interest income (expenses), net  6,664   (218,316)
Gain on derecognition of note payable and accrued interest  83,667   - 
Settlement agreement with shareholders  (779,000)  - 
Gain on accounts payable forgiveness  352,008   - 
Loss on settlement of related party notes payable  -   (331,912)
Other income  -   392 
   (336,661)  (549,836)
NET LOSS $(2,932,462) $(3,385,340)
         
Less: Deemed dividend on convertible preferred shares  -   (596,878)
         
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $(2,932,462) $(3,982,218)
         
LOSS PER SHARE        
BASIC $(0.03) $(0.14)
DILUTED $(0.03) $(0.14)
         
WEIGHTED AVERAGE COMMON SHARE OUTSTANDING        
BASIC  93,851,170   28,244,361 
DILUTED  93,851,170   28,244,361 
         

(a)  Includes share-based compensation of $828,203 and $1,800,181 for the Years Endedyears ended December 31, 2018 and 2015 and 2014

  Year  Year 
  Ended  Ended 
  December 31,  December 31, 
  2015  2014 
       
NET REVENUES      
Sales  200,601  $116,265 
Royalties  16,667   8,333 
         
TOTAL NET REVENUE  217,268   124,598 
         
COST OF SALES  65,723   113,024 
         
GROSS PROFIT  151,545   11,574 
         
OPERATING EXPENSES        
General and administrative  449,483   811,916 
Legal and accounting  458,801   344,903 
Payroll expenses (a)  1,875,488   1,611,376 
Research and development (b)  2,412,833   10,590,271 
Sales and marketing (c)  197,430   218,443 
Total operating expenses  5,394,035   13,576,909 
         
LOSS BEFORE OTHER INCOME  (5,242,490)  (13,565,335)
         
OTHER INCOME (EXPENSE)        
Interest expense  (61,438)  (199,364)
Gain (loss) on extinguishment of debt  332,523   (82,000)
Change in fair value of warrants  2,669,520   5,128,204 
Change in fair value of embedded derivative liability  -   800,000 
   2,940,605   5,646,840 
         
NET LOSS $(2,301,885) $(7,918,495)
         
LOSS PER SHARE        
BASIC $(0.47) $(2.22)
DILUTED $(0.47) $(2.22)
         
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
BASIC  4,848,738   3,573,511 
DILUTED  4,848,738   3,573,511 
(a) - includes share based compensation of $1,259,670 and $860,235 for the years ended December 31, 2015 and 2014
(b) - includes share based compensation of $2,000,000 and $10,236,089 for the years ended December 31, 2015 and 2014
(c) - includes share based compensation of $88,937 and $0 for the years ended December 31, 2015 and 2014
2017, respectively.

The accompanying notes are an integral part toof these financial statements.

F-17

VerifyMe, Inc.

Statements of Cash Flows

  Year Ended 
  December 31, 2018  December 31, 2017 
CASH FLOWS FROM OPERATING ACTIVITIES      
     Net loss $(2,932,462) $(3,385,340)
     Adjustments to reconcile net loss to net cash used in        
        operating activities:        
Stock based compensation  44,120   139,808 
Fair value of options and warrants issued in exchange for services  329,193   1,295,741 
Fair value of restricted stock and restricted stock units issued in exchange for services  454,890   66,825 
Common stock and warrants issued for services  -   297,807 
Gain on accounts payable forgiveness  (352,008)  - 
Share-based payment for settlement agreement with shareholders  279,000   - 
Gain on derecognition of note payable and accrued interest  (83,667)  - 
Amortization of debt discount  -   174,517 
Interest rolled into principal  -   30,000 
Loss on conversion of related party notes payable and accrued interest  -   331,912 
Amortization and depreciation  20,963   43,095 
Changes in operating assets and liabilities:        
Accounts Receivable  (30,373)  - 
Inventory  (41,982)  17,093 
Prepaid expenses and other current assets  (7,113)  (9,243)
Accounts payable and accrued expenses  (57,275)  61,867 
Net cash used in operating activities  (2,376,714)  (935,918)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of Patents  (38,505)  (2,650)
Capitalized Software Costs  (70,231)  - 
Net cash used in investing activities  (108,736)  (2,650)
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from exercise of warrants  2,312,005   - 
Proceeds from issuance of related party notes payable  -   281,000 
Proceeds from sale of common stock  1,153,645   1,327,925 
Net cash provided by financing activities  3,465,650   1,608,925 
         
NET INCREASE  IN CASH AND        
CASH EQUIVALENTS  980,200   670,357 
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD  693,001   22,644 
         
CASH AND CASH EQUIVALENTS - END OF PERIOD $1,673,201  $693,001 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid during the year for:        
Interest $-  $- 
Income taxes $-  $- 
         
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES        
         
Cumulative effect of adoption of ASU 2017-11 $-  $623,462 
Series A Convertible Preferred Stock converted to common stock $400  $1,460 
Series B Convertible Preferred Stock converted to common stock $599  $- 

F-18
Statement of Changes in Stockholders’ Deficit
Table of Contents
For the Two Years Ended December 31, 2015
  Series A  Series B                      
  Convertible  Convertible                      
  Preferred  Preferred  Common                
  Stock  Stock  Stock  Additional             
  Number of     Number of     Number of     Paid-In  Treasury  Deferred  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Compensation  Deficit  Total 
                                  
Balance at December 31, 2013  21,111,111  $633,333         290,066,139  $(13,893) $23,272,739  $(113,389)    $(29,777,910) $(5,999,121)
                                          
Issuance of shares of common stock for services  -   -         6,349,206   6,349   393,651   -      -   400,000 
Cashless exercise of options  -   -         2,714,285   2,714   (2,714)  -      -   - 
Fair value of employee stock options  -   -         -   -   860,235   -      -   860,235 
Issuance of shares of common stock for settlement of debt  -   -         8,448,519   8,449   498,139   -      -   506,588 
Forgiveness of related party debt  -   -         -   -   25,000   -      -   25,000 
Net income for the year ended December 31, 2014  -   -         -   -   -   -      (7,918,495)  (7,918,495)
                                          
Balance at December 31, 2014  248,366  $633,333   -  $-   3,618,566  $3,618  $25,047,050  $(113,389) $-  $(37,696,405) $(12,125,793)
                                             
Conversion of Series A Convertible Preferred Stock into common stock  (248,366)  (633,333)  -   -   248,366   248   633,085   -   -   -   - 
Sale of Series A Convertible Preferred Stock  389,668   390   -   -   -   -   1,278,111   -   -   -   1,278,501 
Conversion of stockholder deferred compensation into Series A Convertible
Preferred Stock
  10,667   10   -   -   -   -   34,990   -   -   -   35,000 
Conversion of notes payable and accrued interest into Series A Convertible Preferred Stock  41,603   42   -   -   -   -   136,771   -   -   -   136,813 
Conversion of accrued expenses into Series B Convertible Preferred Stock  -   -   1   -   -   -   8,367,417   -   -   -   8,367,417 
Sale of common stock  -   -   -   -   304,785   305   49,695   -   -   -   50,000 
Conversion of warrants into common stock  -   -   -   -   51,372   51   36,949   -   -   -   37,000 
Conversion of stockholder notes payable and accrued interest into common stock  -   -   -   -   673,706   674   730,752   -   -   -   731,426 
Conversion of accounts payable and accrued expenses into common stock  -   -   -   -   116,997   117   99,330   -   -   -   99,447 
Cashless exercise of warrants into common stock  -   -   -   -   2,353   2   (2)  -   -   -   - 
Issuance of stock for services  -   -   -   -   960,000   960   2,415,690   -   (2,416,650)  -   - 
Decrease in fair value of restricted stock units  -   -   -   -           (75,500)  -   75,500   -   - 
Forgiveness of stockholder compensation  -   -   -   -   -   -   175,287   -   -   -   175,287 
Amortization of deferred compensation  -   -   -   -   -   -   -   -   498,816   -   498,816 
Fair value of employee stock options  -   -   -   -   -   -   849,791   -   -   -   849,791 
Rounding of partial shares relative to reverse split      -   -   -   885   1   (1)  -   -   -   - 
Net loss  -   -   -   -   -   -   -   -   -   (2,301,885)  (2,301,885)
                                             
Balance at December 31, 2015  441,938  $442   1  $-   5,977,030  $5,977  $39,779,414  $(113,389) $(1,842,334) $(39,998,290) $(2,168,180)

Series C Convertible Preferred Stock converted to common stock $-  $4,768 
Series D Convertible Preferred Stock converted to common stock $-  $496 
Cashless Exercise of Stock Options $4,028  $- 
Cashless Exercise of Warrants $183  $- 
Common Stock and Warrants Issued for Common Stock Payable $122,478  $- 
Deemed divided distribution on issuance of common stock for conversion of Series C and Series D $-  $596,878 
Warrants issued as discount to notes payable $-  $113,586 
Conversion Preferred C - warrants into common stock $-  $6,175 
Conversion Preferred D - warrants into common stock $-  $1,986 
Conversion of related party notes payable and accrued interest into common stock $-  $273,623 
Common stock payable for conversion of related party notes payable and accrued interest $-  $122,478 
Sale of common stock - past issuances $-  $503 

The accompanying notes are an integral part toof these financial statements.

F-19

VerifyMe, Inc.

StatementsStatement of Cash Flows

For the Years Ended and 2015 and 2014

  Year  Year 
  Ended  Ended 
  December 31,  December 31, 
  2015  2014 
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $(2,301,885) $(7,918,495)
Adjustments to reconcile net loss to net cash used in        
operating activities        
Gain on conversion of debt  (332,523)  - 
Fair value of options issued in exchange for services  849,791   860,235 
Accretion of discount on notes payable  10,447   202,377 
Change in fair value of warrant liability  (2,700,917)  (5,128,204)
Change in fair value of embedded derivative liability  -   (800,000)
Fair value of stock in excess of converted notes payable and accrued interest  -   82,000 
Amortization and depreciation  94,123   82,362 
Stock and warrants issued in exchange for technology  -   5,736,089 
Amortization of deferred compensation  498,816   - 
Series B Preferred Stock issued for licensing fees  2,000,000   - 
(Increase) decrease in assets        
Accounts receivable  -   3,573 
Inventory  68,673   (63,089)
Prepaid expenses  4,770   8,388 
Increase (decrease) in liabilities        
Accounts payable and accrued expenses  330,057   4,898,080 
Deferred revenue  (16,667)  16,667 
         
Net cash used in operating activities  (1,495,315)  (2,020,017)
         
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of equipment  (2,432)  - 
Purchase of patents  (100)  - 
         
Net cash used in investing activities  (2,532)  - 
         
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from issuance of notes payable  159,542   798,000 
Repayment of notes payable  (50,000)  - 
Proceeds from sale of Series A Convertible Preferred Stock  1,278,501   - 
Proceeds from sale of common stock  50,000   - 
         
Net cash provided by financing activities  1,438,043   798,000 
         
NET INCREASE (DECREASE) IN CASH AND        
CASH EQUIVALENTS  (59,804)  (1,222,017)
         
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD  63,956   1,285,973 
         
CASH AND CASH EQUIVALENTS - END OF PERIOD $4,152  $63,956 
         
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION        
Cash paid during the year for:        
Interest $6,646  $- 
         
Income taxes $-  $- 
         
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES        
         
Fair value of common stock issued for conversion of notes payable and accrued interest $1,028,039  $506,588 
         
Fair value of warrants issued as debt discount $-  $211,576 
         
Forgiveness of related party debt $-  $25,000 
         
Cashless exercise of warrants $2  $- 
         
Series A Convertible Preferred Stock converted to common stock $633,333  $- 
         
Issuance of Series A Convertible Preferred Stock for deferred compensation $35,000  $- 
         
Issuance of Series A Convertible Preferred Stock for notes payable and accrued interest $136,813  $- 
         
Issuance of Series B Convertible Preferred Stock for accrued expenses $4,500,000  $- 
         
Conversion of warrants into Series B Convertible Preferred Stock $1,867,417  $- 
         
Conversion of warrants to common stock $37,000  $- 
         
Conversion of accounts payable and accrued expenses into common stock $99,447  $- 
         
Common stock issued for deferred compensaton $2,416,650  $- 
         
Forgiveness of stockholder compensation $175,285  $- 
         
Patent costs reclassified from prepaid expenses resulting from purchase of patents $176,316  $- 
         
Revaluation of restricted stock units between additional paid in capital and deferred        
compensation $75,500  $- 
Stockholders' Equity (Deficit)

  Series A  Series B  Series C  Series D                   
  Convertible  Convertible  Convertible  Convertible                   
  Preferred  Preferred  Preferred  Preferred  Common             
  Stock  Stock  Stock  Stock  Stock  Additional          
  Number of     Number of     Number of     Number of     Number of     Paid-In  Treasury  Accumulated    
  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Capital  Stock  Deficit  Total 
                                           
Balance at December 31, 2016  397,778   398   0.92       1,912,500   1,913   166,750   167   8,330,696   8,331   40,469,272   (113,389)  (41,644,545)  (1,277,853)

Cumulative adjustment related to change in accounting

principle (Note 1, Change in Accounting Principle)

  -   -   -   -   -   -   -   -   -   -   

11,924,665

       (11,301,203)   623,462 
Adjusted balance at January 1, 2017  397,778   398   0.92   -   1,912,500   1,913   166,750   167   8,330,696   8,331   52,393,937   (113,389)  (52,945,748)  (654,391
Conversion of Series A Convertible Preferred Stock  (73,000)  (73)  -   -   -   -   -   -   1,460,000   1,460   (1,387)  -   -   - 
Conversion of Series C Convertible Preferred Stock  -   -       -   (1,912,500)  (1,913)  -   -   4,767,858   4,768   (2,855)  -   -   - 
Conversion Preferred C - Warrants  -   -   -   -   -   -   -   -   6,175,000   6,175   (6,175)          - 
Conversion of Series D Convertible Preferred Stock  -   -   -   -   -   -   (166,750)  (167)  496,429   496   (329)  -   -   - 
Conversion Preferred D - Warrants  -   -   -   -   -   -   -   -   1,985,716   1,986   (1,986)          - 
Sale of common stock  -   -   -   -   -   -   -   -   19,451,575   19,452   1,340,798   -   -   1,360,250 
Sale of common stock - Past issuances  -   -   -   -   -   -   -   -   503,432   503   (503)          - 
Stock Based Compensation  -   -   -   -   -   -   -   -   2,050,372   2,050   137,758           139,808 
Stock issuance costs  -   -   -   -   -   -   -   -       -   (32,325)  -   -   (32,325)
Conversion of related party notes payable and accrued interest into common stock  -   -   -   -   -   -   -   -   4,402,079   4,402   601,133   -   -   605,535 
Discount on warrants issued in conjunction with related party notes payable  -   -   -   -   -   -   -   -   -   -   113,586   -   -   113,586 
Fair value of stock option  -   -   -   -   -   -   -   -   -   -   1,295,741   -   -   1,295,741 
Restricted Stock awards  -   -   -   -   -   -   -   -   2,175,000   2,175   64,650   -   -   66,825 
Deemed dividend distribution on issuance of common stock for conversion of Series C and Series D  -   -   -   -   -   -   -   -   -   -   (596,878)          (596,878)

Accretion of deemed dividend distribution on issuance

of common stock for conversion of Series C and Series D

  -   -   -   -   -   -   -   -   -   -   596,878           596,878 
Common stock and warrants issued for services  -   -   -   -   -   -   -   -   1,725,175   1,724   296,083           297,807 
Net loss  -   -   -   -   -   -   -   -   -   -   -   -   (3,385,340)  (3,385,340)
Balance at December 31, 2017  324,778   325  0.92  -  -   -  -   -  53,523,332   53,522  56,198,126   (113,389)  (56,331,088)  (192,504)
Conversion of Series A Convertible Preferred Stock  (20,000)  (20)  -   -   -   -   -   -   400,000   400   (380)  -   -   - 
Conversion of Series B Convertible Preferred Stock  -   -   (0.07)  -   -   -   -   -   599,362   599   (599)  -   -   - 
Sale of common stock  -   -   -   -   -   -   -   -   15,906,168   15,906   1,137,739   -   -   1,153,645 
Settlement Agreement  -   -   -   -   -   -   -   -   1,000,000   1,000   278,000   -   -   279,000 
Conversion of notes payable  -   -   -   -   -   -   -   -   1,749,683   1,750   120,728   -   -   122,478 
Cash Exercise of Warrants  -   -   -   -   -   -   -   -   22,432,184   22,432   2,289,573   -   -   2,312,005 
Cashless Exercise of Warrants  -   -   -   -   -   -   -   -   182,659   183   (183)  -   -   - 
Cashless Exercise of Stock Options  -   -   -   -   -   -   -   -   4,027,778   4,028   (4,028)  -   -   - 
Fair value of stock option  -   -   -   -   -   -   -   -   -   -   329,193   -   -   329,193 
Restricted Stock awards and Restricted Stock Units  -   -   -   -   -   -   -   -   2,212,500   2,213   452,677   -   -   454,890 
Common stock issued for services  -   -   -   -   -   -   -   -   169,500   170   43,950           44,120 
Net loss  -   -   -   -   -   -   -   -   -   -   -   -   (2,932,462)  (2,932,462)

Balance at December 31, 2018

  304,778   305   0.85   -   -   -   -   -   

102,203,166

   

102,203

   

60,844,796

   (113,389)  (59,263,550)  

1,570,365

 

The accompanying notes are an integral part toof these financial statements.

F-20
F-5

VerifyMe, Inc.

Table of Contents


Nature of the Business

On July 14, 2015, LaserLock Technologies, Inc. changed its name to VerifyMe, Inc., effective July 23, 2015. As used in this report, unless the context otherwise indicates, any reference to “VerifyMe,” “our Company,” “the Company,” “us,” “we” and “our” refers to VerifyMe, Inc. a Nevada corporation.

The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in New York,Rochester, New York and its common stock, par value $0.001 per share, (the “Common Stock”), is traded on the over-the-counter market and quoted on the OTC QB, organized by the OTC Markets Group, Inc., and the OTC Bulletin Board under the ticker symbol “VRME.”


OTCQB.

The Company is a technology pioneer in the anti-counterfeiting industry. This broad market encompasses counterfeiting of physical and material goods and products, as well as counterfeiting of identity in digital transactions. The Company deliversis able to deliver security solutions for identification and authentication of people, products and packaging in a variety of applications in the security field for bothphysical transactions and owns digital and physical transactions.patents which are in the same field. The products can be used to manage and issue secure credentials, including national IDs, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications.

The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalizefurther develop the Company’s current technology.

patents.

Basis of Presentation

The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.


Reverse Stock Split

Change in Accounting Principle

In July 2017, the FASB issued ASU 2017-11. Part I relates to the accounting for certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. In the case where the exception from derivative accounting does not apply, warrants must be accounted for as a liability and Changes torecorded at fair value at the date of grant and re-valued at the end of each reporting period.

The Company’s Preferred Stock

On May 26, 2015,warrants and embedded conversion feature on its preferred stock (see Notes 6 and 7) include anti-dilution provisions characterized as down round features and have previously been accounted for as liabilities, with the board of directorsfair value of the liabilities remeasured at each reporting date and the change in liabilities recorded as other non-operating income or loss. The Company (the “Board”), acting by written consenthad recorded a “Warrant liability” and “Embedded derivative liability” of $623,462, in lieuthe aggregate, and gain on the change in fair value of a special meeting, unanimously approvedwarrants and adopted: (a) a reverse stock splitembedded derivative liability of all$11,301,203, in the aggregate, in its “Accumulated deficit” as reported in its Balance Sheets for the year ended December 31, 2016 relating to the warrant liability and embedded derivative liability.

F-21

VerifyMe, Inc.

Notes to Financial Statements

The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s issued and outstanding capital stock based on a minimum 1-for-40 split, up to a maximum 1-for-100 split (the “Reverse Stock Split”), and recommended the samederivative liabilities using Level 3 inputs:

  Total
Balance, January 1, 2016 $1,802,375 
Series C embedded derivative fair value, February 2016  1,235,000 
Effect of conversion of Series C Preferred Stock on embedded derivative liability  (350,500)
Series C warrant liability fair value, February 2016  1,767,576 
Series D embedded derivative fair value, October 2016  42,521 
Series D warrant liability fair value, October 2016  181,942 
Change in fair value of derivative liabilities  (4,055,452)
Balance, December 31, 2016  623,462 
Cumulative adjustments related to change in accounting principle, January 1, 2017  (623,462)
Balance, December 31, 2017 $—   

Except for the down round features in the warrants and embedded conversion feature, the warrants and embedded conversion feature would have been classified in equity under the guidance in Subtopic 815-40 and therefore qualify for the scope exception in ASU 2017-11. As permitted, the Company elected to adopt the accounting principles prescribed by ASU 2017-11 for the year ending December 31, 2017 and has recorded a cumulative-effect adjustment stemming from a change in accounting principle in its financial statements for the year ended December 31, 2017 measured retrospectively to the beginning of 2017. The cumulative effect adjustment appears at the beginning of 2017 in the Company’s stockholdersStatement of Changes in Stockholders Deficit. The results of operations for approval, and (b) a Second Amended Certificate of Designationthe Company for Series A Preferred Stock, which amended the designations, preferences, powers and rightsyear ended December 31, 2017 reflects application of the shareschange in accounting principle from the beginning of 2017.

The following table details the impact stemming from the cumulative effect of the change in accounting principle on the Company’s Series A convertible preferred stock, par value $0.001 per share (the “Series A Preferred Stock”), which were originally set forth in that certain Amended Certificate of Designation for Series A Preferred Stock, dated December 19, 2003.

On May 28, 2015, those stockholdersBalance Sheets as of the Company holding a majoritybeginning of the issued and outstanding shares of Common Stock and Series A Preferred Stock, acting by written consent in lieu of a special meeting, voted to approve the Reverse Stock Split.
On June 11, 2015, at a duly authorized special meeting of the Board, the Board (a) finalized, adopted and approved a resolution setting the Reverse Stock Split exchange ratio to a 1-for-85 split and (b) approved and adopted a new Certificate of Designation for Series B Preferred Stock, establishing the designations, preferences, powers and rights of the shares of the Company’s Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock,” and together with the Series A Preferred Stock, the “Preferred Stock”).
On July 23, 2015,2017.

Balance Sheet Accounts Impacted by
Warrants and Embedded Derivative
Liability
 As
Previously
Reported
December
31, 2016
  Cumulative
Effect
Adjustment at
the Beginning
of 2017
  Reported after the
Effect of a Change
in Accounting
Principle at the
Beginning of 2017
 
Embedded derivative liability $228,718  $(228,718) $- 
Warrant liability  394,744   (394,744)  - 
Additional paid in capital  40,469,272   11,924,665   52,393,937 
Accumulated deficit  (41,644,545)  (11,301,203)  (52,945,748)

Because the Company completedhas retroactively applied the 1-for-85 Reverse Stock Splitchange in accounting principle discussed above to the beginning of all of its outstanding Common Stock and Preferred Stock. The total number of authorized capital stock of2017, the Company remained unchanged at its current total of 750,000,000, with 675,000,000 designated as Common Stockis no longer reporting warrant derivative gains or losses for the warrants and 75,000,000 designated as Preferred Stock. The accompanying financial statements and notes to the financial statements give retroactive effect to the Reverse Stock Split for all periods presented, unless otherwise specified.

embedded conversion feature beginning in 2017.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.


Comprehensive Income
The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220, “Comprehensive Income,” in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).

Fair Value of Financial Instruments

The Company’s financial instruments consist of accounts receivable, accounts payable and accrued expenses, warrantnotes payable, embedded derivative liability and notes payable.warrant liability. The carrying value of accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities.  The Company believes the carrying amount of its notes payable approximate fair value based on rates and other terms currently available to the Company for similar debt instruments.

F-22

VerifyMe, Inc.

Notes to Financial Statements

The Company follows FASB ASC 820, “Fair Value Measurements and Disclosures,” and applies it to all assets and liabilities that are being measured and reported on a fair value basis. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities

Level 2: Observable market basedmarket-based inputs or unobservable inputs that are corroborated by market data

Level 3: Unobservable inputs that are not corroborated by market data

The level in the fair value within which a fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.


Cash and Cash Equivalents

For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.

Concentration of Credit Risk Involving Cash and Cash Equivalents

The Company’s cash and cash equivalents are held at one financial institution. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.

Allowance for Doubtful Accounts

The Company considers allowances for doubtful accounts for estimated losses that may result from the inability of the Company’s customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, such allowances may be required.

Inventory

Inventory principally consists of penlightscanisters and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.

Property and Equipment

Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations.

Patents and Trademark

Trademarks

The current patent portfolio consistsand trademark portfolios consist of ten10 granted US patents and six1 granted European patent validated in 4 countries, 3 pending US and foreign patent applications, pending.   The Company has also purchased a trademark.1 registered US trademark, and 13 pending US and foreign trademark applications. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 2019 years.

F-23

VerifyMe, Inc.

Notes to Financial Statements

Long-Lived Assets

The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.

Deferred Financing Costs

Related Parties

Related parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Companies are also considered to be related if they are subject to common control or common significant influence. During the year ended December 31, 2018, the Company incurred $30,000 related to consulting services performed by a Director of the Board included in General and administrative on the Statement of Operations. 

Capitalized Software

Costs incurred in securing long-termconnection with the development of software related to our proprietary digital products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985 “Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market. Amortization of capitalized software development costs begins once the product is available to the market. Capitalized software development costs are amortized over the estimated life of the related product, generally three years, using the straight-line method. The Company will evaluate its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable. As of December 31, 2018, the Company capitalized $70,231. As of December 31, 2017, the Company had not capitalized any software development costs. The Company has not incurred a depreciation charge as the software was not available for use as of December 31, 2018. 

Notes Payable with detachable warrants

In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt are deferredinstrument without the warrants and amortized,of the warrants themselves at the time of issuance.  The portion allocated to the warrants has been accounted for as a chargediscount to interest expense,the notes payable, and amortized over the term of the related debt.  In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50, “Debt – Modification and Extinguishments.”

Convertible Notes Payable
Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, thenotes.

Revenue Recognition

The Company accounts for revenues according to ASC Topic 606, “Revenue from Contracts with Customers” which establishes principles for reporting information about the valuenature, amount, timing and uncertainty of revenue and cash flows arising from the beneficial conversion feature (BCF) as a debt discount, which is then accretedentity's contracts to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.

Derivative Instruments
provide goods or services to customers.

The Company evaluates its convertible debt, Preferred Stock, warrants or other contractsapplies the following five steps in order to determine if those contracts or embedded componentsthe appropriate amount of those contracts qualify as derivativesrevenue to be separately accounted for in accordance with FASB ASC 480, “Distinguish by Liabilities from Equity” (FASB ASC 480), and FASB ASC 815, “Derivatives and Hedging” (“FASB ASC 815”). The resultrecognized as it fulfills its obligations under each of this accounting treatment is thatits agreements:

·identify the contract with a customer;
·identify the performance obligations in the contract;
·determine the transaction price;
·allocate the transaction price to performance obligations in the contract; and
·recognize revenue as the performance obligation is satisfied.

F-24

VerifyMe, Inc.

Notes to Financial Statements

During the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified as liabilities at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Revenue Recognition
In accordance with FASB ASC 605, “Revenue Recognition,” the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer thatyear ended December 31, 2018, the Company’s product has been used inrevenues were primarily made up of revenue generated from printing labels with the customer’s production process.

Company’s technology.

Income Taxes

The Company follows FASB ASC 740, “Income Taxes,” when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 20122014 through 20152017 remain subject to examination by major tax jurisdictions.


Stock-based Payments

The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.

The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable.

All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity basedequity-based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity basedequity-based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity basedequity-based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity basedequity-based payments are fully vested or the service completed.


Advertising Costs

Advertising costs are expensed as incurred. Advertising costs were approximately $458$3,987 and $62,835$550 for the years ended December 31, 20152018 and 20142017 and are included in salesSales and marketing expenses.

Marketing on the Statement of Operations.

Research and Development Costs

In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the years ended December 31, 20152018 and 20142017 were $2,529,833$187,655 and $10,590,271.

$128,044.

Basic and Diluted Net Income per Share of Common Stock

The Company follows FASB ASC 260, “Earnings Per Share,” when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share.  Because the Company reported a net loss for each of the years presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same.

F-25

VerifyMe, Inc.

Notes to Financial Statements

For the year ended December 31, 2018 and 2017, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented.

For the year ended December 31, 2018 there were approximately 54,173,000 anti-dilutive shares consisting of 22,241,000 relating to warrants, 18,614,000 relating to options and 13,318,000 relating to preferred share agreements.  For the year ended December 31, 2017 there were approximately 68,612,000 anti-dilutive shares consisting of 32,292,000 relating to warrants, 22,013,000 relating to options and 14,307,000 relating to preferred share agreements. 

Segment Information

The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with FASB ASC 280, “Segment Reporting” (“FASB ASC 280”), the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by FASB ASC 280 can be found in the financial statements.


Recently Adopted Accounting Pronouncements

As

In July 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-11,“ Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). Part I relates to the accounting or certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down Round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified as equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted and may be applied on a retrospective basis, including in an interim period. The Company early adopted ASU 2017-11 during the interim period ended December 31, 20152017 and forretrospectively applied the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.

Recently Issuedadoption from January 1, 2017 (see Note 1, Change in Accounting Pronouncements Not Yet Adopted
Principle).

In August 2014,May 2017, the FASB issued ASU 2014-15, Presentation2017-09, “Compensation-Stock Compensation” (Topic 718): Scope of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.Modification Accounting. The amendments in this Update provide guidance about management’s responsibilityon determining which changes to evaluate whether therethe terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718 Compensation-Stock Compensation. An entity should account for the effects of a modification unless all the following are conditionsmet: 1. The fair value (or calculated value or events, considered inintrinsic value, if such an alternative measurement method is used) of the aggregate, that raise substantial doubt aboutmodified award is the entity’s abilitysame as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probablevaluation technique that the entity will be unableuses to meet its obligations as they become due within one yearvalue the award, the entity is not required to estimate the value immediately before and after the date thatmodification. 2. The vesting conditions of the financial statementsmodified award are issued.the same as the vesting conditions of the original award immediately before the original award is modified. 3. The amendments in this Update areclassification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The ASU is effective for the annual period ending after December 15, 2016, andall entities for annual periods, and interim periods thereafter. Early application is permitted. The Company is evaluating the effect of the adoption of this standard.

In November 2014, the FASB issued ASU No. 2014-16, Derivatives and Hedging (Topic 815), Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. The amendments in this Update apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share.
For hybrid financial instruments issued in the form of a share, an entity (an issuer or an investor) should determine the nature of the host contract by considering all stated and implied substantive terms and features of the hybrid financial instrument, weighing each term and feature on the basis of relevant facts and circumstances. That is, an entity should determine the nature of the host contract by considering the economic characteristics and risks of the entire hybrid financial instrument, including the embedded derivative feature that is being evaluated for separate accounting from the host contract.
The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The Company does not anticipate the adoption of this standard to have a material effect on the financial statements.

The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments shall be reflected as of the beginning of the fiscal year that includes that interim period.

In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, the amendments in this Update are effective for financial statements issued for annual periods, beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company does not anticipate the adoption of this standard to have a material effect on the financial statements.

NOTE 2 – GOING CONCERN
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.2017. The Company has incurred significantadopted this guidance effective January 1, 2018, as required.

F-26

VerifyMe, Inc.

Notes to Financial Statements

Going Concern

The Company has suffered recurring losses from operations and experienced negative cash flowflows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

In February 2016, the Company raised net proceeds of $1,217,500 through the sales of Series Preferred C Stock.  Even with the infusion of capital, the Company does not believe that its existing cash resources will be sufficient to sustain operations during the next twelve months.  The Company currently needs to generate revenue in order to sustain its operations. In the event that the Company cannot generate sufficient revenue to sustain itscontinue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to reduce expenses continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or obtain financingpreferred stock, through the salepossible exercise of outstanding options and warrants, through debt financing and/or equitythrough future public offering of our securities. The issuance of additional equity would result in dilution to existing stockholders. If the Company is unable to obtain additional funds when they are needed or if such fundsHowever, management cannot be obtained on terms acceptable to the Company, the Company may be unable to execute upon the business plan or pay costs and expenses as they are incurred, which could have a material, adverse effect on the business, financial condition and results of operations.
If sufficient revenues are not generated to sustain operations or additional funding cannot be obtained in the short term, the Company will need to reduce monthly expenditures to a level that will enable the Company to continue until such funds can be obtained.
Successful completion of the Company’s development program, and the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company’s cost structure. However, there can be noprovide any assurances that the Company will be ablesuccessful in accomplishing any of its plans. The Company’s existing cash resources are sufficient to securesustain the Company’s operations during the next six months, however the Company may need to raise additional equity investmentfunds in the future in order to expand our business or achieve an adequateif sales level.
do not meet our internal budget.

NOTE 32 – PROPERTY AND EQUIPMENT

Equipment consists of the following:

  December 31,  December 31, 
  2015  2014 
Furniture and Fixtures $219,871  $219,871 
Equipment  18,588   16,155 
   238,459   236,026 
Less:  Accumulated depreciation  230,621   161,205 
  $7,838  $74,821 


  Year ended December 31, 
  2018  2017 
Software, furniture and fixtures $200,000  $200,000 
Equipment  3,223   3,223 
Total  203,223   203,223 
Less: accumulated depreciation  (203,223)  (203,223)
Balance $-  $- 

Depreciation of property and equipment was $69,415$0 and $69,253, respectively,$0 for the years ended December 31, 20152018 and 2014.

2017. 

NOTE 43 – PATENTS AND TRADEMARK

The current patent portfolio consists of ten granted patents and six applications pending. Accordingly, costs associated with the registration and legal defense of these patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 20 years. The trademark is also being amortized on a straight-line basis over its estimated useful life of 20 years. TRADEMARKS

During the years ended December 31, 20152018 and 2014,2017, the Company capitalized $100 of$38,505 and $2,650, respectively, for patent costs and trademarks. Amortization and impairment expense for patents and trademarks was $16,813$20,963 and $13,109$43,095 for the years ended December 31, 20152018 and 2014.

On March 30, 2015, the Company was advised by the United States Patent and Trademark Office (“USPTO”) that its petition for an unintentional delayed payment for an unpaid maintenance fee to reinstate its patent was granted by the USPTO. The patent, for a counterfeiting ink detection system, was granted on November 2, 2004.

2017.

NOTE 54 – INCOME TAXES

The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2018 and 2017 is as follows (in thousands):

  Year Ended December 31 
US 2018  2017 
       
Income before income taxes $(2,932) $(3,385)
Taxes under statutory US tax rates  (616)  (1,202)
Increase (decrease) in taxes resulting from:      
Increase (decrease) in valuation allowance  (92)  1,346 
Non-deductible changes in derivative liability and share based transactions  -   1 
All other  857   - 
State taxes  (149)  (145)
Income tax expense $-  $- 

The increase in the Company's net increase in the valuation allowance was caused by continued net operating losses from ongoing operations.

F-27
The Company follows FASB ASC 740-10-10 whereby an entity recognizes

VerifyMe, Inc.

Notes to Financial Statements

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities for future tax consequences or events that have been previously recognized inconsist of the Company’s financial statements or tax returns. The measurementfollowing:

  December 31, 
  2018  2017 
US      
Net operating loss $8,316  $7,035 
Share based compensation  447   1,800 
Reserves and accruals  (21)  - 
Gross deferred tax assets  8,742   8,835 
         
Less valuation allowance  (8,742)  (8,835)
Total deferred tax assets  -   - 
         
Deferred tax liabilities:        
Total deferred tax liabilities  -   - 
Net deferred tax assets / (liabilities) $-  $- 

As of deferred tax assets and liabilities is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not anticipated.

At December 31, 20152018, the Company has ahad federal and state net operating loss (“NOL”)carry forwards of $36.9 million and $10.6 million, respectively that approximates $30.0 million. Consequently, the Company may have NOL carryforwards available for federalbe offset against future taxable income, tax purposes,subject to limitation under IRC Section 382, which would begin to expire in 2019.  DueNo tax benefit has been reported in the December 31, 2018 or 2017 financial statements due to changes in ownership, a portionthe uncertainty surrounding the realizability of the NOL carryforwardbenefit, based on a more likely than not criteria and in consideration of available positive and negative evidence.

Utilization of the net operating losses (NOL) carryforwards may be subject to certaina substantial annual limitation due to ownership change limitations imposed underthat may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code. Deferred tax assets would arise fromCode (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the recognitionamount of anticipated utilization of these net operating lossesNOL carryforwards that can be utilized annually to offset future taxable income.

The income tax benefit (provision) consists In general, an “ownership change” as defined by Section 382 of the following:
  Year Ended  Year Ended 
  December 31,  December 31, 
  2015  2014 
       
       
Current $(1,653,000) $(5,505,000)
Deferred  (395,000)  (372,000)
Change in valuation allowance  2,048,000   5,877,000 
         
  $-  $- 
The following isCode results from a reconciliationtransaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the tax derivedoutstanding stock of a company by applyingcertain stockholders. At the U.S. Federal Statutory Ratetime of 35%closing the books, the Company had not yet completed a study to determine the earnings before income taxes and comparing that to the recorded tax provisions:

  2015  2014 
  Amount  %  Amount  % 
U.S federal income tax benefit at federal statutory rate $(806,000)  (36) $(2,771,000)  (35)
State tax, net of federal tax effect  (135,000)  (6)  (463,000)  (6)
Non-deductible changes in derivative liability and share based transactions  (1,107,000)  (53)  (2,639,000)  (33)
Other  -   -   (4,000)  - 
Change in valuation allowance  2,048,000   95   5,877,000   74 
                 
  $-   -  $-   - 

The primary componentsextent of the Company’s December 31, 2015 and 2014 deferred tax assets, liabilities and related valuation allowance are as follows:
  December 31,  December 31, 
  2015  2014 
       
Deferred tax asset for NOL carryforwards $12,303,000  $10,649,000 
Deferred tax liability for intangibles  (165,000)  (165,000)
Share based compensation  4,589,000   4,205,000 
Non deductible accrued expenses  10,000   - 
Valuation allowance  (16,737,000)  (14,689,000)
         
  $-  $- 
Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits.
limitation.

The Company follows FASB ASC 740-10, which provides guidance forapplied the "more-likely-than-not" recognition and measurement of certainthreshold to all tax positions taken or expected to be taken in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information.

The Company’s policy is to record interest and penalties associated withreturn, which resulted in no unrecognized tax benefits as additional income taxes in the consolidated statement of operations. As of December 31, 20152018 and 2014, theDecember 31, 2017, respectively.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no unrecognized tax benefits. There were no changesaccrual for interest and penalties on the balance sheets and has not recognized interest and/or penalties in the Company’s unrecognized tax benefits duringstatements of operations and comprehensive loss for the years ended December 31, 20152018 and 2014. 2017.

The Company did not recognize any interest or penalties during 2015is subject to taxation in the United States and 2014 relatedvarious state jurisdictions. The Company’s tax years from inception are subject to unrecognizedexamination by the United States and state taxing authorities due to the carryforward of unutilized NOLs.

On December 22, 2017, the United States enacted significant changes to the U.S. tax benefits.


NOTE 6 – RECAPITALIZATION TRANSACTION
On or about June 12, 2015,law following the Company entered into definitive agreementspassage and signing of H.R.1, “An Act to restructure the overall capitalizationProvide for Reconciliation Pursuant to Titles II and V of the CompanyConcurrent Resolution on the Budget for Fiscal Year 2018” (the “Recapitalization Transaction”“Tax Act”) (previously known as “The Tax Cuts and Jobs Act”).  To effectuateThe Tax Act significantly revised the Recapitalization Transaction,U.S. corporate income tax regime by, among other things, lowering the Company entered into a Master Acquisition Agreement (the “Master Agreement”) with OPC Partners LLC, a Delaware limited liability company (“OPC”), VerifyMe Inc., a Texas corporation (“VFM”), Zaah Technologies, Inc., a Delaware corporation (“Zaah”), and an additional private investor (the “Private Investor”).
Pursuantcorporate tax rate from 35% to 21%.  The Tax Act reduced the Master Agreement, the Company entered into several other material definitive agreements (collectively, the “Transaction Documents”) requiredU.S. corporate income tax rate reduction to consummate the Recapitalization Transaction. A brief summary of the Transaction Documents is included below. Each of the Transaction Documents was entered21% becomes effective as of June 12, 2015, upon the closing of the Recapitalization Transaction.
Note Conversion Agreement.January 1, 2018. The Company entered into various Note Conversion Agreements with various holders of promissory notes executed by the Company (the “Noteholders”), pursuant to which the Noteholders converted $731,426 of outstanding notesre-measured its deferred tax assets and accrued interest (net of gain on conversion of $297,370) into 57,265,030 shares (pre Reverse Stock Split) of restricted non-trading Common Stock of the Company at a conversion rate of one (1) share of Common Stock per $0.018 of outstanding principal and interest.
Warrant Conversion Agreement. The Company entered into various Warrant Conversion Agreements with various holders of warrants for the Company’s Common Stock (the “Warrantholders”), pursuant to which the Warrantholders converted 3,700,000 outstanding Common Stock warrants into 3,700,000 shares (pre Reverse Stock Split) of restricted non-trading Common Stock of the Company at a conversion ratio 1:1.
Preferred Stock Conversion Agreement. The Company and VFM entered into a Preferred Stock Conversion Agreement, pursuant to which VFM converted 21,111,111 shares (pre Reverse Stock Split) of Series A Preferred Stock of the Company that it currently owns into shares of Common Stock of the Company on a 1:1 basis (pre Reverse Stock Split).
Patent and Technology License Termination Agreement. Pursuant to a Patent and Technology License Termination Agreement, the Company and VFM terminated that certain Patent and Technology License Agreement, datedliabilities as of December 31, 2012, by2017, applying the reduced corporate income tax rate and between the Company and VFM (the “License”), and VFM agreed to receive eighty five (85) shares (pre Reverse Stock Split) of Series B Preferred Stock in complete satisfaction of $4,500,000 in past due license payments and $2,000,000 exclusivity payments owed by the Company under the License.  Asrecorded a result of the Patent Purchase Agreement explained below, $176,316, net of amortization of $23,684, of prepaid expenses relatedprovisional decrease to the patents were reclassifieddeferred tax assets and liabilities of  $6.2 million, with a corresponding adjustment to patent expense.the valuation allowance.

F-28
Termination of Registration Rights. Pursuant

VerifyMe, Inc.

Notes to a Registration Rights Termination Agreement, the Company and VFM have terminated that certain Registration Rights Agreement, datedFinancial Statements

There are no taxes payable as of December 31, 2012, by and between the Company and VFM.

Termination of Technology and Services Agreement. Pursuant to a Technology and Services Agreement Termination Agreement, the Company and VFM terminated that certain Technology and Services Agreement, dated as of2018 or December 31, 2012, by and between the Company and VFM.
Termination of Investment Agreement. Pursuant to an Investment Agreement Termination Agreement, the Company and VFM terminated that certain Investment Agreement, dated as of December 31, 2012, by and between the Company and VFM.
Patent Purchase Agreement. The Company and VFM entered into and consummated a Patent Purchase Agreement, transferring and assigning over to the Company all of VFM’s rights, title and interest into certain U.S. patents and pending U.S. patent applications.
Termination of Zaah Technology and Services Agreement. Pursuant to a Technology and Services Agreement Termination Agreement, the Company and Zaah terminated that certain Technology and Services Agreement, dated as of December 31, 2012, by and between the Company and Zaah.
Series A Preferred Stock Subscription Agreement. The Company entered into a Subscription Agreement with OPC, pursuant to which the Company issued 37,564,767 shares (pre Reverse Stock Split) of Series A Preferred Stock to OPC for a cash investment $1,278,501, plus the conversion of deferred compensation, notes payable and accrued interest amounting to $171,813, into the Company by OPC.
Common Stock Subscription Agreement. The Company entered into a Subscription Agreement with the Private Investor, pursuant to which the Company issued 25,906,736 shares (pre Reverse Stock Split) of restricted non-trading Common Stock to the Private Investor for a cash investment of $50,000 into the Company by the Private Investor.
Series B Preferred Stock Subscription Agreement. In connection with the termination of the License with VFM, the Company entered into a Subscription Agreement with VFM, pursuant to which to the Company issued 85 shares (pre Reverse Stock Split) of Series B Preferred Stock to VFM.
The foregoing description of the Master Agreement and the related Transaction Documents is a summary, and does not purport to be a complete description of the Master Agreement and the related Transaction Documents, and is qualified in its entirety by reference to the Master Agreement and the related Transaction Documents, copies of which are filed as Exhibits 10.1, 10.2 and 10.3 to the Company’s Report on Form 8-K, filed with the SEC on June 18, 2015.

2017.

NOTE 7 – SENIOR SECURED CONVERTIBLE5– NOTES PAYABLE – RELATED PARTIES

In February 2006, the Company commenced a private placement of up to $800,000 principal amount of 10% senior secured convertible promissory notes due twelve months from the date of issue to certain Company shareholders and other accredited investors. As of December 31, 2006, the Company completed this private placement by selling all notes payable totaling $800,000. The notes are secured by a first priority lien on all of the tangible and intangible personal property of the Company. In May 2007, the due date of these notes was extended to August 2008 and the interest rate increased to 12% per annum during the extension period. In June 2011, the interest rate on all of the notes was reset to 10% and $596,500 of the notes and accrued interest was extended until September 15, 2015. During the fourth quarter of 2012 the remaining $178,749 of unextended notes and the associated accrued interest were extended to September 30, 2015. In June 2013, $225,000 of these notes payable plus accrued interest of $181,125 were converted into 7.4 million shares of the Company’s common stock, which was valued at $1,628,000. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
During the fourth quarter of 2013, $220,000 of senior convertible notes plus accrued interest of $395,000, were converted into 7,900,000 shares of common stock. Since this transaction was with related parties, the conversion was treated as a capital transaction in accordance with FASB ASC 470-50-40-3.
During the second quarter of 2014, $216,249 of principal of the Company’s outstanding senior convertible notes held by a significant shareholder of the Company, plus accrued interest of $208,339, were converted into 8,448,519 shares of common stock. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest, $82,000, was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
On June 12, 2015, as part of the Recapitalization Transaction (see Note 6), the Company restructured the Senior Secured Convertible Notes Payable – Related Parties. As a result the principal balance of $114,000 and accrued interest of $118,775 was converted into 154,184 shares (13,105,662 shares pre Reverse Stock Split at $0.018 per share) of the Company’s Common Stock. This resulted in a gain of $103,456. Of this amount, $17,967 was related to a stockholder and recorded as additional paid in capital, with the remaining $85,489 being recorded as a gain on extinguishment of debt.
NOTE 8 – NOTES PAYABLE

Notes payable consists of the following as of December 31:

  December 31,  December 31, 
  2015  2014 
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015  -  $114,000 
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)  50,000   50,000 
Notes payable; interest at 8% per annum, principal and accrued interest due at December 1, 2014 (past due)  -   650,000 
Notes payable; interest at 5% and 8% per annum, principal and accrued interest due at April 2015  -   123,000 
Less: Debt discount  -   (10,447)
   50,000   926,553 
Less: Current portion  50,000   926,553 
  $-  $- 

  Year ended December 31, 
  2018  2017 
Series A notes payable; interest at 8% per annum; principal and
accrued interest due at maturity in October 2011 (past due)
 $-  $50,000 
Less: current portion  -   (50,000)
Balance $-  $- 

At December 31, 20152018 and 20142017 accrued interest on notes payable was $23,667 and$155,992.

The warrant liabilities in this section were valued using the Black-Scholes option pricing model, with the following assumptions: no dividend yield, expected volatility of 173.7% to 180.7%, risk free interest rate of 1.75%$0 and expected lives of four to five years.
$33,667.

On June 10, 2014,October 28, 2009 the Company issued aan unsecured note payable for $250,000, which included fully vested warrants to purchase 1,000,000 shares pre Reverse Stock Split of Common Stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at $39,650 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of five years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, “Recognition” (“FASB 835-30-25”) and was accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $34,222 was accreted through interest expense.$50,000. The note and accrued interest at 8% per annum was originallywere due in full in October 2011.  The holder has never demanded payment. Since the note matured on December 11, 2014, butSeptember 30, 2011, the holder cannot commence an action to enforce payment of the note as the statute of limitations for the note expired on September 30, 2017. Applying guidance from ASC Topic 405-20, liabilities should be derecognized only when the obligor is legally released from the obligation, which occurred for the Company received approval to extendupon expiration of the maturity until December 31, 2014.statute of limitations. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability was re-valued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the faircarrying value of the warrant liability was $8,113.

As a resultnote payable of the Recapitalization Transaction, the note’s principal balance of $250,000$50,000 and accrued interest of $20,263$33,667 was converted into 176,471 shares (15,000,000 shares pre Reverse Stock Split at $0.018) of Common Stock. This resultedderecognized in a gain of $120,117,the year ended December 31, 2018 and because this individual is a stockholder was recorded as additional paid in capital.
Gain on derecognition of note payable and accrued interest included on the Statement of Operations.

On August 5, 2014,January 24, 2017 and January 31, 2017, the Company issued notes payable for $100,000, which included fully vestedto a director of the board in the amount of $20,000, in addition to warrants to purchase 600,0001,000,000 shares (pre Reverse Stock Split) of Common Stockthe Company’s common stock at an exercise price of $0.05$0.40 per share expiring inand a term of five years. The notes bear interest at the rate of 10% per annum and are due on June 30, 2017. In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance.  The warrants were valued at $29,725$15,896 fair value, using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of five years.warrants.  The relative fair value of the warrants was $22,914 and was recordedwarrant values were treated as a discount to the notesvalue of the note payable in accordance with FASB ASC 835-30-25, Recognition and waswere accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $22,914 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants were subject to anti-dilutive adjustments and were therefore  classified as a liability in accordance with FASB ASC 815. The warrant liability was re-valued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the fair value of the warrant liability was $5,151.

As a result of the Recapitalization Transaction, the principal balance of $50,000 and accrued interest of $3,414 was converted into 34,898 shares (2,966,210 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $23,740, which was recorded as a gain on the extinguishment of debt. The remaining $50,000 was paid in full, plus accrued interest in September 2015. The 3,529 warrants (300,000 warrants pre Reverse Stock Split) to purchase shares of Common Stock associated with the $50,000 note payable remain outstanding and must be re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2015, the warrants were valued at $7,902.

On August 12, 2014,February 13, 2017, the Company issued a note payable for $50,000, which included fully vested warrantsto a director of the board in the amount of $100,000 in addition to a warrant to purchase 300,0005,000,000 shares (pre Reverse Stock Split) of Common Stockthe Company’s common stock at an exercise price of $0.05$0.40 per share expiring inand a term of five years. The notes bear no interest and are due on June 30, 2017. In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance.  The warrants were valued at $26,817 using Black-Scholes option pricing model to calculate the grant-date$76,390 fair value, of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of five years. The relative fair value of the warrants was $17,455 and was recorded as a discount to the note payable in accordance with FASB ASC 835-30-25, and was accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $17,455 was accreted through interest expense.

The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants were subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability was re-valued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the fair value of the warrant liability was $2,575.
As a result of the Recapitalization Transaction, the principal balance of $50,000 and accrued interest of $3,370 was converted into 34,843 shares (2,961,644 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $23,720, which was recorded as a gain on the extinguishment of debt.

On August 14, 2014, the Company issued a note payable for $100,000, which included fully vested warrants to purchase 600,000 shares pre Reverse Stock Split of Common Stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $47,676 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of five years. The relative fair value of the warrants was $32,274 and was recorded as a discount to the note payable in accordance with FASB ASC 835-30-25 and was accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $32,274 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants were subject to anti-dilutive adjustments and were therefore classified as a liability in accordance with FASB ASC 815. The warrant liability was re-valued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the fair value of the warrant liability was $5,153.
As a result of the Recapitalization Transaction, the principal balance of $100,000 and accrued interest of $6,697 was converted into 69,657 shares (5,920,852 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $47,421, which was recorded as a gain on the extinguishment of debt.
On September 8, 2014, the Company issued notes payable for $150,000, which included fully vested warrants to purchase 900,000 shares (pre Reverse Stock Split) of Common Stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $62,544 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of five years. The relative fair value of the warrants was $44,140 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25 and was accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $44,140 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. The warrants were subject to anti-dilutive adjustments and were therefore classified as a liability in accordance with FASB ASC 815. The warrant liability was re-valued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the fair value of the warrant liability was $7,725.
As a result of the Recapitalization Transaction, the principal balance of $150,000 and accrued interest of $9,222 was converted into 103,991 shares (8,839,269 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $70,766, which was recorded as a gain on the extinguishment of debt.
On December 5, 2014, the Company issued a note payable for $23,000 to a stockholder, which bears interest at 5.0% and was due on April 5, 2015. As a result of the Recapitalization Transaction (see Note 6), the principal balance of $23,000 and accrued interest of $609 was converted into 15,418 shares (1,310,510 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $10,493 and because this entity is a stockholder was recorded as additional paid in capital.
On December 31, 2014, the Company issued a note payable for $100,000, which included fully vested warrants to purchase 600,000 shares (pre Reverse Stock Split) of Common Stock at an exercise price of $0.05 per share expiring in five years. The warrants were valued at $11,812 using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 229.0%, risk free interest rate of 1.68% and expected life of five years.warrants.  The relative fair value of the warrants was $10,563 and was recordedwarrant values were treated as a discount to the notesvalue of the note payable in accordance with FASB ASC 835-30-25, Recognition and waswere accreted over the term of the note payable for financial statement purposes. For the three months ended

 On March 31, 2015, the final $10,447 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on April 1, 2015. The warrants were subject to anti-dilution adjustments and were therefore classified as a liability in accordance with FASB ASC 815. The warrant liability was revalued at each reporting period with the change in fair value recorded through earnings. As of June 12, 2015, the date of conversion in conjunction with the Recapitalization Transaction (see Note 6), the fair value of the warrant liability was $5,226.

As a result of the Recapitalization Transaction, the principal balance of $100,000 and accrued interest of $3,689 was converted into 67,637 shares (5,749,163 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $46,084, which was recorded as a gain on the extinguishment of debt.
On February 10, 2015,28, 2017, the Company issued a note payable for $25,000, bearing interest at 5.0% to an accredited investor anda director of the Company. As a result of the recapitalization transaction (see Note 6), the principal balance of $25,000 and accrued interest of $417 was converted into 16,608 shares (1,411,720 shares pre Reverse Stock Split at $0.018) of Common Stock. This resulted in a gain of $11,296 and because this entity is a stockholder was recorded as additional paid in capital.
The conversion of the notes above on June 12, 2015 was treated as an extinguishment of debt. In accordance with FASB ASC 470-50, the difference between the cash acquisition price of the debt and its net carrying amount shall be recognized currently in income in the period of extinguishment as losses or gains. Similar transactions between stockholders was recognized as additional paid in capital.
On March 27, 2015, the Company issued a note payable for $111,102, bearing interest at 8.0% to an accredited investor.
On April 30, 2015, the Company issued a note payable for $4,887, bearing interest at 8.0% to an accredited investor.
On May 15, 2015, the Company issued a note payable for $4,480, bearing interest at 8.0% to an accredited investor.
On May 21, 2015, the Company issued a note payable for $14,074, bearing interest at 8.0% to an accredited investor.
As a result of the Recapitalization Transaction (see Note 6), the principal balance of the above four notes of $134,542 and accrued interest of $2,271 was converted into 41,603 shares (3,536,254 shares pre Reverse Stock Split at $0.0386) of the Company’s Series A Preferred stock as part of the $1,450,000 cash investment.
On June 12, 2015, the conversion of the four notes issued from March 27, 2015 to May 21, 2015, was treated as a troubled debt restructuring in accordance with FASB ASC 470-60-15, “Debt – Troubled Debt Restructurings by Debtors.”
A debtor that issues or otherwise grants an equity interest to a creditor to settle fully a payable, shall account for the equity interest at its fair value. The difference between the fair value of the equity interest granted and the carrying amount of the payable settled was recognized as a gain on restructuring payables.

NOTE 9 – WARRANT LIABILITY
On December 31, 2012, the Company entered into an Investment Agreement, a Technology and Service Agreement, a Patent and Technology License Agreement and an Asset Purchase Agreement with VFM and on the same date entered into a Technology and Service Agreement with Zaah (collectively with the VFM agreements, the “Agreements”). Contemplated by those Agreements were warrant issuances by the Company for the purchase of Common Stock.
Warrants exercisable for 627,451 shares (53,333,333 shares pre Reverse Stock Split) of Common Stock associated with these Agreements are subject to anti-dilution adjustments outlined in the Agreements. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $2.4 million at December 31, 2012. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2015 and 2014, the fair value of the warrant liability was $1,020,632 and $787,544.
On January 1, 2014, the Company issued warrants to purchase 74,697 shares (6,349,245 pre Reverse Stock Split) of Common Stock as consideration for technology received from VFM under to the Patent and Technology License Agreement dated December 31, 2012. The warrants are exercisable at $0.10 per share. The warrants are subject to anti-dilution adjustments outlined in the Agreement. In accordance with FASB ASC 815, the warrants were classified as a liability with an initial fair value of $444,000, which was immediately expensed as research and development costs. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2015 and 2014, the fair value of the warrant liability was $147,524 and $149,090.
The Company made the payment of warrants to VFM on a good faith basis, based on the assumption that the technology conveyed to the Company would be patentable and licensable. The Company had not reached a conclusion at that time that the technology would be patentable and licensable.
As of June 12, 2015, the Company concluded that the technology received from VFM is patentable and licensable, and that the Company was required to make, on January 1, 2015, an additional payment pursuant to Patent and Technology Agreementboard in the amount of $4,500,000,$25,000 in addition to be paid by issuing (i) a number of shares of Common Stock equal to (x) $4,500,000 divided by (y) a price which equals a 10% discount to the market price at the time of issuance and (ii) warrants to purchase an equal number of shares of Common Stock exercisable at a price of $0.10 per share. Based upon the share price of $0.04 per share, this would result in the issuance of approximately an additional 125 million shares of Common Stock and warrants to purchase an additional 125 million shares. The $4,500,000 was accrued at December 31, 2014. The number of warrants to be issued based on a stock price of $0.02 at December 31, 2014 was 250 million warrants. The warrants were valued at $4,892,089 using the Black-Scholes pricing model to calculate the grant-date fair value of the warrants with the following assumptions: no dividend yield, expected volatility of 229.1%, risk free interest rate of 1.65% and expected life of five years.
In conjunction with the Recapitalization Transaction (see Note 6), the Company agreed that an additional $2,000,000 in exclusivity licensing fees was required to be paid and converted the $6,500,000 into shares of Series B Preferred Stock. In addition, the fair value of the associated warrants was $1,867,417 as of June 12, 2015 and was recorded as additional paid in capital on conversion.
The warrants associated with the notes payable (see Note 6) were revalued at June 12, 2015, based on the cashless conversion modification. The total fair value of those warrants was $37,000 and was recorded as additional paid in capital on conversion.
NOTE 10 – CONVERTIBLE PREFERRED STOCK
Subscription Agreement
The Company entered into a Subscription Agreement with VerifyMe on January 31, 2013 (the “Subscription Agreement”). Under the terms of the Subscription Agreement, VerifyMe subscribed to purchase 33,333,333 shares of the Company’s Series A preferred stock (the “Preferred Stock”) and a warrant to purchase 33,333,3331,250,000 shares of the Company’s common stock at an exercise price of $0.12$0.40 per share for $1 million.
At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all,and a term of the capital stock of the Companyfive years. The notes bear no interest and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preferenceare due on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share. This right has not been exercised.
June 30, 2017. In accordance with FASB ASC 480470-20, “Debt with Conversion and 815,Other Options,” the Preferred Stock hasproceeds of notes payable with detachable stock purchase warrants have been classified as permanent equityallocated between the two based on the relative fair values of the debt instrument without the warrants and wasof the warrants themselves at the time of issuance.  The warrants were valued at $1 million at January 31, 2013.
The conversion feature$21,300 fair value, using the Black-Scholes option pricing model to calculate the grant-date fair value of the Preferred Stock is an embedded derivative, which is classifiedwarrants.  The warrant values were treated as a liabilitydiscount to the value of the note payable in accordance with FASB ASC 815835-30-25, Recognition and was valuedwere accreted over the term of the note payable for financial statement purposes. 

F-29

VerifyMe, Inc.

Notes to Financial Statements

On April 13, 2017, the Company issued notes payable to a director of the board in the principal amount of $10,000 in exchange for a loan bearing no interest maturing June 30, 2017.

On April 26, 2017, the Company issued a secured promissory note (the “Note”) to a relative of director of the board in the principal amount of $30,000 in exchange for a loan bearing 10% interest maturing October 31, 2017. The Note is secured by a first lien on all assets of the Company in accordance with FASB ASC 470 as a beneficialsecurity agreement entered into in connection with the Note. In the event the Company completes a financing of at least $750,000 prior to maturity of the Note, the principal of the Note will automatically convert into a number of shares of common stock of the Company equivalent to an investment of $60,000 under the terms of such financing. In the event of such a conversion featureor a voluntary prepayment by the Company, the Company will also pay six months of interest payments on the $60,000 principal of the Note.

In May 2017, the Company issued notes payable to a director of the board in the principal amount of $60,000 in exchange for a loan bearing no interest maturing June 30, 2017.

In June 2017, the Company issued notes payable to a director of the board in the principal amount of $36,000 in exchange for a loan bearing no annual interest maturing June 30, 2017.

On June 30, 2017, all of these notes payable (including the Note) amounting to $360,000 and converting at $390,000 plus accrued interest of $6,101, except for the $50,000 note payable from 2009, were converted into 6,151,762 shares of the Company’s common stock and warrants to purchase 6,151,762 shares of the Company’s common stock at an exercise price of $0.15, with a term of five years.  As of December 31, 2017, from the 6,151,762 shares of common stock and 6,151,762 warrants to purchase shares of the Company, 4,402,079 shares of common stock and 4,402,079 shares of warrants had been issued to convert $270,000 principal (including the Note) and $3,623 accrued interest.

The fair value of $0the warrants issued in connection with the settlement of the notes payable were valued at June 12, 2015 and $800,000 at$605,535 resulting in a Loss on settlement of related party notes payable of $331,912 included in the Statement of Operations.  An increase of $30,000 in the Note principal upon conversion was included in Interest expenses in the Statement of Operations.

As of December 31, 2014. This2017, 1,749,683 shares of common stock and 1,749,683 of warrants issuable upon conversion for $120,000 principal and $2,478 accrued interest had not yet been issued and as such the amount has been recorded as Common Stock payable included on the Balance Sheets. During the year ended December 31, 2018, those shares of common stock and warrants were issued and delivered.

Pursuant to ASC 470-50- 40 Modifications and Extinguishments, the Company assessed the nature of the transaction and based on its assessment concluded it is a capital transaction in essence, and as such accounted for it through Additional Paid-In Capital with no gain or loss recognized in the Income Statement during the period.


Interest expense including accretion of debt discount for the years ended December 31, 2018 and 2017 was classified as an embedded derivative liability$0 and a discount to Preferred Stock. Because the$218,316.

NOTE 6 – CONVERTIBLE PREFERRED STOCK

The Company has outstanding Series A Preferred Stock can be converted at any time, the full amount of the original fair value was accreted(the “Series A”) and classified as a reduction to the discount onSeries B Preferred Stock (the “Series B”). As of December 31, 2018, there were 37,564,767 authorized and a deemed dividend distribution in the full amount of $1 million, in 2013.

On August 5, 2013, 12,222,222304,778 outstanding shares (pre Reverse Stock Split) of Series A and 85 authorized and 0.85 outstanding shares of Series B. Each share of Series A and B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and B have beneficial ownership limitations.

Series A Convertible Preferred Stock

During the year ended December 31, 2017, 73,000 shares of Series A Convertible Preferred Stock were converted into 12,222,2221,460,000 shares (pre Reverse Stock Split) of Common Stock.

The Company has determined that the Series A Preferred Stock issuance in the Recapitalization Transaction does not meet the requirements of FASB ASC 480-10 for liability treatment and therefore has been classified as permanent equity. Additionally, it was determined that the economic characteristics of the beneficial conversion feature are clearly and closely related to the host, and are based on a fixed conversion rate into shares of Common Stock and therefore do not require bifurcation.
The Series A Preferred Stock was converted into 248,366 (21,111,111 pre Reverse Stock Split) shares of Common Stock on June 12, 2015 in conjunction with the Recapitalization Transaction (see Note 6).
The 392,157 warrants (33,333,333 warrants pre Reverse Stock Split) associated with the Series A Preferred Stock were also classified as a liability since they are subject to anti-dilutive adjustments outlined in the warrant agreement and valued at a fair market value of $2,995,791 at January 31, 2013. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2015 and 2014, the fair value of the warrants was $626,317 and $631,678.
On May 26, 2015, the Company amended its Amended Certificate of Designation, dated February 1, 2013, with respect to its Series A Preferred Stock, to amend the designations, preferences, powers and rights of the Series A Preferred Stock, and authorizing the issuance of up to 37,564,767 shares of Series A Preferred Stock. The Series A Preferred Stock are currently convertible at 20:1. 37,564,767 (pre-Reverse Stock Split) shares of Series A Preferred Stock were issued as part of the Recapitalization Transaction (see Note 6).
Additionally, on May 26, 2015, the Company amended its Amended and Restated Articles of Incorporation, dated December 19, 2003, to establish the Series B Preferred Stock, authorizing the issuance of up to 85 shares of Series B Preferred Stock. The Series B Preferred Stock are convertible currently at 8,496,732:1. 85 shares (pre Reverse Stock Split) of Series B Preferred Stock were issued to settle the $6.5 million of licensing fees due and the associated warrants as part of the Recapitalization Transaction (see Note 6). The foregoing description of the Certificate of Designation is a summary, and does not purport to be a complete description of the Certificate of Designation, and is qualified in its entirety by reference to the Certificate of Designation, a copy of which is filed as Exhibit 3.3 to the Company’s Report on Form 8-K, filed with the SEC on June 18, 2015.
On June 12, 2015, the Company issued 389,668 shares (33,121,777 pre Reverse Stock Split) of Series A Preferred shares to an investor for $1,278,501 as part of the total $1,450,813 transaction with the investor.  Further, an officer of the Company and a stockholder are partial owners in the investor and therefore the investor received an additional 10,667 shares (906,736 pre Reverse Stock Split) of Series A Preferred Stock for the forgiveness of previously accrued but unpaid compensation valued at $35,000 and notes payable and accrued interest were converted into 41,603 shares (3,536,254 pre Reverse Stock Split) of Series A Preferred Stock also as part of the $1,450,813 transaction.
Each of the Series A Preferred Stock and the Series B Preferred Stock have a preference in liquidation that the holders of the Series A Preferred Stock and the Series B Preferred Stock are to be paid out of assets available for distribution prior to holders of Common Stock. The holders Series A Preferred Stock and the Series B Preferred Stock may cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock and the Series B Preferred Stock can be converted, with certain limitations. In addition, the holders of Series A Preferred Stock and the Series B Preferred Stock are to be paid dividends, based on the number of shares of Series A Preferred Stock and the Series B Preferred Stock, as the case may be, as if the shares had been converted to Common Stock, prior to the holders of Common Stock receiving a dividend.
NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS
Derivative Liabilities
For purposes of determining whether certain instruments are derivatives for accounting treatment, the Company follows the accounting standard that provides guidance for determining whether an equity-linked financial instrument, or embedded feature, is indexed to an entity’s own stock. The standard applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock.
Liabilities measured at fair value on a recurring basis are summarized as follows:
  Level 1  Level 2  Level 3  Total 
Derivative liability related to fair value of warrants $-  $-  $1,802,375  $1,802,375 
Total $-  $-  $1,802,375  $1,802,375 

The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
Common Stock.

F-30
     
Balance at January 1, 2015 $6,370,709 
Conversion of notes payable, net of interest expense  (31,397)
Conversion of warrants related to licensing fees  (1,867,417)
Change in fair value of derivative liabilities  (2,669,520)
     
Balance at December 31, 2015 $1,802,375 
Table of Contents
The Company has no assets that are measured at fair value on a recurring basis. There were no assets or liabilities measured at fair value on a non-recurring basis during

VerifyMe, Inc.

Notes to Financial Statements

During the year ended December 31, 2015.2018, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock.

Series B Convertible Preferred Stock

During the year ended December 31, 2017, there were no conversions of Series B Convertible Preferred Stock into shares of the Company’s common stock.

During the year ended December 31, 2018 0.07 shares of Series B Convertible Preferred Stock were converted into 599,362 shares of the Company’s Common Stock.

Series C Convertible Preferred Stock

The Series C Convertible Preferred Stock (the “Series C”) described below converted on June 30, 2017 and a Certificate of Withdrawal for the Series C Certificate of Designation was subsequently filed.

On May 30, 2017, the Company entered into Securities Exchange Agreements (the “Agreements”) with the holders of approximately 87% of the outstanding shares of the Company’s 0% Series C and the holders of 100% of the outstanding shares of the Company’s 0% Series D Convertible Preferred Stock (the “Series D”) and certain warrants to purchase the Company’s common stock held by the Series C and Series D holders. The effectiveness of the Agreements was contingent upon the Company raising at least $500,000 in a debt or equity financing transaction which closed on June 30, 2017. Pursuant to the Agreements, the holders exchanged each share of Series C for 2.857 shares of common stock and each warrant for two shares of common stock. The Agreements also eliminate a covenant in the Securities Purchase Agreements with the Series C and Series D investors which adversely affects the Company’s ability to issue securities and incur debt. 

On July 19, 2017, the Company authorized the withdrawal of the Certificates of Designation for Series C and Series D and on July 13, 2017, the Company ratified the authorization to issue shares of common stock to the holders of Series C and Series D.

On April 14, 2017, 375,000 shares of Series C were converted into 375,000 shares of the Company’s Common Stock.

On June 30, 2017, pursuant to the Agreement, 1,537,500 shares of Series C were converted into 4,392,858 shares of the Company’s Common Stock; 3,087,500 shares of warrants were converted into 6,175,000 shares of the Company’s Common Stock, out of which 230,000 shares was issued to a director of the Board. $473,604 deemed dividend to Series C holders and $473,604 accretion of deemed distribution to Series C holders was recorded in conjunction with the transaction. 

Series D Convertible Preferred Stock

The Series D described below converted on June 30, 2017 and a Certificate of Withdrawal Series D Certificate of Designation was subsequently filed.

As noted, above, on May 30, 2017, the Company entered into Agreements with the holders of approximately 87% of the outstanding shares of the Company’s Series C and certain warrants to purchase the Company’s common stock held by the Series C holders. The Company had an oral agreement with the holder of the outstanding shares of the Company’s Series D to convert the Series D when the Series C converted. On July 13, 2017, the Company issued the Series D holder 2,482,145 shares of common stock upon conversion of the Series D and exchange of warrants issued with the Series D. 

On June 30, 2017, 166,750 shares of Series D were converted into 496,429 shares of the Company’s Common Stock; 667,000 shares of warrants were converted into 1,985,716 shares of the Company’s Common Stock. $123,274 deemed dividend to Series D holders and $123,274 accretion of deemed distribution to Series D holders was recorded in conjunction with the transaction. 

F-31

VerifyMe, Inc.

Notes to Financial Statements

NOTE 7 – STOCKHOLDERS’ EQUITY

For the years ended December 31, 2018 and 2017, the Company expensed $8,625 and $6,750 relative to Restricted Stock Units.

For the years ended December 31, 2018 and 2017, the Company expensed $446,265 and $60,075 relative to Restricted Stock awards.

On September 8, 2017, the Company entered into a consulting agreement stipulating partial payment in restricted common stock.  As of December 31, 2015, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings.2017, 120,000 shares have been issued.  These Common Stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:

December 31, 2015
Annual Dividend Yield0.0%
Expected Life (Years)2.0 - 3.0
Risk-Free Interest Rate1.06% - 1.31%
Expected Volatility178.5% - 179.3%

Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants. The Company had no reason to believe future volatility over the expected remaining life of these warrants was likely to differ materially from historical volatility. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.

NOTE 12 – STOCKHOLDERS’ EQUITY
On January 1, 2014, under the terms of the Patent and Technology License Agreement, the Company issued 6,349,206 shares (pre Reverse Stock Split) of Common Stock to VFM, in addition to the warrants described in Note 9 above. The shares were issued in payment for the technology received. Under the agreement, $400,000 worth of Common Stock was to be paid by the Company to VFM at a 10% discount to the market at time of payment. The closing price was $0.07 per share discounted 10% to $0.063. The $400,000 payment divided by the $0.063 per share resulted in 6,349,206 shares (pre Reverse Stock Split) to be issued. The entire $400,000 payment was expensed to research and development.
On June 2, 2015, the Company issued 68,236 shares (post Reverse Stock Split) of Common Stock to two vendors to settle outstanding payable balances of $58,000.
On June 12, 2015, the Company issued 304,785 shares (25,906,735 pre Reverse Stock Split) of Common Stock and raised $50,000.
During the three months ended June 30, 2015, one stockholder received 2,353 shares (post Reverse Stock Split) of Common Stock in a cashless exercise.
On June 11, 2015, the Company issued 525,000 Restricted Stock Units (“RSUs”) (44,625,000 pre Reverse Stock Split) to two officers of the Company. The RSUs were valued at the closing stock price of $0.01the Company’s common stock as they became due for a total of $12,000 for the year ended December 31, 2017. During the year ended December 31, 2018, the Company issued 49,500 shares and incurred $44,120 related to this agreement.

During the year ended December 31, 2017, the Company also issued 1,605,175 shares of common stock and 1,605,175 shares of warrants to two directors of the Board for services already rendered under consulting agreements. The 1,605,175 shares of warrants have an exercise price of $0.15 per share and a term of five years. The common stock and warrants were valued and expensed for $285,807.

 On August 9, 2017, the Company granted 300,000 shares of restricted common stock to each of six non-employee directors and one attorney vesting quarterly over one year. The common stock was measured at fair value at the grant date and expensed based on June 11, 2015, at $446,250, fair value. These RSUs are being expensed over the vesting terms.schedule.  Common stock related to the Company’s attorney were revalued as of the year end.  During the year ended December 31, 2017, $60,075 compensation expense was recorded. During the year ended December 31, 2018, $111,105 compensation expense was recorded in relation to these awards. Of this amount $36,855 was related to the compensation of the six non-employee directors. As of December 31, 2018 and 2017, there is $0 and $84,105 unrecognized compensation cost related to these shares of restricted common stock.

 During 2017, 19,451,575 shares of common stock and 19,451,575 shares of warrants to purchase common stock were issued for gross proceeds of $1,360,250 from the sale of units with each unit consisting of 715,000 shares of common stock and 715,00 five-year warrants exercisable at $0.15 per share.  Legal costs related to this offering amounted to $32,325 and were recorded in Additional Paid In Capital.  Net proceeds related to the sale of common stock were $1,327,925 for the year ended December 31, 2017.

In connection with the sale of common stock noted above, 8,712,275 shares were issued and 8,712,275 warrants to purchase common stock were issued for gross proceeds of $609,250 to directors of the Board and relatives of the directors of the Board.

During 2017, 75,000 Restricted Stock Units were vested in relation to a consulting service agreement and a total of $6,750 was expensed.

During 2017, 2,050,372 shares were issued as stock-based compensation with a total non-cash expense of $139,808.  Of this amount 371,800 shares were issued to a director of the Board, for a total non-cash expense of $22,308.

During 2017, 503,432 shares were issued for sale of common stock in prior years.  Of this amount, 479,901 were related to two members of the Board.

During the year ended December 31, 2018, 37,500 restricted stock units were vested in relation to a consulting service agreement and a total of $8,625 was expensed.

During the year ended December 31, 2018, the Company granted a total of 600,000 restricted stock awards to two directors of the Company, each receiving 300,000 shares of restricted common stock, for joining the Board of Directors. On April 25, 2018 the Company approved the immediate vesting of all of the Company’s outstanding restricted common stock issued in 2017 and 2018 to non-employee directors of the Company. During the year ended December 31, 2018, $160,500 compensation expense was recorded in relation to this issuance. As of December 31, 2018, there is $0 unrecognized compensation cost related to these shares of restricted common stock.

F-32

VerifyMe, Inc.

Notes to Financial Statements

During the year ended December 31, 2018, the Company granted a total of 1,425,000 shares of restricted common stock to the directors and the Chief Executive Officer of the Company for their services and 150,000 shares to one attorney, vesting over a one-year period. During the year ended December 31, 2018, $174,660 compensation expense was recorded in relation to this issuance. As of December 31, 2018, there is $161,311 unrecognized compensation cost related to these shares of restricted common stock.

In January 2018, the Chairman of the Board of Directors, made a cashless exercise of 5,000,000 options related to services in 2017, whereby the Chairman disposed of 972,222 shares to the Company as part of his exercise, amounting to an issuance of 4,027,778 shares, see Note 8.

In relation to the 2017 private placement with a maximum offering amount of $2,100,000 allowing investors to purchase units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share, the Company’s Board of Directors increased the size of the private placement by an additional amount beyond the $2,100,000 limit. During the year ended December 31, 2018 the Company raised gross proceeds of $1,153,645 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants. Of these amounts, gross proceeds of $530,777 for the purchase of 7,590,111 shares of common stock and 7,590,111 warrants related to current and then directors and relatives of the directors of the Company.

On January 30, 2018, the Company authorized a 30-day offer, beginning on February 20, 2018, to the holders of the Company’s outstanding warrants exercisable at $0.15 to exercise their warrants at $0.10 per share.  This authorization was extended until June 30, 2018.  The Company authorized certain holders, who had sent in their exercise notices prior to June 30, 2018, to submit payment before July 27, 2018 and exercise their warrants at $0.10 per share. For the year ended December 31, 2015,2018, 20,787,784 warrants were exercised and a total of 20,787,784 shares of common stock were issued for gross proceeds of $2,079,345. Included in the above amounts are gross proceeds of $1,205,458 from current and then directors in exchange for exercise of 12,054,576 warrants and issuance of 12,054,576 shares of common stock.

In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731.

On March 31, 2018, the Company expensed $80,573 relatedentered into a Confidential Settlement Agreement (the “Settlement Agreement”) with Paul Klapper, a member of the Company’s Board, Stephen Silver, PFK Development Group, Ltd. (“PFKD”) and certain other parties named in the Settlement Agreement. Pursuant to the RSUs.

On June 30, 2015,terms of the Settlement Agreement, the Company (i) paid a total of $500,000 (the “Settlement Amount”) to PFKD and Mr. Silver and (ii) issued 48,761them each 500,000 shares (post Reverse Stock Split) of Common Stock to a vendor to settle an outstanding payable balance of $41,447, net of gain on conversion of $35,153.
On July 9, 2015, the Company hired a Chief Operating Officer (“COO”Company’s common stock (the “Settlement Shares”). The COO will receive 225,000 RSUs (19,125,000 pre Reverse Stock Split), vesting over a three-year period, with one-third vesting the first year and one-twelfth vesting ratably on a quarterly basis thereafter. The RSUsshares were valued at fair value$279,000 whereby $139,500 related to common stock issued to a related party and $139,500 related to common stock issued to a third party. The Settlement Agreement provides for cancellation as of $918,000 based onMarch 31, 2018 of certain revenue sharing agreements between the closingCompany and each of Mr. Klapper, Mr. Silver and PFKD, and terminates the Company’s obligation to issue warrants to purchase 3.7 million shares of the Company’s common stock at an exercise price of $4.08 on July 9, 2015. For the year ended December 31, 2015, the Company expensed $153,000 related to the RSUs.
On July 23, 2015, the Company completed the Reverse Stock Split of its outstanding Common Stock and Preferred Stock, as further described in Note 1 and Note 6 above.
On August 10, 2015, the Company agreed to issue the Chief Financial Officer (“CFO”) 20,000 RSUs vesting over six months and 100,000 RSUs vesting annually over three years. The RSUs were valued at a fair value of $692,400 based on the closing stock price of $5.77$0.40 per share on August 10, 2015. For the year ended December 31, 2015, the Company expensed $176,306 related to the RSUs.
On October 1, 2015, the Company agreed to issue 100,000 RSUs to a consultant for services. Of the 100,000 RSUs, 60,000 were issued upon execution of the agreement, 20,000 shares are to be issued on January 1, 2016 and 20,000 shares are to be issued on April 1, 2016. The RSUs were originally valued at $195,000.  The Company expensed $54,250 for the year ended December 31, 2015 relative to these RSUs.
On October 7, 2015, the Company agreed to pay $15,000 to a consultant/stockholder as well as an additional $35,000 based on certain milestones being met. Additionally, as of August 1, 2015 the Company agreed to issue the individual 30,000 RSUs originally valued at $165,000 in quarterly installments on November 1, 2015, February 1, 2016, May 1, 2016 and August 1, 2016, which began vesting on August 1, 2015.  The Company expensed $34,687 for the year ended December 31, 2015 relative to these RSUs. Further the individual will receive a 2% to 5% commission on company sales while this agreement is in effect, however no commissions were earned during 2015.
In accordance with FASB ASC 505-50, “Equity – Equity-Based Payments to Non-Employees,” restricted stock with performance conditions should be revalued based on the modification accounting methodology described in FASB ASC 718-20, “Compensation—Stock Compensation—Awards Classified as Equity.” As such the Company has revalued certain restricted stock with consultants and determined that there was an aggregate decrease in fair value of $75,500.
NOTE 13 – STOCK OPTIONS
During 1999,share. Mr. Klapper joined the Board of Directors (“Board”)on July 14, 2017 and resigned as of March 31, 2018.

In April 2018, the former Chief Executive Officer of the Company adopted,exercised his warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares.

On July 27, 2018 the Company cancelled 607,143 shares as a result of an over-issuance of shares to an investor in connection with the approvalCompany’s 2017 exchange.

On July 31, 2018, a member of the stockholders,Board exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a Stock Option Plan. In 2000, the Board superseded that plan and created a new Stock Option Plan, pursuanttotal price of $215,929.

F-33

VerifyMe, Inc.

Notes to which it is authorized to grant options to purchase up to 1.5 million shares of common stock. Financial Statements

NOTE 8 – STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS

On December 17, 2003, the Board, with approval of the stockholders, superseded the 2000 plan andCompany created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan, the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. The Plan is intended to permit stock options granted to employees under the Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the 2003 Plan, which are not intended to qualify as Incentive Stock Options, are deemed to be non-qualified options (“Non-Statutory Stock Options”).  As of December 31, 2015, options to purchase 298,530 shares of common stock have been issued and are unexercised, and 4,067,631 shares are available for grants under the 2008 Plan.  


During 2013, our Boardthe Company adopted a new omnibus incentive compensation plan that was ratified by the shareholders at the 2013 annual meeting, (the “2013 Plan”Plan���) which will serve as the successor incentive compensation plan to the 2003 Plan.. Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of 20,000,000 shares of common stock.  The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as Incentive Stock Options.  All options granted under the 2013 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be Non-Statutory Stock Options.  As

On November 14, 2017, the Executive Committee of December 31, 2015, under the 2013Company’s Board of Directors adopted the 2017 Equity Incentive Plan grants(the “Plan”) which covers the potential issuance of restricted stock and options to purchase 292,50013 million shares of common stock have been issuedstock. The Plan provides that directors, officers, employees, and are unvested or unexercised, and 19,700,000 sharesconsultants of common stock remain available for grantsthe Company will be eligible to receive equity incentives under the 2013Plan at the discretion of the Board or the Board’s Compensation Committee. The Board’s Compensation Committee may adopt rules and regulations to carry out the terms of the Plan.

The 2013Plan terminates on November 14, 2027 unless sooner terminated.

The 2017 Plan is administered by a committee of the Board (“Compensation Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan.

In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise

Incentive Stock Options under all plans of the companyCompany shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.

The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided.

Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments.

On March 28, 2014, the Company issued options to purchase an aggregate of 6,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board of Directors. The fair value of options issued was $599,893 of which all was expensed immediately. These options were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 229%, risk-free interest rate of 2.73% and expected option life of ten years.
On March 28, 2014 at the urging of the Company’s previous Chairman, Michael Sonnenreich, and after discussion by the Board and suggestions by Board Observers attending the meeting, the Board unanimously voted to extend the exercise period of all existing 10 year options, for a full ten years (as opposed to six months) regardless of their status with the Company. This charge was memorialized and sent in writing to previous Directors by then general counsel Morgan, Lewis & Bockius.
On June 11, 2015, the Company issued options to purchase an aggregate of 1,225,000 shares (104,125,000 pre Reverse Stock Split) of the Common Stock at an exercise price of $0.85 per share, with a term of five years, to three employees and two members of the Board. The fair value of options issued was $993,083. These options were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 176.6%, risk-free interest rate of 1.74% to 1.75% and expected option life of five years. The options are being expensed over the vesting terms for the employees and over the Board members’ remaining service terms as that is shorter than the vesting terms.
On July 9, 2015, the Company hired a COO who received 375,000 options (31,875,000 pre Reverse Stock Split) to purchase shares of Common Stock of the Company, with an exercise price of $0.85 ($0.01 pre reverse split) and valued at $1,502,219. The options vest quarterly over three years. The fair value of the options was valued using the Black-Scholes option pricing model with the following assumptions: no dividend yield, expected volatility of 180.1%, risk free interest rate of 1.58% and expected life of five years. The options are being expensed over the vesting terms.
On August 10, 2015, the Company hired a CFO who received 200,000 options (17,000,000 pre Reverse Stock Split) to purchase shares of Common Stock vesting annually over three years. The options were valued at fair value of $1,107,857, using the Black-Scholes option pricing model with the following assumptions: no dividend yield, expected volatility of 182.2%, risk free rate interest rate of 1.62% and expected life of five years. The options are being expensed over the vesting terms.
On September 25, 2015, the Company issued options to purchase an aggregate of 75,000 shares (6,375,000 pre Reverse Stock Split) of Common Stock at an exercise price of $2.15 per share, with a term of five years to a member of the Board. The fair value of options issued was $155,003. These options were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 183.5%, risk-free interest rate of 1.48% and expected option life of five years. The options are being expensed over the service term as that is shorter than the vesting terms.
For the years ended December 31, 2015 and 2014, the Company expensed $849,791 and $860,235 with respect to the options.

The following table presents the weighted-average assumptions used to estimate the fair values of the stock options granted during the years ended December 31, 20152018 and 2014:2017:

  2018  2017 
       
Risk Free Interest Rate  2.30%  1.90%
Expected Volatility  200.50%  199.20%
Expected Life (in years)  5.0   5.0 
Dividend Yield  0%  0%
Weighted average estimated fair value of        
options during the period $0.17  $0.07 

F-34
  2015  2014 
       
Risk Free Interest Rate  1.69%  2.73%
Expected Volatility  176.6%  229.0%
Expected Life (in years)  5.0   10.0 
Dividend Yield  0%  0%
Weighted average estimated fair value of options during the period $2.00  $1.00 

VerifyMe, Inc.

Notes to Financial Statements

The following table summarizes the activities for ourthe Company’s stock options for the year ended December 31, 2015and 2014:


 Options Outstanding
 
Number of
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term
(in years)
 
Aggregate
Intrinsic
Value
(in 000’s) (1)
          
Balance as of December 31, 2013739,608 $4.25     
Exercised(141,176) $1.70     
Balance as of December 31, 2014598,431 $4.25     
Granted1,875,000 $0.85     
Exercised(7,843)  0.05     
Forfeited/canceled(308,235) $0.06     
Balance as of December 31, 20152,157,353 $1.80 5.0 $226,631
Exercisable as of December 31, 2015626,103 $2.57 6.2   
Exercisable as of December 31, 2015 and expected to
vest thereafter
2,157,353 $1.80 5.0 $
226,631

2018 and 2017:

  Options Outstanding 
        Weighted -    
        Average    
        Remaining  Aggregate 
     Weighted-  Contractual  Intrinsic 
  Number of  Average  Term  

Value

(in 000’)

 
  Shares  Exercise Price  (in years)  (1) 
             
Balance as of December 31, 2016  3,282,647  $0.52        
                
Granted  19,950,000   0.07        
Forfeited/cancelled  (1,219,117)  0.48        
                
Balance December 31, 2017  22,013,529  $0.11        
                
Granted  1,600,000  $0.27        
Exercised  (5,000,000) $0.07        
                
Balance December 31, 2018  18,613,529  $0.14   3.9    
                
Exercisable at December 31, 2018  16,596,863  $0.13   3.9  $2,113 
                
                

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stockquoted price of $2.50 for ourthe Company’s common stock onfor options that were in-the-money at each respective period.  During the years ended December 31, 2015.2018 and 2017, the aggregate intrinsic value of options exercised under the Company’s stock option plans was $2,113,368 and $3,480,567, respectively.
During the year ended December 31, 2015 and 2014, the weighted average fair value of stock options granted during the period was $3,758,162 and $599,893.  The fair value of stock options is expensed over the vesting term in accordance with the terms of the related stock option agreements.

During the year ended December 31, 2015 and 2014, the intrinsic value of stock options exercised during the period was $0.
For the years ended December 31, 2015 and 2014, the Company expensed $849,792 and $860,233, relative to the fair value of stock options granted.
As of December 31, 2015, there was $2,853,537 of unrecognized compensation cost related to outstanding stock options. This amount is expected to be recognized over a weighted-average period of 2.5 years. To the extent the actual forfeiture rate is different from what the Company has estimated, stock-based compensation related to these awards will be different from the Company’s expectations. The difference between the stock options exercisable at December 31, 2015 and the stock options exercisable and expected to vest relates to management’s estimate of options expected to vest in the future.

The following table summarizes the activities of ourfor the Company’s unvested stock options for the year ended December 31, 20152018 and 2014:2017:

   Unvested Options 
      Weighted - 
      Average 
      Grant 
   Number of Unvested  Date Exercise Price 
   Options    
Balance December 31, 2016   -  $- 
          
Granted   19,950,000   0.07 
          
Vested   (16,833,333)  0.07 
          
Cancelled/forfeited/expired   (450,000) ��0.08 
          
Balance December 31, 2017   2,666,667  $0.06 
          
Granted   1,600,000   0.27 
          
Vested   (2,250,001)  0.10 
          
Balance December 31, 2018   2,016,666  $0.18 

F-35

VerifyMe, Inc.

Notes to Financial Statements

During the year ended December 31, 2017, 19,950,000 options were granted a weighted average exercise price of $0.07 with a term of five years.  Of the 19,950,000 options, 450,000 options were issued to a director with a three-month vesting period, 10,000,000 to the Chairman of the Board vesting immediately, 7,000,000 were issued to the Chief Executive Officer of which 5,000,000 vested immediately and 2,000,000 vest over a period of two years and 2,000,000 were issued to a director vesting over a six month period. In February 2017, the Company also issued 500,000 options to purchase common stock to a consultant which vested immediately.


  
Number of
Awards
  
Weighted
Average
Exercise Price
  
Weighted
Average
Remaining
Amortization
Period (Years)
 
Unvested stock options at December 31, 2013  55,882  $6.52     
     Vested  (38,235)   (6.86)     
Unvested stock options at December 31, 2014  17,647  $9.49     
     Granted  1,875,000  $1.43     
     Cancelled/Forfeited  (11,765) $(12.75)     
     Vested  (349,632) $(1.31)     
Unvested stock options at December 31, 2015  1,531,250  $1.48   4.49 





During the year ended December 31, 2017, 769,117 options were forfeited from employees no longer with the Company and 450,000 options were forfeited by a director of the Company.

During the year ended December 31, 2018, the Company amended the consulting agreement held with its Chief Operating Officer and granted him 1,000,000 stock options with an exercise price of $0.2102 with 500,000 stock options vesting immediately and the remaining 500,000 stock options vesting on February 28, 2019 subject to continuing to provide consulting services.

In January 2018, the Chairman of the Board made a cashless exercise of 5,000,000 options related to services in 2017, whereby the Chairman disposed of 972,222 shares to the Company as part of his exercise, amounting to an issuance of 4,027,778 shares, see Note 7.

In November 2018, 600,000 options were granted a weighted average exercise price of $0.37 with a term of five years.  Of the 600,000 options, 500,000 options were issued to an employee of the Company vesting monthly over a six-month period, 100,000 to the Chief Financial Officer vesting quarterly over a one-year period.

For the years ended December 31, 2018 and 2017, the Company expensed $329,193 and $1,295,741 with respect to the options.

As of December 31, 2018, there was $198,438 unrecognized compensation cost related to outstanding stock options expected to vest over the weighted average of 3.9 years.

The following table summarizes the activities for ourthe Company’s warrants for the year ended December 31, 2015:

  Warrants Outstanding 
  
Number of
Shares
  
Weighted-
Average
Exercise Price
  
Weighted-
Average
Remaining
Contractual
Term
(in years)
  
Aggregate
Intrinsic
Value
(in 000’s) (1)
 
    
Balance as of December 31, 2013  1,405,686  $8.80       
Granted  121,755   6.86       
Expired  (66,666)  (12.75)      
Balance as of December 31, 2014  1,460,775  $1.01       
Exercised  (2,353) $0.85       
Cancelled/Forfeited  (43,529) $(4.15)      
Balance as of December 31, 2015  1,414,893  $9.67  4.8  $413 
Exercisable as of December 31, 2015  1,414,893  $9.67  4.8     
Exercisable as of December 31, 2015 and expected to
vest thereafter
  1,414,893  $9.67  4.8  $413 
2018 and 2017:

  Warrants Outstanding 
  Number of
Shares
  

Weighted-

Average

Exercise

Price

  

Weighted -

Average

Remaining

Contractual

Term

in years)

  

Aggregate

Intrinsic

Value

(in 000's)
(1)

 
Balance, December 31, 2016  9,216,451  $1.82         
Issued  33,080,629   0.20         
Cancelled/Forfeited  (10,004,500)  0.40         
                 
Balance, December 31, 2017  32,292,580  $0.30         
Issued  18,727,769   0.15         
Exercised  (22,809,908)  0.11         
Expired  (1,019,608)  0.07         
Cancelled/Forfeited  (4,950,000)  0.40         
                 
Balance, December 31, 2018  22,240,833  $0.31   3.70     
                 
Exercisable at December 31, 2018  22,240,833  $0.31   3.70  $1,858 

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $2.50$0.22 for our common stock on December 31, 2015.2018.

F-36

VerifyMe, Inc.

Notes to Financial Statements

All warrants were vested on the date of grant.


NOTE 14 – OPERATING LEASES
Series C Preferred Stock and 3,087,500 warrants exchanged these securities for 6,175,000 shares of common stock.  See Note 7.

During the year ended December 31, 2017, holders of Series D Preferred Stock and 667,000 warrants exchanged these securities for 1,985,716 shares of common stock.  See Note 7.

During the year ended December 31, 2017, the Company issued 19,451,575 warrants to purchase common stock with an exercise price of $0.15 in connection to the sale of units occurring during the year.  See Note 7.

During the year ended December 31, 2017, the Company issued 4,402,079 warrants to purchase common stock with an exercise price of $0.15 in connection with the settlement or related party note payables.  The fair value of the warrants accounted for in Additional Paid in Capital, for the year ended December 31, 2017, was $113,586. See Note 7.

 During the year ended December 31, 2017, a director was issued and then cancelled 6,250,000 warrants to purchase common stock in connection with the settlement of the related party note payable.

During the year ended December 31, 2017, a director was issued 1,000,000 warrants to purchase common stock at an exercise price of $0.40 in connection with the issuance of notes payable.

During the year ended December 31, 2017, the Company issued 1,976,975 warrants to directors of the Board to purchase common stock at an exercise price of $0.15 in connection with services provided. See Note 7.

For the year ended December 31, 2018, the Company has received gross proceeds of $1,153,645 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants in relation to the private placement.  See Note 7.

In January 2018, the Company issued 1,749,683 shares of common stock and 1,749,683 warrants with an exercise price of $0.15 to Mr. Klapper relating to the Note payable conversion that took place in June 2017.  Additionally, 3,700,000 warrants were forfeited. See Note 5.

During the year ended December 31, 2018, in relation to the Settlement Agreement, the Company issued 464,775 warrants at an exercise price of $0.15 which were paid for in 2014 but had not been previously issued. See Note 7.

For the year ended December 31, 2018, 20,787,784 shares of warrants were exercised and 2013,a total of 20,787,784 shares of common stock were issued for gross proceeds of $2,079,345. See Note 7.

In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731, see Note 7.

In April 2018, the former Chief Executive Officer of the Company exercised 100,000 warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares, see Note 7.

On July 31, 2018, a member of the Board exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929. See note 7.

In August 2018, a warrant holder, made a cashless exercise of 366,047 warrants, whereby the warrant holder disposed of 190,386 shares to the Company as part of this exercise, amounting to an issuance of 175,661 shares.

F-37

VerifyMe, Inc.

Notes to Financial Statements

In October 2018, a warrant holder, made a cashless exercise of 11,678 warrants, whereby the warrant holder disposed of 4,680 shares to the Company as part of this exercise, amounting to an issuance of 6,998 shares.

During the year ended December 31, 2018 an additional 1,250,000 warrants were forfeited in relation to a note payable conversion

occurring in the prior year.

NOTE 9 – DEBT FORGIVENESS

During the year ended December 31, 2018 the Company negotiated with certain vendors regarding balances outstanding for prior year services resulting in a Gain on accounts payable forgiveness included in the Statement of Operations for $352,008.

NOTE 10 – OPERATING LEASES

For the year ended December 31, 2018 and 2017, total rent expense under leases amounted to $55,153$12,395 and $65,950.$12,674. At December 31, 2015,2018, the Company was not obligated under any non-cancelable operating leases.

NOTE 15 – RELATED PARTY TRANSACTIONS

At June 12, 2015, three stockholders of the Company held $317,000 of the senior secured convertible notes payable and were owed accrued interest of $42,713. The notes and accrued interest were converted into 234,735 shares (19,952,489 pre Reverse Stock Split) of Common Stock as further described in Note 7 and 8.
NOTE 1611 – MAJOR CUSTOMERS/VENDORS

During the yearsyear ended December 31, 2015 and 2014, three2018, four customers accounted for 100.0% of total sales.  During the year ended December 31, 2017 there were no sales. Generally, a substantial percentage of the Company's sales has been made to a small number of customers and is typically on an open account basis.


During the years ended December 31, 20152018 and 2014, we2017, the Company purchased 100.0% of our pigment from one vendor.

Additionally, during the years ended December 31, 2018 and 2017, the Company purchased 100.0% of canisters from one vendor.

As of December 31, 2018, two customers accounted for 100% of total accounts receivable.

NOTE 1712 – SUBSEQUENT EVENTS

In January 2019, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock.

On February 27, 2019 three Board Members provided their resignations as members of the Company’s Board of Directors, effective March 1, 2019.

On March 5, 2019 the Company appointed Mr. Eugene Robin to the Company’s Board of Directors.

On March 20, 2019 the Company granted three directors the option of each receiving 240,000 shares of restricted stock or 240,000 restricted units, either of which shall vest over a one-year period in equal increments from March 15, 2019. Each of the directors elected to receive restricted stock awards.

In March 2019, the Company appointed Dr. Arthur Laffer to its Board of Directors and granted 240,000 shares of restricted which shall vest over a one-year period in equal quarterly increments from March 15, 2019.

In March 2019, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock.

F-38
As

$8,000,000 of Units

Each Unit Consisting of

One Share of Common Stock and

One Warrant to Purchase One Share of Common Stock

______________________

______________________

PROSPECTUS

Sole Book-Running Manager

Maxim Group LLC

______________________

______________________

, 2019

Through and including            , 2019 (the 25th day after the date of this filing, the 10,667 shares (906,736 pre Reverse Stock Split) of Series A Preferred Stock haveprospectus), all dealers that effect transactions in these securities, whether or not been distributed to the officer of the Company and the stockholder, as further discussedparticipating in Note 10.


On February 9, 2016, the Company issued 2,587,500 shares of 0% Series C Convertible Preferred Stock, par value $0.001 per share (“Series C Preferred Stock”) at a purchase price of $0.40 per share with gross proceeds to the Company of $1,035,000. In connection with the sale of the Series C Preferred Stock, the Company issued to the purchasers warrants to purchase in the aggregate 2,587,500 shares of the Company’s common stock at an exercise price of $0.40 per share. Further, as a part of the samethis offering, on February 29, 2016, the Company issued 500,000 shares of Series C Preferred Stock, at a purchase price of $0.40 per share with gross proceeds to the Company of $200,000. In connection with the sale of the Series C Preferred Stock, the Company issued to the purchasers warrants to purchase in the aggregate 500,000 shares of the Company’s common stock at an exercise price of $0.40per share. Each share of Series C Preferred Stock is convertible into one share of common stock. The Series C Preferred Stock provides for certain adjustments that may be made to the exercise price and the number of shares issuable upon exercise due to future corporate events or otherwise, including, for a proscribed period of time, upon the issuance of securities at a price that is less than the exercise price of the Series C Preferred Stock.
The Company entered into a Registration Rights Agreement with each of the Investors (the “Registration Rights Agreement”), pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (“SEC”) covering the resale of the Conversion Shares, as well as the shares of Common Stock that are issuable upon exercise of the Warrants (the “Warrant Shares”).
The following is a brief summary of the Purchase Agreement, the Registration Rights Agreement, the Series C Preferred Stock and the Warrants, which are qualified in their entirety by reference to the full text of such documents.
Purchase Agreement
The Purchase Agreement contains representations and warranties by the Company and the Investors and covenants of the Company and the Investors (including indemnification from the Company in the event of breaches of its representations and warranties), which the Company believes are customary for transactions of this type. The Purchase Agreement provides for certain restrictive covenants, including the restriction on the Company to issue any securities for a period of sixty days from the date of the Purchase Agreement. Additionally, pursuant to the Purchase Agreement, during the Protection Period (as such term is defined in the Purchase Agreement), the Company is prohibited from entering into any variable rate transaction. Additionally, provided the Protection Period has not expired, for the period beginning on the date that the Company’s securities are listed on a national securities exchange and until the expiration of the Protection Period, the Company is prohibited from issuing any securities or incurring any financing debt, subject to certain exceptions.
Registration Rights Agreement
Pursuant to the Registration Rights Agreement, the Company is required to prepare and file a registration statement (the “Registration Statement”) with the SEC under the Securities Act of 1933, as amended, covering the resale of the Conversion Shares and the Warrant Shares (collectively, the “Registrable Securities”). The Company will be required to file such Registration Statement within 45 calendar days following the closing date of the Offering (the “Filing Deadline”). The Company will be requireddeliver a prospectus. This is in addition to use its best effortsa dealer’s obligation to have the Registration Statement declared effective as soon as practicable, but in no event later than 60 days from the closing of the Offering (or, in the event ofdeliver a “full review” by the SEC, 120 days) (the “Effectiveness Deadline”). Pursuant to the Registration Rights Agreement, the Company will incur certain liquidated damages upon the occurrence of certain events, including if: (i) the Registration Statement is not filed with the SEC on or prior to the Filing Deadline; (ii) the Company fails to file with the SEC a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the SEC pursuant to the Securities Act of 1933 (the “Securities Act”), within five trading days of the date that the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be “reviewed” or will not be subject to further review; (iii) prior to the effective date of the Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the SEC in respect of such Registration Statement within eighteen (18) calendar days after the receipt of comments by or notice from the SEC that such amendment is required in order for such Registration Statement to be declared effective, (iv) the Registration Statement is not declared effective by the SEC on or prior to the Effectiveness Deadline, and (v) after the effective date of the Registration Statement and prior to the expiration of the Effectiveness Period, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the holders of the Registrable Securities are otherwise not permitted to utilize the prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive trading days or more than an aggregate of twenty (20) trading days (which need not be consecutive trading days) during any 12-month period (each such failure is referred to hereinwhen acting as an “Event”).underwriter and with respect to an unsold allotment or subscription.

On each date that an Event occurs and on each monthly anniversary of such date, the Company shall pay to each holder of Registrable Securities an amount in cash equal to 1.0% multiplied by the aggregate subscription amount paid by such holder of Registrable Securities, up to a maximum of 6.0%. If the Company fails to pay such amount when due, the Company will pay interest thereon at a rate of 18% per annum.
The Registration Rights Agreement also contains mutual indemnifications by the Company and each Investor, which the Company believes are customary for transactions of this type.
Series C Preferred Stock
The Series C Preferred Stock was created pursuant to a Certificate of Designation.
Warrants
The Warrants are exercisable, in full or in part, at any time prior to the third anniversary of their issuance, at an exercise price of $0.40 per share. The Warrants provide for certain adjustments that may be made to the exercise price and the number of shares issuable upon exercise due to future corporate events or otherwise, including, for a proscribed period of time, upon the issuance of securities at a price per share that is less than the exercise price of the Warrants then in effect. In the case of certain fundamental transactions affecting the Company, the holders of Warrants, upon exercise of such Warrants after such fundamental transaction, will have the right to receive, in lieu of shares of the Common Stock, the same amount and kind of securities, cash or property that such holder would have been entitled to receive upon the occurrence of the fundamental transaction, had the Warrants been exercised immediately prior to such fundamental transaction. The Warrants contain a “cashless exercise” feature that allows the holders to exercise the warrants without a cash payment to the Company upon the terms set forth in the Warrants.   Due to the adjustment features of the exercise price, the fair value of the warrants will be recorded as a liability and not equity.

On February 29, 2016, the Company appointed a new Chairman of the Board.  In connection with this appointment, the Chairman was granted a stock option to purchase 100,000 shares of Common Stock at an exercise price of $0.60 per share under the Company’s 2013 Comprehensive Incentive Compensation Plan.


Shares


Common Stock
______________________

PROSPECTUS
______________________

________, 2016

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution

The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with the issuance and distribution of the securities being registered. All of the amounts shown are estimated except the SEC Registration Fee.

SEC Registration Fee $361 
     
Printing and engraving expenses  2,000 
     
Legal fees and expense  45,000 
     
Accounting fees and expenses  1,000 
     
Miscellaneous  5,000 
     
Total $53,361 

SEC Registration Fee$1,286 
    
Nasdaq listing fees * 
    
FINRA filing fee * 
    
Fees of transfer agent and warrant agent * 
    
Accounting fees * 
    
Legal fees and expenses * 
    
Miscellaneous * 
    
Total$* 

* To be completed by amendment.

Item 14. Indemnification of Directors and Officers

Nevada law provides that a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation (i.e., a “non-derivative proceeding”), by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he or she:

·Is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation; or

·Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

In addition, a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor (i.e., a “derivative proceeding”), by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys' fees actually and reasonably incurred by him or her in connection with the defense or settlement of the action or suit if he:

·Is not liable under Section 78.138 of the Nevada Revised Statute for breach of his or her fiduciary duties to the corporation; or

II-1

·Acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation.

Under Nevada law, indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any non-derivative proceeding or any derivative proceeding, or in defense of any claim, issue or matter therein, the corporation is obligated to indemnify him or her against expenses, including attorneys' fees, actually and reasonably incurred in connection with the defense.

Further, Nevada law permits a Nevada corporation to purchase and maintain insurance or to make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer, employee or agent, or arising out of his or her status as such, whether or not the corporation has the authority to indemnify him or her against such liability and expenses.

Under our amended and restated articles of incorporation, we are obligatedthe liability of our officers and directors will be eliminated or limited to indemnify,the fullest extent permitted by Nevada law. If Nevada law is amended to further eliminate or limit, or authorize further corporate action to further eliminate or limit, the liability of officers and directors, the liability of officers and directors shall be eliminated or limited to the fullest extent permitted by Nevada law then in effect.

The Company has entered into indemnification agreements with its officers and directors pursuant to which the Company agrees to indemnify said officer or director, to the fullest extent permitted by Nevada law, against any director or officer who was or is a party or is threatenedand all losses resulting from any claims relating to be made a party to, or is involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”), by reason of the fact that the director or officer, or a person of whom he or she is the legal representative, is or was a director, or officer, of VerifyMe, or a member of any committee of our board of directors, or is or was serving at our request as a director, officer, partner, trustee, employee, or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of the proceeding is alleged action in an official capacity as a director, officer, partner, trustee, employee or agent or inCompany. The indemnitee will be fully indemnified for any other capacity while serving as a director officer, partner, trustee, employee or agent; against all expense, liability and loss (including attorneys' fees, judgments, fines, excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by the director or officer in connection with the proceeding. In addition, indemnification is required to continue as to a person who has ceased to be a director, officer, partner, trustee, employee or agent and inures to the benefit of his or her heirs, executors and administrators. However, subject to the exceptions detailed below, we may indemnify a person seeking indemnification in connection with a proceeding (or part thereof) initiated by the person seeking indemnification only if the proceeding (or part thereof) was authorized by our board of directors. We may indemnify any employee or agent of VerifyMe to an extent greater than required by law only if andclaims (i) to the extent that our directors, in their discretion, may determine.

If we do not pay a claim for indemnification under our articles of incorporation in full within 30 days after a written claim has been received by us, the claimant may at any time thereafter bring suit against us to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant also will be entitled to be paid the expense of prosecuting such claim. With some exceptions, we may defend against an action brought for this purpose that the claimant has not met the standards of conduct which make it permissible under Chapter 78 of the Nevada Revised Statutes for us to indemnify the claimant for the amount claimed, but the burden of proving such defense is on us. Neither our failure (including the failure of our board of directors, independent legal counsel or our stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has metwas successful on the merits in defense of said claims in a court of law; or (ii) to the extent that he or she is serving as a witness and not as a party, in connection with said claim. If items (i) and (ii) do not apply, the Company will indemnify its directors and officers for any losses resulting from any claims, so long as they have complied with the applicable standard of conduct set forth in Chapter 78under Nevada law as determined by (i) a majority vote of disinterested directors; or (ii) the written opinion of independent counsel, as applicable. The indemnification agreement also provides the officer or director with the right to request that we advance their expenses prior to final disposition of the claim so long as they execute an undertaking to repay all advances in the event that a Nevada Revised Statutes, nor an actual determination bycourt ultimately determines that they were not entitled indemnification. The officer or director is required under the indemnification agreement to give us (includingnotice in writing of a claim as soon as practicable and we are not responsible to provide indemnification if we were not given a reasonable and timely opportunity to participate in the defense of the claim at our board of directors, independent legal counsel or our stockholders) that the claimant has not met such applicable standard of conduct is a defense to the action or creates a presumption that the claimant has not met the applicable standard of conduct.  We have obtained director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us. 
own expense.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of VerifyMethe Company pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

The Company plans to enter into an underwriting agreement in connection with this offering that provides that the underwriters are obligated, under some circumstances, to indemnify the Company’s directors, officers and controlling persons against specified liabilities, including liabilities under the Securities Act.

II-2

Item 15. Recent Sales of Unregistered Securities

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act.

(a)Exchanges Exempt Under Section 3(a)(9) of the Securities Act

On May 29, 2019, the Company issued 4,895,569 shares of common stock upon conversion of 244,778 shares of Series A Convertible Preferred Stock.

On May 29, 2019, a former director completed a cashless exercise of 200,000 warrants and was issued 71,774 shares of the Company’s common stock.

On April 16, 2019, the Company issued 400,000 shares of common stock upon conversion of 20,000 shares of Series A Convertible Preferred Stock.

On March 22, 2019, the Company issued 400,000 shares of common stock upon conversion of 20,000 shares of Series A Convertible Preferred Stock.

On January 19, 2019, the Company issued 400,000 shares of common stock upon conversion of 20,000 shares of Series A Convertible Preferred Stock.

On October 12, 2018, an investor completed the cashless exercise of 11,678 warrants and was issued 6,998 shares of the Company’s common stock.

On August 22, 2018, a warrant holder made a cashless exercise of 366,047 warrants, and was issued 175,662 shares of the Company’s common stock.

On June 11, 2018, the Company issued 37,500 shares of common stock in relation to 37,500 restricted stock units that were vested in relation to a consulting service.

In February 2018, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 of the Company’s common stock.

In January 2018, the Company issued 1,749,683 shares of common stock and 1,749,683 warrants to purchase common stock at an exercise price of $0.15 per share to entities controlled by a former member of the Board, relating to a note payable conversion.

On January 26, 2018, 0.0706 shares of Series B Convertible Preferred Stock were converted into 599,362 shares of common stock and transferred to a then director and to a shareholder of the Company.

In January 2018, a member of the Board made a cashless exercise of 5,000,000 options related to services rendered in 2017, resulting in the issuance of 4,027,778 shares of common stock.

On June 30, 2017, 166,750 shares of Series D Convertible Preferred Stock were converted into 496,429 shares of the Company’s common stock and 667,000 warrants were converted into 1,985,716 shares of the Company’s common stock.

On June 30, 2017, notes payable in the principal amount of $240,000 were converted into 4,402,079 shares of common stock and five-year warrants to purchase 4,402,079 shares of common stock at an exercise price of $0.15 per share.

In 2017, the Company issued 75,000 shares of common stock to a consultant upon delivery of shares underlying a restricted stock unit agreement dated June 11, 2015.

 a) II-3Issuances of Capital Stock

On February 29, 2016 in a private placement of securities, the Company issued 500,000June 30, 2017, 1,537,500 shares of Series C Convertible Preferred Stock par value $0.001were converted into 4,392,858 shares of the Company’s common stock and 3,087,500 warrants were converted into 6,175,000 shares of the Company’s common stock, of which 230,000 shares were issued to a then director.

On June 30, 2017, the Company converted $43,750 of fees payable into 625,625 shares of common stock.

On June 30, 2017, the Company converted $68,500 of accounts payable into 979,550 shares of common stock and five-year warrants to purchase 979,550 shares of common stock at an exercise price of $0.15. In connection with this transaction, the consultant forfeited 450,000 options to purchase shares of common stock and also converted $31,500 of consulting fees into 450,450 shares of common stock and warrants to purchase 450,450 shares of common stock in equal increments through December 31, 2017.

On June 30, 2017, the Company issued 464,775 shares of common stock and 464,775 warrants to an investor, in connection with a $25,000 loan made to the Company on October 9, 2014, by an entity he controls.

On April 14, 2017, 375,000 shares of Series C Convertible Preferred Stock were converted into 375,000 shares of the Company’s common stock.

In 2017, 73,000 shares of Series A Convertible Preferred Stock were converted into 1,460,000 shares of the Company’s common stock.

On October 14, 2016, 125,000 shares of Series C Convertible Preferred Stock were converted into 125,000 shares of common stock.

On October 5, 2016, 0.0451 shares of Series B Convertible Preferred Stock were converted into 383,203 shares of common stock.

The issuance of shares of common stock upon the exercise of warrants or the conversion of notes or preferred stock as set forth above, was made without registration, in reliance on the exemptions provided by Section 3(a)(9) of the Securities Act, and in reliance on similar exemptions under applicable state laws, for exchanges of securities with existing security holders.

(b)Sales Exempt Under Section 4(a)(2) of the Securities Act

On September 19, 2019, in connection with the Bridge Financing, the Company issued two Debentures for aggregate gross proceeds of $540,000. The Debentures mature on September 18, 2020. In addition, the Company issued 1,000,000 restricted shares of common stock in connection with the Bridge Financing.

In September 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relation services

In August 2019, the Company granted 400,000 shares of restricted common stock in relation to consulting services.

In August 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relation services.

In August 2019, the Company granted 200,000 shares of restricted common stock in relation to consulting services.

On July 15, 2019, the Company granted 33,333 shares of restricted common stock in relation to investor relations services.

On June 14, 2019, the Company issued 28,753 shares of common stock and on May 15, 2019, the Company issued 20,833 shares of common stock to an entity in relation to investor relations services.

II-4

On May 10, 2019, the Company issued 240,000 shares of restricted common stock to a director which vest over a one-year period in equal quarterly increments from May 8, 2019, subject to continued service as a director at each applicable vesting date.

On April 15, 2019, the Company issued 21,739 shares of common stock to an entity in relation to investor relations services.

On March 23, 2019, the Company issued 240,000 shares of restricted common stock to a director. The shares vest quarterly over a one-year period in equal increments from March 15, 2019, subject to continued service as a director on each applicable vesting date.

On March 21, 2019, the Company issued 240,000 shares of restricted common stock to each of three directors of the Company. The shares vest quarterly over a one-year period in equal increments from March 15, 2019, subject to continued service as a director on each applicable vesting date.

In 2018, the Company received total gross proceeds of approximately $2,079,345 from the exercise of warrants under the Warrant Reduction Program and issued a total of 20,787,784 shares of common stock upon such exercises.

On July 31, 2018, one of our then directors exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929.

On June 27, 2018, the Company authorized a grant of 1,425,000 shares of restricted common stock, vesting quarterly over a one-year period, to the Company’s current and then directors.

On June 27, 2018, the Company granted 150,000 shares of common stock to an entity for services rendered, vesting immediately.

In April 2018, the former Chief Executive Officer of the Company exercised warrants at an exercise price of $0.01 per share, resulting in the issuance of 100,000 shares of the Company’s common stock.

On April 25, 2018, the Company granted 300,000 shares of restricted common stock to a then director in connection with his service as a member of the Board. On the same date, the Company approved a grant of 150,000 shares of vested restricted common stock to the estate of a former director of the Company. The 150,000 previously unvested shares of restricted common stock granted to said director were forfeited upon his death.

On March 31, 2018, the Company entered into a Confidential Settlement Agreement with a then member of the Board, and certain other parties named in the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the Company (i) paid a total of $500,000 to a fund controlled by the former director and an additional party and (ii) issued a total of 1,000,000 shares of the Company’s common stock to the fund and the third party.

On March 13, 2018, the Company granted a then director 300,000 shares of restricted common stock vesting quarterly over one year subject to continued service as of each applicable vesting date.

In 2018, the Company issued shares of restricted common stock in connection with a consulting services agreement for services performed in January through June 2018 as follows: 40,000 shares on each of January 11, 2018, February 11, 2018 and March 11, 2018; 13,500 shares on each of April 11, 2018, May 11, 2018 and June 11, 2018; and 9,000 shares on June 30, 2018.

In January 2018, a then member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731.

In 2017, the Company issued shares of restricted common stock in connection with a consulting services agreement for services performed in October through December 2017 as follows: 40,000 shares on each of October 11, 2017, November 11, 2017 and December 11, 2017.

II-5

On August 31, 2017, the Company granted each director (except its chairman and CEO), 300,000 shares of restricted common stock, or a total of 2,100,000 shares, vesting quarterly over a one-year period subject to continued service as of each applicable vesting date.

In 2017, the Company conducted a private placement offering with a maximum offering amount of $2,100,000 comprised of units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share. In January 2018, the Company raised gross proceeds of $1,153,645 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants. Prior to December 2017,the Company raised gross proceeds of $1,360,250 for the purchase of19,451,575shares of common stock and19,451,575warrants.

On July 19, 2017, the Company issued 371,800 shares of common stock and 371,800 warrants to purchase common stock at an exercise price of $0.15 per share to a former director.

In June 2017, the Company issued notes payable in the aggregate principal amount of $36,000 in exchange for a loan bearing 10% annual interest maturing June 30, 2017.

In May 2017, the Company issued notes payable in the aggregate principal amount of $60,000 in exchange for a loan bearing 10% annual interest maturing June 30, 2017.

On April 26, 2017, the Company issued a secured promissory note in the principal amount of $30,000 in exchange for a loan bearing 10% annual interest maturing October 31, 2017.

On April 13, 2017, the Company issued notes payable in the principal amount of $10,000 in exchange for a loan bearing 10% annual interest maturing June 30, 2017.

On March 28, 2017, the Company issued a note payable in the amount of $25,000 and five-year warrants to purchase 1,250,000 shares of common stock at $0.40 per share.

On February 13, 2017, the Company issued a note payable to a director in the amount of $100,000 and a five-year warrant to purchase 5,000,000 shares of the Company’s common stock at an exercise price of $0.40 per share.

On January 24, 2017 and January 31, 2017, the Company issued notes payable to a then director in the aggregate amount of $20,000, and five-year warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.40 per share.

In 2017, 1,678,572 shares of common stock were issued as stock-based compensation.

In 2017, 38,657 shares of common stock were issued in relation to sales of common stock in prior years.

On October 24, 2016, the Company issued 166,750 shares of 0% Series D Convertible Preferred Stock at a purchase price of $0.40 per share with gross proceeds to the Company of $200,000.$66,700. In connection with the sale of the Series CD Convertible Preferred Stock, the Company issued to the accredited investorspurchasers warrants to purchase in the aggregate 500,000667,000 shares of the Company’s common stock at an exercise price of $0.40 per share. Each share of Series C Preferred Stock is convertible into one share of common stock, subject

The securities described above were issued to adjustment. The offer and sale of these private placement shares was not registered under the Securities Actinvestors in reliance upon the exemption from the registration underrequirements of the Securities Act, as set forth in Section 4(a)(2) of the Securities Act as suchand/or Regulation D promulgated thereunder relative to transactions did not involve a public offering of securities. This offering was a part of the February 9, 2016 offering discussed immediately below.

On February 9, 2016 in a private placement of securities, the Company issued 2,587,500 shares of Series C Preferred Stock to accredited investors at a purchase price of $0.40 per share with gross proceeds to the Company of $1,035,000. In connection with the sale of the Series C Preferred Stock, the Company issued to the accredited investors warrants to purchase in the aggregate 2,587,500 shares of the Company’s common stock at an exercise price of $0.40 per share. Each share of Series C Preferred Stock is convertible into one share of common stock, subject to adjustment. The offer and sale of these private placement shares was not registered under the Securities Act in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act as such transactions did not involve a public offering of securities.
On June 12, 2015, the Company converted its restricted non-trading common stock at a conversion rate of one (1) share for each $0.018 of outstanding principal and accrued but unpaid interest. In addition, the Company also converted 4,000,000 of outstanding warrants into 4,000,000 shares of its restricted non-trading common stock on a 1:1 basis. Also in connection with the issued shares of the Company’s Series A Preferred Stock, having a par value of $0.001, into 21,111,111 shares of the Company’s restricted non-trading common stock on a 1:1 basis; (b) convert $6,500,000 of outstanding royalty payments owed by the Company under a Patent and Technology License Agreement, dated as of December 31, 2012, into 85 shares of the Company’s newly-created Series B Preferred Stock, having a par value of $0.001. Further in connection with the Recapitalization Transaction, the Company issued (a) 37,564,767 shares of its Series A Preferred Stock, in exchange for a cash investment of $1,450,000, and (b) 25,906,736 shares of its restricted non-trading common stock, in exchange for a cash investment of $50,000.
On September 8, 2014, the Company issued notes payable for $150,000, which included fully vested warrants to purchase 900,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $62,544 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $44,140 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and nine months ended September 30, 2014, $11,700 was accreted through interest expense. The note and accrued interest at 8% per annum are due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of September 30, 2014, the fair value of the warrant liability was $44,566 and the note payable balance was $117,560, net of $32,440 discount. This note is in default.
On August 14, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $47,676 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $32,274 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and nine months ended September 30, 2014, $14,045 was accreted through interest expense. The note and accrued interest at 8% per annum are due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of September 30, 2014, the fair value of the warrant liability was $29,697 and the note payable balance was $81,771, net of $18,229 discount. This note is in default.
On August 12, 2014, the Company issued notes payable for $50,000, which included fully vested warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $26,817 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $17,455 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and nine months ended September 30, 2014, $7,775 was accreted through interest expense. The note and accrued interest at 8% per annum are due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of September 30, 2014, the fair value of the warrant liability was $14,848 and the note payable balance was $40,320, net of $9,680 discount. This note is in default.
On August 5, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $29,725 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $22,914 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and nine months ended September 30, 2014, $10,653 was accreted through interest expense. The note and accrued interest at 8% per annum are due in full on December 1, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of September 30, 2014, the fair value of the warrant liability was $29,692 and the note payable balance was $87,739, net of $12,261 discount. This note is in default.
On June 10, 2014, the Company issued a note payable for $250,000, which included fully vested warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at $39,650 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition and is being accreted over the term of the note payable for financial statement purposes. For the three and nine months ended September 30, 2014, $26,617 and $34,222, respectively, were accreted through interest expense. The note and accrued interest at 8% per annum as was originally due on September 11, 2014, but the Company received approval to extend the maturity until December 11, 2014. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of September 30, 2014, the fair value of the warrant liability was $49,026 and the note payable balance was $250,000. This note is in default.
b)Grants and Exercises of Stock Options
Since April 14, 2013, we have granted stock options that are still outstanding to purchase an aggregate of 2,457,353 shares of our common stock, with 282,353 of such stock options having an exercise price of $4.25 per share, 1,600,000 of such stock options having an exercise price of $0.85 per share, 200,000 of such stock options having an exercise price of $5.77 per share,75,000 of such stock options having an exercise price of $2.15 per share, 100,000 of such stock options having an exercise price of $0.60 per share, 150,000 of such stock options having an Exercise price of $0.58 per share, and 50,000 of such stock options having an exercise price of $0.43 per share, to employees, directors and consultants pursuant to our Plan. Since April 14, 2013, we have issued and sold an aggregate of 39,776 shares of our common stock upon exercise of stock options granted pursuant to our Plan for aggregate consideration of $0. The issuances of common stock upon exercise of the options were exempt either pursuant to Rule 701, as a transaction pursuant to a compensatory benefit plan, or pursuant to Section 4(a)(2), as a transaction by an issuer not involving aany public offering.offering, to the extent an exemption from such registration was required. The sharesrecipients of common stock issued upon exercise of options are deemed restrictedthe securities in the transactions described above acquired the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof. Appropriate legends were affixed to the purposes of the Securities Act.instruments representing such securities issued in such transactions.

II-6

Item 16. Exhibits and Financial Statement Schedules

The following exhibits to this registration statement are listedincluded in the Exhibit Index to this registration statement, which Exhibit Index is herebyExhibits are incorporated by reference.

INDEX TO EXHIBITS

Exhibit No.Description
1.1**

Form of Underwriting Agreement.

3.1

Amended and Restated Articles of Incorporation of the Company, as amended (incorporated herein by reference from Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015).

3.2

Second Amended Certificate of Designation for Series A Convertible Preferred Stock (incorporated herein by reference from Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on June 18, 2015).

3.3

Certificate of Designation for Series B Convertible Preferred Stock (incorporated herein by reference from Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on June 18, 2015).

3.4

Certificate of Withdrawal of Certificate of Designation for Series C and Series D Convertible Preferred Stock (incorporated herein by reference from Exhibit 4.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018).

3.5

Amended and Restated Bylaws of the Company (incorporated herein by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 15, 2017).

4.1

Form of Warrant for the Purchase of Common Stock (incorporated herein by reference from Exhibit 10.29 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017).

4.2**

Form of Warrant.

4.3**

Form of Warrant Agreement.

4.4**

Form of Representative’s Warrant.

5.1**

Opinion of Harter Secrest & Emery LLP, counsel to the Registrant, with respect to the legality of securities being registered.

10.1#

Form of Employment Agreement for Patrick White dated August 9, 2017 (incorporated herein by reference from Exhibit 10.17 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017).

10.2#*

Amendment to Employment Agreement for Patrick White dated August 13, 2019.

10.3#*

Employment Agreement for Margaret Gezerlis dated November 15, 2018.

10.4#

Form of Consulting Agreement with Norman Gardner, dated June 29, 2017 (incorporated herein by reference from Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017).

10.5#

Consulting Agreement dated September 1, 2017 and First Amendment to Consulting Agreement dated March 1, 2018 for Keith Goldstein (incorporated herein by reference from Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017).

II-7

10.6#

Second Amendment to the Consulting Agreement dated April 9, 2019 for Keith Goldstein (incorporated herein by reference from Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).

10.7#

2017 Equity Incentive Plan (incorporated herein by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 20, 2017).

10.8#

Amendment to the 2017 Equity Incentive Plan (incorporated herein by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 29, 2019).

10.9#

The LaserLock Technologies, Inc. 2013 Omnibus Equity Compensation Plan (incorporated herein by reference from the Company’s Definitive Proxy Statement filed on November 19, 2013).

10.10#

Option Agreement dated January 31, 2017 under the LaserLock Technologies, Inc. 2013 Omnibus Equity Compensation Plan (incorporated herein by reference from Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017).

10.11#

Option Agreement dated February 6, 2017 under the LaserLock Technologies, Inc. 2013 Omnibus Equity Compensation Plan (incorporated herein by reference from Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017).

10.12#

Option Agreement dated February 6, 2017 under the LaserLock Technologies, Inc. 2013 Omnibus Equity Compensation Plan (incorporated herein by reference from Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017).

10.13#*

Non-Qualified Stock Option Agreement dated February 2018 between the Company and Patrick White.

10.14#*

Non-Qualified Stock Option Agreement dated August 2017 between the Company and Patrick White.

10.15#*

Incentive Stock Option Agreement dated August 14, 2019 between the Company and Patrick White.

10.16#*

Incentive Stock Option Agreement dated March 11, 2019 between the Company and Margaret Gezerlis.

10.17#*

Non-Qualified Stock Option Agreement dated January 22, 2018 between the Company and Norman Gardner.

10.18#

Form of Restricted Stock Agreement (incorporated herein by reference from Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018).

10.19

Form of Amended Securities Purchase Agreement (incorporated herein by reference from Exhibit 10.28 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017).

10.20

Securities Purchase Agreement dated September 18, 2019 with Peak One Opportunity Fund, L.P. (incorporated herein by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

10.21

Securities Purchase Agreement dated September 18, 2019 with TFK Investments, LLC (incorporated herein by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

10.22

Debenture dated September 18, 2019 with Peak One Opportunity Fund, L.P. (incorporated herein by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

II-8

10.23

Debenture dated September 18, 2019 with TFK Investments, LLC (incorporated herein by reference from Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

10.24

Security Agreement dated September 18, 2019 with Peak One Opportunity Fund, L.P. (incorporated herein by reference from Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

10.25

Security Agreement dated as of September 18, 2019 with TFK Investments, LLC (incorporated herein by reference from Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on September 23, 2019).

23.1*Consent of MaloneBailey, LLP, independent registered public accounting firm.
23.2**Consent of Harter Secrest & Emery LLP (included in Exhibit 5.1).
24.1*Power of Attorney (included on signature page of this registration statement).
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document 
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** To be filed by amendment.

# Denotes management compensation plan or contract

Item 17. Undertakings

(a)The undersigned Registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.

(b)The undersigned registrant hereby undertakes:

(1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

(iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

II-9

(2)That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i)Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (§230.424 of this chapter);

(ii)Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii)The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv)Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b)           Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-10

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of New York,Rochester, State of New York, on April 14, 2016.

October 10, 2019.

 VERIFYME, INC. 
   
   
 /s/ Paul DonfriedPatrick White 
 Paul DonfriedPatrick White 
 President and Chief Executive Officer 

II-11
SIGNATURES AND

POWER OF ATTORNEY


We

Each of the undersigned officershereby constitutes and directors of VerifyMe, Inc., hereby severally constituteappoints Patrick White and appoint Paul Donfried and Scott McPherson,Margaret Gezerlis, and each of them, singly, ourhis true and lawful attorneysattorney-in-fact and agent, each with full power to any of them,substitution and to each of them singly, to signresubstitution, for ushim and in our nameshis name, place and stead, in the capacities indicated below the registration statement on Form S-1 filed herewith and any and all pre-effectivecapacities, to sign any and post-effectiveall amendments (including post effective amendments) to saidthis registration statement, andor any subsequentrelated registration statement filed pursuant to Rule 462(b)462 under the Securities Act, of 1933, as amended, and to file the same, with all exhibits thereto, and the other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and generallyagents, and each of them, full power and authority to do and perform each and every act and thing requisite and desirable to be done in as fully and to all such thingsintents and purposes as the undersigned might or could do in our name and behalf in our capacities as officers and directors to enable VerifyMe, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission,person, hereby ratifying and confirming our signatures as they may be signed by ourall acts and things that said attorneys,attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to said registration statement and any and all amendments thereto.


be done by virtue hereof.

Each of the undersigned has executed this power of attorney as of the date indicated.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statementregistration statement has been signed by the following persons in the capacities and on the dates indicated.


Signature
TitleDate
/s/ Paul Donfried
Paul Donfried
Title
President, Chief Executive Officer and
Director (Principal Executive Officer)
April 14, 2016Date
   
/s/ Scott McPherson
Scott McPherson
Patrick White
President, Chief FinancialExecutive Officer and DirectorOctober 10, 2019
Patrick White(Principal Executive Officer)
Financial and Accounting Officer)
April 14, 2016
   
/s/ Michael Madon
Michael Madon
 /s/ Margaret Gezerlis
Chairman of the BoardApril 14, 2016Chief Financial OfficerOctober 10, 2019
Margaret Gezerlis(Principal Financial Officer and
Principal Accounting Officer)
   
/s/ Jonathan Weinberger
Jonathan Weinberger
 /s/ Norman Gardner
DirectorApril 14, 2016Chairman of the BoardOctober 10, 2019
Norman Gardner
   
/s/ Claudio Ballard
Claudio Ballard
 /s/ Chris Gardner
DirectorApril 14, 2016October 10, 2019
Chris Gardner
   
/s/Lawrence Schafran
Lawrence Schafran

 /s/ Marshall Geller

DirectorApril 14, 2016October 10, 2019
Marshall Geller
 /s/ Howard GoldbergDirectorOctober 10, 2019
Howard Goldberg
/s/ Arthur LafferDirectorOctober 10, 2019
Arthur Laffer
EXHIBIT INDEX

Exhibit No.Description
3.1Certificate of Amendment to Amended and Restated Articles of Incorporation of LaserLock Technologies, Inc., as amended (filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 19, 2015 and incorporated herein by reference).
3.2Amended Certificate of Designation of Series A Preferred Stock, dated as of January 31, 2013 (filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2013 and incorporated herein by reference).
3.3Second Amended Certificate of Designation for Series A Preferred Stock, dated as of June 2015 (filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015 and incorporated herein by reference).
3.4
Certificate of Designation for Series B Preferred Stock, dated as of June 2015 (filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015 and incorporated herein by reference).
3.5Certificate of Designation for Series C Preferred Stock, filed with the Nevada Secretary of State on January 27, 2016 (filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016 and incorporated herein by reference).
3.6Amended and Restated Bylaws of LaserLock Technologies, Inc. as amended (filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 19, 2015 and incorporated herein by reference).
3.7Second Amendment to Amended and Restated Bylaws of the Company, dated January 27, 2016 (filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016 and incorporated herein by reference).
4.1Form of Warrant for Purchase of Common Stock (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016 and incorporated herein by reference.
    5.1*Opinion of Baker Donelson Bearman Caldwell & Berkowitz, P.C., counsel to the Registrant, with respect to the legality of securities being registered.
10.1Form of Securities Purchase Agreement by and between the Company and each of the Investors (filed as an Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016 and incorporated herein by reference).
10.2Form of Registration of Rights Agreement by and between the Company and each of the Investors (filed as an Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016 and incorporated herein by reference).
10.3Master Acquisition Agreement by and among OPC Partners LLC, VerifyMe, Inc., Laserlock Technologies, Inc., Zaah Technologies, Inc. and a Common Stock Investor dated as of June 12, 2015 (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.4Form of Promissory Note Conversion Agreement (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.5Form of Warrant Conversion Agreement (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
Exhibit No.Description
10.6@Employment Letter to Paul Donfried from LaserLock Technologies, Inc. (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.7@Employment Letter to Sandy Fliderman from LaserLock Technologies, Inc. (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.8@Independent Director's Agreement between LaserLock Technologies, Inc. and Jonathan Weinberger dated as of June 12, 2015 (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.9@Independent Director's Agreement between LaserLock Technologies, Inc. and Claudio Ballard dated as of June 12, 2015 (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2015).
10.10@Employment Letter to Ben Burrell from LaserLock Technologies, Inc., dated as of June 12, 2015 (filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 15, 2015).
10.11*Independent Director's Agreement between VerifyMe, Inc. and Michael Madon dated as of February 26, 2016.
10.12@The LaserLock Technologies, Inc. 2013 Omnibus Equity Compensation Plan (filed with the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 11, 2013).
23.1*Consent of Morison Cogen LLP, independent registered public accounting firm.
 23.2*Consent of Baker Donelson Bearman Caldwell & Berkowitz, PC (included in Exhibit 5.1).
24.1Power of Attorney (included on signature page of this registration statement).
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document 
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.
** To be filed by amendment
@ Denotes management compensation plan or contract.

II-9